
<html lang="en"     class="pb-page"  data-request-id="c756a081-ade7-4e03-aafb-f0a2c1cc5fbd"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2019.62.issue-5;article:article:10.1021/acs.jmedchem.9b00062;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Novel Aryloxyethyl Derivatives of 1-(1-Benzoylpiperidin-4-yl)methanamine as the Extracellular Regulated Kinases 1/2 (ERK1/2) Phosphorylation-Preferring Serotonin 5-HT1A Receptor-Biased Agonists with Robust Antidepressant-like Activity" /></meta><meta name="dc.Creator" content="Joanna  Sniecikowska" /></meta><meta name="dc.Creator" content="Monika  Gluch-Lutwin" /></meta><meta name="dc.Creator" content="Adam  Bucki" /></meta><meta name="dc.Creator" content="Anna  Więckowska" /></meta><meta name="dc.Creator" content="Agata  Siwek" /></meta><meta name="dc.Creator" content="Magdalena  Jastrzebska-Wiesek" /></meta><meta name="dc.Creator" content="Anna  Partyka" /></meta><meta name="dc.Creator" content="Daria  Wilczyńska" /></meta><meta name="dc.Creator" content="Karolina  Pytka" /></meta><meta name="dc.Creator" content="Krzysztof  Pociecha" /></meta><meta name="dc.Creator" content="Agnieszka  Cios" /></meta><meta name="dc.Creator" content="Elżbieta  Wyska" /></meta><meta name="dc.Creator" content="Anna  Wesołowska" /></meta><meta name="dc.Creator" content="Maciej  Pawłowski" /></meta><meta name="dc.Creator" content="Mark A.  Varney" /></meta><meta name="dc.Creator" content="Adrian  Newman-Tancredi" /></meta><meta name="dc.Creator" content="Marcin  Kolaczkowski" /></meta><meta name="dc.Description" content="Novel 1-(1-benzoylpiperidin-4-yl)methanamine derivatives were designed as “biased agonists” of serotonin 5-HT1A receptors. The compounds were tested in signal transduction assays (ERK1/2 phosphoryl..." /></meta><meta name="Description" content="Novel 1-(1-benzoylpiperidin-4-yl)methanamine derivatives were designed as “biased agonists” of serotonin 5-HT1A receptors. The compounds were tested in signal transduction assays (ERK1/2 phosphoryl..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 5, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b00062" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00062" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b00062" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00062" /></link>
        
    
    

<title>Novel Aryloxyethyl Derivatives of 1-(1-Benzoylpiperidin-4-yl)methanamine as the Extracellular Regulated Kinases 1/2 (ERK1/2) Phosphorylation-Preferring Serotonin 5-HT1A Receptor-Biased Agonists with Robust Antidepressant-like Activity | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b00062" /></meta><meta property="og:title" content="Novel Aryloxyethyl Derivatives of 1-(1-Benzoylpiperidin-4-yl)methanamine as the Extracellular Regulated Kinases 1/2 (ERK1/2) Phosphorylation-Preferring Serotonin 5-HT1A Receptor-Biased Agonists with Robust Antidepressant-like Activity" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0020.jpeg" /></meta><meta property="og:description" content="Novel 1-(1-benzoylpiperidin-4-yl)methanamine derivatives were designed as “biased agonists” of serotonin 5-HT1A receptors. The compounds were tested in signal transduction assays (ERK1/2 phosphorylation, cAMP inhibition, Ca2+ mobilization, and β-arrestin recruitment) which identified ERK1/2 phosphorylation-preferring aryloxyethyl derivatives. The novel series showed high 5-HT1A receptor affinity, &gt;1000-fold selectivity versus noradrenergic α1, dopamine D2, serotonin 5-HT2A, histamine H1, and muscarinic M1 receptors, and favorable druglike properties (CNS-MPO, Fsp3, LELP). The lead structure, (3-chloro-4-fluorophenyl)(4-fluoro-4-(((2-(pyridin-2-yloxy)ethyl)amino)methyl)piperidin-1-yl)methanone (17, NLX-204), displayed high selectivity in the SafetyScreen44 panel (including hERG channel), high solubility, metabolic stability, and Caco-2 penetration and did not block CYP3A4, CYP2D6 isoenzymes, or P-glycoprotein. Preliminary in vivo studies confirmed its promising pharmacokinetic profile. 17 also robustly stimulated ERK1/2 phosphorylation in rat cortex and showed highly potent (MED = 0.16 mg/kg) and efficacious antidepressant-like activity, totally eliminating immobility in the rat Porsolt test. These data suggest that the present 5-HT1A receptor-biased agonists could constitute promising antidepressant drug candidates." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b00062"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00062">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b00062&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b00062&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b00062&amp;href=/doi/10.1021/acs.jmedchem.9b00062" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 5</span><span class="cit-fg-pageRange">, 2750-2771</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/5" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b00053" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b00113" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Novel Aryloxyethyl Derivatives of 1-(1-Benzoylpiperidin-4-yl)methanamine as the Extracellular Regulated Kinases 1/2 (ERK1/2) Phosphorylation-Preferring Serotonin 5-HT<sub>1A</sub> Receptor-Biased Agonists with Robust Antidepressant-like Activity</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Joanna Sniecikowska</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Joanna Sniecikowska</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Kraków, Poland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Joanna++Sniecikowska">Joanna Sniecikowska</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5296-7964" title="Orcid link">http://orcid.org/0000-0002-5296-7964</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Monika Gluch-Lutwin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Monika Gluch-Lutwin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Kraków, Poland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Monika++Gluch-Lutwin">Monika Gluch-Lutwin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Adam Bucki</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Adam Bucki</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Kraków, Poland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Adam++Bucki">Adam Bucki</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0451-9814" title="Orcid link">http://orcid.org/0000-0003-0451-9814</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Anna Więckowska</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anna Więckowska</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Kraków, Poland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anna++Wi%C4%99ckowska">Anna Więckowska</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2549-170X" title="Orcid link">http://orcid.org/0000-0003-2549-170X</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Agata Siwek</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Agata Siwek</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Kraków, Poland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Agata++Siwek">Agata Siwek</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Magdalena Jastrzebska-Wiesek</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Magdalena Jastrzebska-Wiesek</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Kraków, Poland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Magdalena++Jastrzebska-Wiesek">Magdalena Jastrzebska-Wiesek</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Anna Partyka</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anna Partyka</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Kraków, Poland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anna++Partyka">Anna Partyka</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Daria Wilczyńska</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Daria Wilczyńska</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Kraków, Poland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Daria++Wilczy%C5%84ska">Daria Wilczyńska</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Karolina Pytka</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Karolina Pytka</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Kraków, Poland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Karolina++Pytka">Karolina Pytka</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Krzysztof Pociecha</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Krzysztof Pociecha</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Kraków, Poland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Krzysztof++Pociecha">Krzysztof Pociecha</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Agnieszka Cios</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Agnieszka Cios</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Kraków, Poland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Agnieszka++Cios">Agnieszka Cios</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Elżbieta Wyska</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Elżbieta Wyska</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Kraków, Poland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=El%C5%BCbieta++Wyska">Elżbieta Wyska</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Anna Wesołowska</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anna Wesołowska</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Kraków, Poland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anna++Weso%C5%82owska">Anna Wesołowska</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Maciej Pawłowski</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Maciej Pawłowski</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Kraków, Poland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Maciej++Paw%C5%82owski">Maciej Pawłowski</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mark A. Varney</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mark A. Varney</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Neurolixis Inc., 34145 Pacific Coast Highway #504, Dana Point, 92629 California, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mark+A.++Varney">Mark A. Varney</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Adrian Newman-Tancredi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Adrian Newman-Tancredi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Neurolixis Inc., 34145 Pacific Coast Highway #504, Dana Point, 92629 California, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Adrian++Newman-Tancredi">Adrian Newman-Tancredi</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2923-5714" title="Orcid link">http://orcid.org/0000-0002-2923-5714</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Marcin Kolaczkowski</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Marcin Kolaczkowski</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Kraków, Poland</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#cca1adbeafa5a2e2a7a3a0adafb6a7a3bbbfa7a58cb9a6e2a9a8b9e2bca0"><span class="__cf_email__" data-cfemail="c3aea2b1a0aaadeda8acafa2a0b9a8acb4b0a8aa83b6a9eda6a7b6edb3af">[email protected]</span></a>. Phone: (48)126205460. Fax: (48)126205458.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Marcin++Kolaczkowski">Marcin Kolaczkowski</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8402-1121" title="Orcid link">http://orcid.org/0000-0001-8402-1121</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00062&amp;href=/doi/10.1021%2Facs.jmedchem.9b00062" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 5</span><span class="cit-pageRange">, 2750–2771</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 5, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>10 January 2019</li><li><span class="item_label"><b>Published</b> online</span>5 February 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 March 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b00062" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00062</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/authorchoice_termsofuse.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ec-1612971054143.svg" alt="ACS Editors’ Choice" /></img><span>ACS Editors’ Choice</span></a></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b00062"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3764</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">10</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b00062" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Novel Aryloxyethyl Derivatives of 1-(1-Benzoylpiperidin-4-yl)methanamine as the Extracellular Regulated Kinases 1/2 (ERK1/2) Phosphorylation-Preferring Serotonin 5-HT1A Receptor-Biased Agonists with Robust Antidepressant-like Activity&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Joanna&quot;,&quot;last_name&quot;:&quot;Sniecikowska&quot;},{&quot;first_name&quot;:&quot;Monika&quot;,&quot;last_name&quot;:&quot;Gluch-Lutwin&quot;},{&quot;first_name&quot;:&quot;Adam&quot;,&quot;last_name&quot;:&quot;Bucki&quot;},{&quot;first_name&quot;:&quot;Anna&quot;,&quot;last_name&quot;:&quot;Więckowska&quot;},{&quot;first_name&quot;:&quot;Agata&quot;,&quot;last_name&quot;:&quot;Siwek&quot;},{&quot;first_name&quot;:&quot;Magdalena&quot;,&quot;last_name&quot;:&quot;Jastrzebska-Wiesek&quot;},{&quot;first_name&quot;:&quot;Anna&quot;,&quot;last_name&quot;:&quot;Partyka&quot;},{&quot;first_name&quot;:&quot;Daria&quot;,&quot;last_name&quot;:&quot;Wilczyńska&quot;},{&quot;first_name&quot;:&quot;Karolina&quot;,&quot;last_name&quot;:&quot;Pytka&quot;},{&quot;first_name&quot;:&quot;Krzysztof&quot;,&quot;last_name&quot;:&quot;Pociecha&quot;},{&quot;first_name&quot;:&quot;Agnieszka&quot;,&quot;last_name&quot;:&quot;Cios&quot;},{&quot;first_name&quot;:&quot;Elżbieta&quot;,&quot;last_name&quot;:&quot;Wyska&quot;},{&quot;first_name&quot;:&quot;Anna&quot;,&quot;last_name&quot;:&quot;Wesołowska&quot;},{&quot;first_name&quot;:&quot;Maciej&quot;,&quot;last_name&quot;:&quot;Pawłowski&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;A. Varney&quot;},{&quot;first_name&quot;:&quot;Adrian&quot;,&quot;last_name&quot;:&quot;Newman-Tancredi&quot;},{&quot;first_name&quot;:&quot;Marcin&quot;,&quot;last_name&quot;:&quot;Kolaczkowski&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;05&quot;,&quot;issue&quot;:&quot;5&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;2750-2771&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b00062&quot;},&quot;abstract&quot;:&quot;Novel 1-(1-benzoylpiperidin-4-yl)methanamine derivatives were designed as “biased agonists” of serotonin 5-HT1A receptors. The compounds were tested in signal transduction assays (ERK1/2 phosphorylation, cAMP inhibition, Ca2+ mobilization, and β-arrestin recruitment) which identified ERK1/2 phosphorylation-preferring aryloxyethyl derivatives. The novel series showed high 5-HT1A receptor affinity, &gt;1000-fold selectivity versus noradrenergic α1, dopamine D2, serotonin 5-HT2A, histamine H1, and muscarinic M1 receptors, and favorable druglike properties (CNS-MPO, Fsp3, LELP). The lead structure, (3-chloro-4-fluorophenyl)(4-fluoro-4-(((2-(pyridin-2-yloxy)ethyl)amino)methyl)piperidin-1-yl)methanone (17, NLX-204), displayed high selectivity in the SafetyScreen44 panel (including hERG channel), high solubility, metabolic stability, and Caco-2 penetration and did not block CYP3A4, CYP2D6 isoenzymes, or P-glycoprotein. Preliminary in vivo studies confirmed its promising pharmacokinetic profile. 17 also robustly stimula&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00062&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00062" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00062&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00062" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00062&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00062" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00062&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00062&amp;href=/doi/10.1021/acs.jmedchem.9b00062" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b00062" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b00062" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b00062%26sid%3Dliteratum%253Aachs%26pmid%3D30721053%26genre%3Darticle%26aulast%3DSniecikowska%26date%3D2019%26atitle%3DNovel%2BAryloxyethyl%2BDerivatives%2Bof%2B1-%25281-Benzoylpiperidin-4-yl%2529methanamine%2Bas%2Bthe%2BExtracellular%2BRegulated%2BKinases%2B1%252F2%2B%2528ERK1%252F2%2529%2BPhosphorylation-Preferring%2BSerotonin%2B5-HT1A%2BReceptor-Biased%2BAgonists%2Bwith%2BRobust%2BAntidepressant-like%2BActivity%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D5%26spage%3D2750%26epage%3D2771%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=292589" title="Agonists">Agonists</a>,</li><li><a href="/action/doSearch?ConceptID=290969" title="Cell and molecular biology">Cell and molecular biology</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a>,</li><li><a href="/action/doSearch?ConceptID=290682" title="Post-translational modification">Post-translational modification</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/5" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/jmcmar.2019.62.issue-5/20190314/jmcmar.2019.62.issue-5.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/medium/jm-2019-00062d_0020.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00062&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Novel 1-(1-benzoylpiperidin-4-yl)methanamine derivatives were designed as “biased agonists” of serotonin 5-HT<sub>1A</sub> receptors. The compounds were tested in signal transduction assays (ERK1/2 phosphorylation, cAMP inhibition, Ca<sup>2+</sup> mobilization, and β-arrestin recruitment) which identified ERK1/2 phosphorylation-preferring aryloxyethyl derivatives. The novel series showed high 5-HT<sub>1A</sub> receptor affinity, >1000-fold selectivity versus noradrenergic α<sub>1</sub>, dopamine D<sub>2</sub>, serotonin 5-HT<sub>2A</sub>, histamine H<sub>1</sub>, and muscarinic M<sub>1</sub> receptors, and favorable druglike properties (CNS-MPO, Fsp<sup>3</sup>, LELP). The lead structure, (3-chloro-4-fluorophenyl)(4-fluoro-4-(((2-(pyridin-2-yloxy)ethyl)amino)methyl)piperidin-1-yl)methanone (<b>17</b>, NLX-204), displayed high selectivity in the SafetyScreen44 panel (including hERG channel), high solubility, metabolic stability, and Caco-2 penetration and did not block CYP3A4, CYP2D6 isoenzymes, or P-glycoprotein. Preliminary in vivo studies confirmed its promising pharmacokinetic profile. <b>17</b> also robustly stimulated ERK1/2 phosphorylation in rat cortex and showed highly potent (MED = 0.16 mg/kg) and efficacious antidepressant-like activity, totally eliminating immobility in the rat Porsolt test. These data suggest that the present 5-HT<sub>1A</sub> receptor-biased agonists could constitute promising antidepressant drug candidates.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45082" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45082" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Despite the clinical availability of a large number of antidepressant drugs, the treatment of depressive disorders still remains an area of unmet medical need. With few exceptions, current antidepressants target inhibition of monoamine neurotransmitter reuptake into brain neurons.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The clinical efficacy of this strategy is less than optimal, as indicated by the substantial proportion of patients that fail to respond to treatment or that show only partial treatment response.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2,3)</a> Furthermore, current antidepressants usually require several weeks of administration before clinical efficacy is observed—this protracted delay in therapeutic onset is a source of distress to families, of increased medical burden, and of potential suicide risk for patients.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4,5)</a> Nevertheless, recent findings suggest that the development of rapidly acting and highly clinically efficacious novel antidepressants is a realistic prospect. Indeed, the discovery that ketamine, a general anesthetic drug acting primarily as a noncompetitive <i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate (NMDA) receptor antagonist, can reverse depressive symptoms in profoundly depressed and treatment-resistant patients has given new hope that depressive states can be treated efficaciously and rapidly. Accordingly, the S-enantiomer of ketamine is currently being evaluated by the FDA as a rapid-acting antidepressant for treatment-resistant depression.<a onclick="showRef(event, 'ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8">(6−8)</a> At a molecular level, ketamine was found to mediate its antidepressant effects in rats via several mechanisms including AMPA and mTOR activation and, of particular interest in the present context, extracellular regulated kinase (ERK) phosphorylation in prefrontal cortex (PFC). The latter mechanism has attracted considerable attention as a substrate for ketamine’s antidepressant activity. Indeed, ketamine elicits robust phosphorylation of ERK in this brain region,<a onclick="showRef(event, 'ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11">(9−11)</a> and correspondingly, inhibition of ERK phosphorylation using inhibitors of mitogen-activated proteins kinase (MEK) blocked the antidepressant-like effects of ketamine in rat models, an observation that was also seen with another NMDA receptor antagonist, Ro 25-6981.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> These results strongly suggest that mechanisms that elicit robust activation of cortical ERK phosphorylation could constitute an effective and novel strategy to discover improved antidepressant drugs which, like ketamine, could (i) show efficacy in profoundly depressed and treatment-resistant patients, (ii) be effective following short durations of treatment (or even acutely, like ketamine), and (iii) target new neurobiological mechanisms distinct from classical monoamine reuptake inhibitors. Nevertheless, ketamine presents several notable limitations that prevent its widespread use as an antidepressant, including the induction of dissociative states which may be difficult to separate from the antidepressant effects,<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13,14)</a> cardiovascular and urinary tract side effects,<a onclick="showRef(event, 'ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17">(15−17)</a> and neurotoxicity and neurocognitive dysfunction. These considerations highlight the ongoing medical need for novel and well-tolerated antidepressant drugs. In the search for a suitable target to achieve such a profile, it is interesting that ketamine’s mechanism of action involves serotonergic pathways and, notably, activation of the 5-HT<sub>1A</sub> receptor subtype, at least in certain animal tests.<a onclick="showRef(event, 'ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref18 ref19 ref20">(18−20)</a> Presynaptic 5-HT<sub>1A</sub> autoreceptors have been implicated in the delay of therapeutic onset of antidepressants, but postsynaptic 5-HT<sub>1A</sub> receptors, notably in cortical brain regions, are known to mediate potent antidepressant-like effects in animal models.<a onclick="showRef(event, 'ref21 ref22 ref23 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref21 ref22 ref23 ref24 ref25">(21−25)</a> In addition, a moderately selective 5-HT<sub>1A</sub> receptor agonist, flesinoxan, was shown to have promising antidepressant properties,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> whereas partial agonists at 5-HT<sub>1A</sub> receptors (e.g., buspirone) have failed to show robust antidepressant effects. It therefore appears that full-agonist targeting of 5-HT<sub>1A</sub> receptors may be a promising strategy for identification of novel antidepressants, potentially mimicking the remarkable antidepressant effects of ketamine. However, targeting of 5-HT<sub>1A</sub> receptors may require preferential activation in specific brain regions, notably frontal cortex. Although there is only a single gene sequence for 5-HT<sub>1A</sub> receptors, which does not contain introns or splice variants, the effects of 5-HT<sub>1A</sub> receptor activation in different brain regions can be quite diverse, and even divergent, because of coupling of the receptors to distinct signal transduction responses. Thus, although the amino acid sequence of the 5-HT<sub>1A</sub> receptor itself is unchanged, the latter’s interaction with intracellular signaling proteins varies depending on the brain region. Thus, if agonists preferentially elicit coupling of the receptors to particular G-proteins or second messengers, this would be anticipated to result in preferential activation of distinct brain regions.</div><div class="NLM_p">The recent discovery and characterization of 5-HT<sub>1A</sub> receptor-biased agonists offer a way forward in this respect. F15599 (<b>1</b>), also known as NLX-101, is a highly-selective 5-HT<sub>1A</sub> receptor agonist with a unique profile, preferentially activating ERK phosphorylation versus other signaling pathways in vitro,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> as well as ex vivo in frontal cortex.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Notably, <b>1</b> elicited strong antidepressant-like activity in the rat forced swim test (FST), completely abolishing immobility, even upon acute administration—as is the case with ketamine, suggesting that the preferential activation of cortical ERK phosphorylation via cortical 5-HT<sub>1A</sub> receptors translates to enhanced antidepressant potential.<a onclick="showRef(event, 'ref29 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref29 ref30 ref31">(29−31)</a></div><div class="NLM_p">However, <b>1</b> has so far been the only compound displaying such a promising “biased agonist” profile of activity, and some close chemical analogues (notably F13714 or befiradol) display quite different signal transduction properties in vitro and in vivo.<a onclick="showRef(event, 'ref31 ref32 ref33 ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref31 ref32 ref33 ref34 ref35">(31−35)</a> In addition, the latter compounds do not exhibit preferential activation of cortical 5-HT<sub>1A</sub> receptors which, as discussed above, is important for improved antidepressant activity.<a onclick="showRef(event, 'ref29 ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref29 ref36 ref37">(29,36,37)</a> The structure–activity relationships of these compounds with respect to preferential ERK phosphorylation have not been established, and it therefore remains to be determined whether increased “bias” for ERK phosphorylation can elicit even superior antidepressant profiles.</div><div class="NLM_p last">On the basis of these considerations, the present work used <b>1</b> as a model structure to explore the synthesis and characterization of a series of novel 5-HT<sub>1A</sub> receptor-targeted antidepressants. To establish their comprehensive functional selectivity profiles, the whole novel series was tested in four signal transduction assays (ERK1/2 phosphorylation, cAMP inhibition, Ca<sup>2+</sup> mobilization, and β-arrestin recruitment), for the first time in the case of the 5-HT<sub>1A</sub> receptor agonists. Specifically, we sought to identify the structural motifs that confer a “biased” ERK-preferential activity of the compounds as well as to determine whether they possess favorable drug-like properties that are compatible with successful pharmaceutical development. Finally, to confirm the therapeutic potential of the series, we tested a lead compound in a recognized in vivo model of antidepressant-like activity.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18300" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18300" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Design, Synthesis, and Biological Evaluation of 1-(1-Benzoylpiperidin-4-yl)methanamine Derivatives</h3><div class="NLM_p">As a framework for the design of novel compounds, we used a docking-derived ligand–receptor complex of <b>1</b> in the homology model of the 5-HT<sub>1A</sub> receptor<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). The analysis of the binding mode revealed crucial interactions, commonly found for a vast majority of monoaminergic ligands, namely, (i) charge-reinforced hydrogen bond between the protonated central nitrogen atom and the carboxyl group of the aspartic acid Asp3.32 as well as (ii) CH−π stacking between the pyrimidine ring and phenylalanine Phe6.52. The additional interactions included (iii) a hydrogen bond between the oxygen atom of the amide moiety and the NH group from the main chain of the isoleucine Ile189 in the second extracellular loop, (iv) π–π stacking between the benzoyl moiety and phenylalanine Phe3.28, and (v) cation−π interaction between the protonated central nitrogen atom and phenylalanine Phe6.51.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/medium/jm-2019-00062d_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Predicted binding mode of compound <b>1</b> in the site of the serotonin 5-HT<sub>1A</sub> receptor. Amino acid residues engaged in ligand binding (within 4 Å from the ligand atoms) are displayed as sticks, whereas crucial residues, for example, forming H-bonds (dotted yellow lines), π–π/CH−π stacking (dotted cyan lines), and cation−π interactions (dotted green line), are represented as thick sticks. ECL2 residues were hidden for clarity; ECL—extracellular loop. The homology model of the 5-HT<sub>1A</sub> receptor was prepared based on the crystal structure of the 5-HT<sub>1B</sub> receptor (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4IAR">4IAR</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00062&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Although the observed interactions seem to be optimal for binding to the 5-HT<sub>1A</sub> receptor, we noticed that the pyrimidine ring does not fully penetrate the hydrophobic binding pocket of the receptor. At this point, it is worth noting that this region of the binding site of GPCRs accommodates moieties that are crucial for eliciting particular functional activity.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Thus, we hypothesized that diversification of the fragment of the molecule that binds within the pocket may yield compounds with various functional profiles. In our attempt to develop novel ligands that would more effectively fill this hydrophobic binding pocket, we initially focused on extension of the one-unit methylene linker to three-unit linker between the central amine function and pyrimidine ring of <b>1</b>. We introduced a propylene linker and a number of analogues with one of the methylene units replaced with heteroatoms such as nitrogen, sulfur, and oxygen (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/medium/jm-2019-00062d_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. General structure of the new series of selective 5-HT<sub>1A</sub> receptor agonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00062&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We have validated our hypothesis in the docking studies where we compared the binding modes of <b>1</b> and newly designed ligands, exemplified by compounds <b>16</b> and <b>17</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). As expected, the extension of the linker shifted the aromatic ring toward Phe6.52, markedly shortening the CH−π bond (3.27 Å for <b>1</b> vs 2.85 and 2.96 Å for compounds <b>16</b> and <b>17</b>, respectively) and optimizing the geometry of the interactions. The derivatives with three-unit linkers more effectively filled the hydrophobic binding pocket near the transmembrane helix 6 (TMH6), which accounted for better fitting to the receptor and promoted the reduction of binding energy. Encouraged by the results of docking studies, we moved to the synthesis and biological evaluation of the compounds.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/medium/jm-2019-00062d_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Predicted binding mode of compound <b>1</b> (green) together with <b>16</b> (pink) and <b>17</b> (white) in the site of the serotonin 5-HT<sub>1A</sub> receptor. Amino acid residues engaged in ligand binding (within 4 Å from the ligand atoms) are displayed as sticks, whereas crucial residues, for example, forming H-bonds (dotted yellow lines), π–π/CH−π stacking (dotted cyan lines), and cation−π interactions (dotted green line), are represented as thick sticks. ECL2 residues were hidden for clarity; ECL—extracellular loop. The homology model of the 5-HT<sub>1A</sub> receptor prepared based on the crystal structure of the 5-HT<sub>1B</sub> receptor (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4IAR">4IAR</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00062&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The synthetic pathway to the target compounds was based on the one previously developed and reported,<a onclick="showRef(event, 'ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref40 ref41">(40,41)</a> as presented in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>.</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/medium/jm-2019-00062d_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of 1-(1-Benzoyl-4-fluoropiperidin-4-yl)methanamine Derivatives<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00062&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Et<sub>3</sub>N, DCM, 0 °C then rt, 12 h, yield: 47–60%; (b) chloroacetonitrile, 30% NaOH, TBABr, DCM, rt, 3 h, yield: 80–87%; (c) HF/pyridine, DCM, −10 °C, 30 min then rt 24–36 h, yield: 54–68%; and (d) DABCO, NaCNBH<sub>3</sub>, FeSO<sub>4</sub> × 7H<sub>2</sub>O, molecular sieves, MeOH, rt, 36–72 h, yield: 23–66%.</p></p></figure><div class="NLM_p">In the first step, the commercially available 4-piperidone was acylated by the appropriate benzoyl chloride derivatives <b>2</b> or <b>3</b> in the presence of triethylamine. Then, a Darzens reaction between the obtained benzoylpiperidin-4-one derivatives <b>4</b> or <b>5</b> and chloroacetonitrile, using tetrabutylammonium bromide as a phase-transfer catalyst,<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> gave the corresponding cyanoepoxides <b>6</b> or <b>7</b>. The epoxides <b>6</b> or <b>7</b> underwent a regioselective ring-opening reaction with poly(hydrogen fluoride)pyridine<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43,44)</a> to obtain the corresponding cyanohydrins <b>8</b> or <b>9</b>. The final compounds <b>9–27</b> were prepared via reductive amination using cyanohydrins <b>8</b> or <b>9</b> and the appropriate amines in the presence of a base and sodium cyanoborohydride as a reducing agent and with addition of iron sulfate heptahydrate.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a></div><div class="NLM_p">The affinity of the compounds for the 5-HT<sub>1A</sub> receptor was determined in the radioligand binding assay (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). All but one (compound <b>11</b>) displayed affinities higher than that of <b>1</b>, with p<i>K</i><sub>i</sub> values ranging from 8.73 to 10.83 versus 8.66 for <b>1</b>. The affinity was most significantly increased for the compounds with the oxyethylene linker (<b>16–19</b>), which showed subnanomolar affinities (p<i>K</i><sub>i</sub> = 10.19–10.83). These results unequivocally confirmed our hypothesis derived from molecular modeling and allowed us to choose the oxyethylene linker for further studies. The superiority of the oxyethylene linker over other linkers tested may be due to the fact that the oxygen atom is the best bioisostere of the crucial nitrogen atom embedded in the aromatic moiety of <b>1</b> (electronegative, H-bond accepting). At this stage, we tested the para position of the benzoyl fragment, by the replacement of fluorine with a chlorine atom (compounds <b>18</b> and <b>19</b>). This modification increased the binding affinity (<b>18</b> vs <b>16</b> and <b>19</b> vs <b>17</b>), but a comparison of LELP scores showed that it had resulted from an increase in lipophilicity and most probably nonspecific interactions. Therefore, we used the 3-chloro-4-fluorobenzoil core in further studies.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. 5-HT<sub>1A</sub> Receptor Affinity and Developability Parameters of Compounds <b>10–19</b> and the References</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/medium/jm-2019-00062d_0012.gif" alt="" id="GRAPHIC-d7e772-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/medium/jm-2019-00062d_0013.gif" alt="" id="gr12" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">All binding affinity values are represented as p<i>K</i><sub>i</sub>, that is, −log <i>K</i><sub>i</sub> and expressed as means ± SEM from at least three experiments performed in duplicates.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Radioligand binding was performed using CHO-K1 cells.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Radioligand binding was performed using rat cortex.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">The affinity values were determined using [<sup>3</sup>H]8-OH-DPAT.</p></div><div class="footnote" id="t1fn5"><sup><sup>e</sup></sup><p class="last">The affinity values were determined using [<sup>3</sup>H]-prazosin, phentolamine p<i>K</i><sub>i</sub> = 7.95.</p></div><div class="footnote" id="t1fn6"><sup><sup>f</sup></sup><p class="last">The affinity values were determined using [<sup>3</sup>H]-methylspiperone, haloperidol p<i>K</i><sub>i</sub> = 8.85.</p></div><div class="footnote" id="t1fn7"><sup><sup>g</sup></sup><p class="last">Fraction of sp<sup>3</sup> carbon atoms.</p></div><div class="footnote" id="t1fn8"><sup><sup>h</sup></sup><p class="last">Ligand efficiency-dependent lipophilicity score.</p></div><div class="footnote" id="t1fn9"><sup><sup>i</sup></sup><p class="last">Central nervous system multiparameter optimization score.</p></div><div class="footnote" id="t1fn10"><sup><sup>j</sup></sup><p class="last">NT—not tested.</p></div></div><div></div></div><div class="NLM_p">Next, we explored the optimal position of a nitrogen atom in the aryloxy moiety (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). We observed a gradual decrease in the binding affinity to a p<i>K</i><sub>i</sub> of 8.82 for the pyridin-3-yloxy derivative (<b>20</b>) and an unacceptably low binding value (p<i>K</i><sub>i</sub> 6.41) for the pyridin-4-yloxy derivative (<b>21</b>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. 5-HT<sub>1A</sub> Receptor Affinity and Developability Parameters of Compound’s <b>17</b> Analogues <b>20–27</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/medium/jm-2019-00062d_0014.gif" alt="" id="GRAPHIC-d7e894-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/medium/jm-2019-00062d_0015.gif" alt="" id="gr13" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">All the binding affinity values were represented as p<i>K</i><sub>i</sub>, that is, −log <i>K</i><sub>i</sub> and expressed as means ± SEM from at least three experiments performed in duplicates.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Radioligand binding was performed using CHO-K1 cells.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">Radioligand binding was performed using rat cortex.</p></div><div class="footnote" id="t2fn4"><sup><sup>d</sup></sup><p class="last">The affinity values were determined using [<sup>3</sup>H]8-OH-DPAT.</p></div><div class="footnote" id="t2fn5"><sup><sup>e</sup></sup><p class="last">The affinity values were determined using [<sup>3</sup>H]-prazosin, phentolamine p<i>K</i><sub>i</sub> = 7.95.</p></div><div class="footnote" id="t2fn6"><sup><sup>f</sup></sup><p class="last">The affinity values were determined using [<sup>3</sup>H]-methylspiperone, haloperidol p<i>K</i><sub>i</sub> = 8.85.</p></div><div class="footnote" id="t2fn7"><sup><sup>g</sup></sup><p class="last">Fraction of sp<sup>3</sup> carbon atoms.</p></div><div class="footnote" id="t2fn8"><sup><sup>h</sup></sup><p class="last">Ligand efficiency-dependent lipophilicity score.</p></div><div class="footnote" id="t2fn9"><sup><sup>i</sup></sup><p class="last">Central nervous system multiparameter optimization score.</p></div></div><div></div></div><div class="NLM_p last">Subsequently, we explored heterocycles with two nitrogen atoms (<b>22–25</b>). Only the 2-pyrazine derivative, compound <b>22</b> with p<i>K</i><sub>i</sub> 9.28 kept the desired level of affinity (p<i>K</i><sub>i</sub> > 8). Interestingly, <b>22</b> can be considered a hybrid of 2- and 3-pyridine, and its p<i>K</i><sub>i</sub> value is intermediate between that of <b>17</b> (10.19) and that of <b>20</b> (8.82). We have also prepared compound <b>26</b> that is a direct analogue of befiradol and compound <b>27</b>—an analogue of <b>1</b>—to investigate the effect of the methyl substituent at the 5 position of the aryl ring. Compound <b>26</b> displayed significantly decreased affinity compared to compound <b>17</b> (p<i>K</i><sub>i</sub> 8.42 vs 10.19, respectively) while compound <b>27</b> showed a modest increase in affinity relative to its unsubstituted analogue <b>23</b> (p<i>K</i><sub>i</sub> 7.86 vs 7.45, respectively). These contrasting results indicate that the substitution pattern at the aromatic ring will require further investigation.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Developability Analysis—In Silico-Supported Predictions</h3><div class="NLM_p">To provide an early assessment of the developability of the designed series, we analyzed all the compounds using in silico-supported measures of drug likeness. All the compounds fulfilled Lipinski’s rule of five (Ro5) for good oral bioavailability and displayed exceptionally high central nervous system multiparameter optimization (CNS MPO) values with a median value of 5.10.<a onclick="showRef(event, 'ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref45 ref46">(45,46)</a></div><div class="NLM_p">Another important parameter that is especially important in the context of compounds’ solubility is the fraction of sp<sup>3</sup> atoms (Fsp<sup>3</sup>). A majority of the compounds tested, mostly those with two nitrogen atoms in the aryl ring, showed very high and favorable Fsp<sup>3</sup> values of 0.42–0.45, while all the others were characterized by acceptable values of 0.38–0.41.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a></div><div class="NLM_p">Next, we used ligand efficiency-dependent lipophilicity (LELP), a function that combines physicochemical properties with compounds’ activity to predict drug likeness. The median LELP value for all the compounds was 6.75, which is the desirable value for drug candidates.<a onclick="showRef(event, 'ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref48 ref49">(48,49)</a> Six compounds displayed excellent values ≤5.9, reaching an exceptionally favorable value for compound <b>22</b> (LELP = 3.4) (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>).</div><div class="NLM_p">Finally, we have used SwissADME web tool<a onclick="showRef(event, 'ref50 ref51 ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref50 ref51 ref52 ref53">(50−53)</a> to identify pan-assay interference compounds (PAINS) as well as toxicophores within the investigated group of compounds. The analysis showed no alerts for any of the tested compounds.</div><div class="NLM_p last">Summing up, the vast majority of the designed compounds were characterized by favorable values of physicochemical properties and multivariate scoring functions, as well as good results of safety filters, which suggest a favorable developability potential of the designed series.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Developability Analysis—In Vitro Assays</h3><div class="NLM_p">Next, to confirm the favorable developability profile predicted in silico, compound <b>17</b> was selected as a lead structure to be examined in a series of additional in vitro experiments. To this end, the SafetyScreen44 Panel (plus additional antitargets), the bioavailability panel, and CYP3A4, CYP2D6, and P-glycoprotein (P-gp) inhibition assays were performed at Eurofins Pharma Discovery Services. The SafetyScreen44 Panel is one of the most commonly used set of assays for in vitro pharmacological profiling of target selectivity.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> The bioavailability panel consists of solubility, permeability, protein binding, and metabolic stability assays, which are used for the prediction of ADME properties, a very important issue in the drug development process.</div><div class="NLM_p">Data from the safety pharmacology profiling revealed excellent overall selectivity of the investigated lead structure. Compound <b>17</b>, tested at a concentration of 10 μM, showed substantial binding inhibition (higher than 50%) for only 3 among 52 off-targets, namely, adrenergic α<sub>1A</sub> and α<sub>2A</sub> and dopaminergic D<sub>2S</sub> receptors (91–99%) (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Compound <b>17</b> was subsequently tested at a concentration of 1 μM for these antitargets and exhibited much lower binding inhibition at D<sub>2</sub> (9.5%) and α<sub>2A</sub> (29.9%) receptors but maintained a relatively high value for the α<sub>1A</sub> receptor (87.6%). The precise affinity for the latter was therefore determined and the p<i>K</i><sub>i</sub> was found to be 6.78, an affinity which is more than 1000-fold lower than the affinity of compound <b>17</b> for the 5-HT<sub>1A</sub> receptor (p<i>K</i><sub>i</sub> = 10.19; see <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). In addition to testing the binding affinity of <b>17</b> for the hERG channel in the SafetyScreen44, we also tested it using an automated patch-clamp method. Patch clamp methods are considered to provide a more reliable assessment of hERG interaction, even at an early stage of drug discovery process.<a onclick="showRef(event, 'ref55 ref56 ref57'); return false;" href="javascript:void(0);" class="ref ref55 ref56 ref57">(55−57)</a> This study was performed at three concentrations (0.1, 1.0, and 10.0 μM) showing only 0.1, 10.5, and 46.5% inhibition of tail current, respectively. This indicates that <b>17</b> has a low propensity for hERG channel blockade and suggests that the investigated series has a low risk with respect to hERG-related cardiac safety.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. SafetyScreen44 Panel and Additional Antitarget Results for Compound <b>17</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">target</th><th class="colsep0 rowsep0" align="center">assay</th><th class="colsep0 rowsep0" align="center">% inhibition of control specific binding at 10 μM/1 μM<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">target</th><th class="colsep0 rowsep0" align="center">assay</th><th class="colsep0 rowsep0" align="center">% inhibition of control specific binding at 10 μM/1 μM<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>GPCR</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>GPCR</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">adenosine</td><td class="colsep0 rowsep0" align="left">A<sub>2A</sub></td><td class="colsep0 rowsep0" align="left">11.8</td><td class="colsep0 rowsep0" align="left">serotonin</td><td class="colsep0 rowsep0" align="left">5-HT<sub>1B</sub></td><td class="colsep0 rowsep0" align="left">–9.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">adrenergic</td><td class="colsep0 rowsep0" align="left">α<sub>1A</sub></td><td class="colsep0 rowsep0" align="left">99.7/87.6</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">5-HT<sub>1D</sub></td><td class="colsep0 rowsep0" align="left">NT/25.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">α<sub>1B</sub></td><td class="colsep0 rowsep0" align="left">NT/32.2</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">5-HT<sub>2A</sub></td><td class="colsep0 rowsep0" align="left">9.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">α<sub>2A</sub></td><td class="colsep0 rowsep0" align="left">94.3/29.9</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">5-HT<sub>2B</sub></td><td class="colsep0 rowsep0" align="left">39.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">β<sub>1</sub></td><td class="colsep0 rowsep0" align="left">2.2</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">5-HT<sub>2C</sub></td><td class="colsep0 rowsep0" align="left">NT/–26.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">β<sub>2</sub></td><td class="colsep0 rowsep0" align="left">3.8</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">5-HT<sub>6</sub></td><td class="colsep0 rowsep0" align="left">NT/12.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cannabinoid</td><td class="colsep0 rowsep0" align="left">CB<sub>1</sub></td><td class="colsep0 rowsep0" align="left">0.4</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">5-HT<sub>7</sub></td><td class="colsep0 rowsep0" align="left">NT/13.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">CB<sub>2</sub></td><td class="colsep0 rowsep0" align="left">–3.1*</td><td class="colsep0 rowsep0" align="left"><b>TRANSPORTERS</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cholecystokinin</td><td class="colsep0 rowsep0" align="left">CCK<sub>1</sub> (CCK<sub>A</sub>)</td><td class="colsep0 rowsep0" align="left">–30.3</td><td class="colsep0 rowsep0" align="left">dopamine</td><td class="colsep0 rowsep0" align="left">DAT</td><td class="colsep0 rowsep0" align="left">20.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dopamine</td><td class="colsep0 rowsep0" align="left">D<sub>1</sub></td><td class="colsep0 rowsep0" align="left">38.2</td><td class="colsep0 rowsep0" align="left">norepinephrine</td><td class="colsep0 rowsep0" align="left">NET</td><td class="colsep0 rowsep0" align="left">–2.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">D<sub>2S</sub></td><td class="colsep0 rowsep0" align="left">91.3/9.5</td><td class="colsep0 rowsep0" align="left">serotonin</td><td class="colsep0 rowsep0" align="left">SERT</td><td class="colsep0 rowsep0" align="left">0.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">D<sub>3</sub></td><td class="colsep0 rowsep0" align="left">NT/39.1</td><td class="colsep0 rowsep0" align="left"><b>ION CHANNELS</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">endothelin</td><td class="colsep0 rowsep0" align="left">ET<sub>A</sub></td><td class="colsep0 rowsep0" align="left">–13.8</td><td class="colsep0 rowsep0" align="left">gaba channel</td><td class="colsep0 rowsep0" align="left">BZD (central)</td><td class="colsep0 rowsep0" align="left">–11.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">histamine</td><td class="colsep0 rowsep0" align="left">H<sub>1</sub></td><td class="colsep0 rowsep0" align="left">–0.5</td><td class="colsep0 rowsep0" align="left">glutamate channel</td><td class="colsep0 rowsep0" align="left">NMDA</td><td class="colsep0 rowsep0" align="left">–1.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">H<sub>2</sub></td><td class="colsep0 rowsep0" align="left">–15.1</td><td class="colsep0 rowsep0" align="left">nicotinic channel</td><td class="colsep0 rowsep0" align="left">N neuronal α4β2</td><td class="colsep0 rowsep0" align="left">–5.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">H<sub>3</sub></td><td class="colsep0 rowsep0" align="left">NT/–10.9</td><td class="colsep0 rowsep0" align="left">serotonin channel</td><td class="colsep0 rowsep0" align="left">5-HT<sub>3</sub></td><td class="colsep0 rowsep0" align="left">–12.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">H<sub>4</sub></td><td class="colsep0 rowsep0" align="left">NT/–10.9</td><td class="colsep0 rowsep0" align="left">Ca<sup>2+</sup> channel</td><td class="colsep0 rowsep0" align="left">Ca<sup>2+</sup> channel (L) (dihydropyridine site)</td><td class="colsep0 rowsep0" align="left">18.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">muscarinic</td><td class="colsep0 rowsep0" align="left">M<sub>1</sub></td><td class="colsep0 rowsep0" align="left">12.9</td><td class="colsep0 rowsep0" align="left">K<sup>+</sup> channels</td><td class="colsep0 rowsep0" align="left">hERG ([<sup>3</sup>H]Dofetilide)</td><td class="colsep0 rowsep0" align="left">16.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">M<sub>2</sub></td><td class="colsep0 rowsep0" align="left">6.3</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">K<sub>v</sub> channel</td><td class="colsep0 rowsep0" align="left">3.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">M<sub>3</sub></td><td class="colsep0 rowsep0" align="left">9.7</td><td class="colsep0 rowsep0" align="left">Na<sup>+</sup> channel</td><td class="colsep0 rowsep0" align="left">Na<sup>+</sup> channel (site 2)</td><td class="colsep0 rowsep0" align="left">48.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">M<sub>4</sub></td><td class="colsep0 rowsep0" align="left">NT/8.8</td><td class="colsep0 rowsep0" align="left"><b>KINASES</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">opioid & opioid like</td><td class="colsep0 rowsep0" align="left">δ<sub>2</sub> (DOP)</td><td class="colsep0 rowsep0" align="left">7.2</td><td class="colsep0 rowsep0" align="left">CTK</td><td class="colsep0 rowsep0" align="left">Lck kinase</td><td class="colsep0 rowsep0" align="left">18.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">κ (KOP)</td><td class="colsep0 rowsep0" align="left">34.6</td><td class="colsep0 rowsep0" align="left"><b>OTHER NON-KINASE ENZYMES</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">μ (MOP)</td><td class="colsep0 rowsep0" align="left">42.9</td><td class="colsep0 rowsep0" align="left">AA metabolism</td><td class="colsep0 rowsep0" align="left">COX<sub><b>1</b></sub></td><td class="colsep0 rowsep0" align="left">11.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">vasopresin</td><td class="colsep0 rowsep0" align="left"><b>V</b><sub><b>1a</b></sub></td><td class="colsep0 rowsep0" align="left">7.0</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">COX<sub>2</sub></td><td class="colsep0 rowsep0" align="left">–9.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">monoamine & neurotransmitter</td><td class="colsep0 rowsep0" align="left">AChE</td><td class="colsep0 rowsep0" align="left">–2.9</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>NUCLEAR RECEPTORS</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">MAO-A</td><td class="colsep0 rowsep0" align="left">–3.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">steroid nuclear receptors</td><td class="colsep0 rowsep0" align="left">AR</td><td class="colsep0 rowsep0" align="left">–20.5</td><td class="colsep0 rowsep0" align="left">phosphodiesterases</td><td class="colsep0 rowsep0" align="left">PDE3A</td><td class="colsep0 rowsep0" align="left">–3.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">GR</td><td class="colsep0 rowsep0" align="left">–5.1</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">PDE4D2</td><td class="colsep0 rowsep0" align="left">–10.7</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Assays, in which % inhibition of control specific binding was over 50% in 10 μM, were repeated at 1 μM concentration. For some targets, only the test at 1 μM was performed—marked as NT/value. *Low to moderate negative values (<50%) have no real meaning and are attributable to variability of the signal around the control level.</p></div></div></div><div class="NLM_p">In the bioavailability panel, compound <b>17</b> exhibited desirable druglike ADME attributes (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). It was characterized by high aqueous solubility in phosphate-buffered saline (PBS 7.4), simulated intestinal fluid (SIF), and simulated gastric fluid (SGF) (192.2, 192.2, and 200 μM, respectively) as well as excellent permeability on Caco-2 cells (<i>P</i><sub>app</sub> > 10 × 10<sup>–6</sup> cm/s). Moreover, the final efflux ratio value (ER = basolateral to apical [BA]/apical to basolateral [AB] permeability) was lower than 2.5 (ER = 0.86), which means that compound <b>17</b> is not a P-gp substrate.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Those values are comparable with the reference drug propranolol, which belongs to the class 1 of biopharmaceutics classification system—high permeability/high solubility—suggesting good oral absorption and reliable in vitro–in vivo correlation.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. In Vitro Bioavailability Panel and CYP3A4, CYP2D6, and P-gp Inhibition Assay Results for Compound <b>17</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" colspan="2" align="center">assay</th><th class="rowsep1 colsep0" align="center">compound <b>17</b> (10 μM<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a>)</th><th class="rowsep1 colsep0" align="center">reference</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">solubility<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a></td><td class="colsep0 rowsep0" align="left">PBS<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">192.2 μM</td><td class="colsep0 rowsep0" align="left">180.8 μM (metoprolol)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">SGF<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">200 μM</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">SIF<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">192.2 μM</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">permeability<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a></td><td class="colsep0 rowsep0" align="left">A–B<a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">25.90 [10<sup>–6</sup> cm/s]</td><td class="colsep0 rowsep0" align="left">23.70 [10<sup>–6</sup> cm/s] (propranolol)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">B–A<a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">22.45 [10<sup>–6</sup> cm/s]</td><td class="colsep0 rowsep0" align="left">27.40 [10<sup>–6</sup> cm/s] (propranolol)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">metabolic stability<a class="ref internalNav" href="#t4fn6" aria-label="f">f</a><a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a></td><td class="colsep0 rowsep0" align="left">intrinsic clearance (CL<sub>int</sub>)</td><td class="colsep0 rowsep0" align="left"><115 [μL/min/mg]</td><td class="colsep0 rowsep0" align="left"><115 [μL/min/mg] (propranolol)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">half-Life (<i>T</i><sub>1/2</sub>)</td><td class="colsep0 rowsep0" align="left">>60 [min]</td><td class="colsep0 rowsep0" align="left">>60 [min] (propranolol)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">protein binding<a class="ref internalNav" href="#t4fn7" aria-label="g">g</a><a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">93.2%</td><td class="colsep0 rowsep0" align="left">99% (warfarin)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">P-gp inhibition<a class="ref internalNav" href="#t4fn8" aria-label="h">h</a><a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">6.5%</td><td class="colsep0 rowsep0" align="left">15 μM [IC<sub>50</sub>] (verapamil)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CYP3A4 inhibition<a class="ref internalNav" href="#t4fn9" aria-label="i">i</a><a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">23.2%</td><td class="colsep0 rowsep0" align="left">0.24 μM [IC<sub>50</sub>] (ketoconazole)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CYP2D6 inhibition<a class="ref internalNav" href="#t4fn9" aria-label="i">i</a><a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">15.9%</td><td class="colsep0 rowsep0" align="left">0.0081 μM [IC<sub>50</sub>] (quinidine)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Metabolic stability study was performed at the concentration of 0.1 μM; solubility study was performed in a 200 μM concentration.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Aqueous solubility at buffer pH 7.4.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">Aqueous solubility in SGF.</p></div><div class="footnote" id="t4fn4"><sup><sup>d</sup></sup><p class="last">Aqueous solubility at simulated intestinal fluid.</p></div><div class="footnote" id="t4fn5"><sup><sup>e</sup></sup><p class="last">Caco-2, pH 6.5/7.4.</p></div><div class="footnote" id="t4fn6"><sup><sup>f</sup></sup><p class="last">Liver microsomes–human.</p></div><div class="footnote" id="t4fn7"><sup><sup>g</sup></sup><p class="last">Plasma human.</p></div><div class="footnote" id="t4fn8"><sup><sup>h</sup></sup><p class="last">MDR1-MDCKII cell line.</p></div><div class="footnote" id="t4fn9"><sup><sup>i</sup></sup><p class="last">Human recombinant.</p></div></div></div><div class="NLM_p last">Compound <b>17</b> also exhibited high microsomal stability, with intrinsic clearance (CL<sub>int</sub>) lower than 115 [μL/min/mg] and a half-life greater than 60 min. Noteworthy, it is the best possible result in the given experimental setting, suggesting high metabolic stability and therefore a low risk of significant first pass effect. Overall, the abovementioned results suggest favorable oral bioavailability of compound <b>17</b> and are in line with the favorable CNS MPO (5.42), Fsp<sup>3</sup> (0.40), and LELP (5.5) values predicted in silico for compound <b>17</b>. Furthermore, compound <b>17</b> displayed no P-gp inhibition (6.5% of inhibition at 10 μM) as well as negligible inhibition of CYP3A4 and CYP2D6 (23.2 and 15.9% at 10 μM, respectively). Together with the moderate plasma protein binding (93.2%), this suggests a relatively low drug–drug interaction potential. Taken together, these data provide compelling evidence supporting desirable druglike properties of compound <b>17</b>, suggesting its good developability potential and promising similarly favorable properties for the whole series.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Selectivity Versus Key Antitargets</h3><div class="NLM_p">As the goal of the present study was to obtain selective 5-HT<sub>1A</sub> receptor agonists, it was essential to verify the selectivity of the novel ligands. To this end, the affinity for the most important antitargets was determined for all of the obtained compounds. The determination of the affinities for α<sub>1</sub> and D<sub>2</sub> receptors was prioritized because activities at such receptors may interfere in vivo with the activity elicited by 5-HT<sub>1A</sub> receptor activation.<a onclick="showRef(event, 'ref65 ref66 ref67'); return false;" href="javascript:void(0);" class="ref ref65 ref66 ref67">(65−67)</a> Moreover, the pertinence of testing those targets was also highlighted by the results of SafetyScreen44 for compound <b>17</b>, which showed relatively higher affinity for α<sub>1</sub> and D<sub>2</sub> receptors than for other off-targets. Concerning α<sub>1</sub> receptor affinity, the majority of the compounds showed substantial selectivity for the 5-HT<sub>1A</sub> receptor (over 1000–10 000-fold). Selectivity dropped lower than 100-fold only for compounds <b>11</b>, <b>13</b>, and <b>15</b>, which are pyridine analogues with the nonoxygen linker. In the case of the D<sub>2</sub> receptor, none of the compounds had p<i>K</i><sub>i</sub> over 6 (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). Additionally, we examined the binding affinity of each compound for serotonin 5-HT<sub>2A</sub>, muscarinic M<sub>1</sub>, and histamine H<sub>1</sub> receptors (see <a href="/doi/suppl/10.1021/acs.jmedchem.9b00062/suppl_file/jm9b00062_si_001.pdf" class="ext-link">Supporting Information</a> Table S3). None of the tested compounds exceed 50% of control specific binding at a concentration of 1 μM in these assays.</div><div class="NLM_p last">Considering the above and bearing in mind that the selected lead structure <b>17</b> showed substantial selectivity also versus the other 49 off-targets (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>), it may be concluded that the designed series is characterized by a high selectivity for 5-HT<sub>1A</sub> receptors.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Structure–Functional Activity Relationships</h3><div class="NLM_p">To investigate the functional profiles of the presented series, we evaluated the functional activity of 12 selected compounds (<b>10–17</b>, <b>19</b>, <b>20</b>, <b>22</b>, and <b>27</b>) in the following pathways engaged in 5-HT<sub>1A</sub> receptor signal transduction: ERK1/2 phosphorylation (pERK1/2), adenylyl cyclase inhibition (cAMP), β-arrestin recruitment (β-arrestin), and calcium mobilization (Ca<sup>2+</sup>) (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/medium/jm-2019-00062d_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Signaling pathways measured after activation of the 5-HT<sub>1A</sub> receptor; adapted from Chilmonczyk et al.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> and modified based on Rojas & Fiedler.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00062&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To our knowledge, the present study is the first in which such a large number of 5-HT<sub>1A</sub> receptor ligands was tested in such a number of intracellular signaling tests. This is also only the second study in which 5-HT<sub>1A</sub> receptor ligands were examined for β-arrestin recruitment.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> Here, we assumed that <i>E</i><sub>max</sub> values higher than 80% relative to the maximal effect of serotonin are characteristic of a full agonist, <i>E</i><sub>max</sub> values between 79 and 21% indicate a partial agonist, and <i>E</i><sub>max</sub> values 20% or less are indicative of an antagonist. The experiments were carried out using cell lines expressing the recombinant human 5-HT<sub>1A</sub> receptor. Although such cell lines may differ from neuronal systems, for example, as concerns their signal transduction machinery or receptor expression levels (336 fmol/mg for CHO-K1 cells and 78 fmol/mg for U2OS cells), they provide an experimentally robust and widely accepted means of comparing drug activities and conducting SAR studies. In the case of the investigated series, the aryloxyethanamine derivatives (<b>16</b>, <b>17</b>, and <b>19</b>) were the ones that showed the highest potency in functional activity assays (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>), as discussed in greater detail below. Dose-response curves for functional activity of all the compounds are presented in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b00062/suppl_file/jm9b00062_si_001.pdf" class="ext-link">Supporting Information</a>.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Functional Activity of Compounds <b>10–17</b>, <b>19</b>, <b>20</b>, <b>22</b>, <b>27</b> and References at 5-HT<sub>1A</sub> Receptors</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/medium/jm-2019-00062d_0016.gif" alt="" id="GRAPHIC-d7e2413-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/medium/jm-2019-00062d_0017.gif" alt="" id="gr14" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">All the functional activity values were expressed as means from at least three experiments performed in duplicates. For the sake of clarity, the SEM values were omitted in this table and presented in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b00062/suppl_file/jm9b00062_si_001.pdf" class="ext-link">Supporting Information</a>—Table 3.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">The functional assay was performed using CHO-K1 cells.</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">The functional assay was performed using U2OS cells (Tango LiveBLAzer assay kit).</p></div><div class="footnote" id="t5fn4"><sup><sup>d</sup></sup><p class="last">NT—not tested.</p></div></div><div></div></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Functional Activity of Compounds <b>10</b>−<b>17</b> and <b>19</b></h3><div id="sec2_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> ERK1/2 Phosphorylation</h4><div class="NLM_p">Derivatives containing S, NH, or CH<sub>2</sub> in the linker were over 1 order of magnitude weaker than their aryloxyethanamine derivatives, with the compound <b>14</b> (phenylsulfanylethanamine derivative) exhibiting the lowest intrinsic activity in this pathway (pEC<sub>50</sub> = 6.77). Except for compounds <b>14</b> and <b>15</b>, no potency differentiation between phenyl derivatives and their pyridine counterparts, as well as between the 3-chloro-4-fluorobenzoyl derivative (<b>17</b>) and its 3,4-dichlorobenzoyl analogue (<b>19</b>) was observed. The potencies of aryloxyethanamines were higher than those of all references, including <b>1</b>.</div><div class="NLM_p last">In contrast to buspirone, the agonist efficacy (<i>E</i><sub>max</sub>) of all the tested compounds was high, that is, between 77 and 95%. The highest agonist efficacy, comparable with 8-OH-DPAT, was observed for compounds <b>11</b> and <b>16</b>; however, none of the compounds reached the 100% efficacy level of <b>1</b>.</div></div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Inhibition of cAMP Production (cAMP)</h3><div class="NLM_p">Among the most potent derivatives with the oxyethylene linker, no differences between the phenyl derivative and the pyridine analogue were observed. By contrast, in the case of the aminoethylene and sulfanylethylene linker, the pyridine counterparts showed higher cAMP potency than their phenyl derivatives (<b>15</b> and <b>13</b> vs <b>14</b> and <b>12</b>). Potencies of the most active compounds (<b>16</b>, <b>17</b>, and <b>19</b>) were higher than those of reference compounds.</div><div class="NLM_p last">In the case of agonist efficacy, most of the compounds behaved as partial agonists; however, their efficacy was higher (71–79%) than for the reference partial agonists, buspirone and 8-OH-DPAT (49 and 63%, respectively). Compounds <b>10</b>, <b>13</b>, <b>16</b>, and <b>17</b> were full agonists with efficacy (86–91%) comparable to <b>1</b>. There were no marked differences between the pyridine and phenyl derivatives, except for the analogues with the propylene linker, where the phenyl derivative <b>10</b> was a full agonist (91%) while its pyridine counterpart <b>11</b> behaved as a partial agonist (74%).</div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> β-Arrestin Recruitment (β-Arrestin)</h3><div class="NLM_p">In the case of the analogues with the oxyethylene linker, the pyridine derivatives were weaker than their phenyl counterparts, whereas in the case of other linkers, they had higher potency. Similar to the previously discussed pathways, the 3,4-dichlorobenzoyl analogue showed lower potency than its 3-chloro-4-fluoro- counterpart. In this pathway, the most active compounds showed potency comparable to that of 8-OH-DPAT and higher than <b>1</b> and buspirone.</div><div class="NLM_p last">Only the phenylsulphanyl derivative <b>14</b> behaved as a partial agonist (70%). The other compounds exhibited <i>E</i><sub>max</sub> values close to 100%, similar to that seen for the reference compounds.</div></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Calcium Mobilization (Ca<sup>2+</sup>)</h3><div class="NLM_p">In this assay, the pyridine derivatives showed higher potency than their phenyl analogues. All the tested compounds had pEC<sub>50</sub> values higher than that of <b>1</b>, with the most potent being <b>11</b> and <b>17</b>.</div><div class="NLM_p last">In comparison to other pathways, efficacies in the calcium mobilization assay were markedly lower, with all compounds except <b>11</b> being partial agonists (52–74%). The propylene derivatives <b>10</b> and <b>11</b> displayed the highest efficacy (74 and 87%, respectively).</div></div><div id="sec2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Functional Activity of the Compound <b>17</b> Analogues: <b>20</b>, <b>22</b>, and <b>27</b></h3><div class="NLM_p last">Changing the position of the nitrogen atom in the aryloxyl moiety from 2 to 3, as well as replacement of 2-pyridine by 2-pyrimidine and 2-pyrazine resulted in decreased potency in each of the pathways. The pyrazin-2-yloxy derivative <b>22</b> was the most potent compound in this group and exhibited potency in a range from 7.54 in the calcium mobilization assay to 8.31 in the ERK1/2 phosphorylation assay. Similar to affinity results, the pEC<sub>50</sub> values of compound <b>22</b> are intermediate between pEC<sub>50</sub> values for pyridin-2-yloxy (<b>17</b>) and pyridin-3-yloxy (<b>20</b>) derivatives. The 5-methylpyrimidin-2-yloxy derivative <b>27</b> showed the lowest potency. Compounds <b>20</b> and <b>22</b> displayed high agonist efficacy (89–101%) in all the performed assays, showing higher efficacy levels than <b>17</b>, especially in the case of ERK1/2 phosphorylation and calcium mobilization. By contrast, compound <b>27</b> behaved as a partial agonist in all the pathways (41–75%, with exception of calcium mobilization, where it was not tested).</div></div><div id="sec2_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Bias Factors</h3><div class="NLM_p">To determine functional selectivity of the tested ligands, bias factors between particular pathways were calculated, according to the following equation<a onclick="showRef(event, 'ref71 ref72 ref73 ref74'); return false;" href="javascript:void(0);" class="ref ref71 ref72 ref73 ref74">(71−74)</a><span class="NLM_disp-formula" id="ueq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/medium/jm-2019-00062d_m001.gif" alt="" id="_i22" /></img></span></div><div class="NLM_p">Bias factor ensures equal comparison between all the pathways, considering the differences in EC<sub>50</sub> and <i>E</i><sub>max</sub> values of both a test ligand and a reference agonist, which was serotonin in this case. Results for all the compounds are presented in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>. Compounds which displayed bias factor higher than 1 (equaling to >10× preference) were highlighted in green (for positive values) and in blue (for negative values). Those compounds which showed significant bias, but with pEC<sub>50</sub> values which were relatively low (<8 in all assays), were considered less interesting and marked in gray.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Bias Factors of Compounds <b>10–17</b>, <b>19</b>, <b>20</b>, <b>22</b>, and <b>27</b> and References at 5-HT<sub>1A</sub> Receptors</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/medium/jm-2019-00062d_0018.gif" alt="" id="GRAPHIC-d7e2913-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/medium/jm-2019-00062d_0019.gif" alt="" id="gr15" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">No data for Ca<sup>2+</sup> assay.</p></div></div><div></div></div><div class="NLM_p">In general, the novel series showed highest bias for ERK1/2 phosphorylation, especially versus cAMP and Ca<sup>2+</sup> (mean bias factors 0.91 and 0.83, respectively). The bias was most pronounced in the case of the aryloxyethanamine derivatives, where high preference (bias factors >1) was observed in majority of cases. In this respect, the novel aryloxyethanamines were the most similar to the reference 5-HT<sub>1A</sub> receptor-biased agonist <b>1</b>, which previously showed preference for ERK1/2 phosphorylation, particularly over cAMP inhibition.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></div><div class="NLM_p last">Noteworthy, as mentioned in the <a class="ref internalNav" href="#sec1" aria-label="Introduction">Introduction</a>, it has been suggested that intensification of signal transduction through phosphorylation of ERK1/2 kinases may be important for antidepressant effects.<a onclick="showRef(event, 'ref75 ref76 ref77'); return false;" href="javascript:void(0);" class="ref ref75 ref76 ref77">(75−77)</a> In fact, in post-mortem examinations of suicide victims with previously diagnosed depression, reduction of ERK1/2 expression and phosphorylation in brain structures was observed.<a onclick="showRef(event, 'ref77 ref78'); return false;" href="javascript:void(0);" class="ref ref77 ref78">(77,78)</a> Furthermore, depression caused by chronic stress was found to be associated with ERK phosphorylation deficits,<a onclick="showRef(event, 'ref79 ref80 ref81 ref82'); return false;" href="javascript:void(0);" class="ref ref79 ref80 ref81 ref82">(79−82)</a> and the chronic administration of ERK inhibitors caused anhedonia and anxiety behavior.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> On the other hand, the inhibition of cAMP synthesis in the hippocampus resulting from the activation of the 5-HT<sub>1A</sub> receptor may lead to reduced phosphorylation of the Ca<sup>2+</sup>/calmodulin-dependent protein kinase II (CaMKII) and thus result in impairment of cognitive functions.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> The above considerations further support the need for selective stimulation of a desired intracellular signaling to achieve optimal therapeutic benefit. In this context, the newly discovered aryloxyethyl derivatives of 1-(1-benzoylpiperidin-4-yl)methanamine represent a favorable extension of the prototype ERK1/2-preferring 5-HT<sub>1A</sub> receptor-biased agonist <b>1</b>, which is, so far, the sole representative of such a functional profile. The present study also evidenced clear difference in functional activity between these compounds and the widely used reference agonist 8-OH-DPAT and the partial agonist buspirone.</div></div><div id="sec2_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> In Vivo and Ex Vivo Studies of the Lead Compound <b>17</b></h3><div id="sec2_12_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> Ex Vivo ERK1/2 Phosphorylation Measurement</h4><div class="NLM_p">In view of the preferential activation of ERK1/2 phosphorylation in vitro by compound <b>17</b> and the key role of ERK1/2 phosphorylation for mediating antidepressant activity, we assessed the level of pERK1/2 in the rat PFC after oral administration of compound <b>17</b>. We found that compound <b>17</b> robustly and significantly increased rat PFC ERK1/2 phosphorylation in a time-dependent manner. The maximal increase of pERK1/2 level was observed after 15 min (<i>T</i><sub>max</sub>), and statistically significant elevation of pERK1/2 was maintained also 30 min after administration (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A).</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/medium/jm-2019-00062d_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A,B) Effect of compound <b>17</b> on phospho-ERK1/2 (pERK1/2) and total-ERK1/2 (tERK1/2) levels in rat PFC. (A) Time-course (5, 15, 30 and 60 min) of the effects induced by a single oral administration of compound <b>17</b> at a dose of 2.5 mg/kg or vehicle (water). (B) Dose response of the effects of compound <b>17</b> tested at 15 min after administration. All samples were tested in duplicate, in two separate experiments. For normalization purposes, the value of phospho-ERK1/2 was divided by a corresponding value of total-ERK1/2 for each sample, and then, the ratios were used for statistical analysis (time course: one-way ANOVA (<i>F</i>(4,30) = 10.87; <i>p</i> < 0.0001; dose response: one-way ANOVA (<i>F</i>(4,31) = 10.19; <i>p</i> < 0.0001) followed by Bonferroni’s post hoc test). For graphical presentations, data are expressed as the mean ± SEM (2 measures for each of 6–8 rats per group), the mean value of the vehicle-treated group was set at 100% (control value), and all data were expressed as a percentage relative to the control value. *<i>p</i> < 0.05, ****<i>p</i> < 0.0001 compared to vehicle group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00062&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Next, we investigated the dose dependence of stimulation of ERK1/2 phosphorylation by compound <b>17</b> at the <i>T</i><sub>max</sub> after oral administration (see Pharmacokinetic Studies and PK/PD Relationship below). Statistically significant elevation of pERK1/2 was observed at the two highest doses (2.5 and 0.63 mg/kg), but a tendency to increase pERK1/2 levels was also seen at lower doses (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B). These results are in agreement with the data obtained previously for selective agonists of 5-HT<sub>1A</sub> receptors.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a></div></div><div id="sec2_12_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> Pharmacokinetic Studies and PK/PD Relationship</h4><div class="NLM_p">To establish the relationship between the pharmacodynamic effects of compound <b>17</b> and its exposure, we performed pharmacokinetic studies, including determination of concentrations of <b>17</b> in serum and brain of the rat. Both the time course and the dose-response profiles of ERK1/2 phosphorylation in PFC were found to correspond closely with the pharmacokinetic data. After oral administration, we found the highest concentration of compound <b>17</b> in both serum and brain after 15 min (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). At this time point, we also observed a dose-dependent increase in serum and brain concentration, with the highest concentrations produced by a dose of 2.5 mg/kg p.o. (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). Noteworthy, concentrations of compound <b>17</b> in brain tissue were higher than those in serum for all doses.</div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/medium/jm-2019-00062d_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Serum and brain concentrations (mean ± SEM) of compound <b>17</b> following oral administration of a dose of 2.5 mg/kg to rats (<i>n</i> = 6–8 per time point).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00062&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/medium/jm-2019-00062d_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Dose dependence in compound <b>17</b> serum and brain concentrations 15 min after oral administration to rats (each bar represents mean of 6–8 concentrations ± SEM).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00062&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To describe quantitatively the PK–PD relationship between ERK1/2 phosphorylation and serum drug concentration, a simple <i>E</i><sub>max</sub> model was applied in Phoenix WinNonlin v.7.0 (Certara Corp., USA) (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>).</div><figure id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/medium/jm-2019-00062d_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Observed (symbols) and pharmacodynamic model-predicted (line) pERK/tERK ratio (normalized to the vehicle control) as a function of mean serum concentrations of compound <b>17</b>. ERK phosphorylation was measured 15 min following compound administration at four different oral doses (0.04, 0.16, 0.63, and 2.5 mg/kg) to rats (<i>n</i> = 6–8 per dose).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00062&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The proposed model captured the experimental data well with an estimated EC<sub>50</sub> value (i.e., the serum concentration of <b>17</b> which elicits half-maximal pERK response) of 17.20 ng/mL. These results point to a clear PK/PD relationship between drug concentrations of <b>17</b> and its induction of pERK1/2 phosphorylation in rat PFC.</div><div class="NLM_p last">To assess rat pharmacokinetic parameters of <b>17</b>, serum concentration versus time data following oral administration were analyzed by a noncompartmental approach. Compound <b>17</b> (2.5 mg/kg p.o.) was rapidly absorbed from the gastrointestinal tract (<i>T</i><sub>max</sub> = 15 min) and reached relatively high serum concentrations (<i>C</i><sub>max</sub> = 104.7 ng/mL). Brain levels followed exactly the same pattern with <i>C</i><sub>max</sub> of 124.4 ng/g. The area under the concentration–time curve from the time of dosing to infinity (AUC<sub>0–∞</sub>) was 8962.3 ng·min/L and 16834.2 ng·min/g for serum and brain, respectively. The apparent volume of distribution (<i>V</i><sub><i>z</i></sub>/<i>F</i>) during terminal phase was 35.9 L/kg. The studied compound was also characterized by a favorable value of serum elimination half-life (<i>t</i><sub>0.5λ<sub>z</sub></sub>) of 89.3 min. The value of this parameter for brain tissue was even higher and it was 104.9 min.</div></div><div id="sec2_12_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> Antidepressant-like Activity</h4><div class="NLM_p">Compound <b>17</b> was tested in the rat forced swim test (FST, Porsolt test), which is one of the most widely used procedures to evaluate antidepressant-like activity.<a onclick="showRef(event, 'ref85 ref86'); return false;" href="javascript:void(0);" class="ref ref85 ref86">(85,86)</a> Given that the <i>T</i><sub>max</sub> for serum and brain exposure was observed at 15 min, which also corresponds to the time point for highest ERK1/2 phosphorylation, we investigated the antidepressant activity of compound <b>17</b> using this pretreatment time. Compound <b>17</b> showed potent activity (minimal effective dose 0.16 mg/kg p.o.) and exhibited a very strong effect, completely abolishing immobility at a dose of 2.5 mg/kg p.o (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>, <a href="/doi/suppl/10.1021/acs.jmedchem.9b00062/suppl_file/jm9b00062_si_001.pdf" class="ext-link">Supporting Information</a> Table S4).</div><figure id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/medium/jm-2019-00062d_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Antidepressant-like activity of compound <b>17</b> in the FST in rats (15 min pretreatment time). Values represent the mean ± SEM of the immobility time during the 5 min test session compared to the vehicle group [one-way ANOVA (<i>F</i>(4,29) = 66.22; <i>p</i> < 0.0000001) followed by Bonferroni’s post hoc test] *<i>p</i> < 0.05, ****<i>p</i> < 0.00001, <i>n</i> = 6–8 per dose.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00062&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To clarify the PK/PD relationship between the behavioral data (immobility time in the FST) and serum concentrations of compound <b>17</b>, the results of FST tests were plotted against mean serum concentrations measured at 15 min after dosing. As presented in <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>, the estimated concentration at which the compound exerts half of its maximal inhibitory effect (IC<sub>50</sub>) was 6.76 ng/mL and was comparable to the EC<sub>50</sub> value obtained for the activation of ERK1/2 phosphorylation in PFC by compound <b>17</b> (see above).</div><figure id="fig10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/medium/jm-2019-00062d_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0002.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Observed (symbols) and pharmacodynamic model-predicted (lines) immobility times (normalized to the vehicle control) as a function of mean serum concentrations of compound <b>17</b>. FST was performed 15 min following compound administration at four different oral doses (0.04, 0.16, 0.63, and 2.5 mg/kg) to rats (<i>n</i> = 6–8 per dose).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00062&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The activity of compound <b>17</b> in the FST was also evaluated 60 min after oral administration, which is a standard pretreatment time used in this type of experiments. The obtained results are very similar to those obtained with a 15 min preadministration time, in both the effective dose range (MED = 0.16 mg/kg, ED<sub>50</sub> = 0.3 mg/kg) and the maximal effect size (total immobility reduction at a dose of 2.5 mg/kg; <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>, <a href="/doi/suppl/10.1021/acs.jmedchem.9b00062/suppl_file/jm9b00062_si_001.pdf" class="ext-link">Table S4</a>). It is noteworthy that the antidepressant-like effect of <b>17</b> was maintained at 60 min, even though its concentrations in serum and brain, as well as pERK1/2 levels were decreased, thus suggesting a protracted behavioral effect of the compound. This observation is also in line with the previous studies of 5-HT<sub>1A</sub> receptor-biased agonists.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> The antidepressant-like effect of compound <b>17</b> in the FST at 60 min was fully reversed by coadministration of the selective 5-HT<sub>1A</sub> receptor antagonist WAY-100635 (0.63 mg/kg s.c.) and was not accompanied by any significant change in the locomotor activity, thus testifying to its specificity and full 5-HT<sub>1A</sub> receptor dependence. Moreover, at the doses tested (0.04–2.5 mg/kg p.o.), compound <b>17</b> did not elicit flat body posture (FBP), a common side effect of the 5-HT<sub>1A</sub> receptor stimulation, suggesting that its preference for activation of 5-HT<sub>1A</sub> receptor-mediated ERK1/2 phosphorylation in vitro translates to preferential antidepressant effects rather than induction of “behavioral syndrome”<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>).</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Behavioral Effects of Compound <b>17</b> and References in the FST and Serotonergic Behavior—FBP (60 min after p.o. Administration)</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">FST (Porsolt test)</th><th class="rowsep1 colsep0" align="center">FBP<a class="ref internalNav" href="#t7fn3" aria-label="c">c</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">route of administration</th><th class="colsep0 rowsep0" align="center">dose range (mg/kg)</th><th class="colsep0 rowsep0" align="center">MED<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a> (mg/kg)</th><th class="colsep0 rowsep0" align="center">MaxED<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a> (mg/kg)</th><th class="colsep0 rowsep0" align="center">MED (mg/kg)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="left">p.o.</td><td class="colsep0 rowsep0" align="left">0.04–5</td><td class="colsep0 rowsep0" align="left">0.16</td><td class="colsep0 rowsep0" align="left">2.5</td><td class="colsep0 rowsep0" align="left">n.s.<a class="ref internalNav" href="#t7fn4" aria-label="d">d</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b><a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></td><td class="colsep0 rowsep0" align="left">p.o.</td><td class="colsep0 rowsep0" align="left">0.04–5</td><td class="colsep0 rowsep0" align="left">0.63</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">n.s.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">8-OH-DPAT<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></td><td class="colsep0 rowsep0" align="left">s.c.</td><td class="colsep0 rowsep0" align="left">0.04–0.63</td><td class="colsep0 rowsep0" align="left">0.16</td><td class="colsep0 rowsep0" align="left"><a class="ref internalNav" href="#t7fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">0.63</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">buspirone<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></td><td class="colsep0 rowsep0" align="left">p.o.</td><td class="colsep0 rowsep0" align="left">0.16–2.5</td><td class="colsep0 rowsep0" align="left">n.s.</td><td class="colsep0 rowsep0" align="left"><a class="ref internalNav" href="#t7fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">n.s.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">imipramine<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a></td><td class="colsep0 rowsep0" align="left">i.p.</td><td class="colsep0 rowsep0" align="left">3–10</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left"><a class="ref internalNav" href="#t7fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">n.t.<a class="ref internalNav" href="#t7fn6" aria-label="f">f</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ketamine<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a></td><td class="colsep0 rowsep0" align="left">i.p.</td><td class="colsep0 rowsep0" align="left">5–15</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left"><a class="ref internalNav" href="#t7fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">n.t.</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">Minimal effective dose.</p></div><div class="footnote" id="t7fn2"><sup><sup>b</sup></sup><p class="last">The first dose at which the effects are maximal (total reduction of immobility time).</p></div><div class="footnote" id="t7fn3"><sup><sup>c</sup></sup><p class="last">Flat Body Posture.</p></div><div class="footnote" id="t7fn4"><sup><sup>d</sup></sup><p class="last">Not significant.</p></div><div class="footnote" id="t7fn5"><sup><sup>e</sup></sup><p class="last">Maximal effect was not achieved (8-OH-DPAT 90% at 0.63 mg/kg, ketamine 43% at 15 mg/kg, and imipramine 25% at 10 mg/kg).</p></div><div class="footnote" id="t7fn6"><sup><sup>f</sup></sup><p class="last">Not tested.</p></div></div></div><div class="NLM_p">Such activity, especially in terms of potency and maximal effect size, is remarkable and was previously observed only for the 5-HT<sub>1A</sub> receptor-biased agonist, <b>1</b>.<a onclick="showRef(event, 'ref27 ref32'); return false;" href="javascript:void(0);" class="ref ref27 ref32">(27,32)</a> Thus, the present results further demonstrate consistency of the pharmacological effects of compound <b>17</b> with those of the reference-biased agonist and suggest a high therapeutic potential of the novel compounds. Noteworthy, both ERK1/2 phosphorylation-preferring biased agonists (<b>17</b> and <b>1</b>) clearly outperformed all the reference compounds in terms of potency, maximal effect, lack of side effect (FBP), and oral activity (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>).</div><div class="NLM_p last">Moreover, under the present conditions, compound <b>17</b> was even more potent than <b>1</b> for reduction of immobility, showing activity at a dose 4 times lower.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> The potency of compound <b>17</b> after oral administration implies favorable gastrointestinal tract absorption and high penetration into the central nervous system. Such observations support the predicted good developability profile of compound <b>17</b> as well as the overall “drug-likeness” of the novel series.</div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i29">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86501" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86501" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Recently, it was suggested that the rapid-acting antidepressant activity of ketamine is mediated by frontal cortex 5-HT<sub>1A</sub> receptors and requires stimulation of ERK1/2 phosphorylation. Together with previous findings on the role of ERK1/2 phosphorylation in mood control, it can be inferred that direct agonist activation of frontocortical 5-HT<sub>1A</sub> receptor signaling by biased agonists offers the prospect of achieving beneficial therapeutic effects on mood without eliciting the dissociative and cognition-disrupting side effects which are seen with ketamine. Study of the first functionally selective agonist of 5-HT<sub>1A</sub> receptors, <b>1</b>, which preferentially activates ERK1/2 phosphorylation, confirmed that biased agonists may offer beneficial therapeutic effects on mood with reduced unwanted effects. However, to date, <b>1</b> was “one of a kind” and there were no SAR studies that would lay a foundation for further development of 5-HT<sub>1A</sub> receptor-biased agonists. In the present study, we therefore characterized a group of selective 5-HT<sub>1A</sub> receptor agonists and carried out comprehensive analyses of structure–functional activity relationships. These allowed us to identify the aryloxyethanamine derivatives as the most biased agonists for ERK1/2 phosphorylation versus cAMP and Ca<sup>2+</sup>. On the basis of all data collected, we selected compound <b>17</b>, characterized by exceptional affinity (p<i>K</i><sub>i</sub> = 10.19), preference for ERK1/2 phosphorylation, and favorable results of in silico predictions of drug-like properties (including CNS MPO and LELP). The results of SafetyScreen44 Panel and other antitargets, the bioavailability panel, and CYP3A4, CYP2D6, and P-glycoprotein (Pgp) inhibition assays revealed its excellent overall selectivity and ADME properties, as well as relatively low drug–drug interaction potential. Finally, compound <b>17</b> stimulated ERK1/2 phosphorylation in rat cortex and outperformed <b>1</b> in vivo, displaying robust antidepressant-like activity in the FST (Porsolt) test at 0.16 mg/kg p.o. and a total reduction of immobility at 2.5 mg/kg p.o. Moreover, this effect was not accompanied by FBP, an observation that confirmed the compound’s preference for activation of 5-HT<sub>1A</sub> receptor signaling pathways that mediate therapeutic-like responses rather than those that mediate side effects. The new chemical scaffold presented herein, represented by compound <b>17</b> (also known as NLX-204), is not only a versatile tool for medicinal chemistry and further exploration of the target but also for drug development. Taken together, these results suggest that compounds in this chemical series may constitute promising candidates for development as novel treatments for mood disorders.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i30">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06711" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06711" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Molecular Modeling</h3><div class="NLM_p">Computer-aided ligand design and further studies on structure–activity relationships were based on ligand–receptor interaction analysis. To capture the distinctive binding mode of a variety of functionally selective ligands, the general procedure for developing ligand-optimized models<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> was adopted in the present studies, regarding the induced-fit technique as both the protein binding site optimization method (in terms of amino acid side chains) and routine docking approach. The previously built preoptimized serotonin 5-HT<sub>1A</sub> receptor homology model<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> served as structural basis for ligand-steered side chain optimization.</div><div class="NLM_p last">In general, the 5-HT<sub>1B</sub> crystal structure (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4IAR">4IAR</a>)<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> was taken as a template for homology modeling. The alignment of amino acid sequences of the 5-HT<sub>1A</sub> (UniProt database ID: <a href="https://P08908" class="ext-link">P08908</a>) and 5-HT<sub>1B</sub> receptors was implemented from hhsearch model via GeneSilico Metaserver,<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> which established the overall amino acid sequence identity for 38%. The basic 5-HT<sub>1A</sub> receptor homology model was obtained via SwissModel platform.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> Then, it was validated by processing in Protein Preparation Wizard. Structure optimization stage, which was performed using induced-fit docking (IFD),<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> resulted in distinct protein–ligand complexes, which were subjected for visual inspection. The glide SP flexible docking procedure using the OPLS3 force field was set for the IFD. The H-bond constraint and the centroid of a grid box for docking to the 5-HT<sub>1A</sub> receptor were located on Asp3.32. Ligand structures were sketched in Maestro 2D Sketcher and optimized using LigPrep tool. Induced fit docking, LigPrep, Maestro, and Protein Preparation Wizard were implemented in Small-Molecule Drug Discovery Suite (Schrödinger, Inc. New York, USA), which was licensed for Jagiellonian University Medical College.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Synthesis</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> General Chemistry Information</h4><div class="NLM_p last">All the reagents were purchased from commercial suppliers (Sigma-Aldrich, Merck, Chempur, Fluorochem, Enamine, Acros Organics, Manchester Organics, POCh, Activate Scientific, Chem-impex International, and Apollo Scientific) and were used without further purification. Analytical thin-layer chromatography (TLC) was performed on Merck Kieselgel 60 F<sub>254</sub> (0.25 mm) precoated aluminum sheets (Merck, Darmstadt, Germany). Compounds were visualized with UV light and by suitable visualization reagents (2.9% solution of ninhydrin in mixture of 1-propanol and acetic acid (100/3, v/v) and Pancaldi reagent [solution of 12.0 g of (NH<sub>4</sub>)<sub>6</sub>Mo<sub>7</sub>O<sub>24</sub>, 0.5 g of Ce(SO<sub>4</sub>)<sub>2</sub>, and 6.8 mL of 98% H<sub>2</sub>SO<sub>4</sub> in 240 mL of water]. Flash chromatography was performed on CombiFlash RF (Teledyne Isco), using disposable silica gel flash columns RediSep Rf (silica gel 60, particle size 40–63 μm) and RediSep Gold (silica gel 60, particle size 20–40 μm) purchased from Teledyne Isco. The microwave reactions were conducted in Discover LabMate (CEM Corporation). The UPLC-MS or UPLC-MS/MS analyses were done on an UPLC-MS/MS system comprising Waters ACQUITY UPLC (Waters Corporation, Milford, MA, USA) coupled with a Waters TQD mass spectrometer (electrospray ionization mode ESI with tandem quadrupole). Chromatographic separations were carried out using the ACQUITY UPLC BEH (bridged ethyl hybrid) C18 column: 2.1 × 100 mm and 1.7 μm particle size. The column was maintained at 40 °C and eluted under gradient conditions using 95 to 0% of eluent A over 10 min, at a flow rate of 0.3 mL/min. Eluent A: 0.1% solution of formic acid in water (v/v); eluent B: 0.1% solution of formic acid in acetonitrile (v/v). A total of 10 μL of each sample was injected, and chromatograms were recorded using a Waters eλ PDA detector. The spectra were analyzed in the range of 200–700 nm with 1.2 nm resolution and at a sampling rate of 20 points/s. The UPLC/MS purity of all the test compounds and key intermediates was determined to be >95%. <sup>1</sup>H NMR, <sup>13</sup>C NMR, and <sup>19</sup>F NMR spectra were obtained in a Varian Mercury spectrometer (Varian Inc., Palo Alto, CA, USA), in CDCl<sub>3</sub>, CD<sub>3</sub>OD, or DMSO-<i>d</i><sub>6</sub> operating at 300 MHz (<sup>1</sup>H NMR), 75 MHz (<sup>13</sup>C NMR), and 282 MHz (<sup>19</sup>F NMR). Chemical shifts are reported as δ values (ppm) relative to TMS δ = 0 (<sup>1</sup>H) as the internal standard. The <i>J</i> values are expressed in hertz (Hz). Signal multiplicities are represented by the following abbreviations: s (singlet), br s (broad singlet), bd (broad doublet), d (doublet), dd (doublet of doublets), dt (doublet of triplets), t (triplet), td (triplet of doublets), tdd (triplet of doublet of doublets), q (quartet), dq (doublet of quartets), and m (multiplet). Elemental analyses were conducted using a Vario EL III elemental analyzer (elementar Analysensystem GmbH). Melting points were determined on a Büchi Melting Point B-540 apparatus using open glass capillaries and are uncorrected.</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Synthetic Procedures</h3><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> General Procedure for the Synthesis of Benzoylpiperidin-4-One Derivatives (<b>4</b>, <b>5</b>)</h4><div class="NLM_p last">4-Piperidone hydrochloride monohydrate (1.0 equiv) was dissolved in a mixture of dry DCM and Et<sub>3</sub>N and cooled to 0 °C. The appropriate benzoyl chloride <b>2</b> or <b>3</b> (1.1 equiv) was added dropwise. The reaction mixture was subsequently warmed to room temperature and stirred for 12 h. The solvent was removed in vacuo; the residue was washed with a mixture of 1.0 M HCl and water (1:1) (30 mL) and extracted with DCM. Organic layers were dried over magnesium sulfate, filtered, and concentrated in vacuo. The crude product was purified by flash chromatography.</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 1-(3-Chloro-4-fluorobenzoyl)piperidin-4-one (<b>4</b>)</h4><div class="NLM_p last">Compound <b>4</b> was prepared using 4-piperidone hydrochloride monohydrate (7.500 g, 49.02 mmol), 3-chloro-4-fluorobenzoyl chloride (<b>2</b>) (10.407 g, 53.92 mmol), and Et<sub>3</sub>N (25 mL) in DCM (125 mL). Purification: <i>n</i>-hexane/EtOAc (6/4, v/v). Yield: 60%; cream-colored crystallizing oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>, δ): 7.56 (dd, <i>J</i> = 2.1, 6.9 Hz, 1H), 7.37 (ddd, <i>J</i> = 2.2, 4.6, 8.4 Hz, 1H), 7.25–7.17 (m, 1H), 3.87 (br s, 4H), 2.51 (br s, 4H). <sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>, δ): −111.5 (s, 1F). Formula: C<sub>12</sub>H<sub>11</sub>ClFNO<sub>2</sub>; MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 256 [M + H<sup>+</sup>].</div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 1-(3,4-Dichlorobenzoyl)piperidin-4-one (<b>5</b>)</h4><div class="NLM_p last">Compound <b>5</b> was prepared using 4-piperidone hydrochloride monohydrate (4.000 g, 29.63 mmol), 3,4-dichlorobenzoyl chloride (<b>3</b>) (6.828 g, 32.59 mmol), and Et<sub>3</sub>N (30 mL) in DCM (100 mL). Purification: <i>n</i>-hexane/EtOAc (5/5, v/v). Yield: 47%; pale yellow crystallizing oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>, δ): 7.58 (d, <i>J</i> = 1.8 Hz, 1H), 7.52 (d, <i>J</i> = 8.2 Hz, 1H), 7.31 (dd, <i>J</i> = 2.1, 8.2 Hz, 1H), 3.86 (br s, 4H), 2.51 (br s, 4H). Formula: C<sub>12</sub>H<sub>11</sub>Cl<sub>2</sub>NO<sub>2</sub>; MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 272 [M + H<sup>+</sup>].</div></div><div id="sec4_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> General Procedure for the Synthesis of Benzoyl-1-oxa-6-azaspiro[2.5]octane-2-carbonitrile Derivatives (<b>6</b>, <b>7</b>)</h4><div class="NLM_p last">To the benzoylpiperidin-4-one derivative <b>4</b> or <b>5</b> (1.00 equiv) and tetrabutylammonium bromide (0.04 equiv) dissolved in DCM and 30% aqueous solution of NaOH, chloroacetonitrile (1.40 equiv) was added dropwise. The mixture was stirred at room temperature for 2 h and then quenched with a saturated, aqueous solution of sodium bicarbonate. Next, the mixture was extracted with DCM, dried over magnesium sulfate, filtered, and concentrated in vacuo. The obtained crude brown oil was purified by flash chromatography to yield the pure product.</div></div><div id="sec4_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 6-(3-Chloro-4-fluorobenzoyl)-1-oxa-6-azaspiro[2.5]octane-2-carbonitrile (<b>6</b>)</h4><div class="NLM_p last">Compound <b>6</b> was prepared using 1-(3-chloro-4-fluorobenzoyl)piperidin-4-one (<b>4</b>) (7.050 g, 27.67 mmol), tetrabutylammonium bromide (0.356 g, 1.11 mmol), chloroacetonitrile (2.44 mL, 38.71 mmol), and 30% aqueous solution of NaOH (19 mL) in DCM (47 mL). Purification: DCM/Et<sub>2</sub>O (7/3, v/v). Yield: 80%; pale yellow crystallizing oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>, δ): 7.52 (dd, <i>J</i> = 2.1, 6.7 Hz, 1H), 7.38–7.29 (m, 1H), 7.24–7.14 (m, 1H), 4.35–3.70 (m, 2H), 3.67–3.49 (m, 2H), 3.41 (s, 1H), 2.20–1.69 (m, 4H). Formula: C<sub>14</sub>H<sub>12</sub>ClFN<sub>2</sub>O<sub>2</sub>; MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 295 [M + H<sup>+</sup>].</div></div><div id="sec4_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 6-(3,4-Dichlorobenzoyl)-1-oxa-6-azaspiro[2.5]octane-2-carbonitrile (<b>7</b>)</h4><div class="NLM_p last">Compound <b>7</b> was prepared using 1-(3,4-dichlorobenzoyl)piperidin-4-one (<b>5</b>) (3.405 g, 12.52 mmol), tetrabutylammonium bromide (0.161 g, 0.50 mmol), chloroacetonitrile (1.11 mL, 17.53 mmol), and 30% aqueous solution of NaOH (8.6 mL) in DCM (21 mL). Purification: EtOAc/Et<sub>2</sub>O/NH<sub>3(aq)</sub> (8.5/1.5/0.02, v/v/v). Yield: 87%; yellow crystallizing oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>, δ): 7.59–7.45 (m, 2H), 7.31–7.19 (m, 1H), 4.44–4.15 (m, 1H), 3.82–3.49 (m, 3H), 3.41 (s, 1H), 1.99–1.37 (m, 4H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>, δ): 168.2, 134.9, 134.6, 133.2, 130.8, 129.2, 126.2, 115.2, 63.1, 47.1, 45.8, 40.8, 32.6, 31.1. Formula: C<sub>14</sub>H<sub>12</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>2</sub>; MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 311 [M + H<sup>+</sup>].</div></div><div id="sec4_3_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> General Procedure for the Synthesis of Cyanohydrine Derivatives (<b>8</b>, <b>9</b>)</h4><div class="NLM_p last">To the appropriate nitrile <b>6</b> or <b>7</b> (1.0 equiv) dissolved in dry dichloromethane at −10 °C in a round-bottom Teflon flask, 70% solution of HF in pyridine (40.0 equiv) was added dropwise and the mixture was stirred at room temperature for 24–36 h. The mixture was then slowly quenched with 10% aqueous solution of potassium carbonate to pH 9, diluted with brine, and extracted with EtOAc. The combined organic layers were dried over magnesium sulfate, filtered, and concentrated in vacuo. Purification by flash chromatography yielded the pure product.</div></div><div id="sec4_3_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 2-(1-(3-Chloro-4-fluorobenzoyl)-4-fluoropiperidin-4-yl)-2-hydroxyacetonitrile (<b>8</b>)</h4><div class="NLM_p last">Compound <b>8</b> was prepared using 6-(3-chloro-4-fluorobenzoyl)-1-oxa-6-azaspiro[2.5]octane-2-carbonitrile (<b>6</b>) (3.450 g, 11.74 mmol) and 70% solution of HF in pyridine (12.1 mL, 466.40 mmol) in DCM (23 mL). Purification: <i>n</i>-hexane/DCM/methanol/NH<sub>3(aq)</sub> (6/3.5/0.5/0.02, v/v/v/v). Yield: 54%; yellow crystallizing oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>, δ): 7.49 (dd, <i>J</i> = 2.1, 6.7 Hz, 1H), 7.34–7.27 (m, 1H), 7.24–7.17 (m, 1H), 4.65 (br s, 1H), 4.40 (d, <i>J</i> = 12.6 Hz, 1H), 3.75 (br s, 1H), 3.51–3.03 (m, 2H), 2.19–1.65 (m, 4H), O<i>H</i> proton not detected. <sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>, δ): −111.6 (s, 1F), −170.7 (s, 1F). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>, δ): 168.5, 159.1 (d, <i>J</i> = 254 Hz), 132.0 (d, <i>J</i> = 4.4 Hz), 129.8, 127.1 (d, <i>J</i> = 7.7 Hz), 121.8 (d, <i>J</i> = 18.2 Hz), 117.0 (d, <i>J</i> = 22 Hz), 116.6 (d, <i>J</i> = 2.8 Hz), 93.3 (d, <i>J</i> = 181.8 Hz), 66.7 (d, <i>J</i> = 28.2 Hz), 42.8, 37.9, 31.4, 30.3. Formula: C<sub>14</sub>H<sub>13</sub>ClF<sub>2</sub>N<sub>2</sub>O<sub>2</sub>; MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 315 [M + H<sup>+</sup>].</div></div><div id="sec4_3_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 2-(1-(3,4-Dichlorobenzoyl)-4-fluoropiperidin-4-yl)-2-hydroxyacetonitrile (<b>9</b>)</h4><div class="NLM_p last">Compound <b>9</b> was prepared using 6-(3,4-dichlorobenzoyl)-1-oxa-6-azaspiro[2.5]octane-2-carbonitrile (<b>7</b>) (3.300 g, 10.61 mmol) and 70% solution of HF in pyridine (11.5 mL, 424.44 mmol) in DCM (16 mL). Purification: <i>n</i>-hexane/DCM/methanol/NH<sub>3(aq)</sub> (6/3.5/0.5/0.02, v/v/v/v). Yield: 68%; yellow crystallizing oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>, δ): 7.55–7.47 (m, 2H), 7.26–7.20 (m, 1H), 4.61 (br s, 1H), 4.39 (d, <i>J</i> = 12.1 Hz, 1H), 3.83–3.61 (m, 1H), 3.45–3.06 (m, 2H), 1.79 (br s, 4H), O<i>H</i> proton not detected. <sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>, δ): −170.8 (s, 1F). Formula: C<sub>14</sub>H<sub>13</sub>Cl<sub>2</sub>FN<sub>2</sub>O<sub>2</sub>; MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 331 [M + H<sup>+</sup>].</div></div><div id="sec4_3_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> General Procedures for the Preparation of 1-(1-benzoylpiperidin-4-yl)methanamine Derivatives (<b>10–27</b>)</h4><div class="NLM_p last">To appropriate cyanohydrin (<b>8</b> or <b>9</b>) (1.0 equiv) dissolved in methanol, DABCO (2.0–12.5 equiv) was added in one portion, followed by the appropriate amine (1.0–1.6 equiv), 4 Å molecular sieves, sodium cyanoborohydride (1.6–7.8 equiv), and iron sulfate heptahydrate (FeSO<sub>4</sub> × 7 H<sub>2</sub>O) (1.1 equiv). The mixture was stirred at room temperature until the cyanohydrin was consumed (24–72 h). After that time, the reaction mixture was filtered, concentrated in vacuo, and next brine was added. The resulting mixture was extracted with EtOAc (three times), organics were combined and dried over magnesium sulfate, filtered, and concentrated. The crude product was purified by flash chromatography.</div></div><div id="sec4_3_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> (3-Chloro-4-fluorophenyl) (4-fluoro-4-(((3-phenylpropyl)amino)methyl)piperidin-1-yl)methanone (<b>10</b>)</h4><div class="NLM_p last">The title compound was prepared using 2-(1-(3-chloro-4-fluorobenzoyl)-4-fluoropiperidin-4-yl)-2-hydroxyacetonitrile (<b>8</b>) (0.120 g, 0.38 mmol), 3-phenylpropan-1-amine (0.072 g, 0.54 mmol), DABCO (0.535 g, 4.78 mmol), sodium cyanoborohydride (0.187 g, 2.98 mmol), molecular sieves (0.900 g), and iron sulfate heptahydrate (0.117 g, 0.42 mmol) in methanol (5 mL). Purification: <i>n</i>-hexane/Et<sub>2</sub>O/DCM/methanol/NH<sub>3(aq)</sub> (3/2/4.5/0.5/0.02, v/v/v/v/v). Yield: 41%; pale beige powder. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>, δ): 7.48 (dd, <i>J</i> = 2.3, 7.0 Hz, 1H), 7.34–7.23 (m, 3H), 7.22–7.10 (m, 4H), 4.50 (br s, 1H), 3.60 (d, <i>J</i> = 19.9 Hz, 1H), 3.46–3.08 (m, 2H), 2.80–2.60 (m, 6H), 2.09–1.90 (m, 2H), 1.87–1.45 (m, 5H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>, δ): 168.0, 158.8 (d, <i>J</i> = 254 Hz), 142.0, 132.9 (d, <i>J</i> = 3.5 Hz), 129.7, 128.4 (2C), 128.3 (2C), 127.1 (d, <i>J</i> = 6.9 Hz), 125.8, 121.5 (d, <i>J</i> = 18.4 Hz), 116.8 (d, <i>J</i> = 22 Hz), 94.3 (d, <i>J</i> = 172 Hz), 57.5 (d, <i>J</i> = 22 Hz), 49.8, 43.6, 38.3, 33.5, 33.2, 32.7, 31.6. Formula: C<sub>22</sub>H<sub>25</sub>ClF<sub>2</sub>N<sub>2</sub>O; MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 407 [M + H<sup>+</sup>]. Melting point: 62–64 °C.</div></div><div id="sec4_3_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> (3-Chloro-4-fluorophenyl)(4-fluoro-4-(((3-(pyridin-2-yl)propyl)amino)methyl)piperidin-1-yl)methanone (<b>11</b>)</h4><div class="NLM_p last">The title compound was prepared using 2-(1-(3-chloro-4-fluorobenzoyl)-4-fluoropiperidin-4-yl)-2-hydroxyacetonitrile (<b>8</b>) (0.100 g, 0.32 mmol), 3-(pyridin-2-yl)propan-1-amine (0.056 g, 0.41 mmol), DABCO (0.444 g, 3.97 mmol), sodium cyanoborohydride (0.155 g, 2.48 mmol), molecular sieves (0.900 g), and iron sulfate heptahydrate (0.097 g, 0.35 mmol) in methanol (5 mL). Purification: <i>n</i>-hexane/EtOAc/methanol/NH<sub>3(aq)</sub> (2/7/1/0.02, v/v/v/v). Yield: 57%; orange oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>, δ): 8.53–8.43 (m, 1H), 7.57 (dt, <i>J</i> = 1.8, 7.6 Hz, 1H), 7.46 (dd, <i>J</i> = 1.8, 7.0 Hz, 1H), 7.32–7.24 (m, 1H), 7.21–7.04 (m, 3H), 4.47 (br s, 1H), 3.57 (br s, 1H), 3.44–3.05 (m, 2H), 2.80 (dd, <i>J</i> = 7.9, 15.5 Hz, 3H), 2.73–2.60 (m, 3H), 2.07–1.84 (m, 4H), 1.69 (br s, 3H). <sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>, δ): −112.7 (s, 1F), −166.6 (s, 1F). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>, δ): 168.0, 161.7, 158.7 (d, <i>J</i> = 254 Hz), 149.2, 136.3, 132.9 (d, <i>J</i> = 4.7 Hz), 129.7, 127.1 (d, <i>J</i> = 8.1 Hz), 122.8, 121.5 (d, <i>J</i> = 18.4 Hz), 121.0, 116.8 (d, <i>J</i> = 22 Hz), 94.3 (d, <i>J</i> = 172 Hz), 57.4 (d, <i>J</i> = 22 Hz), 49.8, 43.7, 38.2, 35.9, 33.6, 32.9, 29.9. Formula: C<sub>21</sub>H<sub>24</sub>ClF<sub>2</sub>N<sub>3</sub>O; MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 408 [M + H<sup>+</sup>].</div></div><div id="sec4_3_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> (3-Chloro-4-fluorophenyl)(4-fluoro-4-(((2-(phenylamino)ethyl)amino)methyl)piperidin-1-yl)methanone (<b>12</b>)</h4><div class="NLM_p last">The title compound was prepared using 2-(1-(3-chloro-4-fluorobenzoyl)-4-fluoropiperidin-4-yl)-2-hydroxyacetonitrile (<b>8</b>) (0.144 g, 0.46 mmol), <i>N</i><sup>1</sup>-phenylethane-1,2-diamine (0.095 g, 0.55 mmol), DABCO (0.103 g, 0.92 mmol), sodium cyanoborohydride (0.046 g, 0.73 mmol), molecular sieves (0.900 g), and iron sulfate heptahydrate (0.140 g, 0.42 mmol) in methanol (5 mL). Purification: <i>n</i>-hexane/EtOAc/methanol/NH<sub>3(aq)</sub> (3/6.5/0.5/0.02, v/v/v/v). Yield: 35%; yellow oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>, δ): 7.48 (dd, <i>J</i> = 1.8, 7.0 Hz, 1H), 7.33–7.24 (m, 1H), 7.22–7.13 (m, 3H), 6.76–6.67 (m, 1H), 6.66–6.58 (m, 2H), 4.51 (br s, 1H), 3.60 (br s, 1H), 3.35 (d, <i>J</i> = 15.8 Hz, 1H), 3.24–3.17 (m, 2H), 3.17–3.02 (m, 1H), 2.91 (t, <i>J</i> = 5.6 Hz, 2H), 2.85–2.71 (m, 2H), 2.02 (br s, 3H), 1.84–1.41 (m, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>, δ): 168.1, 158.8 (d, <i>J</i> = 254 Hz), 148.3, 132.8 (d, <i>J</i> = 3.5 Hz), 129.7, 129.3 (2C), 127.1 (d, <i>J</i> = 6.9 Hz), 121.5 (d, <i>J</i> = 18.4 Hz), 117.6, 116.8 (d, <i>J</i> = 22 Hz), 113.0 (2C), 94.3 (d, <i>J</i> = 172 Hz), 57.0 (d, <i>J</i> = 22 Hz), 48.9, 43.6, 43.3, 38.2, 33.6, 32.8. Formula: C<sub>21</sub>H<sub>24</sub>ClF<sub>2</sub>N<sub>3</sub>O; MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 408 [M + H<sup>+</sup>]; Anal. Calcd for C, 61.84; H, 5.93; N, 10.30. Found: C, 62.85; H, 6.72; N, 9.09.</div></div><div id="sec4_3_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> (3-Chloro-4-fluorophenyl)(4-fluoro-4-(((2-(pyridin-2-ylamino)ethyl)amino)methyl)piperidin-1-yl)methanone (<b>13</b>)</h4><div class="NLM_p last">The title compound was prepared using 2-(1-(3-chloro-4-fluorobenzoyl)-4-fluoropiperidin-4-yl)-2-hydroxyacetonitrile (<b>8</b>) (0.120 g, 0.38 mmol), <i>N</i><sup>1</sup>-(pyridin-2-yl)ethane-1,2-diamine (0.079 g, 0.46 mmol), DABCO (0.085 g, 0.76 mmol), sodium cyanoborohydride (0.038 g, 0.61 mmol), molecular sieves (0.900 g), and iron sulfate heptahydrate (0.117 g, 0.42 mmol) in methanol (5 mL). Purification: EtOAc/methanol (9/1, v/v) and then DCM/methanol/NH<sub>3(aq)</sub> (9.5/0.5/0.02, v/v/v). Yield: 23%; orange oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>, δ): 8.08–8.00 (m, 1H), 7.47 (dd, <i>J</i> = 2.1, 6.7 Hz, 1H), 7.44–7.35 (m, 1H), 7.32–7.26 (m, 1H), 7.20–7.11 (m, 1H), 6.55 (dd, <i>J</i> = 5.3, 6.4 Hz, 1H), 6.39 (d, <i>J</i> = 8.2 Hz, 1H), 5.10 (br s, 1H), 4.48 (br s, 1H), 3.57 (br s, 1H), 3.40–3.08 (m, 4H), 3.00 (br s, 1H), 2.89 (t, <i>J</i> = 5.9 Hz, 2H), 2.78 (d, <i>J</i> = 1.0 Hz, 2H), 2.01 (s, 2H), 1.59 (d, <i>J</i> = 17.0 Hz, 2H). <sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>, δ): −112.6 (s, 1F), −166.7 (s, 1F). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>, δ): 168.1, 158.7, 158.8 (d, <i>J</i> = 251 Hz), 147.9, 137.5, 132.8 (d, <i>J</i> = 3.5 Hz), 129.7, 127.1 (d, <i>J</i> = 7.7 Hz), 121.5 (d, <i>J</i> = 18.4 Hz), 116.8 (d, <i>J</i> = 22 Hz), 112.9, 107.1, 94.3 (d, <i>J</i> = 172 Hz), 57.0 (d, <i>J</i> = 22 Hz), 49.1, 43.6, 41.5, 38.2, 33.6, 32.8. Formula: C<sub>20</sub>H<sub>23</sub>ClF<sub>2</sub>N<sub>4</sub>O; MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 409 [M + H<sup>+</sup>].</div></div><div id="sec4_3_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> (3-Chloro-4-fluorophenyl)(4-fluoro-4-(((2-(phenylthio)ethyl)amino)methyl)piperidin-1-yl)methanone (<b>14</b>)</h4><div class="NLM_p last">The title compound was prepared using 2-(1-(3-chloro-4-fluorobenzoyl)-4-fluoropiperidin-4-yl)-2-hydroxyacetonitrile (<b>8</b>) (0.100 g, 0.32 mmol), 2-(phenylthio)ethanamine (0.063 g, 0.41 mmol), DABCO (0.446 g, 3.98 mmol), sodium cyanoborohydride (0.156 g, 2.48 mmol), molecular sieves (0.800 g), and iron sulfate heptahydrate (0.097 g, 0.35 mmol) in methanol (5 mL). Purification: DCM/methanol/NH<sub>3(aq)</sub> (9.5/0.5/0.02, v/v/v). Yield: 59%; colorless oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>, δ): 7.48 (dd, <i>J</i> = 1.8, 7.0 Hz, 1H), 7.38–7.26 (m, 5H), 7.23–7.14 (m, 2H), 4.50 (br s, 1H), 3.59 (br s, 1H), 3.46–3.10 (m, 2H), 3.09–3.03 (m, 2H), 2.89–2.83 (m, 2H), 2.80–2.68 (m, 2H), 1.97 (br s, 2H), 1.69 (br s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>, δ): 168.0, 158.8 (d, <i>J</i> = 252 Hz), 135.6, 132.9 (d, <i>J</i> = 4.4 Hz), 129.7, 129.0 (4C), 127.1 (d, <i>J</i> = 8.1 Hz), 126.3, 121.5 (d, <i>J</i> = 18.2 Hz), 116.8 (d, <i>J</i> = 22 Hz), 94.3 (d, <i>J</i> = 172 Hz), 56.9 (d, <i>J</i> = 22 Hz), 48.7, 43.7, 38.2, 34.2, 33.7, 32.7. Formula: C<sub>21</sub>H<sub>23</sub>ClF<sub>2</sub>N<sub>2</sub>OS; MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 425 [M + H<sup>+</sup>].</div></div><div id="sec4_3_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> (3-Chloro-4-fluorophenyl)(4-fluoro-4-(((2-(pyridin-2-ylthio)ethyl)amino)methyl)piperidin-1-yl)methanone (<b>15</b>)</h4><div class="NLM_p last">The title compound was prepared using 2-(1-(3-chloro-4-fluorobenzoyl)-4-fluoropiperidin-4-yl)-2-hydroxyacetonitrile (<b>8</b>) (0.150 g, 0.48 mmol), 2-(pyridin-2-ylsulfanyl)ethanamine (0.145 g, 0.76 mmol), DABCO (0.669 g, 5.97 mmol), sodium cyanoborohydride (0.234 g, 3.73 mmol), molecular sieves (1.043 g), and iron sulfate heptahydrate (0.146 g, 0.53 mmol) in methanol (5 mL). Purification: <i>n</i>-hexane/EtOAc/methanol/NH<sub>3(aq)</sub> (8/1.5/0.5/0.02, v/v/v/v). Yield: 64%; pale yellow oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>, δ): 8.39 (td, <i>J</i> = 1.2, 5.5 Hz, 1H), 7.52–7.40 (m, 2H), 7.32–7.26 (m, 1H), 7.21–7.13 (m, 2H), 6.97 (ddd, <i>J</i> = 1.0, 5.0, 7.3 Hz, 1H), 4.50 (br s, 1H), 3.59 (br s, 1H), 3.41–3.07 (m, 4H), 2.96 (t, <i>J</i> = 6.4 Hz, 2H), 2.86–2.72 (m, 2H), 1.97 (br s, 2H), 1.63 (br s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>, δ): 168.0, 158.4, 158.8 (d, <i>J</i> = 254 Hz), 149.4, 135.9, 132.9 (d, <i>J</i> = 4.4 Hz), 129.7, 127.1 (d, <i>J</i> = 7.7 Hz), 122.5, 121.5(d, <i>J</i> = 18.2 Hz), 119.5, 116.8 (d, <i>J</i> = 22 Hz), 94.3 (d, <i>J</i> = 172 Hz), 56.9 (d, <i>J</i> = 22 Hz), 49.4, 43.7, 38.2, 33.8, 32.7, 30.0. Formula: C<sub>20</sub>H<sub>22</sub>ClF<sub>2</sub>N<sub>3</sub>OS; MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 426 [M + H<sup>+</sup>].</div></div><div id="sec4_3_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> (3-Chloro-4-fluorophenyl)(4-fluoro-4-(((2-phenoxyethyl)amino)methyl)piperidin-1-yl)methanone (<b>16</b>)</h4><div class="NLM_p last">The title compound was prepared using 2-(1-(3-chloro-4-fluorobenzoyl)-4-fluoropiperidin-4-yl)-2-hydroxyacetonitrile (<b>8</b>) (0.300 g, 0.96 mmol), 2-phenoxyethanamine (0.2 mL, 1.53 mmol), DABCO (1.36 g, 11.938 mmol), sodium cyanoborohydride (0.468 g, 7.45 mmol), molecular sieves (1.982 g), and iron sulfate heptahydrate (0.294 g, 1.06 mmol) in methanol (9 mL). Purification: <i>n</i>-hexane/EtOAc/methanol/NH<sub>3(aq)</sub> (6/3.5/0.5/0.02, v/v/v/v). Yield: 61%; beige crystallizing oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>, δ): 7.48 (dd, <i>J</i> = 2.1, 7.2 Hz, 1H), 7.33–7.26 (m, 3H), 7.22–7.13 (m, 1H), 6.99–6.86 (m, 3H), 4.51 (br s, 1H), 4.07 (t, <i>J</i> = 5.1 Hz, 2H), 3.71–3.53 (m, 1H), 3.22 (br s, 2H), 3.03 (t, <i>J</i> = 5.1 Hz, 2H), 2.92–2.77 (m, 2H), 2.01 (br s, 2H), 1.67 (br s, 3H). <sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>, δ): −112.6 (s, 1F), −166.5 (s, 1F). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>, δ): 168.1, 158.7 (d, <i>J</i> = 254 Hz), 158.7, 132.9 (d, <i>J</i> = 4 Hz), 129.7, 129.5 (2C), 127.1 (d, <i>J</i> = 7.2 Hz), 121.5 (d, <i>J</i> = 18.2 Hz), 120.9, 116.8 (d, <i>J</i> = 22 Hz), 114.5 (2C), 94.4 (d, <i>J</i> = 172 Hz), 67.2, 57.3 (d, <i>J</i> = 22 Hz), 49.3, 43.8, 38.3, 33.3, 31.1. Formula: C<sub>21</sub>H<sub>23</sub>ClF<sub>2</sub>N<sub>2</sub>O<sub>2</sub>; MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 409 [M + H<sup>+</sup>]; Anal. Calcd for C, 61.69; H, 5.67; N, 6.85. Found: C, 61.95; H, 6.06; N, 6.44.</div></div><div id="sec4_3_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> (3-Chloro-4-fluorophenyl)(4-fluoro-4-(((2-(pyridin-2-yloxy)ethyl)amino)methyl)piperidin-1-yl)methanone (<b>17</b>)</h4><div class="NLM_p last">The title compound was prepared using 2-(1-(3-chloro-4-fluorobenzoyl)-4-fluoropiperidin-4-yl)-2-hydroxyacetonitrile (<b>8</b>) (0.220 g, 0.70 mmol), 2-(pyridin-2-yloxy)ethanamine (0.135 g, 0.98 mmol), DABCO (0.981 g, 8.76 mmol), sodium cyanoborohydride (0.343 g, 5.47 mmol), molecular sieves (1.043 g), and iron sulfate heptahydrate (0.214 g, 0.77 mmol) in methanol (5 mL). Purification: <i>n</i>-hexane/EtOAc/methanol/NH<sub>3(aq)</sub> (3/6.5/0.5/0.02, v/v/v/v). Yield: 53%; white crystallizing oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>, δ): 8.16–8.08 (m, 1H), 7.61–7.52 (m, 1H), 7.47 (dd, <i>J</i> = 1.8, 7.0 Hz, 1H), 7.33–7.26 (m, 1H), 7.20–7.12 (m, 1H), 6.90–6.82 (m, 1H), 6.77–6.68 (m, 1H), 4.50 (br s, 1H), 4.42–4.33 (m, 2H), 3.57 (br s, 1H), 3.46–3.06 (m, 2H), 3.02 (t, <i>J</i> = 5.3 Hz, 2H), 2.91–2.73 (m, 2H), 2.01 (br s, 2H), 1.87–1.52 (m, 3H). <sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>, δ): −112.6 (s, 1F), −166.5 (s, 1F). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>, δ): 168.0, 163.6, 158.8 (d, <i>J</i> = 254 Hz), 146.8, 136.6, 132.9 (d, <i>J</i> = 4.6 Hz), 129.7, 127.1 (d, <i>J</i> = 7.7 Hz), 121.5 (d, <i>J</i> = 18.4 Hz), 116.9, 116.8 (d, <i>J</i> = 21 Hz), 111.0, 94.4 (d, <i>J</i> = 172 Hz), 65.1, 57.2 (d, <i>J</i> = 22 Hz), 49.2, 43.7, 38.4, 33.6, 32.8. Formula: C<sub>20</sub>H<sub>22</sub>ClF<sub>2</sub>N<sub>3</sub>O<sub>2</sub>; MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 410 [M + H<sup>+</sup>].</div></div><div id="sec4_3_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> (3,4-Dichlorophenyl)(4-fluoro-4-(((2-phenoxyethyl)amino)methyl)piperidin-1-yl)methanone (<b>18</b>)</h4><div class="NLM_p last">The title compound was prepared using 2-(1-(3,4-dichlorobenzoyl)-4-fluoropiperidin-4-yl)-2-hydroxyacetonitrile (<b>9</b>) (0.150 g, 0.45 mmol), 2-phenoxyethanamine (0.056 g, 0.41 mmol), DABCO (0.634 g, 5.66 mmol), sodium cyanoborohydride (0.034 g, 0.54 mmol), molecular sieves (0.500 g), and iron sulfate heptahydrate (0.137 g, 0.50 mmol) in methanol (8 mL). Purification: <i>n</i>-hexane/Et<sub>2</sub>O/DCM/methanol/NH<sub>3(aq)</sub> (2/2/5.5/0.5/0.02, v/v/v/v/v). Yield: 44%; yellow oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>, δ): 7.54–7.45 (m, 2H), 7.33–7.26 (m, 2H), 7.23 (dd, <i>J</i> = 2.1, 8.2 Hz, 1H), 7.00–6.86 (m, 3H), 4.52 (br s, 1H), 4.07 (t, <i>J</i> = 5.1 Hz, 2H), 3.58 (br s, 1H), 3.44–3.10 (m, 2H), 3.03 (t, <i>J</i> = 5.1 Hz, 2H), 2.91–2.78 (m, 2H), 2.02 (br s, 2H), 1.61 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>, δ): 167.9, 158.7, 135.7, 134.1, 133.0, 130.6, 129.5 (2C), 129.1, 126.2, 120.9, 114.5 (2C), 94.3 (d, <i>J</i> = 172 Hz), 67.2, 57.3 (d, <i>J</i> = 22 Hz), 49.3, 43.6, 38.2, 33.7, 32.7. Formula: C<sub>21</sub>H<sub>23</sub>Cl<sub>2</sub>FN<sub>2</sub>O<sub>2</sub>; MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 425 [M + H<sup>+</sup>].</div></div><div id="sec4_3_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> (3,4-Dichlorophenyl)(4-fluoro-4-(((2-(pyridin-2-yloxy)ethyl)amino)methyl)piperidin-1-yl)methanone (<b>19</b>)</h4><div class="NLM_p last">The title compound was prepared using 2-(1-(3,4-dichlorobenzoyl)-4-fluoropiperidin-4-yl)-2-hydroxyacetonitrile (<b>9</b>) (0.150 g, 0.45 mmol), 2-(pyridin-2-yloxy)ethanamine (0.081 g, 0.59 mmol), DABCO (0.634 g, 5.66 mmol), sodium cyanoborohydride (0.222 g, 3.53 mmol), molecular sieves (0.900 g), and iron sulfate heptahydrate (0.137 g, 0.50 mmol) in methanol (5 mL). Purification: EtOAc/methanol (9.5/0.5/, v/v). Yield: 41%; yellow oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>, δ): 8.17–8.08 (m, 1H), 7.61–7.53 (m, 1H), 7.52–7.44 (m, 2H), 7.23 (dd, <i>J</i> = 1.8, 8.2 Hz, 1H), 6.91–6.82 (m, 1H), 6.77–6.69 (m, 1H), 4.50 (br s, 1H), 4.43–4.34 (m, 2H), 3.71–3.47 (m, 1H), 3.47–3.07 (m, 2H), 3.03 (t, <i>J</i> = 5.3 Hz, 2H), 2.84 (d, <i>J</i> = 1.0 Hz, 2H), 2.00 (br s, 2H), 1.61 (br s, 3H). <sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>, δ): −166.6 (s, 1F). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>, δ): 167.9, 163.6, 146.8, 138.7, 135.6, 134.1, 133.0, 130.6, 129.1, 126.2, 116.9, 111.0, 94.3 (d, <i>J</i> = 173 Hz), 65.1, 57.2 (d, <i>J</i> = 22 Hz), 49.2, 43.5, 38.2, 33.6, 32.6. Formula: C<sub>20</sub>H<sub>22</sub>Cl<sub>2</sub>FN<sub>3</sub>O<sub>2</sub>; MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 426 [M + H<sup>+</sup>].</div></div><div id="sec4_3_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> (3-Chloro-4-fluorophenyl)(4-fluoro-4-(((2-(pyridin-3-yloxy)ethyl)amino)methyl)piperidin-1-yl)methanone (<b>20</b>)</h4><div class="NLM_p last">The title compound was prepared using 2-(1-(3-chloro-4-fluorobenzoyl)-4-fluoropiperidin-4-yl)-2-hydroxyacetonitrile (<b>8</b>) (0.150 g, 0.48 mmol), 2-(pyridin-3-yloxy)ethanamine (0.105 g, 0.76 mmol), DABCO (0.669 g, 5.97 mmol), sodium cyanoborohydride (0.234 g, 3.73 mmol), molecular sieves (1.043 g), and iron sulfate heptahydrate (0.146 g, 0.53 mmol) in methanol (5 mL). Purification: EtOAc/methanol (9.5/0.5, v/v). Yield: 55%; orange crystallizing oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>, δ): 8.32 (td, <i>J</i> = 1.0, 1.7 Hz, 1H), 8.25–8.21 (m, 1H), 7.48 (dd, <i>J</i> = 2.1, 6.9 Hz, 1H), 7.33–7.26 (m, 1H), 7.23–7.13 (m, 3H), 4.52 (br s, 1H), 4.11 (t, <i>J</i> = 5.1 Hz, 2H), 3.61 (br s, 1H), 3.18 (d, <i>J</i> = 5.1 Hz, 2H), 3.05 (t, <i>J</i> = 5.1 Hz, 2H), 2.90–2.79 (m, 2H), 2.08–1.95 (m, 2H), 1.79 (br s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>, δ): 168.1, 158.8 (d, <i>J</i> = 254 Hz), 154.9, 142.3, 137.9, 132.9 (d, <i>J</i> = 4.4 Hz), 129.7, 127.1 (d, <i>J</i> = 7.7 Hz), 123.8, 121.5 (d, <i>J</i> = 18.2 Hz), 121.1, 116.8 (d, <i>J</i> = 21 Hz), 94.3 (d, <i>J</i> = 172 Hz), 67.8, 57.3 (d, <i>J</i> = 22 Hz), 49.1, 43.6, 38.3, 33.5, 32.8. Formula: C<sub>20</sub>H<sub>22</sub>ClF<sub>2</sub>N<sub>3</sub>O<sub>2</sub>; MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 410 [M + H<sup>+</sup>].</div></div><div id="sec4_3_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> (3-Chloro-4-fluorophenyl)(4-fluoro-4-(((2-(pyridin-4-yloxy)ethyl)amino)methyl)piperidin-1-yl)methanone (<b>21</b>)</h4><div class="NLM_p last">The title compound was prepared using 2-(1-(3-chloro-4-fluorobenzoyl)-4-fluoropiperidin-4-yl)-2-hydroxyacetonitrile (<b>8</b>) (0.300 g, 0.96 mmol), 2-(pyridin-4-yloxy)ethanamine (0.185 g, 1.34 mmol), DABCO (1.34 g, 12.00 mmol), sodium cyanoborohydride (0.467 g, 7.45 mmol), molecular sieves (2.080 g), and iron sulfate heptahydrate (0.292 g, 1.05 mmol) in methanol (9.5 mL). Purification: EtOAc/methanol (9.5/0.5, v/v). Yield: 31%; orange oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>, δ): 8.19–8.13 (m, 2H), 7.47 (dd, <i>J</i> = 2.1, 6.9 Hz, 1H), 7.32–7.27 (m, 1H), 7.21–7.13 (m, 1H), 6.59–6.54 (m, 2H), 4.56 (s, 1H), 3.82 (t, <i>J</i> = 5.9 Hz, 2H), 3.68 (d, <i>J</i> = 18.7 Hz, 2H), 3.33 (br s, 1H), 3.00 (m, 4H), 2.08 (br s, 2H), 1.90 (br s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>, δ): 168.2, 158.9 (d, <i>J</i> = 252 Hz), 154.2, 148.0 (2C), 132.5 (d, <i>J</i> = 4.7 Hz), 129.8, 127.2 (d, <i>J</i> = 6.9 Hz), 121.6 (d, <i>J</i> = 17.5 Hz), 116.9 (d, <i>J</i> = 22 Hz), 107.5 (2C), 95.8 (d, <i>J</i> = 175 Hz), 58.5, 57.7 (d, <i>J</i> = 22 Hz), 52.9, 43.0, 37.8, 33.8, 32.5. Formula: C<sub>20</sub>H<sub>22</sub>ClF<sub>2</sub>N<sub>3</sub>O<sub>2</sub>; MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 410 [M + H<sup>+</sup>].</div></div><div id="sec4_3_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> (3-Chloro-4-fluorophenyl)(4-fluoro-4-(((2-(pyrazin-2-yloxy)ethyl)amino)methyl)piperidin-1-yl)methanone (<b>22</b>)</h4><div class="NLM_p last">The title compound was prepared using 2-(1-(3-chloro-4-fluorobenzoyl)-4-fluoropiperidin-4-yl)-2-hydroxyacetonitrile (<b>8</b>) (0.150 g, 0.48 mmol), 2-(pyrazin-2-yloxy)ethanamine (0.106 g, 0.76 mmol), DABCO (0.669 g, 5.97 mmol), sodium cyanoborohydride (0.234 g, 3.73 mmol), molecular sieves (1.043 g), and iron sulfate heptahydrate (0.146 g, 0.53 mmol) in methanol (5 mL). Purification: EtOAc/methanol (9.8/0.2, v/v). Yield: 40%; yellow crystalizing oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>, δ): 8.22 (d, <i>J</i> = 1.3 Hz, 1H), 8.11 (d, <i>J</i> = 2.8 Hz, 1H), 8.06 (dd, <i>J</i> = 1.4, 2.7 Hz, 1H), 7.47 (dd, <i>J</i> = 2.1, 6.9 Hz, 1H), 7.32–7.26 (m, 1H), 7.21–7.12 (m, 1H), 4.63–4.36 (m, 3H), 3.59 (br s, 1H), 3.27 (br s, 2H), 3.04 (t, <i>J</i> = 5.3 Hz, 2H), 2.90–2.77 (m, 2H), 2.00 (br s, 2H), 1.64 (br s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>, δ): 168.1, 160.1, 158.8 (d, <i>J</i> = 254 Hz), 140.5, 136.7, 135.9, 132.9 (d, <i>J</i> = 4.4 Hz), 129.7, 127.1 (d, <i>J</i> = 7.7 Hz), 121.5 (d, <i>J</i> = 18.2 Hz), 116.8 (d, <i>J</i> = 22 Hz), 94.4 (d, <i>J</i> = 172 Hz), 65.7, 57.3 (d, <i>J</i> = 22 Hz), 48.9, 43.7, 38.3, 33.6, 33.0. Formula: C<sub>19</sub>H<sub>21</sub>ClF<sub>2</sub>N<sub>4</sub>O<sub>2</sub>; MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 411 [M + H<sup>+</sup>].</div></div><div id="sec4_3_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> (3-Chloro-4-fluorophenyl)(4-fluoro-4-(((2-(pyrimidin-2-yloxy)ethyl)amino)methyl)piperidin-1-yl)methanone (<b>23</b>)</h4><div class="NLM_p last">The title compound was prepared using 2-(1-(3-chloro-4-fluorobenzoyl)-4-fluoropiperidin-4-yl)-2-hydroxyacetonitrile (<b>8</b>) (0.500 g, 1.59 mmol), 2-(pyrimidin-2-yloxy)ethanamine (0.537 g, 2.53 mmol), DABCO (1.160 g, 10.36 mmol), sodium cyanoborohydride (0.595 g, 9.46 mmol), molecular sieves (1.140 g), and iron sulfate heptahydrate (0.486 g, 1.75 mmol) in methanol (17 mL). Purification: EtOAc/methanol (9.5/0.5, v/v). Yield: 47%; orange oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>, δ): 8.52–8.51 (m, 2H), 7.49–7.47 (m, 1H), 7.29–7.28 (m, 1H), 7.20–7.16 (m, 1H), 6.97–6.94 (m, 1H), 4.51 (br s, 1H), 4.48–4.45 (t, <i>J</i> = 5.0 Hz, 2H), 3.73–3.15 (m, 3H), 3.08–3.05 (t, <i>J</i> = 5.3 Hz, 2H), 2.85 (m, 2H), 2.01 (br s 2H), 1.77–1.50 (m, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>, δ): 168.0, 165.1, 159.3 (2C), 158.8 (d, <i>J</i> = 252 Hz), 132.9 (d, <i>J</i> = 3.5 Hz), 129.7, 127.1 (d, <i>J</i> = 6.9 Hz), 121.5 (d, <i>J</i> = 17.3 Hz), 116.8 (d, <i>J</i> = 22 Hz), 115.2, 94.2 (d, <i>J</i> = 172 Hz), 66.9, 57.2 (d, <i>J</i> = 22 Hz), 48.9, 43.6, 38.2, 33.4, 32.7. Formula: C<sub>19</sub>H<sub>21</sub>ClF<sub>2</sub>N<sub>4</sub>O<sub>2</sub>; MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 411 [M + H<sup>+</sup>].</div></div><div id="sec4_3_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> (3-Chloro-4-fluorophenyl)(4-fluoro-4-(((2-(pyrimidin-5-yloxy)ethyl)amino)methyl)piperidin-1-yl)methanone (<b>24</b>)</h4><div class="NLM_p last">The title compound was prepared using 2-(1-(3-chloro-4-fluorobenzoyl)-4-fluoropiperidin-4-yl)-2-hydroxyacetonitrile (<b>8</b>) (0.115 g, 0.37 mmol), 2-(pyrimidin-5-yloxy)ethanamine dihydrochloride (0.090 g, 0.51 mmol), DABCO (0.514 g, 4.78 mmol), sodium cyanoborohydride (0.179 g, 2.86 mmol), molecular sieves (0.900 g), and iron sulfate heptahydrate (0.112 g, 0.40 mmol) in methanol (4 mL). Purification: EtOAc/methanol (8/2, v/v). Yield: 53%; yellow crystalizing oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>, δ): 8.85 (s, 1H), 8.41 (s, 2H), 7.47 (dd, <i>J</i> = 2.1, 6.9 Hz, 1H), 7.32–7.26 (m, 1H), 7.21–7.12 (m, 1H), 4.50 (br s, 1H), 4.16 (t, <i>J</i> = 5.0 Hz, 2H), 3.60 (br s, 1H), 3.46–3.12 (m, 2H), 3.07 (t, <i>J</i> = 5.0 Hz, 2H), 2.91–2.78 (m, 2H), 2.00 (br s, 2H), 1.79–1.55 (m, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>, δ): 168.1, 158.8 (d, <i>J</i> = 254 Hz), 152.8, 151.7, 143.6 (2C), 132.8 (d, <i>J</i> = 3.9 Hz), 129.7, 127.1 (d, <i>J</i> = 7.7 Hz), 121.5 (d, <i>J</i> = 17.7 Hz), 116.8 (d, <i>J</i> = 22 Hz), 94.3 (d, <i>J</i> = 172 Hz), 68.3, 57.3 (d, <i>J</i> = 22 Hz), 48.9, 43.6, 38.2, 33.6, 32.8. Formula: C<sub>19</sub>H<sub>21</sub>ClF<sub>2</sub>N<sub>4</sub>O<sub>2</sub>; MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 411 [M + H<sup>+</sup>].</div></div><div id="sec4_3_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> (3-Chloro-4-fluorophenyl)(4-fluoro-4-(((2-(pyridazin-4-yloxy)ethyl)amino)methyl)piperidin-1-yl)methanone (<b>25</b>)</h4><div class="NLM_p last">The title compound was prepared using 2-(1-(3-chloro-4-fluorobenzoyl)-4-fluoropiperidin-4-yl)-2-hydroxyacetonitrile (<b>8</b>) (0.150 g, 0.48 mmol), 2-(pyridazin-4-yloxy)ethanamine hydrochloride (0.134 g, 0.76 mmol), DABCO (0.669 g, 5.97 mmol), sodium cyanoborohydride (0.234 g, 3.73 mmol), molecular sieves (1.043 g), and iron sulfate heptahydrate (0.146 g, 0.53 mmol) in methanol (5 mL). Purification: DCM/methanol (9.5/0.5, v/v). Yield: 66%; beige oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>, δ): 7.88 (d, <i>J</i> = 3.1 Hz, 1H), 7.76 (d, <i>J</i> = 7.7 Hz, 1H), 7.46 (dd, <i>J</i> = 2.1, 6.9 Hz, 1H), 7.31–7.24 (m, 1H), 7.22–7.14 (m, 1H), 6.42 (dd, <i>J</i> = 3.2, 7.8 Hz, 1H), 4.48 (br s, 1H), 4.08–4.00 (m, 2H), 3.59 (br s, 1H), 3.42–3.14 (m, 2H), 3.13–3.05 (m, 2H), 2.81–2.67 (m, 2H), 1.94 (br s, 2H), 1.70 (br s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>, δ): 170.8, 168.1, 158.8 (d, <i>J</i> = 254 Hz), 150.1, 142.1, 132.7 (d, <i>J</i> = 4.4 Hz), 129.7, 127.1 (d, <i>J</i> = 7.7 Hz), 121.6 (d, <i>J</i> = 17.7 Hz), 116.8 (d, <i>J</i> = 22 Hz), 116.6, 94.3 (d, <i>J</i> = 172 Hz), 59.5, 57.1 (d, <i>J</i> = 22 Hz), 48.9, 43.8, 38.2, 33.5, 32.9. Formula: C<sub>19</sub>H<sub>21</sub>ClF<sub>2</sub>N<sub>4</sub>O<sub>2</sub>; MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 411 [M + H<sup>+</sup>].</div></div><div id="sec4_3_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> (3-Chloro-4-fluorophenyl)(4-fluoro-4-(((2-((5-methylpyridin-2-yl)oxy)ethyl)amino)methyl)piperidin-1-yl)methanone (<b>26</b>)</h4><div class="NLM_p last">The title compound was prepared using 2-(1-(3-chloro-4-fluorobenzoyl)-4-fluoropiperidin-4-yl)-2-hydroxyacetonitrile (<b>8</b>) (0.793 g, 2.52 mmol), 2-[(5-methylpyridin-2-yl)oxy]ethanamine (0.500 g, 2.62 mmol), DABCO (1.69 g, 15.24 mmol), sodium cyanoborohydride (1.230 g, 19.66 mmol), molecular sieves (4.580 g), and iron sulfate heptahydrate (0.771 g, 2.77 mmol) in methanol (25 mL). Purification: <i>n</i>-hexane/EtOAc (1/9, v/v) and then EtOAc/methanol (9.5/0.5, v/v). Yield: 47%; white oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>, δ): 7.94–7.9 3 (m, 1H), 7.49–7.47 (m, 1H), 7.41–7.28 (m, 2H), 7.20–7.16 (m, 1H), 6.67–6.65 (d, 1H), 4.51 (m, 1H), 4.38–4.35 (t, <i>J</i> = 5.1 Hz, 2H), 3.64–3.18 (m, 3H), 3.04–3.01 (t, <i>J</i> = 5.3 Hz, 2H), 2.87–2.82 (d, <i>J</i> = 19.9 Hz, 2H), 2.24 (s, 3H), 2.00 (br s, 2H) 1, 83–1.51 (m, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>, δ): 168.1, 161.9, 158.8 (d, <i>J</i> = 252 Hz), 146.2, 139.8, 132.9 (d, <i>J</i> = 3.5 Hz), 129.7, 127.1 (d, <i>J</i> = 8.1 Hz), 125.9, 121.5 (d, <i>J</i> = 17.3 Hz), 116.8 (d, <i>J</i> = 21 Hz), 94.3 (d, <i>J</i> = 172 Hz), 65.0, 57.2 (d, <i>J</i> = 22 Hz), 49.3, 43.7, 38.2, 33.7, 32.9, 17.4. Formula: C<sub>21</sub>H<sub>24</sub>ClF<sub>2</sub>N<sub>3</sub>O<sub>2</sub>; MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 424 [M + H<sup>+</sup>].</div></div><div id="sec4_3_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> (3-Chloro-4-fluorophenyl)(4-fluoro-4-(((2-((5-methylpyrimidin-2-yl)oxy)ethyl)amino)methyl)piperidin-1-yl)methanone (<b>27</b>)</h4><div class="NLM_p last">The title compound was prepared using 2-(1-(3-chloro-4-fluorobenzoyl)-4-fluoropiperidin-4-yl)-2-hydroxyacetonitrile (<b>8</b>) (1.170 g, 3.72 mmol), 2-(5-methylpyrimidin-2-yloxy)ethanamine (0.600 g, 3.92 mmol), DABCO (2.500 g, 22.50 mmol), sodium cyanoborohydride (1.820 g, 29.02 mmol), and molecular sieves (4.800 g) in methanol (17 mL). Purification: EtOAc/methanol/(9.5/0.5, v/v). Yield: 34%; white crystallizing oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>, δ): 8.32 (s, 2H), 7.49–7.47 (m, 1H), 7.32–7.28 (m, 1H), 7.20–7.16 (m, 1H), 4.54 (br s, 1H), 4.44–4.41 (t, <i>J</i> = 5.0 Hz, 2H), 3.60–3.16 (m, 3H), 3.06–3.02 (t, <i>J</i> = 5.3 Hz, 2H), 2.86 (m, 2H), 2.25 (s, 3H), 2.04 (br s, 2H) 1.81–1.52 (m, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>, δ): 168.1, 163.7, 159.1 (2C), 158.8 (d, <i>J</i> = 252 Hz), 132.9 (d, <i>J</i> = 4.6 Hz), 129.7, 127.1 (d, <i>J</i> = 6.9 Hz), 123.9, 121.5 (d, <i>J</i> = 18.4 Hz), 116.8 (d, <i>J</i> = 21 Hz), 94.3 (d, <i>J</i> = 172 Hz), 66.8, 57.3 (d, <i>J</i> = 22 Hz), 49.0, 43.3, 38.1, 33.7, 32.7, 14.6. Formula: C<sub>20</sub>H<sub>23</sub>ClF<sub>2</sub>N<sub>4</sub>O<sub>2</sub>; MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> 425 [M + H<sup>+</sup>].</div></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> Developability Studies</h3><div class="NLM_p">The PAINS and Brenk alerts, as well as fraction of sp<sup>3</sup> atoms (Fsp<sup>3</sup>) were determined using SwissADME server.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a></div><div class="NLM_p">Instant JChem was used for structure database management and prediction of the remaining physicochemical parameters, Instant JChem 15.12.14.0, 2015, ChemAxon (<a href="http://www.chemaxon.com" class="extLink">http://www.chemaxon.com</a>).</div><div class="NLM_p last">The SafetyScreen44 Panel (plus additional antitargets), the bioavailability panel, CYP3A4, CYP2D6, P-glycoprotein inhibition, and cardiac toxicity (hERG automated patch-clamp method) assays were performed by Eurofins Pharma Discovery Services according to the well-known methods. Further methodological details are available on the company Web site (<a href="http://www.eurofinsdiscoveryservices.com" class="extLink">www.eurofinsdiscoveryservices.com</a>) and the appropriate publications.<a onclick="showRef(event, 'ref45 ref60 ref61 ref62 ref63 ref64 ref95 ref96'); return false;" href="javascript:void(0);" class="ref ref45 ref60 ref61 ref62 ref63 ref64 ref95 ref96">(45,60−64,95,96)</a></div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> In Vitro Studies</h3><div class="NLM_p last">The tested compounds were examined for known classes of assay interference compounds. None of the compounds contain substructural features recognized as PAINS, according to SwissADME tool.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a></div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> Radioligand Binding Assays for 5-HT<sub>1A</sub>R, α<sub>1</sub>R, and D<sub>2</sub>R</h3><div id="sec4_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> Preparation of Solutions of Test and Reference compounds</h4><div class="NLM_p last">Stock solutions (1 mM) of tested compounds were prepared in dimethyl sulfoxide (DMSO). Serial dilutions of compounds were prepared in a 96-well microplate in assay buffers using an automated pipetting system epMotion 5070 (Eppendorf). Each compound was tested in 10 concentrations from 1.0 × 10<sup>–6</sup> to 1.0 × 10<sup>–12</sup> M (final concentration).</div></div><div id="sec4_6_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> Serotonin 5-HT<sub>1A</sub> Receptor Binding Assay</h4><div class="NLM_p last">Radioligand binding was performed using membranes from CHO-K1 cells stably transfected with the human 5-HT<sub>1A</sub> receptor (PerkinElmer). All assays were carried out in duplicates. Working solution (50 μL) of the tested compounds, [<sup>3</sup>H]-8-OH-DPAT (50 μL) (final concentration 1 nM), and diluted membranes (150 μL) (10 μg protein per well) prepared in assay buffer (50 mM Tris, pH 7.4, 10 mM MgSO<sub>4</sub>, 0, 5 mM EDTA, 0.1% ascorbic acid) were transferred to a polypropylene 96-well microplate using a 96-well pipetting station Rainin Liquidator (MettlerToledo). Serotonin (10 μM) was used to define nonspecific binding. The microplate was covered with a sealing tape, mixed, and incubated for 60 minutes at 27 °C. The reaction was terminated by rapid filtration through a GF/C filter mate presoaked with 0.3% polyethyleneimine for 30 minutes. Ten rapid washes with 200 μL of 50 mM Tris buffer (4 °C, pH 7.4) were performed using an automated harvester system Harvester-96 MACH III FM (Tomtec). The filter mates were dried at 37 °C in a forced air fan incubator and then a solid scintillator MeltiLex was melted on filter mates at 90 °C for 4 min. Radioactivity was counted in a MicroBeta2 scintillation counter (PerkinElmer). Data were fitted to a one-site curve-fitting equation with Prism 6 (GraphPad Software), and <i>K</i><sub>i</sub> values were estimated from the Cheng–Prusoff equation.</div></div><div id="sec4_6_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> Adrenergic α<sub>1</sub> Receptor Binding Assay</h4><div class="NLM_p last">Radioligand binding was performed using rat cortex. The tissue was homogenized in 20 volumes of ice-cold 50 mM Tris-HCl buffer, pH 7.6 using an Ultra Turrax T25B (IKA) homogenizer. The homogenate was centrifuged at 20 000<i>g</i> for 20 min. The resulting supernatant was decanted, and the pellet was resuspended in the same buffer and centrifuged again in the same conditions. The final pellet was resuspended in an appropriate volume of buffer (10 mg/1 mL). All assays were carried out in duplicates. Working solution (50 μL) of the tested compounds, [<sup>3</sup>H]-prazosin (50 μL) (final concentration 0.2 nM), and tissue suspension (150 μL) were transferred to a polypropylene 96-well microplate using a 96-well pipetting station Rainin Liquidator (MettlerToledo). Phentolamine (10 μM) was used to define nonspecific binding. The microplate was covered with a sealing tape, mixed, and incubated for 30 min at 30 °C. The incubation was terminated by rapid filtration over glass fiber filters FilterMate B (PerkinElmer, USA) using a 96-well FilterMate harvester (PerkinElmer, USA). Five rapid washes were performed with ice-cold 50 mM Tris-HCl buffer, pH 7.6. The filter mates were dried at 37 °C in a forced air fan incubator, and then, a solid scintillator MeltiLex was melted on filter mates at 90 °C for 5 min. Radioactivity was counted in a MicroBeta2 scintillation counter (PerkinElmer). Data were fitted to a one-site curve-fitting equation with Prism 6 (GraphPad Software), and <i>K</i><sub>i</sub> values were estimated from the Cheng–Prusoff equation.</div></div><div id="sec4_6_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> Dopamine D<sub>2</sub> Receptor Binding Assay</h4><div class="NLM_p last">Radioligand binding was performed using membranes from CHO-K1 cells stably transfected with the human D<sub>2</sub> receptor (PerkinElmer). All assays were carried out in duplicates. Working solution (50 μL) of the tested compounds, [<sup>3</sup>H]-methylspiperone (50 μL) (final concentration 0.4 nM), and diluted membranes (150 μL) (3 μg protein per well) prepared in assay buffer (50 mM Tris, pH 7.4, 50 mM HEPES, 50 mM NaCl, 5 mM MgCl<sub>2</sub>, 0.5 mM EDTA) were transferred to a polypropylene 96-well microplate using a 96-well pipetting station Rainin Liquidator (MettlerToledo). Haloperidol (10 μM) was used to define nonspecific binding. The microplate was covered with a sealing tape, mixed, and incubated for 60 min at 37 °C. The reaction was terminated by rapid filtration through a GF/B filter mate presoaked with 0.5% polyethyleneimine for 30 min. Ten rapid washes with 200 μL of 50 mM Tris buffer (4 °C, pH 7.4) were performed using an automated harvester system Harvester-96 MACH III FM (Tomtec). The filter mates were dried at 37 °C in a forced air fan incubator, and then, a solid scintillator MeltiLex was melted on filter mates at 90 °C for 5 min. Radioactivity was counted in a MicroBeta2 scintillation counter (PerkinElmer). Data were fitted to a one-site curve-fitting equation with Prism 6 (GraphPad Software), and <i>K</i><sub>i</sub> values were estimated from the Cheng–Prusoff equation.</div></div><div id="sec4_6_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> 5-HT<sub>1A</sub> Saturation Binding Assay</h4><div class="NLM_p last">[<sup>3</sup>H]-8-OH-DPAT, [propyl-2,3-ring-1,2,3-3H], spec. act. 135.2 Ci/mmol, 1 mCi/mL, PerkinElmer) was used for labeling 5-HT<sub>1A</sub>Rs. Saturation binding studies were performed using membranes from CHO-K1/U2OS cells stably transfected with the human 5-HT<sub>1A</sub> receptor (PerkinElmer). All assays were carried out in triplicates. [<sup>3</sup>H]-8-OH-DPAT solution (50 μL) (10 concentrations ranging from 0.4 to 14 nM), Tris-HCl buffer (50 μL) (total binding) or 10 μM serotonin (50 μL) (nonspecific binding), and diluted membranes (150 μL) (20 μg protein per well) prepared in assay buffer (50 mM Tris, pH 7.4, 10 mM MgSO<sub>4</sub>, 0.5 mM EDTA, 0.1% ascorbic acid) were transferred to a polypropylene 96-well microplate using a 96-well pipetting station Rainin Liquidator (MettlerToledo). The microplate was covered with a sealing tape, mixed, and incubated for 60 min at 27 °C. The reaction was terminated by rapid filtration through a GF/B filter mate presoaked with 0.5% polyethyleneimine for 30 min. Ten rapid washes with 200 μL of 50 mM Tris buffer (4 °C, pH 7.4) were performed using an automated harvester system Harvester-96 MACH III FM (Tomtec). The filter mates were dried at 37 °C in a forced air fan incubator, and then, the solid scintillator MeltiLex was melted on filter mates at 90 °C for 4 min. Radioactivity was counted in a MicroBeta2 scintillation counter (PerkinElmer). Data were calculated using Prism 5 (GraphPad Software) and <i>B</i><sub>max</sub> and <i>K</i><sub>D</sub> values were estimated from the one-site specific binding saturation curve.</div></div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> Functional Assays for the 5-HT<sub>1A</sub> Receptor</h3><div id="sec4_7_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> ERK1/2 Phosphorylation</h4><div class="NLM_p">Test and reference compounds were dissolved in DMSO at a concentration of 10 mM. Serial dilutions were prepared in a 96-well microplate in HBSS with 0.1% BSA added, and eight concentrations were tested.</div><div class="NLM_p last">The CHO-5HT<sub>1A</sub> receptor cells were tested for agonist-induced ERK1/2-phosphorylation using the SureFire ERK1/2-Phosphorylation Alpha LISA assay kit according to the manufacturer’s instruction (PerkinElmer). After thawing, the cells were cultured in the medium [Advanced DMEM/F12 with 1% fetal bovine serum (FBS) dialyzed, 400 μg/mL G-418, 4 mM <span class="smallcaps smallerCapital">l</span>-glutamine]. In the experiment, the cells were plated at 50 000 cells/well of a 96-well tissue culture plate and grown for 7 h in an incubator (5% CO<sub>2</sub>, 37 °C); after this time, the cells were starved (DMEM/F12 with 0, 1% BSA (immunoglobulin- and protease-free) for 12 h. The serial dilutions of compounds were added and incubated for 15 min at 37 °C. The medium was removed, the “lysis buffer” (70 μL) was added, and the plate was gently agitated on a plate shaker (10 min). The plates were frozeneezing at −80 °C. The next day, the plates were thawed on a plate shaker for 10 min and 10 μL was transferred to assay plates (384-OptiPlate, PerkinElmer) in duplicate and 10 μL of the reaction mix AlphaLISA SureFire Ultra assay (PerkinElmer) was added. The plate was incubated for 2 h in 22 °C. After incubation, the assay plate was measured in an EnVision multifunction plate reader (PerkinElmer Life Science). <i>E</i><sub>max</sub> values were defined as the response of the ligand expressed as a percentage of the maximal response elicited by serotonin, determined by nonlinear regression using GraphPad Prism 6.0 software. pEC<sub>50</sub> values correspond to the ligand concentration at which 50% of its own maximal response was measured.</div></div><div id="sec4_7_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> cAMP Inhibition</h4><div class="NLM_p">Tested and reference compounds were dissolved in DMSO to the concentration of 10 mM. Dilutions were prepared in a 96-well microplate in assay buffers. For 5-HT<sub>1A</sub> receptors, adenylyl cyclase activity was determined using cryopreserved CHO-K1 cells with expression of the human serotonin 5-HT<sub>1A</sub> receptor.</div><div class="NLM_p last">The functional assay was performed with the CHO-K1 cells with expression of the 5-HT<sub>1A</sub> human serotonin receptor where the plasmid containing the coding sequence was transfected in. The cells were cultured under selective conditions (400 μg/mL Geneticin G418) (PerkinElmer). Thawed cells were resuspended in stimulation buffer (HBSS, 5 mM HEPES, 0.5 IBMX, and 0.1% BSA at pH 7.4) at 2 × 10<sup>5</sup> cells/mL. The same volume (10 μL) of cell suspension was added to tested compounds with 10 μM forskolin. The samples were loaded onto a white opaque half area 96-well microplate. Cell stimulation was performed for 40 min at room temperature. After incubation, cAMP measurements were performed with homogeneous TR-FRET immunoassay using the LANCE Ultra cAMP kit (PerkinElmer, USA). EucAMP Tracer Working Solution (10 μL) and ULight-anti-cAMP Tracer Working Solution (10 μL) were added, mixed, and incubated for 1 h. The TR-FRET signal was read on an EnVision microplate reader (PerkinElmer, USA). <i>E</i><sub>max</sub> values were defined as the response of the ligand expressed as a percentage of the maximal response elicited by serotonin, determined by nonlinear regression using GraphPad Prism 6.0 software. pEC<sub>50</sub> values correspond to the ligand concentration at which 50% of its own maximal response was measured.</div></div><div id="sec4_7_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> β-Arrestin Recruitment</h4><div class="NLM_p">Test and reference compounds were dissolved in DMSO at a concentration of 10 mM. Serial dilutions were prepared in a 96-well microplate in Dulbecco’s modified Eagle’s medium (DMEM) medium with 10% FBS added, and eight concentrations were tested.</div><div class="NLM_p last">The HTR1A-bla U2OS receptor cells containing the human Serotonin Type 1A receptor linked to a TEV protease site and a Gal4-VP16 transcription factor were tested for agonist-induced ERK1/2-phosphorylation using the Tango LiveBLAzer assay kit according to the manufacturer’s instruction (Life Technologies). After thawing, the cells were cultured in the medium (McCoy’s 5A with 10% FBS dialyzed, 0.1 mM NEAA, 25 mM HEPES, 1 mM sodium pyruvate, 100 μg/mL G-418, 100 U/mL penicillin/streptomycin Antibiotic, 200 μg/mL Zeocin, 50 μg/mL Hygromycin). In the experiment, cells were plated at 10 000 cells/well of a 384-well black, clear-bottom, tissue culture plate and grown for 12 h in an incubator (5% CO<sub>2</sub>, 37 °C) in DMEM medium with 10% FBS added. The serial dilutions of compounds were added and incubated for 5 h (5% CO<sub>2</sub>, 37 °C). After this time, 8 μL of the reaction mix was added. The plate was incubated for 2 h in 22 °C. After incubation, the assay plate was measured in FLUOstar Optima, a multifunction plate reader (PerkinElmer Life Science). <i>E</i><sub>max</sub> values were defined as the response of the ligand expressed as a percentage of the maximal response elicited by serotonin, determined by nonlinear regression using GraphPad Prism 6.0 software. pEC<sub>50</sub> values correspond to the ligand concentration at which 50% of its own maximal response was measured.</div></div><div id="sec4_7_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> Calcium Mobilization Assay</h4><div class="NLM_p last">CHO-K1 cells with stable expression of the human 5HT<sub>1A</sub> receptor were cultured according to the manufacturer’s instruction (PerkinElmer) in standard medium (Advanced DMEM/F12 with 1% FBS dialyzed, 400 μg/mL G-418, 4 mM <span class="smallcaps smallerCapital">l</span>-glutamine). In the experiment, the cells were plated at 60 000 cells/well of a 96-well tissue culture plate and grown for 12 h and incubated (5% CO<sub>2</sub>, 37 °C). The cells grown in 96-well plates were washed two times with HBSS assay buffer (137 mM NaCl, 5.4 mM KCl, 0.25 mM Na<sub>2</sub>HPO<sub>4</sub>, 0.44 mM KH<sub>2</sub>PO<sub>4</sub>, 1.3 mM CaCl<sub>2</sub>, 1.0 mM MgSO<sub>4</sub>, 1.0 mM MgCl<sub>2</sub>, 10 mM glucose, 10 mM HEPES, 2 mM probenecid, 0.1% BSA with pH adjusted to 7.4 using 1.0 M HCl). Next, the 3 μM Fluo-4AM in the loading buffer containing 0.04% w/v Pluronic F-127 at 100 μL was added to each well and the plate was incubated at 37 °C for 1 h. The cells were washed two times with the assay buffer and 100 μL of the assay buffer was dispensed to each well. Fluorescence readings (ex 485 nm, 520 nm) were performed with the Omega POLARStar microplate reader (BMG Labtech, Germany). After recording the baseline, 50 μL of a 3-fold dilution of the tested compounds was added to each well and kinetic was measured for 180 s with 2 s intervals. <i>E</i><sub>max</sub> values were defined as the response of the ligand expressed as a percentage of the maximal response elicited by serotonin, determined by nonlinear regression using GraphPad Prism 6.0 software. pEC<sub>50</sub> values correspond to the ligand concentration at which 50% of its own maximal response was measured.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a></div></div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> In Vivo and Ex Vivo Pharmacodynamic Studies</h3><div id="sec4_8_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> Animals</h4><div class="NLM_p last">The experiments were performed on male Wistar rats (170–200 g) obtained from an accredited animal facility at the Jagiellonian University Medical College, Krakow, Poland. The animals were housed in group of four in a controlled environment (ambient temperature 21 ± 2 °C; relative humidity 50–60%; 12 h light/dark cycles (lights on at 8:00). Standard laboratory food (LSM-B) and filtered water were freely available. Animals were housed for a period of 6 days in polycarbonate Makrolon type 3 cages (dimensions 26.5 × 15 × 42 cm, “open top”) without an enrichment environment (only wooden shavings litter). Each animal was assigned randomly to treatment groups and only used once (no repeated use of animals). All the experiments were performed by two observers unaware of the treatment applied between 9:00 and 14:00 on separate groups of animals. All procedures involving animals and their care were conducted in accordance with current European Community and Polish legislation on animal experimentation. Additionally, efforts were made to minimize animal suffering and to use only the number of animals necessary to produce reliable scientific data. All experimental procedures involving animals were conducted in accordance with the European Union (Directive 2010/63/EU) and Polish legislation acts concerning animal experimentation and approved by the II Local Ethics Committee for Experiments on Animals in Cracow, Poland (approval number: 108/2016). All efforts were made to minimize suffering and to reduce the number of animals used in the experiments.</div></div><div id="sec4_8_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> Drugs</h4><div class="NLM_p last">All drugs were dissolved in distilled water immediately before administration in a volume of 2 mL/kg. The examined compound was administered orally 60 and 15 min before tests. In antagonism experiments, WAY100635 (Tocris, UK) was administered subcutaneously (s.c.) 75 and 30 min before testing. Control animals received vehicle (distilled water) according to the same schedule.</div></div><div id="sec4_8_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> Forced Swim Test</h4><div class="NLM_p last">The experiment was carried out according to the method of Porsolt et al.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> On the 1st day of the experiment, the animals were individually gently placed in Plexiglas cylinders (40 cm high, 18 cm in diameter) containing 17 cm of water maintained at 23–25 °C for 15 min. On removal from water, the rats were placed for 30 min in a Plexiglas box under a 60 W bulb to dry. On the following day (24 h later), the rats were replaced in the cylinder after administration of test compounds and the total duration of immobility was recorded during the 5 min test period. Immobility was considered to occur when no additional activity was observed other than that necessary to keep the rat’s head above the water.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> Fresh water was used for each animal.</div></div><div id="sec4_8_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> Flat Body Posture</h4><div class="NLM_p last">Observations were made from 55 to 65 min after p.o. treatment according to the method described by Kleven et al.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> Animals were observed individually during each 10 min period; every 15 s with a period of 10 s of observation per animal. FBP was scored present (1) if it occurred during the entire observation period; otherwise, the score was 0.</div></div><div id="sec4_8_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> Spontaneous Locomotor Activity</h4><div class="NLM_p last">The experiment was performed using Motor Monitor System (Campden Instruments, Ltd., UK) consisting of two SmartFrame Open Field stations (40 × 40 × 38 cm) with 16 × 16 beams, located in sound attenuating chambers, and connected to PC software by control chassis. Individual vehicle- or drug-injected animals were gently placed in the center of the station. An automated Motor Monitor System recorded ambulation (in <i>X</i> and <i>Y</i> axis), the number of rearing episodes, and total distance covered by a rat for 5 min.</div></div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> Ex Vivo Studies of the pERK1/2 Level in the PFC</h3><div id="sec4_9_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> Experimental Design</h4><div class="NLM_p last">In the time-course study, compound <b>17</b> or vehicle was administered orally at the dose of 2.5 mg/kg and the animals were decapitated at the following time points after administration: 5, 15, 30, and 60 min (<i>n</i> = 6–8 rats per each time point). In the dose-effect study, compound <b>17</b> was administered p.o. at different doses (0.04, 0.16, 0.63, and 2.5 mg/kg; <i>n</i> = 6–8 rats per each dose); then, the rats were decapitated 15 min after administration.</div></div><div id="sec4_9_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> pERK1/2 and Total ERK1/2 Measurement in Brain Tissue</h4><div class="NLM_p last">Brains of the rats were removed immediately after decapitation, cooled on dry ice, and the PFC was isolated. After tissue dissection and storage in −80 °C, the tissue was thawed on dry ice and homogenized with a TissueRuptor homogenizer in 0.35 mL of buffer lysis (PerkinElmer) with the protease inhibitor cocktail added. After homogenization, the tissues were immediately frozen in liquid nitrogen, defrosted on ice, and homogenized again. The tissue lysates were centrifuged at 13 000 rpm for 20 min at 4 °C, and the pellets were discarded. The total protein concentrations in the lysates were determined using a BCA (bicinchoninic acid) assay (Sigma-Aldrich) with bovine serum albumin as the standard. Subsequently, the supernatant fluid was transferred to another tube and stored at −80 °C until phospho-ERK1/2 and total-ERK1/2 were tested. The next day, probes were thawed for 20 min on ice and 10 μL of homogenates containing 10 μg of proteins was transferred to assay plates (384-OptiPlate, PerkinElmer) in duplicate. Then, 10 μL of the reaction mix AlphaLISA SureFire Ultra assay (PerkinElmer) was added. The plates were incubated for 2 h in 22 °C. After incubation, the assay plates were measured in an EnVision multifunction plate reader (PerkinElmer Life Science). All samples were tested in duplicates. The results were calculated as a percent of control after dividing the phospho-ERK1/2 by total-ERK1/2.</div></div><div id="sec4_9_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> Statistical Analysis</h4><div class="NLM_p last">The data of behavioral studies were evaluated by an analysis of variance: one-way ANOVA (when one drug was given) or two-way ANOVA (when two drugs were used) followed by Bonferroni’s post hoc test (statistical significance set at <i>p</i> < 0.05). For the time-course and dose-effect studies, the value of pERK1/2 was divided by the corresponding value of total-ERK1/2 for each sample, and then, the ratios were used for statistical analysis of variance (ANOVA) followed by Bonferroni’s post hoc (<i>p</i> < 0.05 was considered statistically significant). The data were expressed as the mean ± SEM (2 measures for each rat per group). The mean value of the control group was set at 100% (control value), and all data were expressed as a percentage relative to the control value.</div></div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> In Vivo Pharmacokinetic Studies</h3><div id="sec4_10_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> Analytical Method</h4><div id="sec4_10_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i88" class="anchor-spacer"></div><h5 class="article-section__title" id="_i88"> Extraction Procedure</h5><div class="NLM_p last">Serum samples (100 μL) containing compound <b>17</b> were spiked with 10 μL of the internal standard solution (compound <b>16</b>). The samples were alkalized with 100 μL of 1 M sodium hydroxide solution, vortex-mixed, and extracted with 1 mL of ethyl acetate/hexane (30/70, v/v) mixture on a shaker (VXR Vibrax, IKA, Germany) for 15 min. After centrifugation (TDx Centrifuge, Abbott Laboratories, USA), the organic layers were transferred into new tubes containing 100 μL of a methanol and 0.1 M sulfuric acid (10/90, v/v) mixture. Then, the samples were shaken and centrifuged again. Finally, 10–70 μL of each acidic layer was injected into the HPLC system.</div></div><div id="sec4_10_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i89" class="anchor-spacer"></div><h5 class="article-section__title" id="_i89"> Equipment and Chromatographic Conditions</h5><div class="NLM_p">The HPLC system consisted of a P100 pump (Thermo Separation Products, San Jose, CA, USA), an L-2200 autosampler, and an L-2420 UV/vis detector (Merck-Hitachi). EZChrome Elite v. 3.2 software (Merck Hitachi) was used for data acquisition. The pump was used under isocratic conditions on a manual mode. The chromatographic separation of compound <b>17</b> and the internal standard was achieved at room temperature (22 ± 1 °C) on the Supelcosil LC-PCN column 250 × 4.6 mm (Sigma-Aldrich, Germany) with 5 μm particles, protected with the Supelcosil LC-PCN guard column (Sigma-Aldrich, Germany). The mobile phase consisted of 25 mM potassium dihydrogen phosphate buffer, pH 4.6/methanol/acetonitrile (51/40/9, v/v/v). The flow rate was 1.0 mL/min, and the detection wavelength was set at 205 nm.</div><div class="NLM_p last">Validation of the assay was performed according to the FDA guideline (Bioanalytical method validation).<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> This included selectivity, linearity, accuracy and precision, limit of detection and limit of quantitation, recovery, and stability.</div></div><div id="sec4_10_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i90" class="anchor-spacer"></div><h5 class="article-section__title" id="_i90"> Pharmacokinetic Study</h5><div class="NLM_p">To assess pharmacokinetics and brain penetration of compound <b>17</b>, blood samples and brains were harvested following each pharmacological experiment up to 60 min after dosing. The rats were sacrificed by decapitation.</div><div class="NLM_p last">Blood was allowed to clot for 15 min at room temperature and then centrifuged (12 000 rpm for 5 min). The obtained serum and brains were stored frozen at −80 °C until analysis.</div></div><div id="sec4_10_1_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i91" class="anchor-spacer"></div><h5 class="article-section__title" id="_i91"> Pharmacokinetic and PK/PD Analysis</h5><div class="NLM_p last">Serum concentration versus time data were analyzed by a noncompartmental approach. The maximum concentration (<i>C</i><sub>max</sub>) and the time to reach peak concentration (<i>T</i><sub>max</sub>) following oral dosing were obtained directly from the concentration versus time data. The terminal elimination rate constant (λ<sub><i>z</i></sub>) was assessed by linear regression. Terminal half-life (<i>t</i><sub>0.5λ<sub><i>z</i></sub></sub>) was calculated as ln 2/λ<sub><i>z</i></sub>. Area under the concentration–time curve from the time of dosing to infinity (AUC<sub>0–∞</sub>) was calculated by the linear trapezoidal rule. The extrapolated terminal area was defined as <i>C</i><sub><i>n</i></sub>/λ<sub><i>z</i></sub>, where <i>C</i><sub><i>n</i></sub> is the last data point. The apparent volume of distribution (<i>V</i><sub><i>z</i></sub>/<i>F</i>) during terminal phase was estimated as Dosepo/(AUC<sub>inf·λ<sub><i>z</i></sub></sub>), where <i>F</i> is the fraction of dose absorbed. Data were presented as mean ± SEM. The simple <i>E</i><sub>max</sub> or sigmoid inhibitory <i>E</i><sub>max</sub> models were fitted to effect-concentration data using Phoenix WinNonlin v. 7.0 (Pharsight Corporation, a Certara Company, Princeton, NJ, USA).</div></div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i92"><a href="/doi/suppl/10.1021/acs.jmedchem.9b00062" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27034" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27034" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.9b00062" class="ext-link">10.1021/acs.jmedchem.9b00062</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Tables of functional activity data with SEM values, radioligand binding assay results and methodology for 5-HT<sub>2A</sub>, M<sub>1</sub>, and H<sub>1</sub> receptors, dose-response curves for functional activity, and detailed data of the effects of compound <b>17</b> in the FST test (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00062/suppl_file/jm9b00062_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00062/suppl_file/jm9b00062_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00062/suppl_file/jm9b00062_si_001.pdf">jm9b00062_si_001.pdf (532.15 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00062/suppl_file/jm9b00062_si_002.csv">jm9b00062_si_002.csv (2.7 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b00062" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87064" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87064" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marcin Kolaczkowski</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Pharmacy, Jagiellonian University Medical
College, 9 Medyczna Street, 30-688 Kraków, Poland</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8402-1121" title="Orcid link">http://orcid.org/0000-0001-8402-1121</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#8fe2eefdece6e1a1e4e0e3eeecf5e4e0f8fce4e6cffae5a1eaebfaa1ffe3"><span class="__cf_email__" data-cfemail="deb3bfacbdb7b0f0b5b1b2bfbda4b5b1a9adb5b79eabb4f0bbbaabf0aeb2">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joanna Sniecikowska</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Pharmacy, Jagiellonian University Medical
College, 9 Medyczna Street, 30-688 Kraków, Poland</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5296-7964" title="Orcid link">http://orcid.org/0000-0002-5296-7964</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Monika Gluch-Lutwin</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Pharmacy, Jagiellonian University Medical
College, 9 Medyczna Street, 30-688 Kraków, Poland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Adam Bucki</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Pharmacy, Jagiellonian University Medical
College, 9 Medyczna Street, 30-688 Kraków, Poland</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0451-9814" title="Orcid link">http://orcid.org/0000-0003-0451-9814</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anna Więckowska</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Pharmacy, Jagiellonian University Medical
College, 9 Medyczna Street, 30-688 Kraków, Poland</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2549-170X" title="Orcid link">http://orcid.org/0000-0003-2549-170X</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Agata Siwek</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Pharmacy, Jagiellonian University Medical
College, 9 Medyczna Street, 30-688 Kraków, Poland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Magdalena Jastrzebska-Wiesek</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Pharmacy, Jagiellonian University Medical
College, 9 Medyczna Street, 30-688 Kraków, Poland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anna Partyka</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Pharmacy, Jagiellonian University Medical
College, 9 Medyczna Street, 30-688 Kraków, Poland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daria Wilczyńska</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Pharmacy, Jagiellonian University Medical
College, 9 Medyczna Street, 30-688 Kraków, Poland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Karolina Pytka</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Pharmacy, Jagiellonian University Medical
College, 9 Medyczna Street, 30-688 Kraków, Poland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Krzysztof Pociecha</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Pharmacy, Jagiellonian University Medical
College, 9 Medyczna Street, 30-688 Kraków, Poland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Agnieszka Cios</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Pharmacy, Jagiellonian University Medical
College, 9 Medyczna Street, 30-688 Kraków, Poland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elżbieta Wyska</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Pharmacy, Jagiellonian University Medical
College, 9 Medyczna Street, 30-688 Kraków, Poland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anna Wesołowska</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Pharmacy, Jagiellonian University Medical
College, 9 Medyczna Street, 30-688 Kraków, Poland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maciej Pawłowski</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Pharmacy, Jagiellonian University Medical
College, 9 Medyczna Street, 30-688 Kraków, Poland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark A. Varney</span> - <span class="hlFld-Affiliation affiliation">Neurolixis
Inc., 34145 Pacific Coast
Highway #504, Dana Point, 92629 California, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Adrian Newman-Tancredi</span> - <span class="hlFld-Affiliation affiliation">Neurolixis
Inc., 34145 Pacific Coast
Highway #504, Dana Point, 92629 California, United
States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2923-5714" title="Orcid link">http://orcid.org/0000-0002-2923-5714</a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>All authors have contributed and have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): M.A.V. and A.N.-T. are employees and shareholders of Neurolixis Inc. The other authors declare no conflict of interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i94">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31632" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31632" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This study was financially supported by The National Science Centre (NCN) grant no. 2015/19/B/NZ7/03543.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption distribution metabolism and excretion</p></td></tr><tr><td class="NLM_term">BBB</td><td class="NLM_def"><p class="first last">blood brain barrier</p></td></tr><tr><td class="NLM_term">cAMP</td><td class="NLM_def"><p class="first last">cyclic adenosine monophosphate</p></td></tr><tr><td class="NLM_term">CNS MPO</td><td class="NLM_def"><p class="first last">central nervous system multiparameter optimization</p></td></tr><tr><td class="NLM_term">ERK1/2</td><td class="NLM_def"><p class="first last">extracellular signal-regulated kinase 1/2</p></td></tr><tr><td class="NLM_term">F13640 (befiradol)</td><td class="NLM_def"><p class="first last">{[1-(3-chloro-4-fluorobenzoyl)-4-fluoropiperidin-4-yl]methyl}[(5-methylpyridin-2-yl)methyl]amine</p></td></tr><tr><td class="NLM_term">F13714</td><td class="NLM_def"><p class="first last">6-[({[1-(3-chloro-4-fluorobenzoyl)-4-fluoropiperidin-4-yl]methyl}amino)methyl]-<i>N</i>,3-dimethylpyridin-2-amine</p></td></tr><tr><td class="NLM_term"><b>1</b> (F15599)</td><td class="NLM_def"><p class="first last">{[1-(3-chloro-4-fluorobenzoyl)-4-fluoropiperidin-4-yl]methyl}[(5-methylpyrimidin-2-yl)methyl]amine</p></td></tr><tr><td class="NLM_term">FBP</td><td class="NLM_def"><p class="first last">flat body</p></td></tr><tr><td class="NLM_term">FPT</td><td class="NLM_def"><p class="first last">forepaw treading</p></td></tr><tr><td class="NLM_term">Fsp<sup>3</sup></td><td class="NLM_def"><p class="first last">ratio of sp<sup>3</sup> carbons to the total number of carbons within the molecule</p></td></tr><tr><td class="NLM_term">FST</td><td class="NLM_def"><p class="first last">forced swimming test (Porsolt test)</p></td></tr><tr><td class="NLM_term">IFD</td><td class="NLM_def"><p class="first last">induced fit docking</p></td></tr><tr><td class="NLM_term">LE</td><td class="NLM_def"><p class="first last">ligand efficiency</p></td></tr><tr><td class="NLM_term">LELP</td><td class="NLM_def"><p class="first last">ligand efficiency-dependent lipophilicity</p></td></tr><tr><td class="NLM_term">LLE</td><td class="NLM_def"><p class="first last">lipophilic ligand efficiency</p></td></tr><tr><td class="NLM_term">LLR</td><td class="NLM_def"><p class="first last">lower lip retraction</p></td></tr><tr><td class="NLM_term">mPCT</td><td class="NLM_def"><p class="first last">medial prefrontal cortex</p></td></tr><tr><td class="NLM_term">PAINS</td><td class="NLM_def"><p class="first last">pan-assay interference compounds</p></td></tr><tr><td class="NLM_term">PBS</td><td class="NLM_def"><p class="first last">phosphate-buffered saline</p></td></tr><tr><td class="NLM_term">PFC</td><td class="NLM_def"><p class="first last">prefrontal cortex</p></td></tr><tr><td class="NLM_term">Ro5</td><td class="NLM_def"><p class="first last">Lipinski’s rule of five</p></td></tr><tr><td class="NLM_term">SGF</td><td class="NLM_def"><p class="first last">simulated gastric fluid</p></td></tr><tr><td class="NLM_term">SIF</td><td class="NLM_def"><p class="first last">simulated intestinal fluid</p></td></tr><tr><td class="NLM_term">TLC</td><td class="NLM_def"><p class="first last">thin layer chromatography</p></td></tr><tr><td class="NLM_term">WAY-100635</td><td class="NLM_def"><p class="first last"><i>N</i>-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-<i>N</i>-pyridin-2-ylcyclohexanecarboxamide</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i96">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64441" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64441" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 100 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Penn, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tracy, D. K.</span></span> <span> </span><span class="NLM_article-title">The drugs don’t work? antidepressants and the current and future pharmacological management of depression</span>. <i>Ther. Adv. Psychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">188</span>, <span class="refDoi"> DOI: 10.1177/2045125312445469</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1177%2F2045125312445469" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=23983973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A280%3ADC%252BC3sbjtVyhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=179-188&author=E.+Pennauthor=D.+K.+Tracy&title=The+drugs+don%E2%80%99t+work%3F+antidepressants+and+the+current+and+future+pharmacological+management+of+depression&doi=10.1177%2F2045125312445469"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The drugs don't work? antidepressants and the current and future pharmacological management of depression</span></div><div class="casAuthors">Penn Elizabeth; Tracy Derek K</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic advances in psychopharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">179-88</span>
        ISSN:<span class="NLM_cas:issn">2045-1253</span>.
    </div><div class="casAbstract">Depression is a potentially life-threatening disorder affecting millions of people across the globe.  It is a huge burden to both the individual and society, costing over £9 billion in 2000 alone: the World Health Organisation (WHO) cited it as the third leading cause of global disability in 2004 (first in the developed world), and project it will be the leading cause by 2030.  The serendipitous discovery of antidepressants has revolutionized both our understanding and management of depression: however, their efficacy in the treatment of depression has long been debated and recently been brought very much into the public limelight by a controversial publication by Kirsch, in which the role of placebo response in antidepressant efficacy trials is highlighted.  Whilst antidepressants offer benefits in both the short and long term, important problems persist such as intolerability, delayed therapeutic onset, limited efficacy in milder depression and the existence of treatment-resistant depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS4lvXZ8_ey5P6xYuD7tu2XfW6udTcc2eb0CDWLp16TGLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sbjtVyhtg%253D%253D&md5=1528826a1609741dcda82afb14bcc619</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1177%2F2045125312445469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2045125312445469%26sid%3Dliteratum%253Aachs%26aulast%3DPenn%26aufirst%3DE.%26aulast%3DTracy%26aufirst%3DD.%2BK.%26atitle%3DThe%2520drugs%2520don%25E2%2580%2599t%2520work%253F%2520antidepressants%2520and%2520the%2520current%2520and%2520future%2520pharmacological%2520management%2520of%2520depression%26jtitle%3DTher.%2520Adv.%2520Psychopharmacol.%26date%3D2012%26volume%3D2%26spage%3D179%26epage%3D188%26doi%3D10.1177%2F2045125312445469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montgomery, S. A.</span></span> <span> </span><span class="NLM_article-title">Why Do We Need New and Better Antidepressants?</span>. <i>Int. Clin. Psychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">S1</span>– <span class="NLM_lpage">S10</span>, <span class="refDoi"> DOI: 10.1097/01.yic.0000199455.39552.1c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1097%2F01.yic.0000199455.39552.1c" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=16436933" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2006&pages=S1-S10&author=S.+A.+Montgomery&title=Why+Do+We+Need+New+and+Better+Antidepressants%3F&doi=10.1097%2F01.yic.0000199455.39552.1c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1097%2F01.yic.0000199455.39552.1c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.yic.0000199455.39552.1c%26sid%3Dliteratum%253Aachs%26aulast%3DMontgomery%26aufirst%3DS.%2BA.%26atitle%3DWhy%2520Do%2520We%2520Need%2520New%2520and%2520Better%2520Antidepressants%253F%26jtitle%3DInt.%2520Clin.%2520Psychopharmacol.%26date%3D2006%26volume%3D21%26spage%3DS1%26epage%3DS10%26doi%3D10.1097%2F01.yic.0000199455.39552.1c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baghai, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fountoulakis, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasper, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malt, U. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Versiani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Möller, H. J.</span></span> <span> </span><span class="NLM_article-title">General and Comparative Efficacy and Effectiveness of Antidepressants in the Acute Treatment of Depressive Disorders: A Report by the WPA Section of Pharmacopsychiatry</span>. <i>Eur. Arch. Psychiatry Clin. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>261</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">245</span>, <span class="refDoi"> DOI: 10.1007/s00406-011-0259-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1007%2Fs00406-011-0259-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=22033583" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A280%3ADC%252BC38%252Fmt1OrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=261&publication_year=2011&pages=207-245&author=T.+C.+Baghaiauthor=P.+Blierauthor=D.+S.+Baldwinauthor=M.+Bauerauthor=G.+M.+Goodwinauthor=K.+N.+Fountoulakisauthor=S.+Kasperauthor=B.+E.+Leonardauthor=U.+F.+Maltauthor=D.+Steinauthor=M.+Versianiauthor=H.+J.+M%C3%B6ller&title=General+and+Comparative+Efficacy+and+Effectiveness+of+Antidepressants+in+the+Acute+Treatment+of+Depressive+Disorders%3A+A+Report+by+the+WPA+Section+of+Pharmacopsychiatry&doi=10.1007%2Fs00406-011-0259-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry</span></div><div class="casAuthors">Baghai Thomas C; Blier Pierre; Baldwin David S; Bauer Michael; Goodwin Guy M; Fountoulakis Kostas N; Kasper Siegfried; Leonard Brian E; Malt Ulrik F; Stein Dan; Versiani Marcio; Moller Hans-Jurgen</div><div class="citationInfo"><span class="NLM_cas:title">European archives of psychiatry and clinical neuroscience</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">261 Suppl 3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">207-45</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Current gold standard approaches to the treatment of depression include pharmacotherapeutic and psychotherapeutic interventions with social support.  Due to current controversies concerning the efficacy of antidepressants in randomized controlled trials, the generalizability of study findings to wider clinical practice and the increasing importance of socioeconomic considerations, it seems timely to address the uncertainty of concerned patients and relatives, and their treating psychiatrists and general practitioners.  We therefore discuss both the efficacy and clinical effectiveness of antidepressants in the treatment of depressive disorders.  We explain and clarify useful measures for assessing clinically meaningful antidepressant treatment effects and the types of studies that are useful for addressing uncertainties.  This includes considerations of methodological issues in randomized controlled studies, meta-analyses, and effectiveness studies.  Furthermore, we summarize the differential efficacy and effectiveness of antidepressants with distinct pharmacodynamic properties, and differences between studies using antidepressants and/or psychotherapy.  We also address the differential effectiveness of antidepressant drugs with differing modes of action and in varying subtypes of depressive disorder.  After highlighting the clinical usefulness of treatment algorithms and the divergent biological, psychological, and clinical efforts to predict the effectiveness of antidepressant treatments, we conclude that the spectrum of different antidepressant treatments has broadened over the last few decades.  The efficacy and clinical effectiveness of antidepressants is statistically significant, clinically relevant, and proven repeatedly.  Further optimization of treatment can be helped by clearly structured treatment algorithms and the implementation of psychotherapeutic interventions.  Modern individualized antidepressant treatment is in most cases a well-tolerated and efficacious approach to minimize the negative impact of otherwise potentially devastating and life-threatening outcomes in depressive disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRvb7AacIlPvXT4ugvCDgnZfW6udTcc2eaPZN3V-qd9O7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38%252Fmt1OrsQ%253D%253D&md5=0a06880d02aae499c41c455d4d784100</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1007%2Fs00406-011-0259-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00406-011-0259-6%26sid%3Dliteratum%253Aachs%26aulast%3DBaghai%26aufirst%3DT.%2BC.%26aulast%3DBlier%26aufirst%3DP.%26aulast%3DBaldwin%26aufirst%3DD.%2BS.%26aulast%3DBauer%26aufirst%3DM.%26aulast%3DGoodwin%26aufirst%3DG.%2BM.%26aulast%3DFountoulakis%26aufirst%3DK.%2BN.%26aulast%3DKasper%26aufirst%3DS.%26aulast%3DLeonard%26aufirst%3DB.%2BE.%26aulast%3DMalt%26aufirst%3DU.%2BF.%26aulast%3DStein%26aufirst%3DD.%26aulast%3DVersiani%26aufirst%3DM.%26aulast%3DM%25C3%25B6ller%26aufirst%3DH.%2BJ.%26atitle%3DGeneral%2520and%2520Comparative%2520Efficacy%2520and%2520Effectiveness%2520of%2520Antidepressants%2520in%2520the%2520Acute%2520Treatment%2520of%2520Depressive%2520Disorders%253A%2520A%2520Report%2520by%2520the%2520WPA%2520Section%2520of%2520Pharmacopsychiatry%26jtitle%3DEur.%2520Arch.%2520Psychiatry%2520Clin.%2520Neurosci.%26date%3D2011%26volume%3D261%26spage%3D207%26epage%3D245%26doi%3D10.1007%2Fs00406-011-0259-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tylee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, P.</span></span> <span> </span><span class="NLM_article-title">Onset of Action of Antidepressants</span>. <i>BMJ</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>334</i></span>,  <span class="NLM_fpage">911</span>– <span class="NLM_lpage">912</span>, <span class="refDoi"> DOI: 10.1136/bmj.39197.619190.80</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1136%2Fbmj.39197.619190.80" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=334&publication_year=2007&pages=911-912&author=A.+Tyleeauthor=P.+Walters&title=Onset+of+Action+of+Antidepressants&doi=10.1136%2Fbmj.39197.619190.80"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1136%2Fbmj.39197.619190.80&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbmj.39197.619190.80%26sid%3Dliteratum%253Aachs%26aulast%3DTylee%26aufirst%3DA.%26aulast%3DWalters%26aufirst%3DP.%26atitle%3DOnset%2520of%2520Action%2520of%2520Antidepressants%26jtitle%3DBMJ%26date%3D2007%26volume%3D334%26spage%3D911%26epage%3D912%26doi%3D10.1136%2Fbmj.39197.619190.80" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Courtet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Castroman, J.</span></span> <span> </span><span class="NLM_article-title">Antidepressants and Suicide Risk in Depression</span>. <i>World Psychiatr.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">317</span>– <span class="NLM_lpage">318</span>, <span class="refDoi"> DOI: 10.1002/wps.20460</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1002%2Fwps.20460" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=28941085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A280%3ADC%252BC1M%252Fhs1ahsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=317-318&author=P.+Courtetauthor=J.+Lopez-Castroman&title=Antidepressants+and+Suicide+Risk+in+Depression&doi=10.1002%2Fwps.20460"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Antidepressants and suicide risk in depression</span></div><div class="casAuthors">Courtet Philppe; Courtet Philppe; Lopez-Castroman Jorge; Lopez-Castroman Jorge</div><div class="citationInfo"><span class="NLM_cas:title">World psychiatry : official journal of the World Psychiatric Association (WPA)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">317-318</span>
        ISSN:<span class="NLM_cas:issn">1723-8617</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTGBEosanZkZQ5nADWVYHg1fW6udTcc2eaPZN3V-qd9O7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M%252Fhs1ahsQ%253D%253D&md5=4567eb186fcb2e633d52544afb91030d</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1002%2Fwps.20460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fwps.20460%26sid%3Dliteratum%253Aachs%26aulast%3DCourtet%26aufirst%3DP.%26aulast%3DLopez-Castroman%26aufirst%3DJ.%26atitle%3DAntidepressants%2520and%2520Suicide%2520Risk%2520in%2520Depression%26jtitle%3DWorld%2520Psychiatr.%26date%3D2017%26volume%3D16%26spage%3D317%26epage%3D318%26doi%3D10.1002%2Fwps.20460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lener, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadriu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarate, C. A.</span></span> <span> </span><span class="NLM_article-title">Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">381</span>– <span class="NLM_lpage">401</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0702-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1007%2Fs40265-017-0702-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=28194724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC2sXislOisbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=381-401&author=M.+S.+Lenerauthor=B.+Kadriuauthor=C.+A.+Zarate&title=Ketamine+and+Beyond%3A+Investigations+into+the+Potential+of+Glutamatergic+Agents+to+Treat+Depression&doi=10.1007%2Fs40265-017-0702-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression</span></div><div class="casAuthors">Lener, Marc S.; Kadriu, Bashkim; Zarate, Carlos A., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">381-401</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Clin. and preclin. studies suggest that dysfunction of the glutamatergic system is implicated in mood disorders such as major depressive disorder and bipolar depression.  In clin. studies of individuals with major depressive disorder and bipolar depression, rapid redns. in depressive symptoms have been obsd. in response to subanesthetic-dose ketamine, an agent whose mechanism of action involves the modulation of glutamatergic signaling.  The findings from these studies have prompted the repurposing and/or development of other glutamatergic modulators for antidepressant efficacy, both as monotherapy or as an adjunct to conventional monoaminergic antidepressants.  This review highlights the evidence supporting the antidepressant effects of subanesthetic-dose ketamine as well as other glutamatergic modulators, such as D-cycloserine, riluzole, CP-101,606, CERC-301 (previously known as MK-0657), basimglurant, JNJ-40411813, dextromethorphan, nitrous oxide, GLYX-13, and esketamine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKaE4wcW8Kd7Vg90H21EOLACvtfcHk0lhOZMMpBj_tLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXislOisbs%253D&md5=dd210c1370996cf338574a71b5991c48</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0702-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0702-8%26sid%3Dliteratum%253Aachs%26aulast%3DLener%26aufirst%3DM.%2BS.%26aulast%3DKadriu%26aufirst%3DB.%26aulast%3DZarate%26aufirst%3DC.%2BA.%26atitle%3DKetamine%2520and%2520Beyond%253A%2520Investigations%2520into%2520the%2520Potential%2520of%2520Glutamatergic%2520Agents%2520to%2520Treat%2520Depression%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26spage%3D381%26epage%3D401%26doi%3D10.1007%2Fs40265-017-0702-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rakesh, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pae, C.-U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masand, P. S.</span></span> <span> </span><span class="NLM_article-title">Beyond Serotonin: Newer Antidepressants in the Future</span>. <i>Expert Rev. Neurother.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">777</span>– <span class="NLM_lpage">790</span>, <span class="refDoi"> DOI: 10.1080/14737175.2017.1341310</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1080%2F14737175.2017.1341310" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=28598698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVertLfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=777-790&author=G.+Rakeshauthor=C.-U.+Paeauthor=P.+S.+Masand&title=Beyond+Serotonin%3A+Newer+Antidepressants+in+the+Future&doi=10.1080%2F14737175.2017.1341310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Beyond serotonin: newer antidepressants in the future</span></div><div class="casAuthors">Rakesh, Gopalkumar; Pae, Chi-Un; Masand, Prakash S.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Neurotherapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">777-790</span>CODEN:
                <span class="NLM_cas:coden">ERNXAR</span>;
        ISSN:<span class="NLM_cas:issn">1473-7175</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">There are numerous antidepressants for the treatment of major depressive disorder (MDD) on the market.  However, inadequate treatment response, therapeutic lag between drug administration and the onset of clin. improvement, and safety/tolerability issues with the use of contemporary antidepressants have accelerated the search for newer antidepressants with novel mechanisms of action.  The authors review novel antidepressants with rapid efficacy for diverse MDD symptoms and have fewer adverse effects (AEs).  Mechanisms of action for novel therapeutic mols. are through glutamatergic, opiate, cholinergic receptors and neuroplasticity.  We enumerate results from human trials with novel agents in all phases, highlighting proximity to approval and therapeutic potential based on quality of evidence.  There is a huge unmet need to diversify conventional antidepressant targets.  Glutamatergic and opiate agents may be most promising among newer therapeutic agents.  It is also important to develop advanced but flexible synergistic treatment strategies with newer therapeutic agents that are usable in routine clin. practice.  This would include combining newer mols. with existing antidepressants and using mols. that target specific symptom dimensions of MDD.  These strategies would lead to a systematic approach to tackle treatment resistant depression (TRD) and treatment of residual symptoms in partially remitted MDD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6N2oSw1Gh8rVg90H21EOLACvtfcHk0lhzMwWyJIoD7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVertLfF&md5=f732ffd43d8ac805eacac71fca678d9e</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1080%2F14737175.2017.1341310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14737175.2017.1341310%26sid%3Dliteratum%253Aachs%26aulast%3DRakesh%26aufirst%3DG.%26aulast%3DPae%26aufirst%3DC.-U.%26aulast%3DMasand%26aufirst%3DP.%2BS.%26atitle%3DBeyond%2520Serotonin%253A%2520Newer%2520Antidepressants%2520in%2520the%2520Future%26jtitle%3DExpert%2520Rev.%2520Neurother.%26date%3D2017%26volume%3D17%26spage%3D777%26epage%3D790%26doi%3D10.1080%2F14737175.2017.1341310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Serafini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howland, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rovedi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girardi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amore, M.</span></span> <span> </span><span class="NLM_article-title">The Role of Ketamine in Treatment-Resistant Depression: A Systematic Review</span>. <i>Curr. Neuropharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">444</span>– <span class="NLM_lpage">461</span>, <span class="refDoi"> DOI: 10.2174/1570159x12666140619204251</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.2174%2F1570159x12666140619204251" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=25426012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFakurfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=444-461&author=G.+Serafiniauthor=R.+Howlandauthor=F.+Rovediauthor=P.+Girardiauthor=M.+Amore&title=The+Role+of+Ketamine+in+Treatment-Resistant+Depression%3A+A+Systematic+Review&doi=10.2174%2F1570159x12666140619204251"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of Ketamine in Treatment-Resistant Depression: A Systematic Review</span></div><div class="casAuthors">Serafini, Gianluca; Howland, Robert H.; Rovedi, Fabiana; Girardi, Paolo; Amore, Mario</div><div class="citationInfo"><span class="NLM_cas:title">Current Neuropharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">444-461</span>CODEN:
                <span class="NLM_cas:coden">CNUEAN</span>;
        ISSN:<span class="NLM_cas:issn">1875-6190</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Background: At least 10-20% of the patients suffering from depression meet criteria for treatment-resistant depression (TRD).  In the last decades, an important role of glutamate in mood modulation has been hypothesized and ketamine, a non noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptors, has been demonstrated to be effective in both MDD and TRD.  However, concerns emerged about the optimal dosage, and frequency of administration of this treatment. ; Methods: aiming to systematically review the current literature focusing on the main pharmacol. properties and impact of ketamine in TRD, a detailed literature search in PubMed/Medline and ScienceDirect databases was conducted.  Twenty-four manuscripts including a total of 416 patients fulfilled inclusion criteria. ; Results: Most studies demonstrated that the NMDA antagonist ketamine has rapid antidepressant effects in TRD patients, confirming the active role of glutamate in the pathophysiol. of this complex condition.  Ketamine has been demonstrated to be rapidly effective and was assocd. with a significant clin. improvement in depressive symptoms within hours after administration.  Also, ketamine was also found to be effective in reducing suicidality in TRD samples. ; Limitations: The long-term efficacy of ketamine has not been investigated by most studies.  The psychotomimetic properties may complicate the application of this pharmacol. agent. ; Conclusions: Ketamine may be considered a valid and intriguing antidepressant option for the treatment of TRD.  Further studies are needed to evaluate its long-term antidepressant efficacy in patients with TRD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqypkbEXkKfV7Vg90H21EOLACvtfcHk0lhzMwWyJIoD7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFakurfI&md5=27d7a3cde89794743ffc6843539ca612</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.2174%2F1570159x12666140619204251&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1570159x12666140619204251%26sid%3Dliteratum%253Aachs%26aulast%3DSerafini%26aufirst%3DG.%26aulast%3DHowland%26aufirst%3DR.%26aulast%3DRovedi%26aufirst%3DF.%26aulast%3DGirardi%26aufirst%3DP.%26aulast%3DAmore%26aufirst%3DM.%26atitle%3DThe%2520Role%2520of%2520Ketamine%2520in%2520Treatment-Resistant%2520Depression%253A%2520A%2520Systematic%2520Review%26jtitle%3DCurr.%2520Neuropharmacol.%26date%3D2014%26volume%3D12%26spage%3D444%26epage%3D461%26doi%3D10.2174%2F1570159x12666140619204251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.-W.</span></span> <span> </span><span class="NLM_article-title">Focused Microwave Irradiation-Assisted Immunohistochemistry to Study Effects of Ketamine on Phospho-ERK Expression in the Mouse Brain</span>. <i>Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>1670</i></span>,  <span class="NLM_fpage">86</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1016/j.brainres.2017.05.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2Fj.brainres.2017.05.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=28501494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotFygu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1670&publication_year=2017&pages=86-95&author=A.+Fernandesauthor=Y.-W.+Li&title=Focused+Microwave+Irradiation-Assisted+Immunohistochemistry+to+Study+Effects+of+Ketamine+on+Phospho-ERK+Expression+in+the+Mouse+Brain&doi=10.1016%2Fj.brainres.2017.05.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Focused microwave irradiation-assisted immunohistochemistry to study effects of ketamine on phospho-ERK expression in the mouse brain</span></div><div class="casAuthors">Fernandes, Alda; Li, Yu-Wen</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">1670</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">86-95</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Ketamine produces rapid and long-lasting antidepressant effects in depressive patients.  Preclin. studies demonstrate that ketamine stimulates AMPA receptor transmission and activates BDNF/TrkB-Akt/ERK-mTOR signaling cascades, leading to a sustained increase in synaptic protein synthesis and strengthening of synaptic plasticity, a potential mechanism underlying the antidepressant effects.  The purpose of this study was to develop an immunohistochem. (IHC) assay to map the distribution of extracellular signal-regulated kinase (ERK) phosphorylation in the mouse brain in response to systemic ketamine treatment.  We established a focused microwave irradn.-assisted IHC assay to detect phosphorylated (phospho) proteins including phospho-ERK, phospho- cAMP-response- element-binding protein (CREB), phospho- glutamate receptor 1 (GluR1) and phospho- calcium/calmodulin-dependent protein kinase II (CaMKII) with greater sensitivity and reproducibility in comparison to conventional IHC methods.  A single dose of ketamine produced a robust, dose- and time-dependent increase in phospho-ERK immunoreactive (phospho-ERK-ir) neurons in the medial prefrontal cortex (mPFC) and the central nucleus of the amygdala.  Phospho-ERK-ir neurons in the mPFC were primarily located in the prelimbic and anterior cingulate subregions with the morphol. resembling pyramidal neurons.  An increase in phospho-ERK-ir was also obsd. in the brainstem dorsal raphe nucleus and locus coeruleus.  The NMDA GluN2B subtype receptor antagonist Ro 25-6981 increased phospho-ERK expression in the brain in a similar pattern as ketamine.  In summary, we have established a sensitive and reliable focused microwave irradn.-assisted IHC assay, and defined the activation pattern of ERK, in response to systemic ketamine and Ro 25-6981 treatment, in brain regions that are potentially responsible for mediating the antidepressant effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorq3Wzm3ayRrVg90H21EOLACvtfcHk0lhzMwWyJIoD7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotFygu7o%253D&md5=65a1b9ff548863472c95889f0efa1eaf</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.brainres.2017.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainres.2017.05.008%26sid%3Dliteratum%253Aachs%26aulast%3DFernandes%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DY.-W.%26atitle%3DFocused%2520Microwave%2520Irradiation-Assisted%2520Immunohistochemistry%2520to%2520Study%2520Effects%2520of%2520Ketamine%2520on%2520Phospho-ERK%2520Expression%2520in%2520the%2520Mouse%2520Brain%26jtitle%3DBrain%2520Res.%26date%3D2017%26volume%3D1670%26spage%3D86%26epage%3D95%26doi%3D10.1016%2Fj.brainres.2017.05.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lepack, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwyer, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duman, R. S.</span></span> <span> </span><span class="NLM_article-title">Fast-Acting Antidepressants Rapidly Stimulate ERK Signaling and BDNF Release in Primary Neuronal Cultures</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">242</span>– <span class="NLM_lpage">252</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2016.09.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2Fj.neuropharm.2016.09.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=27634096" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhslyjsb%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2016&pages=242-252&author=A.+E.+Lepackauthor=E.+Bangauthor=B.+Leeauthor=J.+M.+Dwyerauthor=R.+S.+Duman&title=Fast-Acting+Antidepressants+Rapidly+Stimulate+ERK+Signaling+and+BDNF+Release+in+Primary+Neuronal+Cultures&doi=10.1016%2Fj.neuropharm.2016.09.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Fast-acting antidepressants rapidly stimulate ERK signaling and BDNF release in primary neuronal cultures</span></div><div class="casAuthors">Lepack, Ashley E.; Bang, Eunyoung; Lee, Boyoung; Dwyer, Jason M.; Duman, Ronald S.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">242-252</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Recent preclin. and clin. studies demonstrate that three functionally different compds., the NMDA receptor channel blocker ketamine, mGlu2/3 receptor antagonist LY341495, and NMDA receptor glycine site agent GLYX-13 produce rapid and long lasting antidepressant effects.  Furthermore, these agents are reported to stimulate ERK and mTORC1 signaling in brain.  Here we used rat primary cortical culture neurons to further examine the cellular actions of these agents.  The results demonstrate that low concns. of all three compds. rapidly increase levels of the phosphorylated and activated forms of ERK and a downstream target of mTORC1, p70S6 kinase, in a concn. and time dependent manner.  In addn., each compd. rapidly increases BDNF release into the culture media.  Further studies demonstrate that induction of BDNF release, as well as stimulation of phospho-ERK is blocked by incubation with an AMPA receptor antagonist.  The requirement for AMPA receptor stimulation suggests that the effects of these rapid agents are activity dependent.  This possibility is supported by studies demonstrating that neuronal silencing, via incubation with the GABAA receptor agonist muscimol, completely blocks phospho-ERK and BDNF release by each agent.  Finally, incubation with each drug for 24 h increases the no. and length of neuronal branches.  Together, the results demonstrate that these three different rapid acting antidepressant agents increase ERK signaling and BDNF release in an activity dependent manner that leads to increased neuronal complexity.  Further studies will be required to det. the exact mechanisms underlying these effects in cultured neurons and in rodent models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7FoBc4FQVBLVg90H21EOLACvtfcHk0liHKf9WMp-3Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhslyjsb%252FF&md5=ef46f641e3ea8359a523643064f05a2c</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2016.09.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2016.09.011%26sid%3Dliteratum%253Aachs%26aulast%3DLepack%26aufirst%3DA.%2BE.%26aulast%3DBang%26aufirst%3DE.%26aulast%3DLee%26aufirst%3DB.%26aulast%3DDwyer%26aufirst%3DJ.%2BM.%26aulast%3DDuman%26aufirst%3DR.%2BS.%26atitle%3DFast-Acting%2520Antidepressants%2520Rapidly%2520Stimulate%2520ERK%2520Signaling%2520and%2520BDNF%2520Release%2520in%2520Primary%2520Neuronal%2520Cultures%26jtitle%3DNeuropharmacology%26date%3D2016%26volume%3D111%26spage%3D242%26epage%3D252%26doi%3D10.1016%2Fj.neuropharm.2016.09.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Réus, G. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vieira, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abelaira, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michels, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomaz, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">dos Santos, M. A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlessi, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neotti, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matias, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luz, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dal-Pizzol, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quevedo, J.</span></span> <span> </span><span class="NLM_article-title">MAPK Signaling Correlates with the Antidepressant Effects of Ketamine</span>. <i>J. Psychiatr. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1016/j.jpsychires.2014.04.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2Fj.jpsychires.2014.04.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=24819632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A280%3ADC%252BC2cjhvFKruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2014&pages=15-21&author=G.+Z.+R%C3%A9usauthor=F.+G.+Vieiraauthor=H.+M.+Abelairaauthor=M.+Michelsauthor=D.+B.+Tomazauthor=M.+A.+B.+dos+Santosauthor=A.+S.+Carlessiauthor=M.+V.+Neottiauthor=B.+I.+Matiasauthor=J.+R.+Luzauthor=F.+Dal-Pizzolauthor=J.+Quevedo&title=MAPK+Signaling+Correlates+with+the+Antidepressant+Effects+of+Ketamine&doi=10.1016%2Fj.jpsychires.2014.04.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">MAPK signaling correlates with the antidepressant effects of ketamine</span></div><div class="casAuthors">Reus Gislaine Z; Vieira Flavio Geraldo; Abelaira Helena M; Tomaz Debora B; dos Santos Maria Augusta B; Carlessi Anelise S; Neotti Morgana V; Matias Beatriz I; Luz Jaine R; Michels Monique; Dal-Pizzol Felipe; Quevedo Joao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of psychiatric research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15-21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Studies have pointed to a relationship between MAPK kinase (MEK) signaling and the behavioral effects of antidepressant drugs.  So, in the present study we examined the behavioral and molecular effects of ketamine, an antagonist of the N-methyl-d-aspartate receptor (NMDA), which has been shown to have an antidepressant effect after the inhibition of MEK signaling in Wistar rats.  Our results showed that acute administration of the MEK inhibitor PD184161, produced depressive-like behavior and stopped antidepressant-like effects of ketamine in the forced swimming test.  The phosphorylation of extracellular signal-regulated kinase 1/2 (pERK 1/2) was decreased by PD184161 in the amygdala and nucleus accumbens, and the effects of ketamine on pERK 1/2 in the prefrontal cortex and hippocampus were inhibited by PD184161.  The ERK 2 levels were decreased by PD184161 in the nucleus accumbens; and the effects of ketamine were blocked in this brain area.  The p38 protein kinase (p38MAPK) and proBDNF were inhibited by PD184161, and the MEK inhibitor prevented the effects of ketamine in the nucleus accumbens.  In addition, ketamine increased pro-BDNF levels in the hippocampus.  In conclusion, our findings demonstrated that an acute blockade of MAPK signaling lead to depressive-like behavior and stopped the antidepressant response of ketamine, suggesting that the effects of ketamine could be mediated, at least in part, by the regulation of MAPK signaling in these specific brain areas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQx1WDbnTu0v-3MPKNEWB5RfW6udTcc2ebGrU4KwD8M1Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cjhvFKruw%253D%253D&md5=70c513c4c1b6d37e613f32cdf6a25633</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.jpsychires.2014.04.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpsychires.2014.04.010%26sid%3Dliteratum%253Aachs%26aulast%3DR%25C3%25A9us%26aufirst%3DG.%2BZ.%26aulast%3DVieira%26aufirst%3DF.%2BG.%26aulast%3DAbelaira%26aufirst%3DH.%2BM.%26aulast%3DMichels%26aufirst%3DM.%26aulast%3DTomaz%26aufirst%3DD.%2BB.%26aulast%3Ddos%2BSantos%26aufirst%3DM.%2BA.%2BB.%26aulast%3DCarlessi%26aufirst%3DA.%2BS.%26aulast%3DNeotti%26aufirst%3DM.%2BV.%26aulast%3DMatias%26aufirst%3DB.%2BI.%26aulast%3DLuz%26aufirst%3DJ.%2BR.%26aulast%3DDal-Pizzol%26aufirst%3DF.%26aulast%3DQuevedo%26aufirst%3DJ.%26atitle%3DMAPK%2520Signaling%2520Correlates%2520with%2520the%2520Antidepressant%2520Effects%2520of%2520Ketamine%26jtitle%3DJ.%2520Psychiatr.%2520Res.%26date%3D2014%26volume%3D55%26spage%3D15%26epage%3D21%26doi%3D10.1016%2Fj.jpsychires.2014.04.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pochwat, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rafało-Ulińska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misztak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szewczyk, B.</span></span> <span> </span><span class="NLM_article-title">Involvement of Extracellular Signal-Regulated Kinase (ERK) in the Short and Long-Lasting Antidepressant-like Activity of NMDA Receptor Antagonists (Zinc and Ro 25-6981) in the Forced Swim Test in Rats</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">333</span>– <span class="NLM_lpage">342</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2017.08.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2Fj.neuropharm.2017.08.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=28802646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlKmsLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2017&pages=333-342&author=B.+Pochwatauthor=A.+Rafa%C5%82o-Uli%C5%84skaauthor=H.+Dominauthor=P.+Misztakauthor=G.+Nowakauthor=B.+Szewczyk&title=Involvement+of+Extracellular+Signal-Regulated+Kinase+%28ERK%29+in+the+Short+and+Long-Lasting+Antidepressant-like+Activity+of+NMDA+Receptor+Antagonists+%28Zinc+and+Ro+25-6981%29+in+the+Forced+Swim+Test+in+Rats&doi=10.1016%2Fj.neuropharm.2017.08.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Involvement of extracellular signal-regulated kinase (ERK) in the short and long-lasting antidepressant-like activity of NMDA receptor antagonists (zinc and Ro 25-6981) in the forced swim test in rats</span></div><div class="casAuthors">Pochwat, Bartlomiej; Rafalo-Ulinska, Anna; Domin, Helena; Misztak, Paulina; Nowak, Gabriel; Szewczyk, Bernadeta</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">333-342</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Short and long acting NMDA receptor (NMDAR) antagonists exert their antidepressant-like effects by activating signaling pathways involved in the synthesis of synaptic proteins and formation of new synaptic connections in the prefrontal cortex (PFC) of rats.  The blockade of the ERK pathway abolishes ketamine and Ro 25-6981 antidepressant potency.  However, the role of ERK in the antidepressant-like activity of short acting NMDAR antagonists is still unclear.  More puzzling is the fact that the precise role of ERK in the short and long lasting effects of long-acting NMDAR antagonists is unknown.  In this study, we show that zinc, (Zn) a short-acting NMDAR antagonist evokes only transient ERK activation, which is obsd. 7 min after its administration in the PFC of rats.  In contrast to Zn, the long acting NMDAR antagonist Ro 25-6981 produces persistent ERK activation lasting up to 24 h.  Pretreatment with the MAPK/ERK inhibitor (U0126) totally abolished Zn and Ro 25-6981 antidepressant-like activities in the forced swim test in rats.  However, when U0126 is administered 15 min after Zn or Ro 25-6981 both compds. maintain their short-lasting antidepressant-like activity.  On the other hand, posttreatment with U0126 significantly attenuated the long lasting antidepressant-like activity of Ro 25-6981.  These results indicate that the activation of ERK is crucial for the short- and long lasting antidepressant-like activity obsd. in the FST in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNtx86wbhMyLVg90H21EOLACvtfcHk0ligoe6PUOSiVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlKmsLbM&md5=f20a82e808abcfcb84b9819b149ea540</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2017.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2017.08.006%26sid%3Dliteratum%253Aachs%26aulast%3DPochwat%26aufirst%3DB.%26aulast%3DRafa%25C5%2582o-Uli%25C5%2584ska%26aufirst%3DA.%26aulast%3DDomin%26aufirst%3DH.%26aulast%3DMisztak%26aufirst%3DP.%26aulast%3DNowak%26aufirst%3DG.%26aulast%3DSzewczyk%26aufirst%3DB.%26atitle%3DInvolvement%2520of%2520Extracellular%2520Signal-Regulated%2520Kinase%2520%2528ERK%2529%2520in%2520the%2520Short%2520and%2520Long-Lasting%2520Antidepressant-like%2520Activity%2520of%2520NMDA%2520Receptor%2520Antagonists%2520%2528Zinc%2520and%2520Ro%252025-6981%2529%2520in%2520the%2520Forced%2520Swim%2520Test%2520in%2520Rats%26jtitle%3DNeuropharmacology%26date%3D2017%26volume%3D125%26spage%3D333%26epage%3D342%26doi%3D10.1016%2Fj.neuropharm.2017.08.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niciu, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shovestul, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaso, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farmer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luckenbaugh, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brutsche, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarate, C. A.</span></span> <span> </span><span class="NLM_article-title">Features of Dissociation Differentially Predict Antidepressant Response to Ketamine in Treatment-Resistant Depression</span>. <i>J. Affective Disord.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>232</i></span>,  <span class="NLM_fpage">310</span>– <span class="NLM_lpage">315</span>, <span class="refDoi"> DOI: 10.1016/j.jad.2018.02.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2Fj.jad.2018.02.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=29501990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC1cXks1yltbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=232&publication_year=2018&pages=310-315&author=M.+J.+Niciuauthor=B.+J.+Shovestulauthor=B.+A.+Jasoauthor=C.+Farmerauthor=D.+A.+Luckenbaughauthor=N.+E.+Brutscheauthor=L.+T.+Parkauthor=E.+D.+Ballardauthor=C.+A.+Zarate&title=Features+of+Dissociation+Differentially+Predict+Antidepressant+Response+to+Ketamine+in+Treatment-Resistant+Depression&doi=10.1016%2Fj.jad.2018.02.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression</span></div><div class="casAuthors">Niciu, Mark J.; Shovestul, Bridget J.; Jaso, Brittany A.; Farmer, Cristan; Luckenbaugh, David A.; Brutsche, Nancy E.; Park, Lawrence T.; Ballard, Elizabeth D.; Zarate, Carlos A. Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Affective Disorders</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">232</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">310-315</span>CODEN:
                <span class="NLM_cas:coden">JADID7</span>;
        ISSN:<span class="NLM_cas:issn">0165-0327</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Ketamine induces rapid and robust antidepressant effects, and many patients also describe dissocn., which is assocd. with antidepressant response.  This follow-up study investigated whether antidepressant efficacy is uniquely related to dissociative symptom clusters.  Treatment-resistant patients with major depressive disorder (MDD) or bipolar disorder (BD) (n = 126) drawn from three studies received a single subanesthetic (0.5 mg/kg) ketamine infusion.  Dissociative effects were measured using the Clinician-Administered Dissociative States Scale (CADSS).  Antidepressant response was measured using the 17-item Hamilton Depression Rating Scale (HAM-D).  A confirmatory factor anal. established the validity of CADSS subscales (derealization, depersonalization, amnesia), and a general linear model with repeated measures was fitted to test whether subscale scores were assocd. with antidepressant response.  Factor validity was supported, with a root mean square error of approxn. of .06, a comparative fit index of .97, and a Tucker-Lewis index of .96.  Across all studies and timepoints, the depersonalization subscale was pos. related to HAM-D percent change.  A significant effect of derealization on HAM-D percent change was obsd. at one timepoint (Day 7) in one study.  The amnesia subscale was unrelated to HAM-D percent change.  Possible inadequate blinding; combined MDD/BD datasets might have underrepresented ketamine's antidepressant efficacy; the possibility of Type I errors in secondary analyses.  From a psychometric perspective, researchers may elect to administer only the CADSS depersonalization subscale, given that it was most closely related to antidepressant response.  From a neurobiol. perspective, mechanistic similarities may exist between ketamine-induced depersonalization and antidepressant response, although off-target effects cannot be excluded.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeGfMHJm_zZbVg90H21EOLACvtfcHk0ligoe6PUOSiVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXks1yltbY%253D&md5=1985c7fa8f1b975dd35624f35e8bcf60</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.jad.2018.02.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jad.2018.02.049%26sid%3Dliteratum%253Aachs%26aulast%3DNiciu%26aufirst%3DM.%2BJ.%26aulast%3DShovestul%26aufirst%3DB.%2BJ.%26aulast%3DJaso%26aufirst%3DB.%2BA.%26aulast%3DFarmer%26aufirst%3DC.%26aulast%3DLuckenbaugh%26aufirst%3DD.%2BA.%26aulast%3DBrutsche%26aufirst%3DN.%2BE.%26aulast%3DPark%26aufirst%3DL.%2BT.%26aulast%3DBallard%26aufirst%3DE.%2BD.%26aulast%3DZarate%26aufirst%3DC.%2BA.%26atitle%3DFeatures%2520of%2520Dissociation%2520Differentially%2520Predict%2520Antidepressant%2520Response%2520to%2520Ketamine%2520in%2520Treatment-Resistant%2520Depression%26jtitle%3DJ.%2520Affective%2520Disord.%26date%3D2018%26volume%3D232%26spage%3D310%26epage%3D315%26doi%3D10.1016%2Fj.jad.2018.02.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bartoli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clerici, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrà, G.</span></span> <span> </span><span class="NLM_article-title">Antidepressant Response and Dissociative Effects After Ketamine Treatment</span>. <i>J. Clin. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>78</i></span>, <span class="NLM_elocation-id">e1318</span> <span class="refDoi"> DOI: 10.4088/jcp.17lr11789</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.4088%2Fjcp.17lr11789" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=29345870" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2017&author=F.+Bartoliauthor=M.+Clericiauthor=G.+Carr%C3%A0&title=Antidepressant+Response+and+Dissociative+Effects+After+Ketamine+Treatment&doi=10.4088%2Fjcp.17lr11789"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.4088%2Fjcp.17lr11789&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4088%252Fjcp.17lr11789%26sid%3Dliteratum%253Aachs%26aulast%3DBartoli%26aufirst%3DF.%26aulast%3DClerici%26aufirst%3DM.%26aulast%3DCarr%25C3%25A0%26aufirst%3DG.%26atitle%3DAntidepressant%2520Response%2520and%2520Dissociative%2520Effects%2520After%2520Ketamine%2520Treatment%26jtitle%3DJ.%2520Clin.%2520Psychiatry%26date%3D2017%26volume%3D78%26doi%3D10.4088%2Fjcp.17lr11789" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeng, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, T.-C.</span></span> <span> </span><span class="NLM_article-title">Ketamine-Associated Ulcerative Cystitis</span>. <i>Tzu Chi Med. J.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">144</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.1016/s1016-3190(08)60026-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2Fs1016-3190%2808%2960026-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2008&pages=144-146&author=Y.-C.+Huangauthor=C.-M.+Jengauthor=T.-C.+Cheng&title=Ketamine-Associated+Ulcerative+Cystitis&doi=10.1016%2Fs1016-3190%2808%2960026-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fs1016-3190%2808%2960026-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs1016-3190%252808%252960026-9%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.-C.%26aulast%3DJeng%26aufirst%3DC.-M.%26aulast%3DCheng%26aufirst%3DT.-C.%26atitle%3DKetamine-Associated%2520Ulcerative%2520Cystitis%26jtitle%3DTzu%2520Chi%2520Med.%2520J.%26date%3D2008%26volume%3D20%26spage%3D144%26epage%3D146%26doi%3D10.1016%2Fs1016-3190%2808%2960026-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Riva-Posse, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiff, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Job, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galendez, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garlow, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saah, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunlop, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, W. M.</span></span> <span> </span><span class="NLM_article-title">Blood Pressure Safety of Subanesthetic Ketamine for Depression: A Report on 684 Infusions</span>. <i>J. Affective Disord.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>236</i></span>,  <span class="NLM_fpage">291</span>– <span class="NLM_lpage">297</span>, <span class="refDoi"> DOI: 10.1016/j.jad.2018.02.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2Fj.jad.2018.02.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=29525051" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC1cXks1yku7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=236&publication_year=2018&pages=291-297&author=P.+Riva-Posseauthor=C.+M.+Reiffauthor=J.+A.+Edwardsauthor=G.+P.+Jobauthor=G.+C.+Galendezauthor=S.+J.+Garlowauthor=T.+C.+Saahauthor=B.+W.+Dunlopauthor=W.+M.+McDonald&title=Blood+Pressure+Safety+of+Subanesthetic+Ketamine+for+Depression%3A+A+Report+on+684+Infusions&doi=10.1016%2Fj.jad.2018.02.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Blood pressure safety of subanesthetic ketamine for depression: A report on 684 infusions</span></div><div class="casAuthors">Riva-Posse, Patricio; Reiff, Collin R.; Edwards, Johnathan A.; Job, Gregory P.; Galendez, Gail C.; Garlow, Steven J.; Saah, Tammy C.; Dunlop, Boadie W.; McDonald, William M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Affective Disorders</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">236</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">291-297</span>CODEN:
                <span class="NLM_cas:coden">JADID7</span>;
        ISSN:<span class="NLM_cas:issn">0165-0327</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The dissociative anesthetic agent ketamine is increasingly being utilized to treat depression, despite not having FDA (Food and Drug Administration) approval for this indication.  There are many questions about the potential risks of this treatment and hence the proper setting and degree of monitoring required to ensure patient safety.  There is limited data about the cardiovascular safety of ketamine when administered at subanesthetic doses to treat depression.66 patients in the Department of Psychiatry at Emory University received a total of 684 ketamine infusions between 2014 and 2016.  Ketamine was dosed at 0.5 mg/kg body wt. and infused over 40 min.  Blood pressure was measured every 10 min during the infusions and every 15 min thereafter.Mean age of the patients was 56.7 years, 87.9% had unipolar depression and 36.1% had essential hypertension.  No infusions were discontinued due to instability of vital signs, adverse physiol. consequences or acute psychotomimetic effects.  The biggest increases in blood pressure were measured at 30 min (systolic 3.28 mmHg, diastolic 3.17 mmHg).  Hypertensive patients had higher blood pressure peaks during the infusions.  Blood pressures returned to baseline during post-infusion monitoring.  There was no development of tolerance to the blood pressure elevating effects of ketamine between the first and sixth infusions.  This is a single site, retrospective anal., of patients who were spontaneously seeking clin. care.  The blood pressure changes obsd. when ketamine is administered over 40 min at 0.5 mg/kg for the treatment of depression are small, well tolerated and clin. insignificant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo300Juo_t0ULVg90H21EOLACvtfcHk0lgjNG9wrrPcpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXks1yku7g%253D&md5=12a334bd3433c8d4631267dbbaf253a0</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.jad.2018.02.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jad.2018.02.025%26sid%3Dliteratum%253Aachs%26aulast%3DRiva-Posse%26aufirst%3DP.%26aulast%3DReiff%26aufirst%3DC.%2BM.%26aulast%3DEdwards%26aufirst%3DJ.%2BA.%26aulast%3DJob%26aufirst%3DG.%2BP.%26aulast%3DGalendez%26aufirst%3DG.%2BC.%26aulast%3DGarlow%26aufirst%3DS.%2BJ.%26aulast%3DSaah%26aufirst%3DT.%2BC.%26aulast%3DDunlop%26aufirst%3DB.%2BW.%26aulast%3DMcDonald%26aufirst%3DW.%2BM.%26atitle%3DBlood%2520Pressure%2520Safety%2520of%2520Subanesthetic%2520Ketamine%2520for%2520Depression%253A%2520A%2520Report%2520on%2520684%2520Infusions%26jtitle%3DJ.%2520Affective%2520Disord.%26date%3D2018%26volume%3D236%26spage%3D291%26epage%3D297%26doi%3D10.1016%2Fj.jad.2018.02.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mason, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cottrell, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corrigan, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillatt, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchelmore, A. E.</span></span> <span> </span><span class="NLM_article-title">Ketamine-Associated Lower Urinary Tract Destruction: A New Radiological Challenge</span>. <i>Clin. Radiol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">795</span>– <span class="NLM_lpage">800</span>, <span class="refDoi"> DOI: 10.1016/j.crad.2010.05.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2Fj.crad.2010.05.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=20797465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A280%3ADC%252BC3cjpt12muw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2010&pages=795-800&author=K.+Masonauthor=A.+M.+Cottrellauthor=A.+G.+Corriganauthor=D.+A.+Gillattauthor=A.+E.+Mitchelmore&title=Ketamine-Associated+Lower+Urinary+Tract+Destruction%3A+A+New+Radiological+Challenge&doi=10.1016%2Fj.crad.2010.05.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Ketamine-associated lower urinary tract destruction: a new radiological challenge</span></div><div class="casAuthors">Mason K; Cottrell A M; Corrigan A G; Gillatt D A; Mitchelmore A E</div><div class="citationInfo"><span class="NLM_cas:title">Clinical radiology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">795-800</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">AIM:  Ketamine is a short-acting dissociative anaesthetic whose hallucinogenic side effects have led to an increase in its illicit use amongst club and party goers.  There is a general misconception amongst users that it is a safe drug with few long term side effects, however ketamine abuse is associated with severe urinary tract dysfunction.  Presenting symptoms include urinary frequency, nocturia, dysuria, haematuria and incontinence.  MATERIALS AND METHODS:  We describe the radiological findings found in a series of 23 patients, all with a history of ketamine abuse, who presented with severe lower urinary tract symptoms (LUTS).  Imaging techniques used included ultrasonography (US), intravenous urography (IVU), and computed tomography (CT).  These examinations were reviewed to identify common imaging findings.  All patients with positive imaging findings had also undergone cystoscopy and bladder wall biopsies, which confirmed the diagnosis.  The patients in this series have consented to the use of their data in the ongoing research into ketamine-induced bladder pathology.  RESULTS:  Ultrasound demonstrated small bladder volume and wall thickening.  CT revealed marked, generalized bladder wall thickening, mucosal enhancement, and perivesical inflammation.  Ureteric wall thickening and enhancement were also observed.  In advanced cases ureteric narrowing and strictures were identified using both CT and IVU.  Correlation of clinical history, radiological and pathological findings was performed to confirm the diagnosis.  CONCLUSION:  This case series illustrates the harmful effects of ketamine on the urinary tract and the associated radiological findings.  Delayed diagnosis can result in irreversible renal tract damage requiring surgical intervention.  It is important that radiologists are aware of this emerging clinical entity as early diagnosis and treatment are essential for successful management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRdwVg4GK2qdtbHMBt0mMIXfW6udTcc2eaw1wTJPbg_Ibntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjpt12muw%253D%253D&md5=9d4b6f425edc86d9202212f8edd2cd75</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.crad.2010.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.crad.2010.05.003%26sid%3Dliteratum%253Aachs%26aulast%3DMason%26aufirst%3DK.%26aulast%3DCottrell%26aufirst%3DA.%2BM.%26aulast%3DCorrigan%26aufirst%3DA.%2BG.%26aulast%3DGillatt%26aufirst%3DD.%2BA.%26aulast%3DMitchelmore%26aufirst%3DA.%2BE.%26atitle%3DKetamine-Associated%2520Lower%2520Urinary%2520Tract%2520Destruction%253A%2520A%2520New%2520Radiological%2520Challenge%26jtitle%3DClin.%2520Radiol.%26date%3D2010%26volume%3D65%26spage%3D795%26epage%3D800%26doi%3D10.1016%2Fj.crad.2010.05.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gigliucci, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Dowd, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibney, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harkin, A.</span></span> <span> </span><span class="NLM_article-title">Ketamine Elicits Sustained Antidepressant-like Activity via a Serotonin-Dependent Mechanism</span>. <i>Psychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>228</i></span>,  <span class="NLM_fpage">157</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1007/s00213-013-3024-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1007%2Fs00213-013-3024-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=23455595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtlykuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=2013&pages=157-166&author=V.+Gigliucciauthor=G.+O%E2%80%99Dowdauthor=S.+Caseyauthor=D.+Eganauthor=S.+Gibneyauthor=A.+Harkin&title=Ketamine+Elicits+Sustained+Antidepressant-like+Activity+via+a+Serotonin-Dependent+Mechanism&doi=10.1007%2Fs00213-013-3024-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Ketamine elicits sustained antidepressant-like activity via a serotonin-dependent mechanism</span></div><div class="casAuthors">Gigliucci, Valentina; O'Dowd, Grainne; Casey, Sheena; Egan, Danielle; Gibney, Sinead; Harkin, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Heidelberg, Germany)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">228</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">157-166</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Rationale: Behavioral antidepressant-like effects of ketamine have been reported in the forced swimming test (FST).  The mechanisms mediating such effects are unknown.  Objectives: As serotonin (5-HT) is an important transmitter mediating antidepressant responsiveness in the FST, the influence of 5-HT depletion on the antidepressant-like effect of ketamine was assessed.  Methods: The effect of ketamine (25 mg/kg, i.p., 1 or 24 h prior to test) was assessed in the FST in naive rats or animals subjected to 5-HT depletion, repeated stress or following a combination of 5-HT depletion and stress.  Endogenous 5-HT was depleted using the tryptophan hydroxylase inhibitor para-chlorophenylalanine (3 × 150 mg/kg, i.p.).  Stress was induced by phys. restraint (2 h/day for 10 days).  Results: In naive rats, ketamine administered 24 or 1 h prior to test produced a characteristic antidepressant-like redn. in immobility time in the FST.  Depletion of 5-HT blocked this redn. in immobility when ketamine was administered 24 h prior FST, indicative of 5-HT dependency.  The increase in immobility provoked by repeated restraint stress (2 h/day for 10 days) was blocked by ketamine when administered 24 h prior to FST, but this effect dissipated when animals were subjected to 5-HT depletion.  Conclusions: These observations are consistent with a role for 5-HT in mediating sustained antidepressant activity of ketamine in the FST.  Mol. and cellular changes induced by ketamine may produce a rapid adaptation of 5-HT transmission which underlies the antidepressant response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxzV815691OLVg90H21EOLACvtfcHk0lgjNG9wrrPcpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtlykuro%253D&md5=017d811af5d2f0ac5733d32acd4e7e8c</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1007%2Fs00213-013-3024-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-013-3024-x%26sid%3Dliteratum%253Aachs%26aulast%3DGigliucci%26aufirst%3DV.%26aulast%3DO%25E2%2580%2599Dowd%26aufirst%3DG.%26aulast%3DCasey%26aufirst%3DS.%26aulast%3DEgan%26aufirst%3DD.%26aulast%3DGibney%26aufirst%3DS.%26aulast%3DHarkin%26aufirst%3DA.%26atitle%3DKetamine%2520Elicits%2520Sustained%2520Antidepressant-like%2520Activity%2520via%2520a%2520Serotonin-Dependent%2520Mechanism%26jtitle%3DPsychopharmacology%26date%3D2013%26volume%3D228%26spage%3D157%26epage%3D166%26doi%3D10.1007%2Fs00213-013-3024-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fukumoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iijima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funakoshi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaki, S.</span></span> <span> </span><span class="NLM_article-title">Role of 5-HT1A Receptor Stimulation in the Medial Prefrontal Cortex in the Sustained Antidepressant Effects of Ketamine</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">371</span>– <span class="NLM_lpage">381</span>, <span class="refDoi"> DOI: 10.1093/ijnp/pyx116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1093%2Fijnp%2Fpyx116" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2017&pages=371-381&author=K.+Fukumotoauthor=M.+Iijimaauthor=T.+Funakoshiauthor=S.+Chaki&title=Role+of+5-HT1A+Receptor+Stimulation+in+the+Medial+Prefrontal+Cortex+in+the+Sustained+Antidepressant+Effects+of+Ketamine&doi=10.1093%2Fijnp%2Fpyx116"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1093%2Fijnp%2Fpyx116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fijnp%252Fpyx116%26sid%3Dliteratum%253Aachs%26aulast%3DFukumoto%26aufirst%3DK.%26aulast%3DIijima%26aufirst%3DM.%26aulast%3DFunakoshi%26aufirst%3DT.%26aulast%3DChaki%26aufirst%3DS.%26atitle%3DRole%2520of%25205-HT1A%2520Receptor%2520Stimulation%2520in%2520the%2520Medial%2520Prefrontal%2520Cortex%2520in%2520the%2520Sustained%2520Antidepressant%2520Effects%2520of%2520Ketamine%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2017%26volume%3D21%26spage%3D371%26epage%3D381%26doi%3D10.1093%2Fijnp%2Fpyx116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fukumoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iijima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaki, S.</span></span> <span> </span><span class="NLM_article-title">Serotonin-1A Receptor Stimulation Mediates Effects of a Metabotropic Glutamate 2/3 Receptor Antagonist, 2S-2-Amino-2-(1S,2S-2-Carboxycycloprop-1-Yl)-3-(Xanth-9-Yl)Propanoic Acid (LY341495), and an N-Methyl-D-Aspartate Receptor Antagonist, Ketamine, in the Novelty-Suppressed Feeding Test</span>. <i>Psychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>231</i></span>,  <span class="NLM_fpage">2291</span>– <span class="NLM_lpage">2298</span>, <span class="refDoi"> DOI: 10.1007/s00213-013-3378-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1007%2Fs00213-013-3378-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=24402133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC2cXksFOnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=231&publication_year=2014&pages=2291-2298&author=K.+Fukumotoauthor=M.+Iijimaauthor=S.+Chaki&title=Serotonin-1A+Receptor+Stimulation+Mediates+Effects+of+a+Metabotropic+Glutamate+2%2F3+Receptor+Antagonist%2C+2S-2-Amino-2-%281S%2C2S-2-Carboxycycloprop-1-Yl%29-3-%28Xanth-9-Yl%29Propanoic+Acid+%28LY341495%29%2C+and+an+N-Methyl-D-Aspartate+Receptor+Antagonist%2C+Ketamine%2C+in+the+Novelty-Suppressed+Feeding+Test&doi=10.1007%2Fs00213-013-3378-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Serotonin-1A receptor stimulation mediates effects of a metabotropic glutamate 2/3 receptor antagonist, 2S-2-amino-2-(1S,2S-2-carboxycycloprop-1-yl)-3-(xanth-9-yl)propanoic acid (LY341495), and an N-methyl-D-aspartate receptor antagonist, ketamine, in the novelty-suppressed feeding test</span></div><div class="casAuthors">Fukumoto, Kenichi; Iijima, Michihiko; Chaki, Shigeyuki</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Heidelberg, Germany)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">231</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2291-2298</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Rationale: α-Amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor stimulation has been proposed to be a common neural mechanism of metabotropic glutamate 2/3 (mGlu2/3) receptor antagonists and an N-methyl-D-aspartate receptor antagonist, ketamine, exerting antidepressant effects in animal models.  AMPA receptor stimulation has also been shown to mediate an increase in the extracellular level of serotonin (5-HT) in the medial prefrontal cortex by an mGlu2/3 receptor antagonist in rats.  However, involvement of the serotonergic system in the actions of mGlu2/3 receptor antagonists and ketamine is not well understood.  Objectives: We investigated involvement of the serotonergic system in the effects of an mGlu2/3 receptor antagonist, 2S-2-amino-2-(1S,2S-2-carboxycycloprop-1-yl)-3-(xanth-9-yl)propanoic acid (LY341495), and ketamine in a novelty-suppressed feeding (NSF) test in mice.  Results: The i.p. administration of LY341495 or ketamine at 30 min prior to the test significantly shortened latency to feed, which was attenuated by an AMPA receptor antagonist, 2,3-dioxo-6-nitro-1,2,3,4-tetrahydr-obenzo[f]quinoxaline-7-sulfonamide (NBQX).  The effects of LY341495 and ketamine were no longer obsd. in mice pretreated with a tryptophan hydroxylase inhibitor, para-chlorophenylalanine (PCPA).  Moreover, the effects of LY341495 and ketamine were blocked by a 5-HT1A receptor antagonist, N-{2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl}-N-(2-pyridynyl) cyclohexane-carboxamide (WAY100635), but not by a 5-HT2A/2C receptor antagonist, ritanserin.  Likewise, an AMPA receptor potentiator, 2,3-dihydro-1,4-benzodioxin-7-yl-(1-piperidyl)methanone (CX546), shortened latency to feed in the NSF test, which was prevented by depletion of 5-HT and blockade of 5-HT1A receptor.  Conclusions: These results suggest that AMPA receptor-dependent 5-HT release and subsequent 5-HT1A receptor stimulation may be involved in the actions of an mGlu2/3 receptor antagonist and ketamine in the NSF test.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXxOAK0MC9U7Vg90H21EOLACvtfcHk0ljEZbSHf9aO4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXksFOnsA%253D%253D&md5=0b6fbc2993f11b4863f4451d00786297</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1007%2Fs00213-013-3378-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-013-3378-0%26sid%3Dliteratum%253Aachs%26aulast%3DFukumoto%26aufirst%3DK.%26aulast%3DIijima%26aufirst%3DM.%26aulast%3DChaki%26aufirst%3DS.%26atitle%3DSerotonin-1A%2520Receptor%2520Stimulation%2520Mediates%2520Effects%2520of%2520a%2520Metabotropic%2520Glutamate%25202%252F3%2520Receptor%2520Antagonist%252C%25202S-2-Amino-2-%25281S%252C2S-2-Carboxycycloprop-1-Yl%2529-3-%2528Xanth-9-Yl%2529Propanoic%2520Acid%2520%2528LY341495%2529%252C%2520and%2520an%2520N-Methyl-D-Aspartate%2520Receptor%2520Antagonist%252C%2520Ketamine%252C%2520in%2520the%2520Novelty-Suppressed%2520Feeding%2520Test%26jtitle%3DPsychopharmacology%26date%3D2014%26volume%3D231%26spage%3D2291%26epage%3D2298%26doi%3D10.1007%2Fs00213-013-3378-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Albert, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vahid-Ansari, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luckhart, C.</span></span> <span> </span><span class="NLM_article-title">Serotonin-Prefrontal Cortical Circuitry in Anxiety and Depression Phenotypes: Pivotal Role of Pre- and Post-Synaptic 5-HT1A Receptor Expression</span>. <i>Front. Behav. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">199</span>, <span class="refDoi"> DOI: 10.3389/fnbeh.2014.00199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.3389%2Ffnbeh.2014.00199" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=24936175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A280%3ADC%252BC2cflvF2ktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=199&author=P.+R.+Albertauthor=F.+Vahid-Ansariauthor=C.+Luckhart&title=Serotonin-Prefrontal+Cortical+Circuitry+in+Anxiety+and+Depression+Phenotypes%3A+Pivotal+Role+of+Pre-+and+Post-Synaptic+5-HT1A+Receptor+Expression&doi=10.3389%2Ffnbeh.2014.00199"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Serotonin-prefrontal cortical circuitry in anxiety and depression phenotypes: pivotal role of pre- and post-synaptic 5-HT1A receptor expression</span></div><div class="casAuthors">Albert Paul R; Vahid-Ansari Faranak; Luckhart Christine</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in behavioral neuroscience</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">199</span>
        ISSN:<span class="NLM_cas:issn">1662-5153</span>.
    </div><div class="casAbstract">Decreased serotonergic activity has been implicated in anxiety and major depression, and antidepressants directly or indirectly increase the long-term activity of the serotonin system.  A key component of serotonin circuitry is the 5-HT1A autoreceptor, which functions as the major somatodendritic autoreceptor to negatively regulate the "gain" of the serotonin system.  In addition, 5-HT1A heteroreceptors are abundantly expressed post-synaptically in the prefrontal cortex (PFC), amygdala, and hippocampus to mediate serotonin actions on fear, anxiety, stress, and cognition.  Importantly, in the PFC 5-HT1A heteroreceptors are expressed on at least two antagonist neuronal populations: excitatory pyramidal neurons and inhibitory interneurons.  Rodent models implicate the 5-HT1A receptor in anxiety- and depression-like phenotypes with distinct roles for pre- and post-synaptic 5-HT1A receptors.  In this review, we present a model of serotonin-PFC circuitry that integrates evidence from mouse genetic models of anxiety and depression involving knockout, suppression, over-expression, or mutation of genes of the serotonin system including 5-HT1A receptors.  The model postulates that behavioral phenotype shifts as serotonin activity increases from none (depressed/aggressive not anxious) to low (anxious/depressed) to high (anxious, not depressed).  We identify a set of conserved transcription factors including Deaf1, Freud-1/CC2D1A, Freud-2/CC2D1B and glucocorticoid receptors that may confer deleterious regional changes in 5-HT1A receptors in depression, and how future treatments could target these mechanisms.  Further studies to specifically test the roles and regulation of pyramidal vs. interneuronal populations of 5-HT receptors are needed better understand the role of serotonin in anxiety and depression and to devise more effective targeted therapeutic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTQeWflPetSDSjiVMCqkKxVfW6udTcc2ebsUIX9saVOurntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cflvF2ktg%253D%253D&md5=8594327308f364e47912b31720c3be41</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.3389%2Ffnbeh.2014.00199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnbeh.2014.00199%26sid%3Dliteratum%253Aachs%26aulast%3DAlbert%26aufirst%3DP.%2BR.%26aulast%3DVahid-Ansari%26aufirst%3DF.%26aulast%3DLuckhart%26aufirst%3DC.%26atitle%3DSerotonin-Prefrontal%2520Cortical%2520Circuitry%2520in%2520Anxiety%2520and%2520Depression%2520Phenotypes%253A%2520Pivotal%2520Role%2520of%2520Pre-%2520and%2520Post-Synaptic%25205-HT1A%2520Receptor%2520Expression%26jtitle%3DFront.%2520Behav.%2520Neurosci.%26date%3D2014%26volume%3D8%26spage%3D199%26doi%3D10.3389%2Ffnbeh.2014.00199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kimbrell, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ketter, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Little, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benson, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willis, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herscovitch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Post, R. M.</span></span> <span> </span><span class="NLM_article-title">Regional Cerebral Glucose Utilization in Patients with a Range of Severities of Unipolar Depression</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">237</span>– <span class="NLM_lpage">252</span>, <span class="refDoi"> DOI: 10.1016/s0006-3223(01)01216-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2Fs0006-3223%2801%2901216-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=11839367" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BD38Xht1ajsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2002&pages=237-252&author=T.+A.+Kimbrellauthor=T.+A.+Ketterauthor=M.+S.+Georgeauthor=J.+T.+Littleauthor=B.+E.+Bensonauthor=M.+W.+Willisauthor=P.+Herscovitchauthor=R.+M.+Post&title=Regional+Cerebral+Glucose+Utilization+in+Patients+with+a+Range+of+Severities+of+Unipolar+Depression&doi=10.1016%2Fs0006-3223%2801%2901216-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Regional cerebral glucose utilization in patients with a range of severities of unipolar depression</span></div><div class="casAuthors">Kimbrell, Tim A.; Ketter, Terence A.; George, Mark S.; Little, John T.; Benson, Brenda E.; Willis, Mark W.; Herscovitch, Peter; Post, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">237-252</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">Patients with unipolar depression are most often reported to have decreased regional cerebral glucose metab. (rCMRglu) in dorsal prefrontal and anterior cingulate cortices compared with healthy control subjects, often correlating inversely with severity of depression.  We measured rCMRglu with fluorine-18 deoxyglucose positron emission tomog. (PET) in 38 medication-free patients with unipolar depression and 37 healthy control subjects performing an auditory continuous performance task to further investigate potential prefrontal and anterior paralimbic rCMRglu abnormalities in patients attending to this task.  Compared with control subjects, the subgroup of patients with Hamilton depression scores of 22 or greater demonstrated decreased abs. rCMRglu in right prefrontal cortex and paralimbic/amygdala regions as well as bilaterally in the insula and temporoparietal cortex (right > left); they also exhibited increased normalized metabolic activity bilaterally in the cerebellum, lingula/cuneus, and brain stem.  Severity of depression neg. correlated with abs. rCMRglu in almost the entire extent of the right cingulate cortex as well as bilaterally in prefrontal cortex, insula, basal ganglia, and temporoparietal cortex (right > left).  Conclusions: Areas of frontal, cingulate, insula, and temporal cortex appear hypometabolic in assocn. with different components of the severity and course of illness in treatment-resistant unipolar depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIEel89Cl1bLVg90H21EOLACvtfcHk0ljEZbSHf9aO4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xht1ajsbg%253D&md5=d24e8724bf7ddce23ed525323690745f</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fs0006-3223%2801%2901216-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0006-3223%252801%252901216-1%26sid%3Dliteratum%253Aachs%26aulast%3DKimbrell%26aufirst%3DT.%2BA.%26aulast%3DKetter%26aufirst%3DT.%2BA.%26aulast%3DGeorge%26aufirst%3DM.%2BS.%26aulast%3DLittle%26aufirst%3DJ.%2BT.%26aulast%3DBenson%26aufirst%3DB.%2BE.%26aulast%3DWillis%26aufirst%3DM.%2BW.%26aulast%3DHerscovitch%26aufirst%3DP.%26aulast%3DPost%26aufirst%3DR.%2BM.%26atitle%3DRegional%2520Cerebral%2520Glucose%2520Utilization%2520in%2520Patients%2520with%2520a%2520Range%2520of%2520Severities%2520of%2520Unipolar%2520Depression%26jtitle%3DBiol.%2520Psychiatry%26date%3D2002%26volume%3D51%26spage%3D237%26epage%3D252%26doi%3D10.1016%2Fs0006-3223%2801%2901216-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cervo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samanin, R.</span></span> <span> </span><span class="NLM_article-title">Potential antidepressant properties of 8-hydroxy-2-(di-n-propylamino) tetralin, a selective serotonin1A receptor agonist</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">223</span>– <span class="NLM_lpage">229</span>, <span class="refDoi"> DOI: 10.1016/0014-2999(87)90523-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2F0014-2999%2887%2990523-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=2963752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADyaL1cXkvFamtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=1987&pages=223-229&author=L.+Cervoauthor=R.+Samanin&title=Potential+antidepressant+properties+of+8-hydroxy-2-%28di-n-propylamino%29+tetralin%2C+a+selective+serotonin1A+receptor+agonist&doi=10.1016%2F0014-2999%2887%2990523-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Potential antidepressant properties of 8-hydroxy-2-(di-n-propylamino)tetralin, a selective serotonin1A receptor agonist</span></div><div class="casAuthors">Cervo, L.; Samanin, R.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">223-9</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    </div><div class="casAbstract">The title compd., 8-OH-DPAT, a selective serotonin S1A receptor agonist, was studied for its anti-immobility activity in the forced-swimming test after different schedules of treatment.  Single doses of 0.250 and 0.500 mg 8-OH-DPAT/kg s.c., reduced the immobility time of rats with no effect on open-field activity.  Similar results were obtained with a 3-injection course of 8-OH-DPAT in 24 h (0.125-0.500 mg/kg, s.c.) or with a once daily injection of 0.250 mg/kg, s.c., for 7 or 21 days.  Methiothepin (0.2 mg/kg, s.c.) and l-propranolol (20 mg/kg, s.c.) antagonized the anti-immobility effect of 3 injections of 0.25 mg 8-OH-DPAT/kg, s.c., but 2 mg metergoline/kg, i.p., had no such effect.  The effect of 8-OH-DPAT was also antagonized both by 0.5 mg haloperidol/kg, i.p., and 100 mg sulpiride/kg, i.p., and in animals given an intracerebroventricular injection of 150 μg 5,7-dihydroxytryptamine to deplete brain serotonin levels.  Apparently, 8-OH-DPAT, by acting on serotonin neurons in the brain, produces disinhibitory effects in a rat model predictive of antidepressant activity.  Serotonin S1A agonists such as 8-OH-DPAT may constitute a novel class of fast acting antidepressant drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjYXTcCqxgs7Vg90H21EOLACvtfcHk0ljd9k0uZXtymA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXkvFamtA%253D%253D&md5=5fb67229822b635b0eee1bc20f0f3452</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2887%2990523-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252887%252990523-1%26sid%3Dliteratum%253Aachs%26aulast%3DCervo%26aufirst%3DL.%26aulast%3DSamanin%26aufirst%3DR.%26atitle%3DPotential%2520antidepressant%2520properties%2520of%25208-hydroxy-2-%2528di-n-propylamino%2529%2520tetralin%252C%2520a%2520selective%2520serotonin1A%2520receptor%2520agonist%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1987%26volume%3D144%26spage%3D223%26epage%3D229%26doi%3D10.1016%2F0014-2999%2887%2990523-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luscombe, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchins, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gosden, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heal, D. J.</span></span> <span> </span><span class="NLM_article-title">Mediation of the Antidepressant-like Effect of 8-OH-DPAT in Mice by Postsynaptic 5-HT1A Receptors</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">669</span>– <span class="NLM_lpage">677</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.1993.tb12859.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1111%2Fj.1476-5381.1993.tb12859.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=8467355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADyaK3sXit1GnurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=1993&pages=669-677&author=G.+P.+Luscombeauthor=K.+F.+Martinauthor=L.+J.+Hutchinsauthor=J.+Gosdenauthor=D.+J.+Heal&title=Mediation+of+the+Antidepressant-like+Effect+of+8-OH-DPAT+in+Mice+by+Postsynaptic+5-HT1A+Receptors&doi=10.1111%2Fj.1476-5381.1993.tb12859.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Mediation of the antidepressant-like effect of 8-OH-DPAT in mice by postsynaptic 5-HT1A receptors</span></div><div class="casAuthors">Luscombe, Graham P.; Martin, Keith F.; Hutchins, Lisa J.; Gosden, Jane; Heal, David J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">669-77</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    </div><div class="casAbstract">The 5-HT1A agonist 8-hydroxy-2-(dipropylamino)tetralin (8-OH-DPAT) was evaluated in a mouse model used for the detection of potential antidepressants by the Porsolt test.  The effects of various receptor antagonists, lesions of brain monoaminergic neurons, and chronic drug treatments on 8-OH-DPAT-induced responses were detd.  8-OH-DPAT (0.3-10.0 mg/kg s.c.) dose-dependently increased the mobility of mice in the Porsolt test.  Other selective 5-HT1A receptor ligands (0.3-30 mg/kg s.c.) either mimicked the 8-OH-DPAT responses (ipsapirone at 10 and 30 mg/kg s.c.) or were inactive (buspirone and gepirone).  These compds. (≤100 mg/kg orally) inhibited the responses to 8-OH-DPAT (3 mg/kg s.c.) when given concurrently.  The putative 5-HT1A antagonists spiroxatrine (1-30 mg/kg), (±)-pindolol (30 mg/kg), and methiothepin (3-10 mg/kg), given orally each attenuated the 8-OH-DPAT (3 mg/kg s.c.)-induced increases in mobility.  The dopaminergic D1 receptor antagonist SCH-23390 (3-10 mg/kg orally) weakly reversed the 8-OH-DPAT responses.  Antagonists at the 5-HT1C/5-HT2 receptors (ketanserin 0.1-3.0 mg/kg), 5-HT3 receptors (ondansetron 0.03-10 mg/kg), α1-adrenoceptors (prazosin 1-3 mg/kg), α2-adrenoceptors (idazoxan 3-30 mg/kg), β1-adrenoceptors (metoprolol 1-30 mg/kg), β2-adrenoceptors (ICI-118,551 1-30 mg/kg), dopaminergic D2 receptors (sulpiride 10-300 mg/kg), and opiate receptors (naloxone 3-100 mg/kg) given orally had no effect on the 8-OH-DPAT responses.  Selective destruction of 5-HT neurons with 5,7-dihydroxytryptamine or inhibition of 5-HT synthesis with p-chlorophenylalanine did not change the 8-OH-DPAT responses in the Porsolt test.  The responses were also unaltered by pretreatment with the noradrenergic neurotoxin DSP-4.  Administration of 8-OH-DPAT (3 mg/kg s.c.) twice-daily for 10 days attenuated hypothermia, but not the increased mobility induced by 8-OH-DPAT at 93 mg/kg s.c.).  Repeated administration of amitriptyline (3-30 mg/kg), desipramine (3-30 mg/kg), or dothiepin (10-100 mg/kg) also attenuated the former, but not the latter, response.  Thus, 8-OH-DPAT has an antidepressant-like effect mediated by postsynaptic 5-HT1A receptors in the Porsolt test.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyNIFX2lf4ZLVg90H21EOLACvtfcHk0ljd9k0uZXtymA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXit1GnurY%253D&md5=a11231401cc5ef3e2e44c29aa4bbe919</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.1993.tb12859.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.1993.tb12859.x%26sid%3Dliteratum%253Aachs%26aulast%3DLuscombe%26aufirst%3DG.%2BP.%26aulast%3DMartin%26aufirst%3DK.%2BF.%26aulast%3DHutchins%26aufirst%3DL.%2BJ.%26aulast%3DGosden%26aufirst%3DJ.%26aulast%3DHeal%26aufirst%3DD.%2BJ.%26atitle%3DMediation%2520of%2520the%2520Antidepressant-like%2520Effect%2520of%25208-OH-DPAT%2520in%2520Mice%2520by%2520Postsynaptic%25205-HT1A%2520Receptors%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1993%26volume%3D108%26spage%3D669%26epage%3D677%26doi%3D10.1111%2Fj.1476-5381.1993.tb12859.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miyata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamei, J.</span></span> <span> </span><span class="NLM_article-title">Diabetes Attenuates the Antidepressant-like Effect Mediated by the Activation of 5-HT1A Receptor in the Mouse Tail Suspension Test</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">461</span>– <span class="NLM_lpage">469</span>, <span class="refDoi"> DOI: 10.1038/sj.npp.1300354</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1038%2Fsj.npp.1300354" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2003&pages=461-469&author=S.+Miyataauthor=S.+Hiranoauthor=J.+Kamei&title=Diabetes+Attenuates+the+Antidepressant-like+Effect+Mediated+by+the+Activation+of+5-HT1A+Receptor+in+the+Mouse+Tail+Suspension+Test&doi=10.1038%2Fsj.npp.1300354"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fsj.npp.1300354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.npp.1300354%26sid%3Dliteratum%253Aachs%26aulast%3DMiyata%26aufirst%3DS.%26aulast%3DHirano%26aufirst%3DS.%26aulast%3DKamei%26aufirst%3DJ.%26atitle%3DDiabetes%2520Attenuates%2520the%2520Antidepressant-like%2520Effect%2520Mediated%2520by%2520the%2520Activation%2520of%25205-HT1A%2520Receptor%2520in%2520the%2520Mouse%2520Tail%2520Suspension%2520Test%26jtitle%3DNeuropsychopharmacology%26date%3D2003%26volume%3D29%26spage%3D461%26epage%3D469%26doi%3D10.1038%2Fsj.npp.1300354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prinsze, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, G.</span></span> <span> </span><span class="NLM_article-title">Flesinoxan in the Treatment of Major Depressive Disorder: A Fixed Dose, Placebo-Controlled Trial</span>. <i>Eur. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">S4</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.1016/0924-977x(96)83084-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2F0924-977x%2896%2983084-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1996&pages=S4-73&author=C.+Prinszeauthor=G.+Stevens&title=Flesinoxan+in+the+Treatment+of+Major+Depressive+Disorder%3A+A+Fixed+Dose%2C+Placebo-Controlled+Trial&doi=10.1016%2F0924-977x%2896%2983084-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2F0924-977x%2896%2983084-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0924-977x%252896%252983084-7%26sid%3Dliteratum%253Aachs%26aulast%3DPrinsze%26aufirst%3DC.%26aulast%3DStevens%26aufirst%3DG.%26atitle%3DFlesinoxan%2520in%2520the%2520Treatment%2520of%2520Major%2520Depressive%2520Disorder%253A%2520A%2520Fixed%2520Dose%252C%2520Placebo-Controlled%2520Trial%26jtitle%3DEur.%2520Neuropsychopharmacol.%26date%3D1996%26volume%3D6%26spage%3DS4%26epage%3D73%26doi%3D10.1016%2F0924-977x%2896%2983084-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Newman-Tancredi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martel, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assié, M.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buritova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauressergues, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heusler, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruins Slot, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colpaert, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cussac, D.</span></span> <span> </span><span class="NLM_article-title">Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1Areceptor agonist</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>156</i></span>,  <span class="NLM_fpage">338</span>– <span class="NLM_lpage">353</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2008.00001.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1111%2Fj.1476-5381.2008.00001.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=19154445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1Wlsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2009&pages=338-353&author=A.+Newman-Tancrediauthor=J.-C.+Martelauthor=M.-B.+Assi%C3%A9author=J.+Buritovaauthor=E.+Lauresserguesauthor=C.+Cosiauthor=P.+Heuslerauthor=L.+Bruins+Slotauthor=F.+Colpaertauthor=B.+Vacherauthor=D.+Cussac&title=Signal+transduction+and+functional+selectivity+of+F15599%2C+a+preferential+post-synaptic+5-HT1Areceptor+agonist&doi=10.1111%2Fj.1476-5381.2008.00001.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonist</span></div><div class="casAuthors">Newman-Tancredi, A.; Martel, J.-C.; Assie, M.-B.; Buritova, J.; Lauressergues, E.; Cosi, C.; Heusler, P.; Slot, L. Bruins; Colpaert, F. C.; Vacher, B.; Cussac, D.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">338-353</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Activation of post-synaptic 5-HT1A receptors may provide enhanced therapy against depression.  We describe the signal transduction profile of F15599, a novel 5-HT1A receptor agonist.  F15599 was compared with a chem. congener, F13714, and with (+)8-OH-DPAT in models of signal transduction in vitro and ex vivo.  F15599 was highly selective for 5-HT1A receptors in binding expts. and in [35S]-GTPγS autoradiog. of rat brain, where F15599 increased labeling in regions expressing 5-HT1A receptors.  In cell lines expressing h5-HT1A receptors, F15599 more potently stimulated extracellular signal-regulated kinase (ERK1/2) phosphorylation, compared with G-protein activation, internalization of h5-HT1A receptors or inhibition of cAMP accumulation.  F13714, (+)8-OH-DPAT and 5-HT displayed a different rank order of potency for these responses.  F15599 stimulated [35S]-GTPγS binding more potently in frontal cortex than raphe.  F15599, unlike 5-HT, more potently and efficaciously stimulated Gαi than Gαo activation.  In rat prefrontal cortex (a region expressing post-synaptic 5-HT1A receptors), F15599 potently activated ERK1/2 phosphorylation and strongly induced c-fos mRNA expression.  In contrast, in raphe regions (expressing pre-synaptic 5-HT1A receptors) F15599 only weakly or did not induce c-fos mRNA expression.  Finally, despite its more modest affinity in vitro, F15599 bound to 5-HT1A receptors in vivo almost as potently as F13714.  F15599 showed a distinctive activation profiles for 5-HT1A receptor-mediated signaling pathways, unlike those of ref. agonists and consistent with functional selectivity at 5-HT1A receptors.  In rat, F15599 potently activated signaling in prefrontal cortex, a feature likely to underlie its beneficial effects in models of depression and cognition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrB5iCRk8KT7LVg90H21EOLACvtfcHk0lic4sy_p_negQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1Wlsrw%253D&md5=59559010ca0e8c57848a1a433fe15f59</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2008.00001.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2008.00001.x%26sid%3Dliteratum%253Aachs%26aulast%3DNewman-Tancredi%26aufirst%3DA.%26aulast%3DMartel%26aufirst%3DJ.-C.%26aulast%3DAssi%25C3%25A9%26aufirst%3DM.-B.%26aulast%3DBuritova%26aufirst%3DJ.%26aulast%3DLauressergues%26aufirst%3DE.%26aulast%3DCosi%26aufirst%3DC.%26aulast%3DHeusler%26aufirst%3DP.%26aulast%3DBruins%2BSlot%26aufirst%3DL.%26aulast%3DColpaert%26aufirst%3DF.%26aulast%3DVacher%26aufirst%3DB.%26aulast%3DCussac%26aufirst%3DD.%26atitle%3DSignal%2520transduction%2520and%2520functional%2520selectivity%2520of%2520F15599%252C%2520a%2520preferential%2520post-synaptic%25205-HT1Areceptor%2520agonist%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2009%26volume%3D156%26spage%3D338%26epage%3D353%26doi%3D10.1111%2Fj.1476-5381.2008.00001.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maurel, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Autin, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman-Tancredi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colpaert, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacher, B.</span></span> <span> </span><span class="NLM_article-title">High-Efficacy 5-HT1AAgonists for Antidepressant Treatment: A Renewed Opportunity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">5024</span>– <span class="NLM_lpage">5033</span>, <span class="refDoi"> DOI: 10.1021/jm070714l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070714l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=5024-5033&author=J.+L.+Maurelauthor=J.-M.+Autinauthor=P.+Funesauthor=A.+Newman-Tancrediauthor=F.+Colpaertauthor=B.+Vacher&title=High-Efficacy+5-HT1AAgonists+for+Antidepressant+Treatment%3A+A+Renewed+Opportunity&doi=10.1021%2Fjm070714l"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm070714l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070714l%26sid%3Dliteratum%253Aachs%26aulast%3DMaurel%26aufirst%3DJ.%2BL.%26aulast%3DAutin%26aufirst%3DJ.-M.%26aulast%3DFunes%26aufirst%3DP.%26aulast%3DNewman-Tancredi%26aufirst%3DA.%26aulast%3DColpaert%26aufirst%3DF.%26aulast%3DVacher%26aufirst%3DB.%26atitle%3DHigh-Efficacy%25205-HT1AAgonists%2520for%2520Antidepressant%2520Treatment%253A%2520A%2520Renewed%2520Opportunity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D5024%26epage%3D5033%26doi%3D10.1021%2Fjm070714l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Becker, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolbos, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costes, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redouté, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman-Tancredi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmer, L.</span></span> <span> </span><span class="NLM_article-title">Selective Serotonin 5-HT1A Receptor Biased Agonists Elicitdistinct Brain Activation Patterns: A PharmacoMRI Study</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">26633</span>, <span class="refDoi"> DOI: 10.1038/srep26633</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1038%2Fsrep26633" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=27211078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC28XosVSlsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=26633&author=G.+Beckerauthor=R.+Bolbosauthor=N.+Costesauthor=J.+Redout%C3%A9author=A.+Newman-Tancrediauthor=L.+Zimmer&title=Selective+Serotonin+5-HT1A+Receptor+Biased+Agonists+Elicitdistinct+Brain+Activation+Patterns%3A+A+PharmacoMRI+Study&doi=10.1038%2Fsrep26633"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Selective serotonin 5-HT1A receptor biased agonists elicit distinct brain activation patterns: a pharmacoMRI study</span></div><div class="casAuthors">Becker, G.; Bolbos, R.; Costes, N.; Redoute, J.; Newman-Tancredi, A.; Zimmer, L.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">26633</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Serotonin 1A (5-HT1A) receptors are involved in several physiol. and pathol. processes and constitute therefore an important therapeutic target.  The recent pharmacol. concept of biased agonism asserts that highly selective agonists can preferentially direct receptor signaling to specific intracellular responses, opening the possibility of drugs targeting a receptor subtype in specific brain regions.  The present study brings addnl. support to this concept thanks to functional magnetic resonance imaging (7 T-fMRI) in anesthetized rats.  Three 5-HT1A receptor agonists (8-OH-DPAT, F13714 and F15599) and one 5-HT1A receptor antagonist (MPPF) were compared in terms of influence on the brain blood oxygen level-dependent (BOLD) signal.  Our study revealed for the first time contrasting BOLD signal patterns of biased agonists in comparison to a classical agonist and a silent antagonist.  By providing functional information on the influence of pharmacol. activation of 5-HT1A receptors in specific brain regions, this neuroimaging approach, translatable to the clinic, promises to be useful in exploring the new concept of biased agonism in neuropsychopharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptDDMqKoAGBbVg90H21EOLACvtfcHk0lhs1fIPjGVTQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosVSlsrY%253D&md5=c054e4c2e584080164f76f64a9675c81</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fsrep26633&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep26633%26sid%3Dliteratum%253Aachs%26aulast%3DBecker%26aufirst%3DG.%26aulast%3DBolbos%26aufirst%3DR.%26aulast%3DCostes%26aufirst%3DN.%26aulast%3DRedout%25C3%25A9%26aufirst%3DJ.%26aulast%3DNewman-Tancredi%26aufirst%3DA.%26aulast%3DZimmer%26aufirst%3DL.%26atitle%3DSelective%2520Serotonin%25205-HT1A%2520Receptor%2520Biased%2520Agonists%2520Elicitdistinct%2520Brain%2520Activation%2520Patterns%253A%2520A%2520PharmacoMRI%2520Study%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D26633%26doi%3D10.1038%2Fsrep26633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lladó-Pelfort, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assié, M.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman-Tancredi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artigas, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celada, P.</span></span> <span> </span><span class="NLM_article-title">Preferential in vivo action of F15599, a novel 5-HT1A receptor agonist, at postsynaptic 5-HT1A receptors</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>160</i></span>,  <span class="NLM_fpage">1929</span>– <span class="NLM_lpage">1940</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2010.00738.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1111%2Fj.1476-5381.2010.00738.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=20649591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1KjurzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2010&pages=1929-1940&author=L.+Llad%C3%B3-Pelfortauthor=M.-B.+Assi%C3%A9author=A.+Newman-Tancrediauthor=F.+Artigasauthor=P.+Celada&title=Preferential+in+vivo+action+of+F15599%2C+a+novel+5-HT1A+receptor+agonist%2C+at+postsynaptic+5-HT1A+receptors&doi=10.1111%2Fj.1476-5381.2010.00738.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Preferential in vivo action of F15599, a novel 5-HT1A receptor agonist, at postsynaptic 5-HT1A receptors</span></div><div class="casAuthors">Llado-Pelfort, L.; Assie, M.-B.; Newman-Tancredi, A.; Artigas, F.; Celada, P.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1929-1940</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">F15599, a novel 5-hydroxytryptamine (5-HT)1A receptor agonist with 1000-fold selectivity for 5-HT compared with other monoamine receptors, shows antidepressant and procognitive activity at very low doses in animal models.  We examd. the in vivo activity of F15599 at somatodendritic autoreceptors and postsynaptic 5-HT1A heteroreceptors.  In vivo single unit and local field potential recordings and microdialysis in the rat.  F15599 increased the discharge rate of pyramidal neurons in medial prefrontal cortex (mPFC) from 0.2 μg·kg-1 i.v and reduced that of dorsal raphe 5-hydroxytryptaminergic neurons at doses >10-fold higher (minimal ED 8.2 μg·kg-1 i.v.).  Both effects were reversed by the 5-HT1A antagonist (±)WAY100635.  F15599 did not alter low frequency oscillations (∼1 Hz) in mPFC.  In microdialysis studies, F15599 increased dopamine output in mPFC (an effect dependent on the activation of postsynaptic 5-HT1A receptors) with an ED50 of 30 μg·kg-1 i.p., whereas it reduced hippocampal 5-HT release (an effect dependent exclusively on 5-HT1A autoreceptor activation) with an ED50 of 240 μg·kg-1 i.p.  Likewise, application of F15599 by reverse dialysis in mPFC increased dopamine output in a concn.-dependent manner.  All neurochem. responses to F15599 were prevented by administration of (±)WAY100635.  These results indicate that systemic administration of F15599 preferentially activates postsynaptic 5-HT1A receptors in PFC rather than somatodendritic 5-HT1A autoreceptors.  This regional selectivity distinguishes F15599 from previously developed 5-HT1A receptor agonists, which preferentially activate somatodendritic 5-HT1A autoreceptors, suggesting that F15599 may be particularly useful in the treatment of depression and of cognitive deficits in schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5_O5rsSUv3LVg90H21EOLACvtfcHk0lhs1fIPjGVTQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1KjurzF&md5=062adb7f40fdbd9ae10fdd6900713e97</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2010.00738.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2010.00738.x%26sid%3Dliteratum%253Aachs%26aulast%3DLlad%25C3%25B3-Pelfort%26aufirst%3DL.%26aulast%3DAssi%25C3%25A9%26aufirst%3DM.-B.%26aulast%3DNewman-Tancredi%26aufirst%3DA.%26aulast%3DArtigas%26aufirst%3DF.%26aulast%3DCelada%26aufirst%3DP.%26atitle%3DPreferential%2520in%2520vivo%2520action%2520of%2520F15599%252C%2520a%2520novel%25205-HT1A%2520receptor%2520agonist%252C%2520at%2520postsynaptic%25205-HT1A%2520receptors%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D160%26spage%3D1929%26epage%3D1940%26doi%3D10.1111%2Fj.1476-5381.2010.00738.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Assié, M.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auclair, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carilla-Durand, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Depoortère, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koek, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleven, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colpaert, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman-Tancredi, A.</span></span> <span> </span><span class="NLM_article-title">F15599, a highly selective post-synaptic 5-HT1A receptor agonist: in-vivo profile in behavioural models of antidepressant and serotonergic activity</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1285</span>– <span class="NLM_lpage">1298</span>, <span class="refDoi"> DOI: 10.1017/s1461145709991222</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1017%2Fs1461145709991222" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=20059805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1aktb3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=1285-1298&author=M.-B.+Assi%C3%A9author=L.+Bardinauthor=A.+L.+Auclairauthor=E.+Carilla-Durandauthor=R.+Depoort%C3%A8reauthor=W.+Koekauthor=M.+S.+Klevenauthor=F.+Colpaertauthor=B.+Vacherauthor=A.+Newman-Tancredi&title=F15599%2C+a+highly+selective+post-synaptic+5-HT1A+receptor+agonist%3A+in-vivo+profile+in+behavioural+models+of+antidepressant+and+serotonergic+activity&doi=10.1017%2Fs1461145709991222"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">F15599, a highly selective post-synaptic 5-HT1A receptor agonist: in-vivo profile in behavioural models of antidepressant and serotonergic activity</span></div><div class="casAuthors">Assie, Marie-Bernadette; Bardin, Laurent; Auclair, Agnes L.; Carilla-Durand, Elisabeth; Depoortere, Ronan; Koek, Wouter; Kleven, Mark S.; Colpaert, Francis; Vacher, Bernard; Newman-Tancredi, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1285-1298</span>CODEN:
                <span class="NLM_cas:coden">IJNUFB</span>;
        ISSN:<span class="NLM_cas:issn">1461-1457</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">F15599 is a novel agonist with high selectivity and efficacy at serotonin 5-HT1A receptors (5-HT1ARs).  In signal transduction, electrophysiol. and neurochem. tests, F15599 preferentially activates post-synaptic 5-HT1ARs in rat frontal cortex.  Such a profile may translate to an improved profile of therapeutic activity for mood disorders.  The in-vivo effects of F15599 were therefore compared with those of a related compd., F13714, in rat models of antidepressant activity and 5-HT1AR activation: forced swimming test (FST), conditioned stress-induced ultrasonic vocalization, 5-HT syndrome, plasma corticosterone and body temp.  Acute administration of F15599 or F13714 reduced immobility in the FST at low doses; these effects were long lasting and the effects of F15599 were maintained after repeated (5 d, p.o.) administration.  Both compds. decreased ultrasonic vocalization duration at low doses.  In contrast, higher doses of F15599 were required to induce lower lip retraction, elements of the 5-HT behavioral syndrome, hypothermia and to increase plasma corticosterone levels.  Notably, there was a greater sepn. of ED50 between FST and other effects for F15599 than for F13714.  Thus, the in-vivo potency of F15599 in models of antidepressant/anti-stress activity is similar to that of F13714, despite the fact that the latter has an in-vitro potency two orders of magnitude greater.  In contrast F15599 has a lower propensity than F13714 to induce other serotonergic signs.  The distinctive pharmacol. profile of F15599 suggests that preferential targeting of post-synaptic 5-HT1ARs constitutes a promising strategy for improved antidepressant therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo195YLEeqRsLVg90H21EOLACvtfcHk0lhs1fIPjGVTQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1aktb3L&md5=a979820d0f8a211519ce86d4c56c8fd4</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1017%2Fs1461145709991222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252Fs1461145709991222%26sid%3Dliteratum%253Aachs%26aulast%3DAssi%25C3%25A9%26aufirst%3DM.-B.%26aulast%3DBardin%26aufirst%3DL.%26aulast%3DAuclair%26aufirst%3DA.%2BL.%26aulast%3DCarilla-Durand%26aufirst%3DE.%26aulast%3DDepoort%25C3%25A8re%26aufirst%3DR.%26aulast%3DKoek%26aufirst%3DW.%26aulast%3DKleven%26aufirst%3DM.%2BS.%26aulast%3DColpaert%26aufirst%3DF.%26aulast%3DVacher%26aufirst%3DB.%26aulast%3DNewman-Tancredi%26aufirst%3DA.%26atitle%3DF15599%252C%2520a%2520highly%2520selective%2520post-synaptic%25205-HT1A%2520receptor%2520agonist%253A%2520in-vivo%2520profile%2520in%2520behavioural%2520models%2520of%2520antidepressant%2520and%2520serotonergic%2520activity%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2010%26volume%3D13%26spage%3D1285%26epage%3D1298%26doi%3D10.1017%2Fs1461145709991222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jastrzębska-Więsek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Partyka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rychtyk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Śniecikowska, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kołaczkowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wesołowska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varney, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman-Tancredi, A.</span></span> <span> </span><span class="NLM_article-title">Activity of Serotonin 5-HT1AReceptor Biased Agonists in Rat: Anxiolytic and Antidepressant-like Properties</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1040</span>– <span class="NLM_lpage">1050</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.7b00443</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.7b00443" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=1040-1050&author=M.+Jastrz%C4%99bska-Wi%C4%99sekauthor=A.+Partykaauthor=J.+Rychtykauthor=J.+%C5%9Aniecikowskaauthor=M.+Ko%C5%82aczkowskiauthor=A.+Weso%C5%82owskaauthor=M.+A.+Varneyauthor=A.+Newman-Tancredi&title=Activity+of+Serotonin+5-HT1AReceptor+Biased+Agonists+in+Rat%3A+Anxiolytic+and+Antidepressant-like+Properties&doi=10.1021%2Facschemneuro.7b00443"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.7b00443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.7b00443%26sid%3Dliteratum%253Aachs%26aulast%3DJastrz%25C4%2599bska-Wi%25C4%2599sek%26aufirst%3DM.%26aulast%3DPartyka%26aufirst%3DA.%26aulast%3DRychtyk%26aufirst%3DJ.%26aulast%3D%25C5%259Aniecikowska%26aufirst%3DJ.%26aulast%3DKo%25C5%2582aczkowski%26aufirst%3DM.%26aulast%3DWeso%25C5%2582owska%26aufirst%3DA.%26aulast%3DVarney%26aufirst%3DM.%2BA.%26aulast%3DNewman-Tancredi%26aufirst%3DA.%26atitle%3DActivity%2520of%2520Serotonin%25205-HT1AReceptor%2520Biased%2520Agonists%2520in%2520Rat%253A%2520Anxiolytic%2520and%2520Antidepressant-like%2520Properties%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2017%26volume%3D9%26spage%3D1040%26epage%3D1050%26doi%3D10.1021%2Facschemneuro.7b00443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
Goethem, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman-Tancredi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varney, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prickaerts, J.</span></span> <span> </span><span class="NLM_article-title">Divergent effects of the ‘biased’ 5-HT1Areceptor agonists F15599 and F13714 in a novel object pattern separation task</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">2532</span>– <span class="NLM_lpage">2543</span>, <span class="refDoi"> DOI: 10.1111/bph.13071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1111%2Fbph.13071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=25572672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVent77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2015&pages=2532-2543&author=N.+P.+van%0AGoethemauthor=R.+Schreiberauthor=A.+Newman-Tancrediauthor=M.+Varneyauthor=J.+Prickaerts&title=Divergent+effects+of+the+%E2%80%98biased%E2%80%99+5-HT1Areceptor+agonists+F15599+and+F13714+in+a+novel+object+pattern+separation+task&doi=10.1111%2Fbph.13071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Divergent effects of the 'biased' 5-HT1A receptor agonists F15599 and F13714 in a novel object pattern separation task</span></div><div class="casAuthors">van Goethem, N. P.; Schreiber, R.; Newman-Tancredi, A.; Varney, M.; Prickaerts, J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2532-2543</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : Pattern sepn., i.e., the formation of distinct representations from similar inputs, is an important hippocampal process implicated in cognitive domains like episodic memory.  A deficit in pattern sepn. could lead to memory impairments in several psychiatric and neurol. disorders.  Hence, mechanisms by which pattern sepn. can be increased are of potential therapeutic interest.  Exptl. approach : 5-HT1A receptors are involved in spatial memory.  Herein we tested the 'biased' 5-HT1A receptor agonists F15599, which preferentially activates post-synaptic heteroreceptors, and F13714, which preferentially activates raphe-located autoreceptors, in rats in a novel spatial task assessing pattern sepn., the object pattern sepn. (OPS) task.  Key Results : The acetylcholinesterase inhibitor donepezil, which served as a pos. control, significantly improved spatial pattern sepn. at a dose of 1 mg·kg-1, p.o.  F15599 increased pattern sepn. at 0.04 mg·kg-1, i.p., while F13714 decreased pattern sepn. at 0.0025 mg·kg-1, i.p.  The selective 5-HT1A receptor antagonist WAY-100635 (0.63 mg·kg-1, s.c.) counteracted the effects of both agonists.  These data suggest that acute preferential activation of post-synaptic 5-HT1A heteroreceptors improves spatial pattern sepn., whereas acute preferential activation of raphe-located 5-HT1A autoreceptors impairs performance.  Conclusions and Implications : We successfully established and validated a novel, simple and robust OPS task and obsd. a diverging profile of response with 'biased' 5-HT1A receptor agonists based on their targeting of receptors in distinct brain regions.  Our data suggest that the post-synaptic 5-HT1A receptor consists of a potential novel mol. target to improve pattern sepn. performance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYOfTXnh6VkrVg90H21EOLACvtfcHk0lgBz_KGqQetmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVent77M&md5=e9434ddb0cae42d46626cd05e73ef1e1</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1111%2Fbph.13071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.13071%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BGoethem%26aufirst%3DN.%2BP.%26aulast%3DSchreiber%26aufirst%3DR.%26aulast%3DNewman-Tancredi%26aufirst%3DA.%26aulast%3DVarney%26aufirst%3DM.%26aulast%3DPrickaerts%26aufirst%3DJ.%26atitle%3DDivergent%2520effects%2520of%2520the%2520%25E2%2580%2598biased%25E2%2580%2599%25205-HT1Areceptor%2520agonists%2520F15599%2520and%2520F13714%2520in%2520a%2520novel%2520object%2520pattern%2520separation%2520task%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D172%26spage%3D2532%26epage%3D2543%26doi%3D10.1111%2Fbph.13071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Newman-Tancredi, A.</span></span> <span> </span><span class="NLM_article-title">Biased Agonism at Serotonin 5HT1A Receptors: Preferential Postsynaptic Activity for Improved Therapy of CNS Disorders</span>. <i>Neuropsychiatry</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">149</span>, <span class="refDoi"> DOI: 10.2217/npy.11.12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.2217%2Fnpy.11.12" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2011&pages=149&author=A.+Newman-Tancredi&title=Biased+Agonism+at+Serotonin+5HT1A+Receptors%3A+Preferential+Postsynaptic+Activity+for+Improved+Therapy+of+CNS+Disorders&doi=10.2217%2Fnpy.11.12"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.2217%2Fnpy.11.12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fnpy.11.12%26sid%3Dliteratum%253Aachs%26aulast%3DNewman-Tancredi%26aufirst%3DA.%26atitle%3DBiased%2520Agonism%2520at%2520Serotonin%25205HT1A%2520Receptors%253A%2520Preferential%2520Postsynaptic%2520Activity%2520for%2520Improved%2520Therapy%2520of%2520CNS%2520Disorders%26jtitle%3DNeuropsychiatry%26date%3D2011%26volume%3D1%26spage%3D149%26doi%3D10.2217%2Fnpy.11.12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Depoortère, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auclair, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colpaert, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman-Tancredi, A.</span></span> <span> </span><span class="NLM_article-title">F15599, a Preferential Post-Synaptic 5-HT1A Receptor Agonist: Activity in Models of Cognition in Comparison with Reference 5-HT1A Receptor Agonists</span>. <i>Eur. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">641</span>– <span class="NLM_lpage">654</span>, <span class="refDoi"> DOI: 10.1016/j.euroneuro.2010.04.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2Fj.euroneuro.2010.04.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=20488670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC3cXps1ehurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=641-654&author=R.+Depoort%C3%A8reauthor=A.+L.+Auclairauthor=L.+Bardinauthor=F.+C.+Colpaertauthor=B.+Vacherauthor=A.+Newman-Tancredi&title=F15599%2C+a+Preferential+Post-Synaptic+5-HT1A+Receptor+Agonist%3A+Activity+in+Models+of+Cognition+in+Comparison+with+Reference+5-HT1A+Receptor+Agonists&doi=10.1016%2Fj.euroneuro.2010.04.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">F15599, a preferential post-synaptic 5-HT1A receptor agonist: Activity in models of cognition in comparison with reference 5-HT1A receptor agonists</span></div><div class="casAuthors">Depoortere, Ronan; Auclair, Agnes L.; Bardin, Laurent; Colpaert, Francis C.; Vacher, Bernard; Newman-Tancredi, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">European Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">641-654</span>CODEN:
                <span class="NLM_cas:coden">EURNE8</span>;
        ISSN:<span class="NLM_cas:issn">0924-977X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We assessed the activity of F15599, a selective and high efficacy 5-HT1A agonist that preferentially activates post- vs. pre-synaptic receptors, in rat cognition/memory models.  F15599 (0.16 mg/kg i.p.) partially alleviated detrimental effects of phencyclidine on working and ref. memory deficit in a hole-board model.  It also attenuated phencyclidine-induced deficit of cognitive flexibility in a reversal learning task, without effects of its own.  F13714 (0.04 mg/kg) a chem. congener of F15599, and 8-OH-DPAT (0.01 or 0.16), were inactive against these phencyclidine-induced deficits, and/or even worsened basal performances.  F15599 (0.04-2.5) was less disruptive than F13714 (0.005-0.16) or 8-OH-DPAT (0.01-0.63), on basal performance in models of attention (5-choice serial reaction time task) and working memory (delayed non-matching to position).  Finally, unlike either comparator, F15599 reduced PPI with modest potency and only partially.  To conclude, F15599, in models of memory/cognition, has a more favorable profile than F13714 and 8-OH-DPAT.  This suggests that preferential activation of post-synaptic 5-HT1A receptors could prove useful in pathologies characterized by cognitive/memory deficiencies, such as schizophrenia and depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3znexqVaNSbVg90H21EOLACvtfcHk0lgBz_KGqQetmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXps1ehurk%253D&md5=f1598c2e68a80c345f34f0be89707c1d</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.euroneuro.2010.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.euroneuro.2010.04.005%26sid%3Dliteratum%253Aachs%26aulast%3DDepoort%25C3%25A8re%26aufirst%3DR.%26aulast%3DAuclair%26aufirst%3DA.%2BL.%26aulast%3DBardin%26aufirst%3DL.%26aulast%3DColpaert%26aufirst%3DF.%2BC.%26aulast%3DVacher%26aufirst%3DB.%26aulast%3DNewman-Tancredi%26aufirst%3DA.%26atitle%3DF15599%252C%2520a%2520Preferential%2520Post-Synaptic%25205-HT1A%2520Receptor%2520Agonist%253A%2520Activity%2520in%2520Models%2520of%2520Cognition%2520in%2520Comparison%2520with%2520Reference%25205-HT1A%2520Receptor%2520Agonists%26jtitle%3DEur.%2520Neuropsychopharmacol.%26date%3D2010%26volume%3D20%26spage%3D641%26epage%3D654%26doi%3D10.1016%2Fj.euroneuro.2010.04.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mawatari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawasaki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onoe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman-Tancredi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onoe, H.</span></span> <span> </span><span class="NLM_article-title">Marmoset Serotonin 5-HT1A Receptor Mapping with a Biased Agonist PET Probe 18F-F13714: Comparison with an Antagonist Tracer 18F-MPPF in Awake and Anesthetized States</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">pyw079</span>, <span class="refDoi"> DOI: 10.1093/ijnp/pyw079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1093%2Fijnp%2Fpyw079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=27608810" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2016&pages=pyw079&author=C.+Yokoyamaauthor=A.+Mawatariauthor=A.+Kawasakiauthor=C.+Takedaauthor=K.+Onoeauthor=H.+Doiauthor=A.+Newman-Tancrediauthor=L.+Zimmerauthor=H.+Onoe&title=Marmoset+Serotonin+5-HT1A+Receptor+Mapping+with+a+Biased+Agonist+PET+Probe+18F-F13714%3A+Comparison+with+an+Antagonist+Tracer+18F-MPPF+in+Awake+and+Anesthetized+States&doi=10.1093%2Fijnp%2Fpyw079"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1093%2Fijnp%2Fpyw079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fijnp%252Fpyw079%26sid%3Dliteratum%253Aachs%26aulast%3DYokoyama%26aufirst%3DC.%26aulast%3DMawatari%26aufirst%3DA.%26aulast%3DKawasaki%26aufirst%3DA.%26aulast%3DTakeda%26aufirst%3DC.%26aulast%3DOnoe%26aufirst%3DK.%26aulast%3DDoi%26aufirst%3DH.%26aulast%3DNewman-Tancredi%26aufirst%3DA.%26aulast%3DZimmer%26aufirst%3DL.%26aulast%3DOnoe%26aufirst%3DH.%26atitle%3DMarmoset%2520Serotonin%25205-HT1A%2520Receptor%2520Mapping%2520with%2520a%2520Biased%2520Agonist%2520PET%2520Probe%252018F-F13714%253A%2520Comparison%2520with%2520an%2520Antagonist%2520Tracer%252018F-MPPF%2520in%2520Awake%2520and%2520Anesthetized%2520States%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2016%26volume%3D19%26spage%3Dpyw079%26doi%3D10.1093%2Fijnp%2Fpyw079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Boer, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman-Tancredi, A.</span></span> <span> </span><span class="NLM_article-title">Anti-aggressive effects of the selective high-efficacy ‘biased’ 5-HT1A receptor agonists F15599 and F13714 in male WTG rats</span>. <i>Psychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>233</i></span>,  <span class="NLM_fpage">937</span>– <span class="NLM_lpage">947</span>, <span class="refDoi"> DOI: 10.1007/s00213-015-4173-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1007%2Fs00213-015-4173-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=26694810" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=233&publication_year=2015&pages=937-947&author=S.+F.+de%0ABoerauthor=A.+Newman-Tancredi&title=Anti-aggressive+effects+of+the+selective+high-efficacy+%E2%80%98biased%E2%80%99+5-HT1A+receptor+agonists+F15599+and+F13714+in+male+WTG+rats&doi=10.1007%2Fs00213-015-4173-x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1007%2Fs00213-015-4173-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-015-4173-x%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BBoer%26aufirst%3DS.%2BF.%26aulast%3DNewman-Tancredi%26aufirst%3DA.%26atitle%3DAnti-aggressive%2520effects%2520of%2520the%2520selective%2520high-efficacy%2520%25E2%2580%2598biased%25E2%2580%2599%25205-HT1A%2520receptor%2520agonists%2520F15599%2520and%2520F13714%2520in%2520male%2520WTG%2520rats%26jtitle%3DPsychopharmacology%26date%3D2015%26volume%3D233%26spage%3D937%26epage%3D947%26doi%3D10.1007%2Fs00213-015-4173-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bucki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcinkowska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Śniecikowska, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Więckowski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawłowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Głuch-Lutwin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gryboś, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siwek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pytka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jastrzębska-Więsek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Partyka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wesołowska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mierzejewski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kołaczkowski, M.</span></span> <span> </span><span class="NLM_article-title">Novel 3-(1,2,3,6-Tetrahydropyridin-4-Yl)-1H-Indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7483</span>– <span class="NLM_lpage">7501</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00839</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00839" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1KrtbbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7483-7501&author=A.+Buckiauthor=M.+Marcinkowskaauthor=J.+%C5%9Aniecikowskaauthor=K.+Wi%C4%99ckowskiauthor=M.+Paw%C5%82owskiauthor=M.+G%C5%82uch-Lutwinauthor=A.+Grybo%C5%9Bauthor=A.+Siwekauthor=K.+Pytkaauthor=M.+Jastrz%C4%99bska-Wi%C4%99sekauthor=A.+Partykaauthor=A.+Weso%C5%82owskaauthor=P.+Mierzejewskiauthor=M.+Ko%C5%82aczkowski&title=Novel+3-%281%2C2%2C3%2C6-Tetrahydropyridin-4-Yl%29-1H-Indole-Based+Multifunctional+Ligands+with+Antipsychotic-Like%2C+Mood-Modulating%2C+and+Procognitive+Activity&doi=10.1021%2Facs.jmedchem.7b00839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity</span></div><div class="casAuthors">Bucki, Adam; Marcinkowska, Monika; Sniecikowska, Joanna; Wieckowski, Krzysztof; Pawlowski, Maciej; Gluch-Lutwin, Monika; Grybos, Anna; Siwek, Agata; Pytka, Karolina; Jastrzebska-Wiesek, Magdalena; Partyka, Anna; Wesolowska, Anna; Mierzejewski, Pawel; Kolaczkowski, Marcin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7483-7501</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The most troublesome aspects of behavioral and psychol. symptoms of dementia (BPSD) are nowadays addressed by antidepressant, anxiolytic, and antipsychotic drugs, often administered off-label.  Considering their modest effectiveness in dementia patients, the increased risk of adverse events and cognitive decline, there is an unmet need for well-tolerated and effective therapy of BPSD.  We designed and synthesized multifunctional ligands characterized in vitro as high-affinity partial agonists of D2R, antagonists of 5-HT6R, and blockers of SERT.  Moreover, the mols. activated 5-HT1AR and blocked 5-HT7R while having no relevant affinity for off-target M1R and hERG channel.  Compd. I, (N-{2-[4-(5-chloro-1H-indol-3-yl)-1,2,3,6-tetrahydropyridin-1-yl]ethyl}-3-methylbenzene-1-sulfonamide), exhibited a broad antipsychotic-, antidepressant-, and anxiolytic-like activity, not eliciting motor impairments in mice.  Most importantly, I showed memory-enhancing properties and it ameliorated memory deficits induced by scopolamine.  The mol. outperformed most important comparators in selected tests, indicating its potential in the treatment of both cognitive and noncognitive (behavioral and psychol.) symptoms of dementia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_i47_Akgt17Vg90H21EOLACvtfcHk0lgcjMy83_g1-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1KrtbbF&md5=9bb21d4918f0c0575aeef817b89b9b19</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00839%26sid%3Dliteratum%253Aachs%26aulast%3DBucki%26aufirst%3DA.%26aulast%3DMarcinkowska%26aufirst%3DM.%26aulast%3D%25C5%259Aniecikowska%26aufirst%3DJ.%26aulast%3DWi%25C4%2599ckowski%26aufirst%3DK.%26aulast%3DPaw%25C5%2582owski%26aufirst%3DM.%26aulast%3DG%25C5%2582uch-Lutwin%26aufirst%3DM.%26aulast%3DGrybo%25C5%259B%26aufirst%3DA.%26aulast%3DSiwek%26aufirst%3DA.%26aulast%3DPytka%26aufirst%3DK.%26aulast%3DJastrz%25C4%2599bska-Wi%25C4%2599sek%26aufirst%3DM.%26aulast%3DPartyka%26aufirst%3DA.%26aulast%3DWeso%25C5%2582owska%26aufirst%3DA.%26aulast%3DMierzejewski%26aufirst%3DP.%26aulast%3DKo%25C5%2582aczkowski%26aufirst%3DM.%26atitle%3DNovel%25203-%25281%252C2%252C3%252C6-Tetrahydropyridin-4-Yl%2529-1H-Indole-Based%2520Multifunctional%2520Ligands%2520with%2520Antipsychotic-Like%252C%2520Mood-Modulating%252C%2520and%2520Procognitive%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D7483%26epage%3D7501%26doi%3D10.1021%2Facs.jmedchem.7b00839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nygaard, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frimurer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holst, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenkilde, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, T. W.</span></span> <span> </span><span class="NLM_article-title">Ligand Binding and Micro-Switches in 7TM Receptor Structures</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">249</span>– <span class="NLM_lpage">259</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2009.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2Fj.tips.2009.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=19375807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltlKktr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=249-259&author=R.+Nygaardauthor=T.+M.+Frimurerauthor=B.+Holstauthor=M.+M.+Rosenkildeauthor=T.+W.+Schwartz&title=Ligand+Binding+and+Micro-Switches+in+7TM+Receptor+Structures&doi=10.1016%2Fj.tips.2009.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand binding and micro-switches in 7TM receptor structures</span></div><div class="casAuthors">Nygaard, Rie; Frimurer, Thomas M.; Holst, Birgitte; Rosenkilde, Mette M.; Schwartz, Thue W.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">249-259</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The past couple of years have seen several novel X-ray structures of 7 transmembrane (7TM) receptors in complex with antagonists and even with a peptide fragment of a G protein.  These structures demonstrate that the main ligand-binding pocket in 7TM receptors is like a funnel with a partial 'lid' in which extracellular loop 2b, in particular, functions as a gating element.  Small-mol. antagonists and inverse agonists bind in very different modes: some very deeply and others more superficially, even reaching out above the transmembrane region.  Several highly conserved residues seem to function as micro-switches of which ArgIII:26 (Arg3.50) in its active conformation interacts directly with the G protein.  These micro-switches together with a hydrogen-bond network between conserved polar residues and structural water mols. are proposed to constitute an extended allosteric interface between the domains (i.e. esp. TM-VI), which performs the large, global toggle switch movements connecting ligand binding with intracellular signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0A3KKnq_9dLVg90H21EOLACvtfcHk0lgcjMy83_g1-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltlKktr8%253D&md5=d0384d34d39e08f9b82e6752c358a6cb</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2009.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2009.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DNygaard%26aufirst%3DR.%26aulast%3DFrimurer%26aufirst%3DT.%2BM.%26aulast%3DHolst%26aufirst%3DB.%26aulast%3DRosenkilde%26aufirst%3DM.%2BM.%26aulast%3DSchwartz%26aufirst%3DT.%2BW.%26atitle%3DLigand%2520Binding%2520and%2520Micro-Switches%2520in%25207TM%2520Receptor%2520Structures%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2009%26volume%3D30%26spage%3D249%26epage%3D259%26doi%3D10.1016%2Fj.tips.2009.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vacher, B.</span>; <span class="NLM_string-name">Maurel, J. L.</span>; <span class="NLM_string-name">Brunel, S.</span></span> <span> </span><span class="NLM_article-title">Method for Preparing (3-Chloro-4-Fluorophenyl)-(4-Fluoro-4-{[(5methyl-Pyrimidin-2-Ylmethyl)-Amino]-Methyl}-Piperidin-1-Yl)-Methanone and Novel Intermediate Pyrimidine Derivatives</span>. WO <span class="NLM_patent">039499 A1</span>, Sept 22, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=B.+Vacher&author=J.+L.+Maurel&author=S.+Brunel&title=Method+for+Preparing+%283-Chloro-4-Fluorophenyl%29-%284-Fluoro-4-%7B%5B%285methyl-Pyrimidin-2-Ylmethyl%29-Amino%5D-Methyl%7D-Piperidin-1-Yl%29-Methanone+and+Novel+Intermediate+Pyrimidine+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DVacher%26aufirst%3DB.%26atitle%3DMethod%2520for%2520Preparing%2520%25283-Chloro-4-Fluorophenyl%2529-%25284-Fluoro-4-%257B%255B%25285methyl-Pyrimidin-2-Ylmethyl%2529-Amino%255D-Methyl%257D-Piperidin-1-Yl%2529-Methanone%2520and%2520Novel%2520Intermediate%2520Pyrimidine%2520Derivatives%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maurel, J. L.</span>; <span class="NLM_string-name">Bonnaud, B.</span>; <span class="NLM_string-name">Ribet, J.-P.</span>; <span class="NLM_string-name">Vacher, B.</span></span> <span> </span><span class="NLM_article-title">Synthesis Method and Intermediates of Pyridin-2-Yl-Methylamine</span>. WO <span class="NLM_patent">064585 A1</span>, Feb 11, <span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=J.+L.+Maurel&author=B.+Bonnaud&author=J.-P.+Ribet&author=B.+Vacher&title=Synthesis+Method+and+Intermediates+of+Pyridin-2-Yl-Methylamine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMaurel%26aufirst%3DJ.%2BL.%26atitle%3DSynthesis%2520Method%2520and%2520Intermediates%2520of%2520Pyridin-2-Yl-Methylamine%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jończyk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedoryński, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mąkosza, M.</span></span> <span> </span><span class="NLM_article-title">Reactions of Organic Anions. XLIII. Catalytic Method for Synthesis of Glycidic Nitriles in Aqueous Medium</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1972</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">2395</span>– <span class="NLM_lpage">2396</span>, <span class="refDoi"> DOI: 10.1016/s0040-4039(01)85312-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2Fs0040-4039%2801%2985312-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1972&pages=2395-2396&author=A.+Jo%C5%84czykauthor=M.+Fedory%C5%84skiauthor=M.+M%C4%85kosza&title=Reactions+of+Organic+Anions.+XLIII.+Catalytic+Method+for+Synthesis+of+Glycidic+Nitriles+in+Aqueous+Medium&doi=10.1016%2Fs0040-4039%2801%2985312-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fs0040-4039%2801%2985312-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0040-4039%252801%252985312-0%26sid%3Dliteratum%253Aachs%26aulast%3DJo%25C5%2584czyk%26aufirst%3DA.%26aulast%3DFedory%25C5%2584ski%26aufirst%3DM.%26aulast%3DM%25C4%2585kosza%26aufirst%3DM.%26atitle%3DReactions%2520of%2520Organic%2520Anions.%2520XLIII.%2520Catalytic%2520Method%2520for%2520Synthesis%2520of%2520Glycidic%2520Nitriles%2520in%2520Aqueous%2520Medium%26jtitle%3DTetrahedron%2520Lett.%26date%3D1972%26volume%3D13%26spage%3D2395%26epage%3D2396%26doi%3D10.1016%2Fs0040-4039%2801%2985312-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vacher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnaud, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jubault, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koek, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assié, M.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleven, M.</span></span> <span> </span><span class="NLM_article-title">Novel Derivatives of 2-Pyridinemethylamine as Selective, Potent, and Orally Active Agonists at 5-HT1AReceptors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">1648</span>– <span class="NLM_lpage">1660</span>, <span class="refDoi"> DOI: 10.1021/jm9806906</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9806906" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=1648-1660&author=B.+Vacherauthor=B.+Bonnaudauthor=P.+Funesauthor=N.+Jubaultauthor=W.+Koekauthor=M.-B.+Assi%C3%A9author=C.+Cosiauthor=M.+Kleven&title=Novel+Derivatives+of+2-Pyridinemethylamine+as+Selective%2C+Potent%2C+and+Orally+Active+Agonists+at+5-HT1AReceptors&doi=10.1021%2Fjm9806906"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm9806906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9806906%26sid%3Dliteratum%253Aachs%26aulast%3DVacher%26aufirst%3DB.%26aulast%3DBonnaud%26aufirst%3DB.%26aulast%3DFunes%26aufirst%3DP.%26aulast%3DJubault%26aufirst%3DN.%26aulast%3DKoek%26aufirst%3DW.%26aulast%3DAssi%25C3%25A9%26aufirst%3DM.-B.%26aulast%3DCosi%26aufirst%3DC.%26aulast%3DKleven%26aufirst%3DM.%26atitle%3DNovel%2520Derivatives%2520of%25202-Pyridinemethylamine%2520as%2520Selective%252C%2520Potent%252C%2520and%2520Orally%2520Active%2520Agonists%2520at%25205-HT1AReceptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D1648%26epage%3D1660%26doi%3D10.1021%2Fjm9806906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suga, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamatani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlosser, M.</span></span> <span> </span><span class="NLM_article-title">Regioselective Formation of Fluorohydrins and Their Stereoselective Conversion to Fluoroolefins</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">4247</span>– <span class="NLM_lpage">4254</span>, <span class="refDoi"> DOI: 10.1016/s0040-4020(01)86761-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2Fs0040-4020%2801%2986761-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADyaK3MXmtFCqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=1990&pages=4247-4254&author=H.+Sugaauthor=T.+Hamataniauthor=M.+Schlosser&title=Regioselective+Formation+of+Fluorohydrins+and+Their+Stereoselective+Conversion+to+Fluoroolefins&doi=10.1016%2Fs0040-4020%2801%2986761-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Regioselective formation of fluorohydrins and their stereoselective conversion to fluoroolefins</span></div><div class="casAuthors">Suga, Hiroaki; Hamatani, Takeshi; Schlosser, Manfred</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4247-54</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    </div><div class="casAbstract">When treated with KOCMe3 in THF, fluorohydrin p-tosylates afford fluoro olefins, e.g., Z- or E-Me(CH2)4CF:CH(CH2)4Me, in high yields.  Fluorohydrins are readily and stereoselectively accessible by antiperiplanar addn. of HF to oxiranes.  Terminal epoxides give preferentially 2-fluoro-1-alkanols with HF-pyridine mixt. in PhMe, while mainly 1-fluoro-2-alkanols result from reaction with Huenig's hydrofluoride (i.e., the adduct of HF and (Me2CH)2NEt.  With 2-hydroxymethyl-substituted oxiranes, 3-fluoro-1,2-alkanediols are obtained predominantly if not exclusively.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0t0to3qWYaLVg90H21EOLACvtfcHk0ljKVCgCKtN4Rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXmtFCqsQ%253D%253D&md5=63e5111920196b068df6dd832e9460f6</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fs0040-4020%2801%2986761-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0040-4020%252801%252986761-2%26sid%3Dliteratum%253Aachs%26aulast%3DSuga%26aufirst%3DH.%26aulast%3DHamatani%26aufirst%3DT.%26aulast%3DSchlosser%26aufirst%3DM.%26atitle%3DRegioselective%2520Formation%2520of%2520Fluorohydrins%2520and%2520Their%2520Stereoselective%2520Conversion%2520to%2520Fluoroolefins%26jtitle%3DTetrahedron%26date%3D1990%26volume%3D46%26spage%3D4247%26epage%3D4254%26doi%3D10.1016%2Fs0040-4020%2801%2986761-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipinski, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominy, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feeney, P. J.</span></span> <span> </span><span class="NLM_article-title">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3-25. 1</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1016/s0169-409x(00)00129-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2Fs0169-409x%2800%2900129-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=11259830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitVOhs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2001&pages=3-26&author=C.+A.+Lipinskiauthor=F.+Lombardoauthor=B.+W.+Dominyauthor=P.+J.+Feeney&title=Experimental+and+computational+approaches+to+estimate+solubility+and+permeability+in+drug+discovery+and+development+settings+1PII+of+original+article%3A+S0169-409X%2896%2900423-1.+The+article+was+originally+published+in+Advanced+Drug+Delivery+Reviews+23+%281997%29+3-25.+1&doi=10.1016%2Fs0169-409x%2800%2900129-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span></div><div class="casAuthors">Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">3-26</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">A review with 50 refs.  Exptl. and computational approaches to est. soly. and permeability in discovery and development settings are described.  In the discovery setting 'the rule of 5' predicts that poor absorption or permeation is more likely when there are more than 5 H-bond donors, 10 H-bond acceptors, the mol. wt. (MWT) is greater than 500 and the calcd. Log P (CLogP) is greater than 5 (or MlogP >4.15).  Computational methodol. for the rule-based Moriguchi Log P (MLogP) calcn. is described.  Turbidimetric soly. measurement is described and applied to known drugs.  High throughput screening (HTS) leads tend to have higher MWT and Log P and lower turbidimetric soly. than leads in the pre-HTS era.  In the development setting, soly. calcns. focus on exact value prediction and are difficult because of polymorphism.  Recent work on linear free energy relationships and Log P approaches are critically reviewed.  Useful predictions are possible in closely related analog series when coupled with exptl. thermodn. soly. measurements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYDqa02g16urVg90H21EOLACvtfcHk0lhXY-HBtJ_R4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitVOhs7o%253D&md5=c60bb89da68f051c0ee7ac4c0468a0e4</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fs0169-409x%2800%2900129-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0169-409x%252800%252900129-0%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DDominy%26aufirst%3DB.%2BW.%26aulast%3DFeeney%26aufirst%3DP.%2BJ.%26atitle%3DExperimental%2520and%2520computational%2520approaches%2520to%2520estimate%2520solubility%2520and%2520permeability%2520in%2520drug%2520discovery%2520and%2520development%2520settings%25201PII%2520of%2520original%2520article%253A%2520S0169-409X%252896%252900423-1.%2520The%2520article%2520was%2520originally%2520published%2520in%2520Advanced%2520Drug%2520Delivery%2520Reviews%252023%2520%25281997%2529%25203-25.%25201%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2001%26volume%3D46%26spage%3D3%26epage%3D26%26doi%3D10.1016%2Fs0169-409x%2800%2900129-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wager, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhoest, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villalobos, A.</span></span> <span> </span><span class="NLM_article-title">Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike Properties</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">435</span>– <span class="NLM_lpage">449</span>, <span class="refDoi"> DOI: 10.1021/cn100008c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn100008c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvVejtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=435-449&author=T.+T.+Wagerauthor=X.+Houauthor=P.+R.+Verhoestauthor=A.+Villalobos&title=Moving+beyond+Rules%3A+The+Development+of+a+Central+Nervous+System+Multiparameter+Optimization+%28CNS+MPO%29+Approach+To+Enable+Alignment+of+Druglike+Properties&doi=10.1021%2Fcn100008c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike Properties</span></div><div class="casAuthors">Wager, Travis T.; Hou, Xinjun; Verhoest, Patrick R.; Villalobos, Anabella</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">435-449</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The interplay among commonly used physicochem. properties in drug design was examd. and utilized to create a prospective design tool focused on the alignment of key druglike attributes.  Using a set of six physicochem. parameters ((a) lipophilicity, calcd. partition coeff. (ClogP); (b) calcd. distribution coeff. at pH = 7.4 (ClogD); (c) mol. wt. (MW); (d) topol. polar surface area (TPSA); (e) no. of hydrogen bond donors (HBD); (f) most basic center (pKa)), a druglikeness central nervous system multiparameter optimization (CNS MPO) algorithm was built and applied to a set of marketed CNS drugs (N = 119) and Pfizer CNS candidates (N = 108), as well as to a large diversity set of Pfizer proprietary compds. (N = 11 303).  The novel CNS MPO algorithm showed that 74% of marketed CNS drugs displayed a high CNS MPO score (MPO desirability score ≥ 4, using a scale of 0-6), in comparison to 60% of the Pfizer CNS candidates.  This anal. suggests that this algorithm could potentially be used to identify compds. with a higher probability of successfully testing hypotheses in the clinic.  In addn., a relationship between an increasing CNS MPO score and alignment of key in vitro attributes of drug discovery (favorable permeability, P-glycoprotein (P-gp) efflux, metabolic stability, and safety) was seen in the marketed CNS drug set, the Pfizer candidate set, and the Pfizer proprietary diversity set.  The CNS MPO scoring function offers advantages over hard cutoffs or utilization of single parameters to optimize structure-activity relationships (SAR) by expanding medicinal chem. design space through a holistic assessment approach.  Based on six physicochem. properties commonly used by medicinal chemists, the CNS MPO function may be used prospectively at the design stage to accelerate the identification of compds. with increased probability of success.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB3Mvkgm_X5bVg90H21EOLACvtfcHk0lhXY-HBtJ_R4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvVejtr8%253D&md5=e94998f65a420be6ee4dec4a987cb983</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fcn100008c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn100008c%26sid%3Dliteratum%253Aachs%26aulast%3DWager%26aufirst%3DT.%2BT.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DVerhoest%26aufirst%3DP.%2BR.%26aulast%3DVillalobos%26aufirst%3DA.%26atitle%3DMoving%2520beyond%2520Rules%253A%2520The%2520Development%2520of%2520a%2520Central%2520Nervous%2520System%2520Multiparameter%2520Optimization%2520%2528CNS%2520MPO%2529%2520Approach%2520To%2520Enable%2520Alignment%2520of%2520Druglike%2520Properties%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2010%26volume%3D1%26spage%3D435%26epage%3D449%26doi%3D10.1021%2Fcn100008c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waring, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrowsmith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandrell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pairaudeau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennie, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickett, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, A.</span></span> <span> </span><span class="NLM_article-title">An Analysis of the Attrition of Drug Candidates from Four Major Pharmaceutical Companies</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">475</span>– <span class="NLM_lpage">486</span>, <span class="refDoi"> DOI: 10.1038/nrd4609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1038%2Fnrd4609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=26091267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=475-486&author=M.+J.+Waringauthor=J.+Arrowsmithauthor=A.+R.+Leachauthor=P.+D.+Leesonauthor=S.+Mandrellauthor=R.+M.+Owenauthor=G.+Pairaudeauauthor=W.+D.+Pennieauthor=S.+D.+Pickettauthor=J.+Wangauthor=O.+Wallaceauthor=A.+Weir&title=An+Analysis+of+the+Attrition+of+Drug+Candidates+from+Four+Major+Pharmaceutical+Companies&doi=10.1038%2Fnrd4609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">An analysis of the attrition of drug candidates from four major pharmaceutical companies</span></div><div class="casAuthors">Waring, Michael J.; Arrowsmith, John; Leach, Andrew R.; Leeson, Paul D.; Mandrell, Sam; Owen, Robert M.; Pairaudeau, Garry; Pennie, William D.; Pickett, Stephen D.; Wang, Jibo; Wallace, Owen; Weir, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">475-486</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The pharmaceutical industry remains under huge pressure to address the high attrition rates in drug development.  Attempts to reduce the no. of efficacy- and safety-related failures by analyzing possible links to the physicochem. properties of small-mol. drug candidates have been inconclusive because of the limited size of data sets from individual companies.  Here, we describe the compilation and anal. of combined data on the attrition of drug candidates from AstraZeneca, Eli Lilly and Company, GlaxoSmithKline and Pfizer.  The anal. reaffirms that control of physicochem. properties during compd. optimization is beneficial in identifying compds. of candidate drug quality and indicates for the first time a link between the physicochem. properties of compds. and clin. failure due to safety issues.  The results also suggest that further control of physicochem. properties is unlikely to have a significant effect on attrition rates and that addnl. work is required to address safety-related failures.  Further cross-company collaborations will be crucial to future progress in this area.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsLfBWrLC3ZLVg90H21EOLACvtfcHk0lhXY-HBtJ_R4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7jM&md5=1fdc374d32816b1e91438152299dd1b1</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1038%2Fnrd4609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4609%26sid%3Dliteratum%253Aachs%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DArrowsmith%26aufirst%3DJ.%26aulast%3DLeach%26aufirst%3DA.%2BR.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DMandrell%26aufirst%3DS.%26aulast%3DOwen%26aufirst%3DR.%2BM.%26aulast%3DPairaudeau%26aufirst%3DG.%26aulast%3DPennie%26aufirst%3DW.%2BD.%26aulast%3DPickett%26aufirst%3DS.%2BD.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWallace%26aufirst%3DO.%26aulast%3DWeir%26aufirst%3DA.%26atitle%3DAn%2520Analysis%2520of%2520the%2520Attrition%2520of%2520Drug%2520Candidates%2520from%2520Four%2520Major%2520Pharmaceutical%2520Companies%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D475%26epage%3D486%26doi%3D10.1038%2Fnrd4609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wager, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandrasekaran, R. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troutman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhoest, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villalobos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, Y.</span></span> <span> </span><span class="NLM_article-title">Defining Desirable Central Nervous System Drug Space through the Alignment of Molecular Properties, in Vitro ADME, and Safety Attributes</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">420</span>– <span class="NLM_lpage">434</span>, <span class="refDoi"> DOI: 10.1021/cn100007x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn100007x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvVaqtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=420-434&author=T.+T.+Wagerauthor=R.+Y.+Chandrasekaranauthor=X.+Houauthor=M.+D.+Troutmanauthor=P.+R.+Verhoestauthor=A.+Villalobosauthor=Y.+Will&title=Defining+Desirable+Central+Nervous+System+Drug+Space+through+the+Alignment+of+Molecular+Properties%2C+in+Vitro+ADME%2C+and+Safety+Attributes&doi=10.1021%2Fcn100007x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Defining Desirable Central Nervous System Drug Space through the Alignment of Molecular Properties, in Vitro ADME, and Safety Attributes</span></div><div class="casAuthors">Wager, Travis T.; Chandrasekaran, Ramalakshmi Y.; Hou, Xinjun; Troutman, Matthew D.; Verhoest, Patrick R.; Villalobos, Anabella; Will, Yvonne</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">420-434</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">As part of our effort to increase survival of drug candidates and to move our medicinal chem. design to higher probability space for success in the Neuroscience therapeutic area, we embarked on a detailed study of the property space for a collection of central nervous system (CNS) mols.  We carried out a thorough anal. of properties for 119 marketed CNS drugs and a set of 108 Pfizer CNS candidates.  In particular, we focused on understanding the relationships between physicochem. properties, in vitro ADME (absorption, distribution, metab., and elimination) attributes, primary pharmacol. binding efficiencies, and in vitro safety data for these two sets of compds.  This scholarship provides guidance for the design of CNS mols. in a property space with increased probability of success and may lead to the identification of druglike candidates with favorable safety profiles that can successfully test hypotheses in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvEMBo2f34BrVg90H21EOLACvtfcHk0lju6l-fMe5mNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvVaqtbk%253D&md5=85716be86290fd85e93c6b8d5621683c</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fcn100007x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn100007x%26sid%3Dliteratum%253Aachs%26aulast%3DWager%26aufirst%3DT.%2BT.%26aulast%3DChandrasekaran%26aufirst%3DR.%2BY.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DTroutman%26aufirst%3DM.%2BD.%26aulast%3DVerhoest%26aufirst%3DP.%2BR.%26aulast%3DVillalobos%26aufirst%3DA.%26aulast%3DWill%26aufirst%3DY.%26atitle%3DDefining%2520Desirable%2520Central%2520Nervous%2520System%2520Drug%2520Space%2520through%2520the%2520Alignment%2520of%2520Molecular%2520Properties%252C%2520in%2520Vitro%2520ADME%252C%2520and%2520Safety%2520Attributes%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2010%26volume%3D1%26spage%3D420%26epage%3D434%26doi%3D10.1021%2Fcn100007x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tarcsay, Á.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyíri, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keserű, G. M.</span></span> <span> </span><span class="NLM_article-title">Impact of Lipophilic Efficiency on Compound Quality</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1252</span>– <span class="NLM_lpage">1260</span>, <span class="refDoi"> DOI: 10.1021/jm201388p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201388p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC38XktVKjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1252-1260&author=%C3%81.+Tarcsayauthor=K.+Ny%C3%ADriauthor=G.+M.+Keser%C5%B1&title=Impact+of+Lipophilic+Efficiency+on+Compound+Quality&doi=10.1021%2Fjm201388p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of Lipophilic Efficiency on Compound Quality</span></div><div class="casAuthors">Tarcsay, Akos; Nyiri, Kinga; Keseru, Gyorgy M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1252-1260</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Lipophilic efficiency indexes such as LLE and LELP were suggested to support balanced optimization of potency and ADMET profile.  Here we investigated the performance of LLE and LELP on multiple data sets representing different stages of drug discovery including fragment and HTS hits and leads, development candidates, phase II compds., and launched drugs.  Analyzing their impact on ADME and safety properties and binding thermodn., we found that both LLE and LELP help identifying better quality compds.  LLE is sensible for the development stages but does not prefer fragment-type hits, while LELP has an advantage for this class of compds. and discriminates preferred starting points effectively.  Both LLE and LELP have significant impact on ADME and safety profiles; however, LELP outperforms LLE in risk assessment at least on the present data set.  On the basis of the results reported here, monitoring lipophilic efficiency metrics could contribute significantly to compd. quality and might improve the output of medicinal chem. programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxB8xs6-5DL7Vg90H21EOLACvtfcHk0lju6l-fMe5mNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktVKjsQ%253D%253D&md5=2536abef781f52806013016971c78bcb</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjm201388p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201388p%26sid%3Dliteratum%253Aachs%26aulast%3DTarcsay%26aufirst%3D%25C3%2581.%26aulast%3DNy%25C3%25ADri%26aufirst%3DK.%26aulast%3DKeser%25C5%25B1%26aufirst%3DG.%2BM.%26atitle%3DImpact%2520of%2520Lipophilic%2520Efficiency%2520on%2520Compound%2520Quality%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1252%26epage%3D1260%26doi%3D10.1021%2Fjm201388p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dahlin, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissink, J. W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strasser, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgins, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, M. A.</span></span> <span> </span><span class="NLM_article-title">PAINS in the Assay: Chemical Mechanisms of Assay Interference and Promiscuous Enzymatic Inhibition Observed during a Sulfhydryl-Scavenging HTS</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">2091</span>– <span class="NLM_lpage">2113</span>, <span class="refDoi"> DOI: 10.1021/jm5019093</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5019093" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVeisbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2091-2113&author=J.+L.+Dahlinauthor=J.+W.+M.+Nissinkauthor=J.+M.+Strasserauthor=S.+Francisauthor=L.+Higginsauthor=H.+Zhouauthor=Z.+Zhangauthor=M.+A.+Walters&title=PAINS+in+the+Assay%3A+Chemical+Mechanisms+of+Assay+Interference+and+Promiscuous+Enzymatic+Inhibition+Observed+during+a+Sulfhydryl-Scavenging+HTS&doi=10.1021%2Fjm5019093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">PAINS in the Assay: Chemical Mechanisms of Assay Interference and Promiscuous Enzymatic Inhibition Observed during a Sulfhydryl-Scavenging HTS</span></div><div class="casAuthors">Dahlin, Jayme L.; Nissink, J. Willem M.; Strasser, Jessica M.; Francis, Subhashree; Higgins, LeeAnn; Zhou, Hui; Zhang, Zhiguo; Walters, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2091-2113</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Significant resources in early drug discovery are spent unknowingly pursuing artifacts and promiscuous bioactive compds., while understanding the chem. basis for these adverse behaviors often goes unexplored in pursuit of lead compds.  Nearly all the hits from our recent sulfhydryl-scavenging high-throughput screen (HTS) targeting the histone acetyltransferase Rtt109 were such compds.  Herein, we characterize the chem. basis for assay interference and promiscuous enzymic inhibition for several prominent chemotypes identified by this HTS, including some pan-assay interference compds. (PAINS).  Protein mass spectrometry and ALARM NMR confirmed these compds. react covalently with cysteines on multiple proteins.  Unfortunately, compds. contg. these chemotypes have been published as screening actives in reputable journals and even touted as chem. probes or preclin. candidates.  Our detailed characterization and identification of such thiol-reactive chemotypes should accelerate triage of nuisance compds., guide screening library design, and prevent follow-up on undesirable chem. matter.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4XTJapoezkrVg90H21EOLACvtfcHk0lju6l-fMe5mNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVeisbY%253D&md5=3f77702544cea2ec4c8184b60dd38b8a</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fjm5019093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5019093%26sid%3Dliteratum%253Aachs%26aulast%3DDahlin%26aufirst%3DJ.%2BL.%26aulast%3DNissink%26aufirst%3DJ.%2BW.%2BM.%26aulast%3DStrasser%26aufirst%3DJ.%2BM.%26aulast%3DFrancis%26aufirst%3DS.%26aulast%3DHiggins%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DWalters%26aufirst%3DM.%2BA.%26atitle%3DPAINS%2520in%2520the%2520Assay%253A%2520Chemical%2520Mechanisms%2520of%2520Assay%2520Interference%2520and%2520Promiscuous%2520Enzymatic%2520Inhibition%2520Observed%2520during%2520a%2520Sulfhydryl-Scavenging%2520HTS%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D2091%26epage%3D2113%26doi%3D10.1021%2Fjm5019093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pouliot, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeanmart, S.</span></span> <span> </span><span class="NLM_article-title">Pan Assay Interference Compounds (PAINS) and Other Promiscuous Compounds in Antifungal Research</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">497</span>– <span class="NLM_lpage">503</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00361</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00361" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=497-503&author=M.+Pouliotauthor=S.+Jeanmart&title=Pan+Assay+Interference+Compounds+%28PAINS%29+and+Other+Promiscuous+Compounds+in+Antifungal+Research&doi=10.1021%2Facs.jmedchem.5b00361"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00361%26sid%3Dliteratum%253Aachs%26aulast%3DPouliot%26aufirst%3DM.%26aulast%3DJeanmart%26aufirst%3DS.%26atitle%3DPan%2520Assay%2520Interference%2520Compounds%2520%2528PAINS%2529%2520and%2520Other%2520Promiscuous%2520Compounds%2520in%2520Antifungal%2520Research%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D59%26spage%3D497%26epage%3D503%26doi%3D10.1021%2Facs.jmedchem.5b00361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brenk, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schipani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krasowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frearson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyatt, P. G.</span></span> <span> </span><span class="NLM_article-title">Lessons Learnt from Assembling Screening Libraries for Drug Discovery for Neglected Diseases</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">435</span>– <span class="NLM_lpage">444</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200700139</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1002%2Fcmdc.200700139" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=18064617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlt1Krtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=435-444&author=R.+Brenkauthor=A.+Schipaniauthor=D.+Jamesauthor=A.+Krasowskiauthor=I.+H.+Gilbertauthor=J.+Frearsonauthor=P.+G.+Wyatt&title=Lessons+Learnt+from+Assembling+Screening+Libraries+for+Drug+Discovery+for+Neglected+Diseases&doi=10.1002%2Fcmdc.200700139"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Lessons learned from assembling screening libraries for drug discovery for neglected diseases</span></div><div class="casAuthors">Brenk, Ruth; Schipani, Alessandro; James, Daniel; Krasowski, Agata; Gilbert, Ian Hugh; Frearson, Julie; Wyatt, Paul Graham</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">435-444</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">To enable the establishment of a drug discovery operation for neglected diseases, out of 2.3 million com. available compds. 222 552 compds. were selected for an in silico library, 57 438 for a diverse general screening library, and 1 697 compds. for a focused kinase set.  Compiling these libraries required a robust strategy for compd. selection.  Rules for unwanted groups were defined and selection criteria to enrich for lead-like compds. which facilitate straightforward structure-activity relationship exploration were established.  Further, a literature and patent review was undertaken to ext. key recognition elements of kinase inhibitors ("core fragments") to assemble a focused library for hit discovery for kinases.  Computational and exptl. characterization of the general screening library revealed that the selected compds. (1) span a broad range of lead-like space, (2) show a high degree of structural integrity and purity, and (3) demonstrate appropriate soly. for the purposes of biochem. screening.  The implications of this study for compd. selection, esp. in an academic environment with limited resources, are considered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy_Ybsdg8QS7Vg90H21EOLACvtfcHk0ljH1ofr2A-65w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlt1Krtb4%253D&md5=b804d0ac8766e954391798e24aa7fbff</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200700139&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200700139%26sid%3Dliteratum%253Aachs%26aulast%3DBrenk%26aufirst%3DR.%26aulast%3DSchipani%26aufirst%3DA.%26aulast%3DJames%26aufirst%3DD.%26aulast%3DKrasowski%26aufirst%3DA.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26aulast%3DFrearson%26aufirst%3DJ.%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26atitle%3DLessons%2520Learnt%2520from%2520Assembling%2520Screening%2520Libraries%2520for%2520Drug%2520Discovery%2520for%2520Neglected%2520Diseases%26jtitle%3DChemMedChem%26date%3D2008%26volume%3D3%26spage%3D435%26epage%3D444%26doi%3D10.1002%2Fcmdc.200700139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michielin, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoete, V.</span></span> <span> </span><span class="NLM_article-title">SwissADME: A Free Web Tool to Evaluate Pharmacokinetics, Drug-Likeness and Medicinal Chemistry Friendliness of Small Molecules</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">42717</span>, <span class="refDoi"> DOI: 10.1038/srep42717</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1038%2Fsrep42717" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=28256516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A280%3ADC%252BC1czisFSrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=42717&author=A.+Dainaauthor=O.+Michielinauthor=V.+Zoete&title=SwissADME%3A+A+Free+Web+Tool+to+Evaluate+Pharmacokinetics%2C+Drug-Likeness+and+Medicinal+Chemistry+Friendliness+of+Small+Molecules&doi=10.1038%2Fsrep42717"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules</span></div><div class="casAuthors">Daina Antoine; Michielin Olivier; Zoete Vincent; Michielin Olivier; Michielin Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">42717</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">To be effective as a drug, a potent molecule must reach its target in the body in sufficient concentration, and stay there in a bioactive form long enough for the expected biologic events to occur.  Drug development involves assessment of absorption, distribution, metabolism and excretion (ADME) increasingly earlier in the discovery process, at a stage when considered compounds are numerous but access to the physical samples is limited.  In that context, computer models constitute valid alternatives to experiments.  Here, we present the new SwissADME web tool that gives free access to a pool of fast yet robust predictive models for physicochemical properties, pharmacokinetics, drug-likeness and medicinal chemistry friendliness, among which in-house proficient methods such as the BOILED-Egg, iLOGP and Bioavailability Radar.  Easy efficient input and interpretation are ensured thanks to a user-friendly interface through the login-free website http://www.swissadme.ch.  Specialists, but also nonexpert in cheminformatics or computational chemistry can predict rapidly key parameters for a collection of molecules to support their drug discovery endeavours.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRl_Uk5dOMKs6qcneEtCi92fW6udTcc2eYhImsd3sPiTLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czisFSrtg%253D%253D&md5=9715b8cb8a34b17c4c73ff69a5a8cc50</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1038%2Fsrep42717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep42717%26sid%3Dliteratum%253Aachs%26aulast%3DDaina%26aufirst%3DA.%26aulast%3DMichielin%26aufirst%3DO.%26aulast%3DZoete%26aufirst%3DV.%26atitle%3DSwissADME%253A%2520A%2520Free%2520Web%2520Tool%2520to%2520Evaluate%2520Pharmacokinetics%252C%2520Drug-Likeness%2520and%2520Medicinal%2520Chemistry%2520Friendliness%2520of%2520Small%2520Molecules%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D42717%26doi%3D10.1038%2Fsrep42717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bowes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarolimek, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldron, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitebread, S.</span></span> <span> </span><span class="NLM_article-title">Reducing Safety-Related Drug Attrition: The Use of in Vitro Pharmacological Profiling</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">909</span>– <span class="NLM_lpage">922</span>, <span class="refDoi"> DOI: 10.1038/nrd3845</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1038%2Fnrd3845" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=23197038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslCnur%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=909-922&author=J.+Bowesauthor=A.+J.+Brownauthor=J.+Hamonauthor=W.+Jarolimekauthor=A.+Sridharauthor=G.+Waldronauthor=S.+Whitebread&title=Reducing+Safety-Related+Drug+Attrition%3A+The+Use+of+in+Vitro+Pharmacological+Profiling&doi=10.1038%2Fnrd3845"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Reducing safety-related drug attrition: the use of in vitro pharmacological profiling</span></div><div class="casAuthors">Bowes, Joanne; Brown, Andrew J.; Hamon, Jacques; Jarolimek, Wolfgang; Sridhar, Arun; Waldron, Gareth; Whitebread, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">909-922</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In vitro pharmacol. profiling is increasingly being used earlier in the drug discovery process to identify undesirable off-target activity profiles that could hinder or halt the development of candidate drugs or even lead to market withdrawal if discovered after a drug is approved.  Here, for the first time, the rationale, strategies and methodologies for in vitro pharmacol. profiling at four major pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Novartis and Pfizer) are presented and illustrated with examples of their impact on the drug discovery process.  We hope that this will enable other companies and academic institutions to benefit from this knowledge and consider joining us in our collaborative knowledge sharing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomVp3wnTONWrVg90H21EOLACvtfcHk0ljH1ofr2A-65w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslCnur%252FJ&md5=7559001563ef3febd610535b8f096a45</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1038%2Fnrd3845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3845%26sid%3Dliteratum%253Aachs%26aulast%3DBowes%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DA.%2BJ.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DJarolimek%26aufirst%3DW.%26aulast%3DSridhar%26aufirst%3DA.%26aulast%3DWaldron%26aufirst%3DG.%26aulast%3DWhitebread%26aufirst%3DS.%26atitle%3DReducing%2520Safety-Related%2520Drug%2520Attrition%253A%2520The%2520Use%2520of%2520in%2520Vitro%2520Pharmacological%2520Profiling%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D909%26epage%3D922%26doi%3D10.1038%2Fnrd3845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gintant, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sager, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stockbridge, N.</span></span> <span> </span><span class="NLM_article-title">Evolution of Strategies to Improve Preclinical Cardiac Safety Testing</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">457</span>– <span class="NLM_lpage">471</span>, <span class="refDoi"> DOI: 10.1038/nrd.2015.34</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1038%2Fnrd.2015.34" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=26893184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC28XivVCju7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=457-471&author=G.+Gintantauthor=P.+T.+Sagerauthor=N.+Stockbridge&title=Evolution+of+Strategies+to+Improve+Preclinical+Cardiac+Safety+Testing&doi=10.1038%2Fnrd.2015.34"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Evolution of strategies to improve preclinical cardiac safety testing</span></div><div class="casAuthors">Gintant, Gary; Sager, Philip T.; Stockbridge, Norman</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">457-471</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The early and efficient assessment of cardiac safety liabilities is essential to confidently advance novel drug candidates.  This article discusses evolving mechanistically based preclin. strategies for detecting drug-induced electrophysiol. and structural cardiotoxicity using in vitro human ion channel assays, human-based in silico reconstructions and human stem cell-derived cardiomyocytes.  These strategies represent a paradigm shift from current approaches, which rely on simplistic in vitro assays that measure blockade of the Kv11.1 current (also known as the hERG current or IKr) and on the use of non-human cells or tissues.  These new strategies have the potential to improve sensitivity and specificity in the early detection of genuine cardiotoxicity risks, thereby reducing the likelihood of mistakenly discarding viable drug candidates and speeding the progression of worthy drugs into clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-kYgmcNzy-bVg90H21EOLACvtfcHk0lg7kkf9ZzZxOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XivVCju7s%253D&md5=0a6fa907a6d85fa0a3b42188a22165b9</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2015.34&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2015.34%26sid%3Dliteratum%253Aachs%26aulast%3DGintant%26aufirst%3DG.%26aulast%3DSager%26aufirst%3DP.%2BT.%26aulast%3DStockbridge%26aufirst%3DN.%26atitle%3DEvolution%2520of%2520Strategies%2520to%2520Improve%2520Preclinical%2520Cardiac%2520Safety%2520Testing%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2016%26volume%3D15%26spage%3D457%26epage%3D471%26doi%3D10.1038%2Fnrd.2015.34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span>; <span class="NLM_string-name">Kerns, E.
H.</span></span> <i>Drug-like Properties: Concepts, Structure Design and Methods: From ADME to Toxicity Optimization</i>; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">Burlington, MA</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=L.+Di&author=E.%0AH.+Kerns&title=Drug-like+Properties%3A+Concepts%2C+Structure+Design+and+Methods%3A+From+ADME+to+Toxicity+Optimization"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26btitle%3DDrug-like%2520Properties%253A%2520Concepts%252C%2520Structure%2520Design%2520and%2520Methods%253A%2520From%2520ADME%2520to%2520Toxicity%2520Optimization%26pub%3DAcademic%2520Press%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wood, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldron, G. J.</span></span> <span> </span><span class="NLM_article-title">Patch Clamping by Numbers</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">434</span>– <span class="NLM_lpage">441</span>, <span class="refDoi"> DOI: 10.1016/s1359-6446(04)03064-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2Fs1359-6446%2804%2903064-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=15109948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjtl2ls7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=434-441&author=C.+Woodauthor=C.+Williamsauthor=G.+J.+Waldron&title=Patch+Clamping+by+Numbers&doi=10.1016%2Fs1359-6446%2804%2903064-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Patch clamping by numbers</span></div><div class="casAuthors">Wood, Claire; Williams, Christine; Waldron, Gareth J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">434-441</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Many ion channels are recognized as amenable targets for a range of disease states and conditions.  However, the process of discovering drugs is highly influenced by the chem. doability, the biol. confidence in rationale of the approach and the 'screen-ability'.  To date, the absence of informative high throughput technologies for ion channel screening has resulted in ion channels remaining a largely unexplored class of drug targets.  This, however, is about to change - a large increase in the no. of data points per day should be achieved by the introduction of automated-high throughput' patch clamp machines.  New automated technologies are set to open up the field of screening compds. for functional effects on ion channels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofJg6-kJcJj7Vg90H21EOLACvtfcHk0lg7kkf9ZzZxOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjtl2ls7c%253D&md5=65614d9614c4faa86bbd8356731731d3</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fs1359-6446%2804%2903064-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs1359-6446%252804%252903064-8%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DC.%26aulast%3DWilliams%26aufirst%3DC.%26aulast%3DWaldron%26aufirst%3DG.%2BJ.%26atitle%3DPatch%2520Clamping%2520by%2520Numbers%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26spage%3D434%26epage%3D441%26doi%3D10.1016%2Fs1359-6446%2804%2903064-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span> </span><span class="NLM_article-title">Research, C. for D. E. and. About the Center
for Drug Evaluation
and Research—The Biopharmaceutics Classification System (BCS)
Guidance</span>. <a href="https://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm128219.htm" class="extLink">https://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm128219.htm</a> (accessed Feb 14, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Research%2C+C.+for+D.+E.+and.+About+the+Center%0Afor+Drug+Evaluation%0Aand+Research%E2%80%94The+Biopharmaceutics+Classification+System+%28BCS%29%0AGuidance.+https%3A%2F%2Fwww.fda.gov%2Faboutfda%2Fcentersoffices%2Fofficeofmedicalproductsandtobacco%2Fcder%2Fucm128219.htm+%28accessed+Feb+14%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DResearch%252C%2520C.%2520for%2520D.%2520E.%2520and.%2520About%2520the%2520Center%250Afor%2520Drug%2520Evaluation%250Aand%2520Research%25E2%2580%2594The%2520Biopharmaceutics%2520Classification%2520System%2520%2528BCS%2529%250AGuidance%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uzawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yawata, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uezono, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narita, M.</span></span> <span> </span><span class="NLM_article-title">Characterization of Methadone as a β-Arrestin-Biased μ-Opioid Receptor Agonist</span>. <i>Mol. Pain</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.1177/1744806916654146</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1177%2F1744806916654146" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVGmsLrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=1-9&author=S.+Doiauthor=T.+Moriauthor=N.+Uzawaauthor=T.+Arimaauthor=T.+Takahashiauthor=M.+Uchidaauthor=A.+Yawataauthor=M.+Naritaauthor=Y.+Uezonoauthor=T.+Suzukiauthor=M.+Narita&title=Characterization+of+Methadone+as+a+%CE%B2-Arrestin-Biased+%CE%BC-Opioid+Receptor+Agonist&doi=10.1177%2F1744806916654146"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of methadone as a β-arrestin-biased μ-opioid receptor agonist</span></div><div class="casAuthors">Doi, Seira; Mori, Tomohisa; Uzawa, Naoki; Arima, Takamichi; Takahashi, Tomoyuki; Uchida, Masashi; Yawata, Ayaka; Narita, Michiko; Uezono, Yasuhito; Suzuki, Tsutomu; Narita, Minoru</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pain</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-9</span>CODEN:
                <span class="NLM_cas:coden">MPOAC5</span>;
        ISSN:<span class="NLM_cas:issn">1744-8069</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Background: Methadone is a unique μ-opioid receptor agonist.  Although several researchers have insisted that the pharmacol. effects of methadone are mediated through the blockade of NMDA receptor, the underlying mechanism by which methadone exerts its distinct pharmacol. effects compared to those of other μ-opioid receptor agonists is still controversial.  In the present study, we further investigated the pharmacol. profile of methadone compared to those of fentanyl and morphine as measured mainly by the discriminative stimulus effect and in vitro assays for NMDA receptor binding, μ-opioid receptor-internalization, and μ-opioid receptor-mediated β-arrestin recruitment.  Results: We found that fentanyl substituted for the discriminative stimulus effects of methadone, whereas a relatively high dose of morphine was required to substitute for the discriminative stimulus effects of methadone in rats.  Under these conditions, the non-competitive NMDA receptor antagonist MK-801 did not substitute for the discriminative stimulus effects of methadone.  In assocn. with its discriminative stimulus effect, methadone failed to displace the receptor binding of MK801 using mouse brain membrane.  Methadone and fentanyl, but not morphine, induced potent μ-opioid receptor internalization accompanied by the strong recruitment of β-arrestin-2 in μ-opioid receptor-overexpressing cells.  Conclusions: These results suggest that methadone may, at least partly, produce its pharmacol. effect as a β-arrestin-biased μ-opioid receptor agonist, similar to fentanyl, and NMDA receptor blockade is not the main contributor to the pharmacol. profile of methadone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXYiSGUxy4PrVg90H21EOLACvtfcHk0lg7kkf9ZzZxOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVGmsLrJ&md5=3a990184826094cd4e6366389975f36c</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1177%2F1744806916654146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1744806916654146%26sid%3Dliteratum%253Aachs%26aulast%3DDoi%26aufirst%3DS.%26aulast%3DMori%26aufirst%3DT.%26aulast%3DUzawa%26aufirst%3DN.%26aulast%3DArima%26aufirst%3DT.%26aulast%3DTakahashi%26aufirst%3DT.%26aulast%3DUchida%26aufirst%3DM.%26aulast%3DYawata%26aufirst%3DA.%26aulast%3DNarita%26aufirst%3DM.%26aulast%3DUezono%26aufirst%3DY.%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DNarita%26aufirst%3DM.%26atitle%3DCharacterization%2520of%2520Methadone%2520as%2520a%2520%25CE%25B2-Arrestin-Biased%2520%25CE%25BC-Opioid%2520Receptor%2520Agonist%26jtitle%3DMol.%2520Pain%26date%3D2016%26volume%3D12%26spage%3D1%26epage%3D9%26doi%3D10.1177%2F1744806916654146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxter, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liston, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silber, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacIntyre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rance, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wastall, P.</span></span> <span> </span><span class="NLM_article-title">The Prediction of Human Pharmacokinetic Parameters from Preclinical and in Vitro Metabolism Data</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">46</span>– <span class="NLM_lpage">58</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=9336307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADyaK2sXmslCltr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=1997&pages=46-58&author=R.+S.+Obachauthor=J.+G.+Baxterauthor=T.+E.+Listonauthor=B.+M.+Silberauthor=B.+C.+Jonesauthor=F.+MacIntyreauthor=D.+J.+Ranceauthor=P.+Wastall&title=The+Prediction+of+Human+Pharmacokinetic+Parameters+from+Preclinical+and+in+Vitro+Metabolism+Data"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data</span></div><div class="casAuthors">Obach, R. Scott; Baxter, James G.; Liston, Theodore E.; Silber, B. Michael; Jones, Barry C.; Macintyre, Flona; Rance, David J.; Wastall, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">46-58</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">A review with 35 refs.  We describe a comprehensive retrospective anal. in which the abilities of several methods by which human pharmacokinetic parameters are predicted from preclin. pharmacokinetic data and/or in vitro metab. data were assessed.  The prediction methods examd. included both methods from the scientific literature as well as some described in this report for the first time.  Four methods were examd. for their ability to predict human vol. of distribution.  Three were highly predictive, yielding, on av., predictions that were within 60% to 90% of actual values.  Twelve methods were assessed for their utility in predicting clearance.  The most successful allometric scaling method yielded clearance predictions that were, on av., within 80% of actual values.  The best methods in which in vitro metab. data from human liver microsomes were scaled to in vivo clearance values yielded predicted clearance values that were, on av., within 70% to 80% of actual values.  Human t1/2 was predicted by combining predictions of human vol. of distribution and clearance.  The best t1/2 prediction methods successfully assigned compds. to appropriate dosing regimen categories (e.g., once daily, twice daily and so forth) 70% to 80% of the time.  In addn., correlations between human t1/2 and t1/2 values from preclin. species were also generally successful (72-87%) when used to predict human dosing regimens.  In summary, this retrospective anal. has identified several approaches by which human pharmacokinetic data can be predicted from preclin. data.  Such approaches should find utility in the drug discovery and development processes in the identification and selection of compds. that will possess appropriate pharmacokinetic characteristics in humans for progression to clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppAngniZ4izLVg90H21EOLACvtfcHk0lgjCZ9zpSu5fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmslCltr0%253D&md5=68d1910d925e26ec4a8ef23043ffb1ed</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DBaxter%26aufirst%3DJ.%2BG.%26aulast%3DListon%26aufirst%3DT.%2BE.%26aulast%3DSilber%26aufirst%3DB.%2BM.%26aulast%3DJones%26aufirst%3DB.%2BC.%26aulast%3DMacIntyre%26aufirst%3DF.%26aulast%3DRance%26aufirst%3DD.%2BJ.%26aulast%3DWastall%26aufirst%3DP.%26atitle%3DThe%2520Prediction%2520of%2520Human%2520Pharmacokinetic%2520Parameters%2520from%2520Preclinical%2520and%2520in%2520Vitro%2520Metabolism%2520Data%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1997%26volume%3D283%26spage%3D46%26epage%3D58" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. A.</span></span> <span> </span><span class="NLM_article-title">Development and Validation of a 96-Well Equilibrium Dialysis Apparatus for Measuring Plasma Protein Binding</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">967</span>– <span class="NLM_lpage">974</span>, <span class="refDoi"> DOI: 10.1002/jps.10332</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1002%2Fjps.10332" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=12712416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjs1ehsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2003&pages=967-974&author=M.+J.+Bankerauthor=T.+H.+Clarkauthor=J.+A.+Williams&title=Development+and+Validation+of+a+96-Well+Equilibrium+Dialysis+Apparatus+for+Measuring+Plasma+Protein+Binding&doi=10.1002%2Fjps.10332"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding</span></div><div class="casAuthors">Banker, Michael J.; Clark, Tracey H.; Williams, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">967-974</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A 96-well equil. dialysis block was designed and constructed that is compatible with most std. 96-well format lab. supplies and instruments.  The unique design of the dialysis app. allows one to dispense and aspirate from either or both the sample and dialyzate sides from the top of the app., which is not possible with systems currently on the market.  This feature permits the investigator to analyze a large no. of samples, time points, or replicates in the same expt.  The novel alignment of the dialysis membrane vertically in the well maximizes the surface-to-vol. ratio, eliminates problems assocd. with trapped air pockets, and allows one to add or remove samples independently or all at once.  Furthermore, the design of the app. allows both the sample and dialyzate sides of the dialysis well to be accessible by robotic systems, so assays can be readily automated.  Teflon construction is used to minimize nonspecific binding of test samples to the app.  The device is reusable, easily assembled, and can be shaken in controlled temp. environments to decrease the time required to reach equil. as well as facilitate dissoln. of test compds.  Plasma protein binding values obtained for 10 diverse compds. using std. dialysis equipment and the 96-well dialysis block validates this method.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp9qyX_9tHHrVg90H21EOLACvtfcHk0lgjCZ9zpSu5fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjs1ehsrs%253D&md5=0948f0a11373c57be06be9e0d604ad40</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1002%2Fjps.10332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.10332%26sid%3Dliteratum%253Aachs%26aulast%3DBanker%26aufirst%3DM.%2BJ.%26aulast%3DClark%26aufirst%3DT.%2BH.%26aulast%3DWilliams%26aufirst%3DJ.%2BA.%26atitle%3DDevelopment%2520and%2520Validation%2520of%2520a%252096-Well%2520Equilibrium%2520Dialysis%2520Apparatus%2520for%2520Measuring%2520Plasma%2520Protein%2520Binding%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2003%26volume%3D92%26spage%3D967%26epage%3D974%26doi%3D10.1002%2Fjps.10332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Polli, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wring, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphreys, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, L. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serabjit-Singh, C. S.</span></span> <span> </span><span class="NLM_article-title">Rational use of in vitro P-glycoprotein assays in drug discovery</span>. <i>J Pharmacol Exp Ther</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>299</i></span>,  <span class="NLM_fpage">620</span>– <span class="NLM_lpage">628</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=11602674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnvV2qt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=299&publication_year=2001&pages=620-628&author=J.+W.+Polliauthor=S.+A.+Wringauthor=J.+E.+Humphreysauthor=L.+Huangauthor=J.+B.+Morganauthor=L.+O.+Websterauthor=C.+S.+Serabjit-Singh&title=Rational+use+of+in+vitro+P-glycoprotein+assays+in+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Rational use of in vitro P-glycoprotein assays in drug discovery</span></div><div class="casAuthors">Polli, Joseph W.; Wring, Stephen A.; Humphreys, Joan E.; Huang, Liyue; Morgan, Jonathon B.; Webster, Lindsey O.; Serabjit-Singh, Cosette S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">299</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">620-628</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">P-glycoprotein (Pgp) affects the absorption, distribution, and clearance of a variety of compds.  Thus, identification of compds. that are Pgp substrates can aid drug candidate selection and optimization.  Our goal was to evaluate three assays used to det. whether compds. are Pgp substrates.  Sixty-six compds. were tested in monolayer efflux, ATPase, and calcein-AM assays.  Assay results yielded two categories of compds.  Category I (n = 35) exhibited concordance across the assays.  Category II (n = 31) revealed differences among the assays that related to the apparent permeability (Papp) of the compds.  Within category II, two groups were discerned based on the absence (group IIA, n = 10, nontransported substrates) or presence (group IIB, n = 21, transported substrates) of monolayer efflux.  Detection of efflux (group IIB) was assocd. with compds. having low/moderate Papp values (mean = 16.6 nm/s), whereas inability to detect efflux (group IIA) was assocd. with compds. having high Papp values (mean = 535 nm/s).  The calcein-AM and ATPase assays revealed Pgp interactions for highly permeable group IIA compds. but were less responsive than monolayer efflux for low/moderate Papp compds. of group IIB.  All assays detected substrates across a broad range of Papp, but the efflux assay was more prone to fail at high Papp, whereas the calcein-AM and ATPase assays were more prone to fail at low Papp.  When Papp is low, efflux is a greater factor in the disposition of Pgp substrates.  The efflux assay is more reliable at low/moderate Papp and is the method of choice for evaluating drug candidates despite low throughput and reliance on liq. chromatog. with tandem mass spectrometry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEXGQjVBl5H7Vg90H21EOLACvtfcHk0lgjCZ9zpSu5fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnvV2qt78%253D&md5=77bd80ec2000fa4806bee5614c31279d</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPolli%26aufirst%3DJ.%2BW.%26aulast%3DWring%26aufirst%3DS.%2BA.%26aulast%3DHumphreys%26aufirst%3DJ.%2BE.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DMorgan%26aufirst%3DJ.%2BB.%26aulast%3DWebster%26aufirst%3DL.%2BO.%26aulast%3DSerabjit-Singh%26aufirst%3DC.%2BS.%26atitle%3DRational%2520use%2520of%2520in%2520vitro%2520P-glycoprotein%2520assays%2520in%2520drug%2520discovery%26jtitle%3DJ%2520Pharmacol%2520Exp%2520Ther%26date%3D2001%26volume%3D299%26spage%3D620%26epage%3D628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stresser, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erve, J. C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dandeneau, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crespi, C. L.</span></span> <span> </span><span class="NLM_article-title">Substrate-Dependent Modulation of CYP3A4 Catalytic Activity: Analysis of 27 Test Compounds with Four Fluorometric Substrates</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1440</span>– <span class="NLM_lpage">1448</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=11095581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BD3cXos1Srsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2000&pages=1440-1448&author=D.+M.+Stresserauthor=A.+P.+Blanchardauthor=S.+D.+Turnerauthor=J.+C.+L.+Erveauthor=A.+A.+Dandeneauauthor=V.+P.+Millerauthor=C.+L.+Crespi&title=Substrate-Dependent+Modulation+of+CYP3A4+Catalytic+Activity%3A+Analysis+of+27+Test+Compounds+with+Four+Fluorometric+Substrates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates</span></div><div class="casAuthors">Stresser, David M.; Blanchard, Andrew P.; Turner, Stephanie D.; Erve, John C. L.; Dandeneau, Andre A.; Miller, Vaughn P.; Crespi, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1440-1448</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Inhibition of cytochrome P 450 catalytic activity is a principal mechanism for pharmacokinetic drug-drug interactions.  Rapid, in vitro testing for cytochrome P 450 inhibition potential is part of the current paradigm for identifying drug candidates likely to give such interactions.  We have explored the extent that qual. and quant. inhibition parameters are dependent on the cytochrome P 450 (CYP) 3A4 probe substrate.  Inhibition potential (e.g., IC50 values from 8-point inhibition curves) or activation potential for most compds. varied dramatically depending on the fluorometric probe substrates for CYP3A4 [benzyloxyresorufin (BzRes), 7-benzyloxy-4-trifluoromethylcoumarin (BFC), 7-benzyloxyquinoline (BQ), and dibenzylfluorescein (DBF)].  For 21 compds. that were primarily inhibitors, the range of IC50 values for the four substrates varied from 2.1- to 195-fold with an av. of 29-fold.  While the rank order of sensitivity among the fluorometric substrates varied among the individual inhibitors, on av., BFC dealkylation was the most sensitive to inhibition, while BQ dealkylation was least sensitive.  Partial inhibition was obsd. with BzRes and BQ but not for BFC and DBF.  BzRes was more prone to activation, whereas dramatic changes in IC50 values were obsd. when the BQ concn. was below the S50.  Three different correlation analyses indicated that IC50 values with BFC, BQ, and DBF correlated well with each other, whereas the response with BzRes correlated more weakly with the other substrates.  One of these correlation analyses was extended to the percent inhibition of 10 μM inhibitor with the std. CYP3A4 probe substrates testosterone, midazolam, and nifedipine.  In this anal. the responses with BQ, BFC and DBF correlated well with testosterone and midazolam but more poorly with nifedipine.  In the aggregate, BFC and DBF appear more suitable as an initial screen for CYP3A4 inhibition.  However, the substrate-dependent effects reported here and by others indicate that all CYP3A4 inhibition data should be interpreted with caution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiXpN24u_VFbVg90H21EOLACvtfcHk0lh-j6E71WZUkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXos1Srsrk%253D&md5=f33b6a772bb3329ce72849ece9efb61d</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStresser%26aufirst%3DD.%2BM.%26aulast%3DBlanchard%26aufirst%3DA.%2BP.%26aulast%3DTurner%26aufirst%3DS.%2BD.%26aulast%3DErve%26aufirst%3DJ.%2BC.%2BL.%26aulast%3DDandeneau%26aufirst%3DA.%2BA.%26aulast%3DMiller%26aufirst%3DV.%2BP.%26aulast%3DCrespi%26aufirst%3DC.%2BL.%26atitle%3DSubstrate-Dependent%2520Modulation%2520of%2520CYP3A4%2520Catalytic%2520Activity%253A%2520Analysis%2520of%252027%2520Test%2520Compounds%2520with%2520Four%2520Fluorometric%2520Substrates%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2000%26volume%3D28%26spage%3D1440%26epage%3D1448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ono, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hotta, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satoh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsutsui, M.</span></span> <span> </span><span class="NLM_article-title">Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation ofin vitrometabolism using cDNA-expressed human P450s and human liver microsomes</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">681</span>– <span class="NLM_lpage">693</span>, <span class="refDoi"> DOI: 10.3109/00498259609046742</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.3109%2F00498259609046742" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=8819299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADyaK28Xkt1Cks7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1996&pages=681-693&author=S.+Onoauthor=T.+Hatanakaauthor=H.+Hottaauthor=T.+Satohauthor=F.+J.+Gonzalezauthor=M.+Tsutsui&title=Specificity+of+substrate+and+inhibitor+probes+for+cytochrome+P450s%3A+evaluation+ofin+vitrometabolism+using+cDNA-expressed+human+P450s+and+human+liver+microsomes&doi=10.3109%2F00498259609046742"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes</span></div><div class="casAuthors">Ono, S.; Hatanaka, T.; Hotta, H.; Satoh, T.; Gonzalez, F. J.; Tsutsui, M.</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">681-693</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis</span>)
        </div><div class="casAbstract">We evaluated the specificity of 15 substrates and 14 inhibitors of the cytochrome P450s using nine human P 450 isoforms expressed in HepG2 cells using a recombinant vaccinia virus and also in human liver microsomes.  Coumarin, 7-ethoxyresorufin, 7-benzyloxyresorufin, tolbutamide, aniline and diazepam were isoform-selective substrates towards CYP2A6, the CYP1A subfamily, CYP2B6, the CYP2C subfamily, CYP2E1 and the CYP3A subfamily, resp.  However, a selective substrate for CYP2D6 was not found among the chems. tested.  SKF-525A inhibited > 40% of the metabolic activity of all substrates tested, and the inhibitory effects differed among P 450 isoforms.  Sulfaphenazole, 7,8-benzoflavone, quinidine and troleandomycin were selective inhibitors of the CYP2C subfamily (except CYP2C19), the CYP1A subfamily, CYP2D6 and the CYP3A subfamily, resp.  Methoxsalen (CYP2A6 inhibitor) inhibited the metabolic activity of CYP1A2 as well as that of CYP2A6.  Diethyldithiocarbamate (CYP2E1 inhibitor) inhibited the metabolic activities of CYP2A6 and CYP2C19 in addn. to that of CYP2E1.  Our results indicated that substrates and inhibitors reported as P 450 selective probes are not necessarily specific for individual human P 450 isoforms.  These results may provide useful information regarding human P 450 substrates and inhibitors in vitro using human liver microsomal samples.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS0KhjocrvGLVg90H21EOLACvtfcHk0lh-j6E71WZUkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xkt1Cks7w%253D&md5=b2a750427667920a3605930dcd021304</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.3109%2F00498259609046742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F00498259609046742%26sid%3Dliteratum%253Aachs%26aulast%3DOno%26aufirst%3DS.%26aulast%3DHatanaka%26aufirst%3DT.%26aulast%3DHotta%26aufirst%3DH.%26aulast%3DSatoh%26aufirst%3DT.%26aulast%3DGonzalez%26aufirst%3DF.%2BJ.%26aulast%3DTsutsui%26aufirst%3DM.%26atitle%3DSpecificity%2520of%2520substrate%2520and%2520inhibitor%2520probes%2520for%2520cytochrome%2520P450s%253A%2520evaluation%2520ofin%2520vitrometabolism%2520using%2520cDNA-expressed%2520human%2520P450s%2520and%2520human%2520liver%2520microsomes%26jtitle%3DXenobiotica%26date%3D1996%26volume%3D26%26spage%3D681%26epage%3D693%26doi%3D10.3109%2F00498259609046742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
Wijngaarden, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tulp, M. T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soudijn, W.</span></span> <span> </span><span class="NLM_article-title">The Concept of Selectivity in 5-HT Receptor Research</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>188</i></span>,  <span class="NLM_fpage">301</span>– <span class="NLM_lpage">312</span>, <span class="refDoi"> DOI: 10.1016/0922-4106(90)90190-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2F0922-4106%2890%2990190-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=2164935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADyaK3cXkvFWnurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=188&publication_year=1990&pages=301-312&author=I.+Van%0AWijngaardenauthor=M.+T.+M.+Tulpauthor=W.+Soudijn&title=The+Concept+of+Selectivity+in+5-HT+Receptor+Research&doi=10.1016%2F0922-4106%2890%2990190-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">The concept of selectivity in 5-HT receptor research</span></div><div class="casAuthors">Van Wijngaarden, I.; Tulp, M. Th. M.; Soudijn, W.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology, Molecular Pharmacology Section</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">188</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">301-12</span>CODEN:
                <span class="NLM_cas:coden">EJPPET</span>;
        ISSN:<span class="NLM_cas:issn">0922-4106</span>.
    </div><div class="casAbstract">A review, with 47 refs., of the serotonin receptor subtype affinity of putative selective ligands from the affinity profiles of 22 ref. compds. for 6 5-HT receptor subtypes and 18 other neurotransmitter receptors.  It is evident that the majority of reputed selective compds. are not selective (ratio ≥100) at all potent and selective ligands are only available for 5-HT1A and 5-HT3 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPzQA5cXCtCLVg90H21EOLACvtfcHk0lh-j6E71WZUkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXkvFWnurw%253D&md5=82109dee9eb325561c57464332a66b52</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2F0922-4106%2890%2990190-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0922-4106%252890%252990190-9%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BWijngaarden%26aufirst%3DI.%26aulast%3DTulp%26aufirst%3DM.%2BT.%2BM.%26aulast%3DSoudijn%26aufirst%3DW.%26atitle%3DThe%2520Concept%2520of%2520Selectivity%2520in%25205-HT%2520Receptor%2520Research%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1990%26volume%3D188%26spage%3D301%26epage%3D312%26doi%3D10.1016%2F0922-4106%2890%2990190-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fattaccini, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adrien, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallissot, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gozlan, H.</span></span> <span> </span><span class="NLM_article-title">Alterations of central serotonin and dopamine turnover in rats treated with ipsapirone and other 5-hydroxytryptamine1A agonists with potential anxiolytic properties</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>246</i></span>,  <span class="NLM_fpage">745</span>– <span class="NLM_lpage">752</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=2457083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADyaL1cXls1ehurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=246&publication_year=1988&pages=745-752&author=M.+Hamonauthor=C.+M.+Fattacciniauthor=J.+Adrienauthor=M.+C.+Gallissotauthor=P.+Martinauthor=H.+Gozlan&title=Alterations+of+central+serotonin+and+dopamine+turnover+in+rats+treated+with+ipsapirone+and+other+5-hydroxytryptamine1A+agonists+with+potential+anxiolytic+properties"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Alterations of central serotonin and dopamine turnover in rats treated with ipsapirone and other 5-hydroxytryptamine1A agonists with potential anxiolytic properties</span></div><div class="casAuthors">Hamon, M.; Fattaccini, C. M.; Adrien, J.; Gallissot, M. C.; Martin, P.; Gozlan, H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">246</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">745-52</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">Measurements of tissue levels of monoamines and their metabolites, and of the rates of 5-hydroxytryptophan and dihydroxyphenylalanine accumulation after blockade of arom. amino acid decarboxylase by benserazid indicated that ipsapirone (1-10 mg/kg, i.p.) decreased 5-HT turnover and accelerated dopamine (DA) turnover in various rat brain regions.  The decreased 5-HT turnover probably resulted from the stimulation of 5-HT1A autoreceptors within the anterior raphe nuclei as in vitro tests [[3H]-8-hydroxy-2-[di-n-propylamino]tetralin (8-OH-DPAT)] binding and adenylate cyclase assays) demonstrated that ipsapirone was a 5-HT1A agonist almost as potent as 8-OH-DPAT, and the same decrease in 5-hydroxytryptophan accumulation could be induced by the i.p. (5 mg/kg) or intraraphe (1 μg) injection of ipsapirone.  Ipsapirone-induced acceleration of DA turnover persisted after the selective degeneration of serotoninergic neurons by intraraphe 5,7-dihydroxytryptamine infusion, and could be reproduced by i.p. administration of other 5-HT1A agonists like buspirone and gepirone, but not 8-OH-DPAT.  Apparently, the ipsapirone-induced acceleration of DA turnover did not result from the stimulation of 5-HT1A (auto)receptors, but involved addnl. target(s) of the drug.  The possible participation of dopaminergic systems in the anxiolytic properties of ipsapirone should deserve further investigations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruw0Ksnve-4LVg90H21EOLACvtfcHk0lje3DpUxlJoXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXls1ehurs%253D&md5=51e2b340e916af876b7bca4e1c39675a</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHamon%26aufirst%3DM.%26aulast%3DFattaccini%26aufirst%3DC.%2BM.%26aulast%3DAdrien%26aufirst%3DJ.%26aulast%3DGallissot%26aufirst%3DM.%2BC.%26aulast%3DMartin%26aufirst%3DP.%26aulast%3DGozlan%26aufirst%3DH.%26atitle%3DAlterations%2520of%2520central%2520serotonin%2520and%2520dopamine%2520turnover%2520in%2520rats%2520treated%2520with%2520ipsapirone%2520and%2520other%25205-hydroxytryptamine1A%2520agonists%2520with%2520potential%2520anxiolytic%2520properties%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1988%26volume%3D246%26spage%3D745%26epage%3D752" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foreman, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuller, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leander, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benvenga, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calligaro, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanson, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucot, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaugh, M. E.</span></span> <span> </span><span class="NLM_article-title">Preclinical Studies on LY228729: A Potent and Selective Serotonin1A Agonist</span>. <i>J Pharmacol Exp Ther</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>267</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">71</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=8229788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADyaK2cXksFOhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=1993&pages=58-71&author=M.+M.+Foremanauthor=R.+W.+Fullerauthor=J.+D.+Leanderauthor=M.+J.+Benvengaauthor=D.+T.+Wongauthor=D.+L.+Nelsonauthor=D.+O.+Calligaroauthor=S.+P.+Swansonauthor=J.+B.+Lucotauthor=M.+E.+Flaugh&title=Preclinical+Studies+on+LY228729%3A+A+Potent+and+Selective+Serotonin1A+Agonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical studies on LY228729: A potent and selective serotonin1A agonist</span></div><div class="casAuthors">Foreman, Mark M.; Fuller, Ray W.; Leander, J. David; Benvenga, Mark J.; Wong, David T.; Nelson, David L.; Calligaro, David O.; Swanson, Steven P.; Lucot, James B.; Flaugh, Michael E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">267</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-71</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">LY228729 is a conformationally restricted tryptamine deriv. with a carboxamide serving as a protophilic group to mimic the hydroxyl in serotonin (5-HT).  LY228729 has high affinity for the 5-HT1A receptor, weak affinity for the 5-HT1D receptor and no significant affinity for other monoaminergic receptors studied.  LY228729 was less effective than 5-carboxamidotrytamine in suppressing K+-evoked release of 3H-5-HT from parietal-occipital cortical slices from guinea pigs, which is in agreement with its weak 5-HT1D receptor affinity.  LY228729 reduced hypothalamic 5-hydroxyindole-3-acetic acid levels and increased serum corticosterone levels in rats.  LY228729n reduced hypothalamic 5-hydroxytryptophan accumulation after decarboxylase inhibition.  LY228729 increased flat posture and lower lip retraction scores in rats at doses between 0.1 and 1 mg/kg s.c. (p.o. doses were 10 times higher) and these effects were blocked by (±) pindolol.  LY228729 induced a hypothermic response in rats, which was blocked by (±) pindolol.  These in vivo responses are characteristics of compds. with 5-HT1A agonist activity.  In the preclin. efficacy models, LY228729 suppressed motion sickness responses in cats; decreased ejaculatory latency and the increased copulatory efficiency and rate in rats and increased punished responding at lower doses than it lowered unpunished responding in rats.  Collectively, these results indicate that LY228729 is potent 5-HT1A agonist with bioavailability properties sufficient for clin. evaluation and with efficacy in preclin. models of anxiety, sexual disorders and motion sickness.  Since the 5-HT1A agonists that have been studied previously have antidepressant activity, this indication will also be evaluated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjdhGlugXjrrVg90H21EOLACvtfcHk0lje3DpUxlJoXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXksFOhsQ%253D%253D&md5=a517f2ba1734a1f77260304bdecd1a61</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DForeman%26aufirst%3DM.%2BM.%26aulast%3DFuller%26aufirst%3DR.%2BW.%26aulast%3DLeander%26aufirst%3DJ.%2BD.%26aulast%3DBenvenga%26aufirst%3DM.%2BJ.%26aulast%3DWong%26aufirst%3DD.%2BT.%26aulast%3DNelson%26aufirst%3DD.%2BL.%26aulast%3DCalligaro%26aufirst%3DD.%2BO.%26aulast%3DSwanson%26aufirst%3DS.%2BP.%26aulast%3DLucot%26aufirst%3DJ.%2BB.%26aulast%3DFlaugh%26aufirst%3DM.%2BE.%26atitle%3DPreclinical%2520Studies%2520on%2520LY228729%253A%2520A%2520Potent%2520and%2520Selective%2520Serotonin1A%2520Agonist%26jtitle%3DJ%2520Pharmacol%2520Exp%2520Ther%26date%3D1993%26volume%3D267%26spage%3D58%26epage%3D71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chilmonczyk, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bojarski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilc, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sylte, I.</span></span> <span> </span><span class="NLM_article-title">Functional Selectivity and Antidepressant Activity of Serotonin 1A Receptor Ligands</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">18474</span>– <span class="NLM_lpage">18506</span>, <span class="refDoi"> DOI: 10.3390/ijms160818474</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.3390%2Fijms160818474" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=26262615" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC28XivVahsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=18474-18506&author=Z.+Chilmonczykauthor=A.+Bojarskiauthor=A.+Pilcauthor=I.+Sylte&title=Functional+Selectivity+and+Antidepressant+Activity+of+Serotonin+1A+Receptor+Ligands&doi=10.3390%2Fijms160818474"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Functional selectivity and antidepressant activity of serotonin 1A receptor ligands</span></div><div class="casAuthors">Chilmonczyk, Zdzislaw; Bojarski, Andrzej Jacek; Pilc, Andrzej; Sylte, Ingebrigt</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">18474-18506</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Serotonin (5-HT) is a monoamine neurotransmitter that plays an important role in physiol. functions.  5-HT has been implicated in sleep, feeding, sexual behavior, temp. regulation, pain, and cognition as well as in pathol. states including disorders connected to mood, anxiety, psychosis and pain.  5-HT1A receptors has for a long time been considered as an interesting target for the action of antidepressant drugs.  It was postulated that postsynaptic 5-HT1A agonists could form a new class of antidepressant drugs, and mixed 5-HT1A receptor ligands/serotonin transporter (SERT) inhibitors seem to possess an interesting pharmacol. profile.  It should, however, be noted that 5-HT1A receptors can activate several different biochem. pathways and signal through both G protein-dependent and G protein-independent pathways.  The variables that affect the multiplicity of 5-HT1A receptor signaling pathways would thus result from the summation of effects specific to the host cell milieu.  Moreover, receptor trafficking appears different at pre- and postsynaptic sites.  It should also be noted that the 5-HT1A receptor cooperates with other signal transduction systems (like the 5-HT1B or 5-HT2A/2B/2C receptors, the GABAergic and the glutaminergic systems), which also contribute to its antidepressant and/or anxiolytic activity.  Thus identifying brain specific mol. targets for 5-HT1A receptor ligands may result in a better targeting, raising a hope for more effective medicines for various pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR_H0f5Gc5qbVg90H21EOLACvtfcHk0ljbWsRGSZ2B9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XivVahsro%253D&md5=4b1bfdaadbb20b31d99622b61a49df2d</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.3390%2Fijms160818474&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms160818474%26sid%3Dliteratum%253Aachs%26aulast%3DChilmonczyk%26aufirst%3DZ.%26aulast%3DBojarski%26aufirst%3DA.%26aulast%3DPilc%26aufirst%3DA.%26aulast%3DSylte%26aufirst%3DI.%26atitle%3DFunctional%2520Selectivity%2520and%2520Antidepressant%2520Activity%2520of%2520Serotonin%25201A%2520Receptor%2520Ligands%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2015%26volume%3D16%26spage%3D18474%26epage%3D18506%26doi%3D10.3390%2Fijms160818474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rojas, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiedler, J. L.</span></span> <span> </span><span class="NLM_article-title">What Do We Really Know About 5-HT1A Receptor Signaling in Neuronal Cells?</span>. <i>Front. Cell. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">272</span>, <span class="refDoi"> DOI: 10.3389/fncel.2016.00272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.3389%2Ffncel.2016.00272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=27932955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtV2itrvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=272&author=P.+S.+Rojasauthor=J.+L.+Fiedler&title=What+Do+We+Really+Know+About+5-HT1A+Receptor+Signaling+in+Neuronal+Cells%3F&doi=10.3389%2Ffncel.2016.00272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">What do we really know about 5-HT1A receptor signaling in neuronal cells?</span></div><div class="casAuthors">Rojas, Paulina S.; Fiedler, Jenny L.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Cellular Neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">272/1-272/8</span>CODEN:
                <span class="NLM_cas:coden">FCNRAH</span>;
        ISSN:<span class="NLM_cas:issn">1662-5102</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Serotonin (5-HT) is a neurotransmitter that plays an important role in neuronal plasticity.  Variations in the levels of 5-HT at the synaptic cleft, expression or dysfunction of 5-HT receptors may alter brain development and predispose to various mental diseases.  Here, we review the transduction pathways described in various cell types transfected with recombinant 5-HT1A receptor (5-HT1AR), specially contrasting with those findings obtained in neuronal cells.  The 5-HT1AR is detected in early stages of neural development and is located in the soma, dendrites and spines of hippocampal neurons.  The 5-HT1AR differs from other 5-HT receptors because it is coupled to different pathways, depending on the targeted cell.  The signaling pathway assocd. with this receptor is detd. by Gα isoforms and some cascades involve βγ signaling.  The activity of 5-HT1AR usually promotes a redn. in neuronal excitability and firing, provokes a variation in cAMP and Ca2+, levels which may be linked to specific types of behavior and cognition.  Furthermore, evidence indicates that 5-HT1AR induces neuritogesis and synapse formation, probably by modulation of the neuronal cytoskeleton through MAPK and phosphoinositide-3-kinase (PI3K)-Akt signaling pathways.  Advances in understanding the actions of 5-HT1AR and its assocn. with different signaling pathways in the central nervous system will reveal their pivotal role in health and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaMzoxXqS0FLVg90H21EOLACvtfcHk0ljbWsRGSZ2B9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtV2itrvO&md5=02d5a8bcf058014fb893fe5c84594759</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.3389%2Ffncel.2016.00272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffncel.2016.00272%26sid%3Dliteratum%253Aachs%26aulast%3DRojas%26aufirst%3DP.%2BS.%26aulast%3DFiedler%26aufirst%3DJ.%2BL.%26atitle%3DWhat%2520Do%2520We%2520Really%2520Know%2520About%25205-HT1A%2520Receptor%2520Signaling%2520in%2520Neuronal%2520Cells%253F%26jtitle%3DFront.%2520Cell.%2520Neurosci.%26date%3D2016%26volume%3D10%26spage%3D272%26doi%3D10.3389%2Ffncel.2016.00272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stroth, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svenningsson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacivita, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leopoldo, M.</span></span> <span> </span><span class="NLM_article-title">Arylpiperazine Agonists of the Serotonin 5-HT1A Receptor Preferentially Activate CAMP Signaling versus Recruitment of β-Arrestin-2</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">4824</span>– <span class="NLM_lpage">4830</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.05.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2Fj.bmc.2015.05.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=26081758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsFaqsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=4824-4830&author=N.+Strothauthor=M.+Nisoauthor=N.+A.+Colabufoauthor=R.+Perroneauthor=P.+Svenningssonauthor=E.+Lacivitaauthor=M.+Leopoldo&title=Arylpiperazine+Agonists+of+the+Serotonin+5-HT1A+Receptor+Preferentially+Activate+CAMP+Signaling+versus+Recruitment+of+%CE%B2-Arrestin-2&doi=10.1016%2Fj.bmc.2015.05.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Arylpiperazine agonists of the serotonin 5-HT1A receptor preferentially activate cAMP signaling versus recruitment of β-arrestin-2</span></div><div class="casAuthors">Stroth, Nikolas; Niso, Mauro; Colabufo, Nicola A.; Perrone, Roberto; Svenningsson, Per; Lacivita, Enza; Leopoldo, Marcello</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4824-4830</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">G protein-coupled receptors (GPCRs) mediate biol. signal transduction through complex mol. pathways.  Therapeutic effects of GPCR-directed drugs are typically accompanied by unwanted side effects, owing in part to the parallel engagement of multiple signaling mechanisms.  The discovery of drugs that are 'functionally selective' towards therapeutic effects, based on their selective control of cellular responses through a given GPCR, is thus a major goal in pharmacol. today.  In the present study, we show that several arylpiperazine ligands of the serotonin 5-HT1A receptor (5-HT1AR) preferentially activate 3',5'-cyclic adenosine monophosphate (cAMP) signaling vs. β-arrestin-2 recruitment.  The pharmacol. of these compds. is thus qual. different from the endogenous agonist serotonin, indicating functional selectivity of 5-HT1AR-mediated response pathways.  Preliminary evidence suggests that phosphorylation of extracellular signal-regulated kinases 1/2 (ERK1/2) downstream of 5-HT1AR is a substrate of functionally selective signaling by partial agonists.  We propose that the compds. described in the present study are useful starting points for the development of signaling pathway-selective drugs targeting 5-HT1AR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPeYBWeUhs9LVg90H21EOLACvtfcHk0lhCLbLLtOwdoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsFaqsLg%253D&md5=58d15ba400884622e76923e88bbe6194</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.05.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.05.042%26sid%3Dliteratum%253Aachs%26aulast%3DStroth%26aufirst%3DN.%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DPerrone%26aufirst%3DR.%26aulast%3DSvenningsson%26aufirst%3DP.%26aulast%3DLacivita%26aufirst%3DE.%26aulast%3DLeopoldo%26aufirst%3DM.%26atitle%3DArylpiperazine%2520Agonists%2520of%2520the%2520Serotonin%25205-HT1A%2520Receptor%2520Preferentially%2520Activate%2520CAMP%2520Signaling%2520versus%2520Recruitment%2520of%2520%25CE%25B2-Arrestin-2%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D4824%26epage%3D4830%26doi%3D10.1016%2Fj.bmc.2015.05.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brust, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roman, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, V. J.</span></span> <span> </span><span class="NLM_article-title">Bias Analyses of Preclinical and Clinical D2 Dopamine Ligands: Studies with Immediate and Complex Signaling Pathways</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">480</span>– <span class="NLM_lpage">493</span>, <span class="refDoi"> DOI: 10.1124/jpet.114.220293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1124%2Fjpet.114.220293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=25539635" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2014&pages=480-493&author=T.+F.+Brustauthor=M.+P.+Hayesauthor=D.+L.+Romanauthor=K.+D.+Burrisauthor=V.+J.+Watts&title=Bias+Analyses+of+Preclinical+and+Clinical+D2+Dopamine+Ligands%3A+Studies+with+Immediate+and+Complex+Signaling+Pathways&doi=10.1124%2Fjpet.114.220293"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.220293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.220293%26sid%3Dliteratum%253Aachs%26aulast%3DBrust%26aufirst%3DT.%2BF.%26aulast%3DHayes%26aufirst%3DM.%2BP.%26aulast%3DRoman%26aufirst%3DD.%2BL.%26aulast%3DBurris%26aufirst%3DK.%2BD.%26aulast%3DWatts%26aufirst%3DV.%2BJ.%26atitle%3DBias%2520Analyses%2520of%2520Preclinical%2520and%2520Clinical%2520D2%2520Dopamine%2520Ligands%253A%2520Studies%2520with%2520Immediate%2520and%2520Complex%2520Signaling%2520Pathways%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D352%26spage%3D480%26epage%3D493%26doi%3D10.1124%2Fjpet.114.220293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figueroa, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehlert, F. J.</span></span> <span> </span><span class="NLM_article-title">Estimation of Agonist Activity at G Protein-Coupled Receptors: Analysis of M2 Muscarinic Receptor Signaling through Gi/o,Gs, and G15</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>321</i></span>,  <span class="NLM_fpage">1193</span>– <span class="NLM_lpage">1207</span>, <span class="refDoi"> DOI: 10.1124/jpet.107.120857</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1124%2Fjpet.107.120857" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=17392404" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmsFeqsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=321&publication_year=2007&pages=1193-1207&author=M.+T.+Griffinauthor=K.+W.+Figueroaauthor=S.+Lillerauthor=F.+J.+Ehlert&title=Estimation+of+Agonist+Activity+at+G+Protein-Coupled+Receptors%3A+Analysis+of+M2+Muscarinic+Receptor+Signaling+through+Gi%2Fo%2CGs%2C+and+G15&doi=10.1124%2Fjpet.107.120857"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Estimation of agonist activity at G protein-coupled receptors: analysis of M2 muscarinic receptor signaling through Gi/o, Gs, and G15</span></div><div class="casAuthors">Griffin, Michael T.; Figueroa, Katherine W.; Liller, Sarah; Ehlert, Frederick J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">321</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1193-1207</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">We developed novel methods for analyzing the concn.-response curve of an agonist to est. the product of obsd. affinity and intrinsic efficacy, expressed relative to that of a std. agonist.  This parameter, termed intrinsic relative activity (RAi), is most applicable for the anal. of responses at G protein-coupled receptors.  RAi is equiv. to the potency ratios that agonists would exhibit in a hypothetical, highly sensitive assay in which all agonists behave as full agonists, even those with little intrinsic efficacy.  We investigated muscarinic responses at the M2 receptor, including stimulation of phosphoinositide hydrolysis through Gα15 in HEK 293T cells, inhibition of cAMP accumulation through Gi in Chinese hamster ovary (CHO) cells, and stimulation of cAMP accumulation through Gs in CHO cells treated with pertussis toxin.  The RAi values of carbachol, oxotremorine-M, and the enantiomers of aceclidine were approx. the same in the three assay systems.  In contrast, the activity of 4-[[N-[3-chlorophenyl]carbamoy]oxy-2-butynyl]trimethylammonium chloride (McN-A-343) was ∼10-fold greater at M2 receptors coupled to Gα15 in HEK 293T cells compared with M2 receptors coupled to Gi in the same cells or in CHO cells.  Our results show that the RAi est. is a useful measure for quantifying agonist activity across different assay systems and for detecting agonist directed signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPP24F4WMXY7Vg90H21EOLACvtfcHk0lhCLbLLtOwdoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmsFeqsLc%253D&md5=f6b6a16a899f634d3be42c6ada98e002</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1124%2Fjpet.107.120857&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.107.120857%26sid%3Dliteratum%253Aachs%26aulast%3DGriffin%26aufirst%3DM.%2BT.%26aulast%3DFigueroa%26aufirst%3DK.%2BW.%26aulast%3DLiller%26aufirst%3DS.%26aulast%3DEhlert%26aufirst%3DF.%2BJ.%26atitle%3DEstimation%2520of%2520Agonist%2520Activity%2520at%2520G%2520Protein-Coupled%2520Receptors%253A%2520Analysis%2520of%2520M2%2520Muscarinic%2520Receptor%2520Signaling%2520through%2520Gi%252Fo%252CGs%252C%2520and%2520G15%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D321%26spage%3D1193%26epage%3D1207%26doi%3D10.1124%2Fjpet.107.120857" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ehlert, F. J.</span></span> <span> </span><span class="NLM_article-title">On the Analysis of Ligand-Directed Signaling at G Protein-Coupled Receptors</span>. <i>Naunyn-Schmiedeberg’s Arch. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">549</span>– <span class="NLM_lpage">577</span>, <span class="refDoi"> DOI: 10.1007/s00210-008-0260-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1007%2Fs00210-008-0260-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=18253722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsVSqtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2008&pages=549-577&author=F.+J.+Ehlert&title=On+the+Analysis+of+Ligand-Directed+Signaling+at+G+Protein-Coupled+Receptors&doi=10.1007%2Fs00210-008-0260-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">On the analysis of ligand-directed signaling at G protein-coupled receptors</span></div><div class="casAuthors">Ehlert, Frederick J.</div><div class="citationInfo"><span class="NLM_cas:title">Naunyn-Schmiedeberg's Archives of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">4-6</span>),
    <span class="NLM_cas:pages">549-577</span>CODEN:
                <span class="NLM_cas:coden">NSAPCC</span>;
        ISSN:<span class="NLM_cas:issn">0028-1298</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  The phenomenon of "ligand-directed signaling" is often considered to be inconsistent with the traditional receptor theory.  In this review, I show how the mathematics of the receptor theory can be used to measure the obsd. affinity and relative efficacy of protean ligands at G protein-coupled receptors.  The basis of this anal. rests on the assumption that the fraction of agonist bound in the form of the active receptor-G protein-guanine nucleotide complex is the biochem. equiv. of the pharmacol. stimulus.  Consequently, this stimulus function is analogous to the current response of a ligand-gated ion channel.  Because guanosine triphosphate (GTP) greatly inhibits the formation of the active quaternary complex, even the most efficacious agonists probably only elicit partial receptor activation, and it seems likely that the ceiling of 100% receptor activation is not reached in the intact cell with high intracellular concns. of GTP.  Under these conditions, the max. of the stimulus function is proportional to the ratio of microscopic affinity consts. of the agonist for ground and active states.  Ligand-directed signaling depends on the existence of different active states of the receptor with different selectivities for different G proteins or other effectors.  This phenomenon can be characterized using classic pharmacol. methods.  Although not widely appreciated, it is possible to est. the product of obsd. affinity and intrinsic efficacy expressed relative to that of another agonist (intrinsic relative activity) through the anal. of the concn.-response curves.  No other information is required.  This approach should be useful in quantifying agonist activity and in converting the two disparate parameters of potency and maximal response into a single parameter dependent only on the agonist-receptor-effector complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjPkYAlcl8-LVg90H21EOLACvtfcHk0lgrFkEbmV03zA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsVSqtr4%253D&md5=31aceaf811a5473e4899088f3f2e177e</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1007%2Fs00210-008-0260-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00210-008-0260-4%26sid%3Dliteratum%253Aachs%26aulast%3DEhlert%26aufirst%3DF.%2BJ.%26atitle%3DOn%2520the%2520Analysis%2520of%2520Ligand-Directed%2520Signaling%2520at%2520G%2520Protein-Coupled%2520Receptors%26jtitle%3DNaunyn-Schmiedeberg%25E2%2580%2599s%2520Arch.%2520Pharmacol.%26date%3D2008%26volume%3D377%26spage%3D549%26epage%3D577%26doi%3D10.1007%2Fs00210-008-0260-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rajagopal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rominger, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gowen-MacDonald, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeWire, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Violin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span> <span> </span><span class="NLM_article-title">Quantifying Ligand Bias at Seven-Transmembrane Receptors</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">367</span>– <span class="NLM_lpage">377</span>, <span class="refDoi"> DOI: 10.1124/mol.111.072801</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1124%2Fmol.111.072801" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=21610196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1ektb7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2011&pages=367-377&author=S.+Rajagopalauthor=S.+Ahnauthor=D.+H.+Romingerauthor=W.+Gowen-MacDonaldauthor=C.+M.+Lamauthor=S.+M.+DeWireauthor=J.+D.+Violinauthor=R.+J.+Lefkowitz&title=Quantifying+Ligand+Bias+at+Seven-Transmembrane+Receptors&doi=10.1124%2Fmol.111.072801"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Quantifying ligand bias at seven-transmembrane receptors</span></div><div class="casAuthors">Rajagopal, Sudarshan; Ahn, Seungkirl; Rominger, David H.; Gowen-MacDonald, William; Lam, Christopher M.; DeWire, Scott M.; Violin, Jonathan D.; Lefkowitz, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">367-377</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Seven transmembrane receptors (7TMRs), commonly referred to as G protein-coupled receptors, form a large part of the "druggable" genome.  7TMRs can signal through parallel pathways simultaneously, such as through heterotrimeric G proteins from different families, or, as more recently appreciated, through the multifunctional adapters, β-arrestins.  Biased agonists, which signal with different efficacies to a receptor's multiple downstream pathways, are useful tools for deconvoluting this signaling complexity.  These compds. may also be of therapeutic use because they have distinct functional and therapeutic profiles from "balanced agonists.".  Although some methods have been proposed to identify biased ligands, no comparison of these methods applied to the same set of data has been performed.  Therefore, at this time, there are no generally accepted methods to quantify the relative bias of different ligands, making studies of biased signaling difficult.  Here, we use complementary computational approaches for the quantification of ligand bias and demonstrate their application to two well known drug targets, the β2 adrenergic and angiotensin II type 1A receptors.  The strategy outlined here allows a quantification of ligand bias and the identification of weakly biased compds.  This general method should aid in deciphering complex signaling pathways and may be useful for the development of novel biased therapeutic ligands as drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwS1RZ3pzY3LVg90H21EOLACvtfcHk0lgrFkEbmV03zA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1ektb7J&md5=3af41d68a6e41d477610338f8e7041f0</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1124%2Fmol.111.072801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.111.072801%26sid%3Dliteratum%253Aachs%26aulast%3DRajagopal%26aufirst%3DS.%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DRominger%26aufirst%3DD.%2BH.%26aulast%3DGowen-MacDonald%26aufirst%3DW.%26aulast%3DLam%26aufirst%3DC.%2BM.%26aulast%3DDeWire%26aufirst%3DS.%2BM.%26aulast%3DViolin%26aufirst%3DJ.%2BD.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26atitle%3DQuantifying%2520Ligand%2520Bias%2520at%2520Seven-Transmembrane%2520Receptors%26jtitle%3DMol.%2520Pharmacol.%26date%3D2011%26volume%3D80%26spage%3D367%26epage%3D377%26doi%3D10.1124%2Fmol.111.072801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fumagalli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molteni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calabrese, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frasca, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Racagni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riva, M. A.</span></span> <span> </span><span class="NLM_article-title">Chronic Fluoxetine Administration Inhibits Extracellular Signal-Regulated Kinase 1/2 Phosphorylation in Rat Brain</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">1551</span>– <span class="NLM_lpage">1560</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.2005.03149.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1111%2Fj.1471-4159.2005.03149.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=15935071" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsFemsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2005&pages=1551-1560&author=F.+Fumagalliauthor=R.+Molteniauthor=F.+Calabreseauthor=A.+Frascaauthor=G.+Racagniauthor=M.+A.+Riva&title=Chronic+Fluoxetine+Administration+Inhibits+Extracellular+Signal-Regulated+Kinase+1%2F2+Phosphorylation+in+Rat+Brain&doi=10.1111%2Fj.1471-4159.2005.03149.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic fluoxetine administration inhibits extracellular signal-regulated kinase 1/2 phosphorylation in rat brain</span></div><div class="casAuthors">Fumagalli, F.; Molteni, R.; Calabrese, F.; Frasca, A.; Racagni, G.; Riva, M. A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1551-1560</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Accumulating evidence indicates that antidepressants alter intracellular signaling mechanisms resulting in long-term synaptic alterations which probably account for the delay in clin. action of these drugs.  Therefore, we investigated the effects of chronic fluoxetine administration on extracellular signal-regulated kinase (ERK) 1 and 2, a group of MAPKs that mediate signal transduction from the cell surface downstream to the nucleus.  Our data demonstrate that 3-wk fluoxetine treatment resulted in long-lasting redn. of phospho-ERK 1 and 2.  Such an effect depends on the length of the treatment given that no changes were obsd. after a single drug injection or after 2 wk of treatment and it is region specific, being obsd. in hippocampus and frontal cortex but not in striatum.  Finally, phospho-ERK 1 and 2 were differently modulated within nucleus and cytosol in hippocampus but similarly reduced in the same compartments of the frontal cortex, highlighting the specific subcellular compartmentalization of fluoxetine.  Conversely, imipramine did not reduce the hippocampal phosphorylation of both ERK subtypes whereas it selectively increased ERK 1 phosphorylation in the cytosolic compartment of frontal cortex suggesting a drug-specific effect on this intracellular target.  These results point to modulation of phosphorylation, rather than altered expression, as the main target in the action of fluoxetine on this pathway.  The redn. of ERK 1/2 function herein reported may be assocd. with the therapeutic effects of fluoxetine in the treatment of depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrf4MNOmugmqbVg90H21EOLACvtfcHk0lgrFkEbmV03zA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsFemsLo%253D&md5=bb08fe951895b30d79ee7f7e2e684f06</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2005.03149.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2005.03149.x%26sid%3Dliteratum%253Aachs%26aulast%3DFumagalli%26aufirst%3DF.%26aulast%3DMolteni%26aufirst%3DR.%26aulast%3DCalabrese%26aufirst%3DF.%26aulast%3DFrasca%26aufirst%3DA.%26aulast%3DRacagni%26aufirst%3DG.%26aulast%3DRiva%26aufirst%3DM.%2BA.%26atitle%3DChronic%2520Fluoxetine%2520Administration%2520Inhibits%2520Extracellular%2520Signal-Regulated%2520Kinase%25201%252F2%2520Phosphorylation%2520in%2520Rat%2520Brain%26jtitle%3DJ.%2520Neurochem.%26date%3D2005%26volume%3D93%26spage%3D1551%26epage%3D1560%26doi%3D10.1111%2Fj.1471-4159.2005.03149.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dwivedi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span> <span> </span><span class="NLM_article-title">Altered ERK1/2 Signaling in the Brain of Learned Helpless Rats: Relevance in Vulnerability to Developing Stress-Induced Depression</span>. <i>Neural Plast.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2016</i></span>,  <span class="NLM_fpage">7383724</span>, <span class="refDoi"> DOI: 10.1155/2016/7383724</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1155%2F2016%2F7383724" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=26839717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A280%3ADC%252BC28nnt1Ojuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2016&publication_year=2016&pages=7383724&author=Y.+Dwivediauthor=H.+Zhang&title=Altered+ERK1%2F2+Signaling+in+the+Brain+of+Learned+Helpless+Rats%3A+Relevance+in+Vulnerability+to+Developing+Stress-Induced+Depression&doi=10.1155%2F2016%2F7383724"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Altered ERK1/2 Signaling in the Brain of Learned Helpless Rats: Relevance in Vulnerability to Developing Stress-Induced Depression</span></div><div class="casAuthors">Dwivedi Yogesh; Zhang Hui</div><div class="citationInfo"><span class="NLM_cas:title">Neural plasticity</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">2016</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">7383724</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Extracellular signal-regulated kinase 1/2- (ERK1/2-) mediated cellular signaling plays a major role in synaptic and structural plasticity.  Although ERK1/2 signaling has been shown to be involved in stress and depression, whether vulnerability to develop depression is associated with abnormalities in ERK1/2 signaling is not clearly known.  The present study examined ERK1/2 signaling in frontal cortex and hippocampus of rats that showed vulnerability (learned helplessness, (LH)) or resiliency (non-learned helplessness, (non-LH)) to developing stress-induced depression.  In frontal cortex and hippocampus of LH rats, we found that mRNA and protein expressions of ERK1 and ERK2 were significantly reduced, which was associated with their reduced activation and phosphorylation in cytosolic and nuclear fractions, where ERK1 and ERK2 target their substrates.  In addition, ERK1/2-mediated catalytic activities and phosphorylation of downstream substrates RSK1 (cytosolic and nuclear) and MSK1 (nuclear) were also lower in the frontal cortex and hippocampus of LH rats without any change in their mRNA or protein expression.  None of these changes were evident in non-LH rats.  Our study indicates that ERK1/2 signaling is differentially regulated in LH and non-LH rats and suggests that abnormalities in ERK1/2 signaling may be crucial in the vulnerability to developing depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSR7Tw4Ij203Vw2ofyr07jXfW6udTcc2eYRgP5I3F3hGrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28nnt1Ojuw%253D%253D&md5=00fff19b4b0173b360f36f272ec0ff60</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1155%2F2016%2F7383724&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2016%252F7383724%26sid%3Dliteratum%253Aachs%26aulast%3DDwivedi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%26atitle%3DAltered%2520ERK1%252F2%2520Signaling%2520in%2520the%2520Brain%2520of%2520Learned%2520Helpless%2520Rats%253A%2520Relevance%2520in%2520Vulnerability%2520to%2520Developing%2520Stress-Induced%2520Depression%26jtitle%3DNeural%2520Plast.%26date%3D2016%26volume%3D2016%26spage%3D7383724%26doi%3D10.1155%2F2016%2F7383724" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dwivedi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizavi, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conley, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamminga, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, G. N.</span></span> <span> </span><span class="NLM_article-title">Reduced Activation and Expression of ERK1/2 MAP Kinase in the Post-Mortem Brain of Depressed Suicide Subjects</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">916</span>– <span class="NLM_lpage">928</span>, <span class="refDoi"> DOI: 10.1046/j.1471-4159.2001.00300.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1046%2Fj.1471-4159.2001.00300.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=11331420" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjs1Wltr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2001&pages=916-928&author=Y.+Dwivediauthor=H.+S.+Rizaviauthor=R.+C.+Robertsauthor=R.+C.+Conleyauthor=C.+A.+Tammingaauthor=G.+N.+Pandey&title=Reduced+Activation+and+Expression+of+ERK1%2F2+MAP+Kinase+in+the+Post-Mortem+Brain+of+Depressed+Suicide+Subjects&doi=10.1046%2Fj.1471-4159.2001.00300.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Reduced activation and expression of ERK1/2 MAP kinase in the post-mortem brain of depressed suicide subjects</span></div><div class="casAuthors">Dwivedi, Y.; Rizavi, H. S.; Roberts, R. C.; Conley, R. C.; Tamminga, C. A.; Pandey, G. N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">916-928</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">The extracellular regulated kinases (ERK) 1 and ERK2 are members of mitogen-activated protein (MAP) kinase family that play an important role in transducing extracellular signals to the nucleus and have been implicated in a broad spectrum of biol. responses.  To test the hypothesis that MAP kinases may be involved in depression, the authors examd. the activation of p44/42 MAP kinase and expression of ERK1 and ERK2 in the post-mortem brain tissue obtained from non-psychiatric control subjects and age- and the post-mortem interval-matched depressed suicide subjects.  The authors obsd. that p44/42 MAP kinase activity was significantly decreased in the prefrontal cortical areas (Brodmann's areas 8, 9 and 10) and the hippocampus of depressed suicide subjects without any change in the cerebellum.  This decrease was assocd. with a decrease in mRNA and protein levels of ERK1 and ERK2.  In addn., the expression of MAP kinase phosphatase (MKP)2, a "dual function" ERK1/2 phosphatase, was increased in the prefrontal cortex and hippocampus.  These studies suggest that p44/42 MAP kinases are less activated in the post-mortem brain of depressed suicide subjects and this may be because of reduced expression of ERK1/2 and increased expression of MKP2.  Given the role of MAP kinases in various physiol. functions and gene expression, alterations in p44/42 MAP kinase activation and expression of ERK1/2 may contribute significantly to the pathophysiol. of depressive disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1ZfmbOoP1j7Vg90H21EOLACvtfcHk0liERnF5ibyOqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjs1Wltr8%253D&md5=4d335c04bce5834af1ab4457bb7123c7</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1046%2Fj.1471-4159.2001.00300.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1471-4159.2001.00300.x%26sid%3Dliteratum%253Aachs%26aulast%3DDwivedi%26aufirst%3DY.%26aulast%3DRizavi%26aufirst%3DH.%2BS.%26aulast%3DRoberts%26aufirst%3DR.%2BC.%26aulast%3DConley%26aufirst%3DR.%2BC.%26aulast%3DTamminga%26aufirst%3DC.%2BA.%26aulast%3DPandey%26aufirst%3DG.%2BN.%26atitle%3DReduced%2520Activation%2520and%2520Expression%2520of%2520ERK1%252F2%2520MAP%2520Kinase%2520in%2520the%2520Post-Mortem%2520Brain%2520of%2520Depressed%2520Suicide%2520Subjects%26jtitle%3DJ.%2520Neurochem.%26date%3D2001%26volume%3D77%26spage%3D916%26epage%3D928%26doi%3D10.1046%2Fj.1471-4159.2001.00300.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dwivedi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizavi, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conley, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, G. N.</span></span> <span> </span><span class="NLM_article-title">Aberrant Extracellular Signal-Regulated Kinase (ERK)1/2 Signalling in Suicide Brain: Role of ERK Kinase 1 (MEK1)</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1337</span>– <span class="NLM_lpage">1354</span>, <span class="refDoi"> DOI: 10.1017/s1461145709990575</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1017%2Fs1461145709990575" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=19835659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1ylsbvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2009&pages=1337-1354&author=Y.+Dwivediauthor=H.+S.+Rizaviauthor=H.+Zhangauthor=R.+C.+Robertsauthor=R.+R.+Conleyauthor=G.+N.+Pandey&title=Aberrant+Extracellular+Signal-Regulated+Kinase+%28ERK%291%2F2+Signalling+in+Suicide+Brain%3A+Role+of+ERK+Kinase+1+%28MEK1%29&doi=10.1017%2Fs1461145709990575"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Aberrant extracellular signal-regulated kinase (ERK)1/2 signalling in suicide brain: role of ERK kinase 1 (MEK1)</span></div><div class="casAuthors">Dwivedi, Yogesh; Rizavi, Hooriyah S.; Zhang, Hui; Roberts, Rosalinda C.; Conley, Robert R.; Pandey, Ghanshyam N.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1337-1354</span>CODEN:
                <span class="NLM_cas:coden">IJNUFB</span>;
        ISSN:<span class="NLM_cas:issn">1461-1457</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">Extracellular signal-regulated kinase (ERK)1/2 signaling plays a crit. role in synaptic and structural plasticity.  Recent preclin. and human brain studies suggest that depression and suicidal behavior are assocd. with aberrant ERK1/2 signaling.  MEK, is a dual-specificity kinase, which is the immediate upstream regulator of ERK1/2.  Two isoforms of MEK (MEK1 and MEK2) exist.  By phosphorylating at Ser and Thr residues, MEK activates ERK1/2, which then phosphorylates cytoplasmic and nuclear substrates.  On the other hand, MEK itself is regulated through phosphorylation by upstream Raf kinases.  Recently, we demonstrated that activation of ERK1/2 and B-Raf was attenuated in the brains of suicide subjects.  To further investigate the regulation of ERK1/2 signaling, we examd. the expression and activation of MEKs, the interaction of MEK with ERKs, MEK-mediated activation of ERK1/2, and ERK1/2-mediated activation of nuclear substrate Elk-1 in the prefrontal cortex and hippocampus of suicide subjects.  In addn., to investigate whether MEK is regulated by B-Raf, we examd. the B-Raf and MEK interaction.  No significant changes were obsd. in expression levels of MEK1 or MEK2; however, the catalytic activity of only MEK1 (not MEK2) was decreased in both the prefrontal cortex and hippocampus of suicide subjects.  The interaction of MEK1 with ERK1 and ERK2 was increased along with decreased phosphorylation and catalytic activity of ERK1/2.  In addn., we found decreased phosphorylation of MEK1 and less interaction of B-Raf with MEK1.  Our results demonstrate abnormalities in MEK1 at multiple levels and suggest that these abnormalities in MEK1 are crucial for aberrant ERK1/2 signaling in suicide brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoM4VBpYyoElLVg90H21EOLACvtfcHk0liERnF5ibyOqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1ylsbvP&md5=006f481c41f554dce39d16fd54380277</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1017%2Fs1461145709990575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252Fs1461145709990575%26sid%3Dliteratum%253Aachs%26aulast%3DDwivedi%26aufirst%3DY.%26aulast%3DRizavi%26aufirst%3DH.%2BS.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DR.%2BC.%26aulast%3DConley%26aufirst%3DR.%2BR.%26aulast%3DPandey%26aufirst%3DG.%2BN.%26atitle%3DAberrant%2520Extracellular%2520Signal-Regulated%2520Kinase%2520%2528ERK%25291%252F2%2520Signalling%2520in%2520Suicide%2520Brain%253A%2520Role%2520of%2520ERK%2520Kinase%25201%2520%2528MEK1%2529%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2009%26volume%3D12%26spage%3D1337%26epage%3D1354%26doi%3D10.1017%2Fs1461145709990575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">First, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil-Ad, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarasenko, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novak, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weizman, A.</span></span> <span> </span><span class="NLM_article-title">The Effects of Fluoxetine Treatment in a Chronic Mild Stress Rat Model on Depression-Related Behavior, Brain Neurotrophins and ERK Expression</span>. <i>J. Mol. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">246</span>, <span class="refDoi"> DOI: 10.1007/s12031-011-9515-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1007%2Fs12031-011-9515-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=21479508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1ajtr7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2011&pages=246&author=M.+Firstauthor=I.+Gil-Adauthor=M.+Talerauthor=I.+Tarasenkoauthor=N.+Novakauthor=A.+Weizman&title=The+Effects+of+Fluoxetine+Treatment+in+a+Chronic+Mild+Stress+Rat+Model+on+Depression-Related+Behavior%2C+Brain+Neurotrophins+and+ERK+Expression&doi=10.1007%2Fs12031-011-9515-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">The Effects of Fluoxetine Treatment in a Chronic Mild Stress Rat Model on Depression-Related Behavior, Brain Neurotrophins and ERK Expression</span></div><div class="casAuthors">First, Maya; Gil-Ad, Irit; Taler, Michal; Tarasenko, Igor; Novak, Nurit; Weizman, Abraham</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Neuroscience</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">246-255</span>CODEN:
                <span class="NLM_cas:coden">JMNEES</span>;
        ISSN:<span class="NLM_cas:issn">0895-8696</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">Depression is assocd. with hippocampus (HC) vol. loss.  Chronic mild stress (CMS) in rats is a model of depression.  Antidepressants attenuate HC vol. loss and reverse the depression-like symptoms of stressed animals.  We evaluated the effect of CMS and the selective serotonin reuptake inhibitor, fluoxetine (FLX) treatment on behavioral and cognitive parameters in rats, and on HC and frontal cortex (FC) neurotrophic factors levels.  Male rats were exposed sequentially, over a period of 5 wk, to a variety of mild stressors.  FLX (5 mg/kg/day i.p.) was administered to the stressed group and controls (unstressed).  After 5 wk of CMS, animals were tested using the Morris Water Maze (MWM).  In the MWM, we obsd. that FLX had a transitory effect on unstressed rats.  CMS reduced insulin-like growth factor-1 receptor (IGF-1R) levels in the HC whereas after FLX treatment these levels reverted to normal range.  CMS rats revealed a significant decrease in extracellular signal-regulated kinase (ERK) phosphorylation in both HC and FC regions, while FLX normalized these levels.  This study suggests that IGF-1R and ERK may have a role in mediating the neural stress response and the mode of action of FLX.  This role seems to be independent of the BDNF alterations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwzM2KCuHqXbVg90H21EOLACvtfcHk0lix2Eypr0bG4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1ajtr7F&md5=fa6c71ef07dbc197c8b81a8f57be7433</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1007%2Fs12031-011-9515-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12031-011-9515-5%26sid%3Dliteratum%253Aachs%26aulast%3DFirst%26aufirst%3DM.%26aulast%3DGil-Ad%26aufirst%3DI.%26aulast%3DTaler%26aufirst%3DM.%26aulast%3DTarasenko%26aufirst%3DI.%26aulast%3DNovak%26aufirst%3DN.%26aulast%3DWeizman%26aufirst%3DA.%26atitle%3DThe%2520Effects%2520of%2520Fluoxetine%2520Treatment%2520in%2520a%2520Chronic%2520Mild%2520Stress%2520Rat%2520Model%2520on%2520Depression-Related%2520Behavior%252C%2520Brain%2520Neurotrophins%2520and%2520ERK%2520Expression%26jtitle%3DJ.%2520Mol.%2520Neurosci.%26date%3D2011%26volume%3D45%26spage%3D246%26doi%3D10.1007%2Fs12031-011-9515-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.-G.</span></span> <span> </span><span class="NLM_article-title">Antidepressant Effects of a Plant-Derived Flavonoid Baicalein Involving Extracellular Signal-Regulated Kinases Cascade</span>. <i>Biol. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">253</span>– <span class="NLM_lpage">259</span>, <span class="refDoi"> DOI: 10.1248/bpb.34.253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1248%2Fbpb.34.253" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=21415537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC38XovFartg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2011&pages=253-259&author=Z.+Xiongauthor=B.+Jiangauthor=P.-F.+Wuauthor=J.+Tianauthor=L.-L.+Shiauthor=J.+Guauthor=Z.-L.+Huauthor=H.+Fuauthor=F.+Wangauthor=J.-G.+Chen&title=Antidepressant+Effects+of+a+Plant-Derived+Flavonoid+Baicalein+Involving+Extracellular+Signal-Regulated+Kinases+Cascade&doi=10.1248%2Fbpb.34.253"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Antidepressant effects of a plant-derived flavonoid baicalein involving extracellular signal-regulated kinases cascade</span></div><div class="casAuthors">Xiong, Zhe; Jiang, Bo; Wu, Peng-Fei; Tian, Jia; Shi, Liang-Liang; Gu, Jun; Hu, Zhuang-Li; Fu, Hui; Wang, Fang; Chen, Jian-Guo</div><div class="citationInfo"><span class="NLM_cas:title">Biological & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">253-259</span>CODEN:
                <span class="NLM_cas:coden">BPBLEO</span>;
        ISSN:<span class="NLM_cas:issn">0918-6158</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">Depression and related mood disorders are among the world's greatest public health problems.  Previous studies have demonstrated that baicalein (Bai), one plant-derived active flavonoid, exhibits neuroprotection against ischemic brain injury and stimulates the levels of phosphorylation of extracellular signal-regulated kinase (pERK) and brain-derived neurotrophic factor (BDNF) expression in vivo.  In this study, the antidepressant-like effects of baicalein was investigated using acute and chronic animal models of depression.  The results showed that acute application of Bai at doses of 1, 2 and 4 mg/kg by i.p. injection (i.p.) significantly reduced the immobility time in the forced swimming test (FST) and tail suspending test (TST) of mice.  In addn., the chronic application of Bai by i.p. for 21 d also reduced the immobility time and improved locomotor activity in chronic unpredictable mild stress (CMS) model rats.  Furthermore, it was shown that Bai reversed the redn. of extracellular ERKs phosphorylation and the level of BDNF expression in the hippocampus of CMS model rats.  These results suggest that Bai produce an antidepressant-like effect and this effect is at least partly mediated by hippocampal ERK-mediated neurotrophic action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEc-MeaJSj3bVg90H21EOLACvtfcHk0lix2Eypr0bG4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovFartg%253D%253D&md5=a582aa1ead3345c64c13a2e77dbed5ac</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1248%2Fbpb.34.253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fbpb.34.253%26sid%3Dliteratum%253Aachs%26aulast%3DXiong%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DP.-F.%26aulast%3DTian%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DL.-L.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DZ.-L.%26aulast%3DFu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DJ.-G.%26atitle%3DAntidepressant%2520Effects%2520of%2520a%2520Plant-Derived%2520Flavonoid%2520Baicalein%2520Involving%2520Extracellular%2520Signal-Regulated%2520Kinases%2520Cascade%26jtitle%3DBiol.%2520Pharm.%2520Bull.%26date%3D2011%26volume%3D34%26spage%3D253%26epage%3D259%26doi%3D10.1248%2Fbpb.34.253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span> <span> </span><span class="NLM_article-title">The Depressive-like Behaviors Are Correlated with Decreased Phosphorylation of Mitogen-Activated Protein Kinases in Rat Brain Following Chronic Forced Swim Stress</span>. <i>Behav. Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>175</i></span>,  <span class="NLM_fpage">233</span>– <span class="NLM_lpage">240</span>, <span class="refDoi"> DOI: 10.1016/j.bbr.2006.08.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2Fj.bbr.2006.08.035" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2006&pages=233-240&author=X.+Qiauthor=W.+Linauthor=J.+Liauthor=Y.+Panauthor=W.+Wang&title=The+Depressive-like+Behaviors+Are+Correlated+with+Decreased+Phosphorylation+of+Mitogen-Activated+Protein+Kinases+in+Rat+Brain+Following+Chronic+Forced+Swim+Stress&doi=10.1016%2Fj.bbr.2006.08.035"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.bbr.2006.08.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbr.2006.08.035%26sid%3Dliteratum%253Aachs%26aulast%3DQi%26aufirst%3DX.%26aulast%3DLin%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DW.%26atitle%3DThe%2520Depressive-like%2520Behaviors%2520Are%2520Correlated%2520with%2520Decreased%2520Phosphorylation%2520of%2520Mitogen-Activated%2520Protein%2520Kinases%2520in%2520Rat%2520Brain%2520Following%2520Chronic%2520Forced%2520Swim%2520Stress%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2006%26volume%3D175%26spage%3D233%26epage%3D240%26doi%3D10.1016%2Fj.bbr.2006.08.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, M.</span></span> <span> </span><span class="NLM_article-title">Fluoxetine Increases the Activity of the ERK-CREB Signal System and Alleviates the Depressive-like Behavior in Rats Exposed to Chronic Forced Swim Stress</span>. <i>Neurobiol. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">278</span>– <span class="NLM_lpage">285</span>, <span class="refDoi"> DOI: 10.1016/j.nbd.2008.05.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2Fj.nbd.2008.05.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=18586506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslOht78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2008&pages=278-285&author=X.+Qiauthor=W.+Linauthor=J.+Liauthor=H.+Liauthor=W.+Wangauthor=D.+Wangauthor=M.+Sun&title=Fluoxetine+Increases+the+Activity+of+the+ERK-CREB+Signal+System+and+Alleviates+the+Depressive-like+Behavior+in+Rats+Exposed+to+Chronic+Forced+Swim+Stress&doi=10.1016%2Fj.nbd.2008.05.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Fluoxetine increases the activity of the ERK-CREB signal system and alleviates the depressive-like behavior in rats exposed to chronic forced swim stress</span></div><div class="casAuthors">Qi, Xiaoli; Lin, Wenjuan; Li, Junfa; Li, Huanhuan; Wang, Weiwen; Wang, Donglin; Sun, Meng</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Disease</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">278-285</span>CODEN:
                <span class="NLM_cas:coden">NUDIEM</span>;
        ISSN:<span class="NLM_cas:issn">0969-9961</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Our previous research indicates that the extracellular signal-regulated kinase (ERK)-cAMP-responsive-element-binding protein (CREB) signal system may be involved in the mol. mechanism of depression.  The present study further investigated the effect of antidepressant fluoxetine on the ERK-CREB signal system and the depressive-like behaviors in rats.  Fluoxetine was administrated to either naive rats or stressed rats for 21 days.  The results showed that chronic forced swim stress induced depressive-like behaviors and decreased the levels of P-ERK2, P-CREB, ERK1/2 and CREB in hippocampus and prefrontal cortex.  Fluoxetine alleviated the depressive-like behaviors and reversed the disruptions of the P-ERK2 and P-CREB in stressed rats.  Fluoxetine also exerted mood-elevating effect and increased the levels of the P-ERK2 and P-CREB in naive rats.  These results suggest that the ERK-CREB signal system may be the targets of the antidepressant action of fluoxetine and participate in the neuronal mechanism of depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcX6qEug-NwbVg90H21EOLACvtfcHk0lix2Eypr0bG4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslOht78%253D&md5=1345027e44afcb8dd7ae24f81d9b38bc</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.nbd.2008.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nbd.2008.05.003%26sid%3Dliteratum%253Aachs%26aulast%3DQi%26aufirst%3DX.%26aulast%3DLin%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DSun%26aufirst%3DM.%26atitle%3DFluoxetine%2520Increases%2520the%2520Activity%2520of%2520the%2520ERK-CREB%2520Signal%2520System%2520and%2520Alleviates%2520the%2520Depressive-like%2520Behavior%2520in%2520Rats%2520Exposed%2520to%2520Chronic%2520Forced%2520Swim%2520Stress%26jtitle%3DNeurobiol.%2520Dis.%26date%3D2008%26volume%3D31%26spage%3D278%26epage%3D285%26doi%3D10.1016%2Fj.nbd.2008.05.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moyano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Río, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frechilla, D.</span></span> <span> </span><span class="NLM_article-title">Role of Hippocampal CaMKII in Serotonin 5-HT(1A) Receptor-Mediated Learning Deficit in Rats</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">2216</span>– <span class="NLM_lpage">2224</span>, <span class="refDoi"> DOI: 10.1038/sj.npp.1300504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1038%2Fsj.npp.1300504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=15199370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVSmsrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2004&pages=2216-2224&author=S.+Moyanoauthor=J.+D.+R%C3%ADoauthor=D.+Frechilla&title=Role+of+Hippocampal+CaMKII+in+Serotonin+5-HT%281A%29+Receptor-Mediated+Learning+Deficit+in+Rats&doi=10.1038%2Fsj.npp.1300504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Role of hippocampal CaMKII in serotonin 5-HT1A receptor-mediated learning deficit in rats</span></div><div class="casAuthors">Moyano, Sonia; Del Rio, Joaquin; Frechilla, Diana</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2216-2224</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The serotonin 5-HT1A receptor agonist, 8-OH-DPAT (8-hydroxy-2-di-n-propylamino-tetralin), impairs retention performance in a passive avoidance learning task in rats.  In the hippocampus of rats trained on this procedure and killed 1 h after the acquisition trial, an increase in the membrane levels of both Ca2+/calmodulin-dependent protein kinase II (CaMKII) and phosphorylated CaMKII, as well as in total and Ca2+-independent enzyme activity in tissue lysates was found.  These effects were learning-specific as no changes in CaMKII levels or activity were found in rats receiving a footshock identical to the trained rats.  The effect of training on CaMKII was prevented by a low 8-OH-DPAT dose.  The 5-HT1A agonist also reduced protein kinase A (PKA) activity and increased the membrane levels of phosphatase 1 (PP1) and PP1 enzyme activity in the hippocampus.  All of the changes induced by 8-OH-DPAT were reversed by the selective 5-HT1A antagonist WAY-100635, indicating receptor-specific effects.  The authors suggest that 5-HT1A receptor-mediated disruption of retention performance is a consequence of the reduced PKA activity and the ensuing enhancement in PP1 activity, possibly through decreased phosphorylation/activation of endogenous PP1 inhibitors, that cause a reduced activity of phosphorylated CaMKII, a key enzyme in early stages of memory formation.  This study provides an in vivo mol. basis for the cognitive deficits induced by stimulation of hippocampal 5-HT1A receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolIn_ZpIZT_rVg90H21EOLACvtfcHk0lhXE5VB4GJ17g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVSmsrbJ&md5=ac56509753dcb3f9afe5efe8687f7408</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1038%2Fsj.npp.1300504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.npp.1300504%26sid%3Dliteratum%253Aachs%26aulast%3DMoyano%26aufirst%3DS.%26aulast%3DR%25C3%25ADo%26aufirst%3DJ.%2BD.%26aulast%3DFrechilla%26aufirst%3DD.%26atitle%3DRole%2520of%2520Hippocampal%2520CaMKII%2520in%2520Serotonin%25205-HT%25281A%2529%2520Receptor-Mediated%2520Learning%2520Deficit%2520in%2520Rats%26jtitle%3DNeuropsychopharmacology%26date%3D2004%26volume%3D29%26spage%3D2216%26epage%3D2224%26doi%3D10.1038%2Fsj.npp.1300504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buritova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berrichon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cathala, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colpaert, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cussac, D.</span></span> <span> </span><span class="NLM_article-title">Region-Specific Changes in 5-HT1A Agonist-Induced Extracellular Signal-Regulated Kinases 1/2 Phosphorylation in Rat Brain: A Quantitative ELISA Study</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">350</span>– <span class="NLM_lpage">361</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2008.09.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2Fj.neuropharm.2008.09.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=18809418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVGjtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2009&pages=350-361&author=J.+Buritovaauthor=G.+Berrichonauthor=C.+Cathalaauthor=F.+Colpaertauthor=D.+Cussac&title=Region-Specific+Changes+in+5-HT1A+Agonist-Induced+Extracellular+Signal-Regulated+Kinases+1%2F2+Phosphorylation+in+Rat+Brain%3A+A+Quantitative+ELISA+Study&doi=10.1016%2Fj.neuropharm.2008.09.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Region-specific changes in 5-HT1A agonist-induced Extracellular signal-Regulated Kinases 1/2 phosphorylation in rat brain: A quantitative ELISA study</span></div><div class="casAuthors">Buritova, Jaroslava; Berrichon, Geraldine; Cathala, Claudie; Colpaert, Francis; Cussac, Didier</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">350-361</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Brain serotonin 5-HT1A receptor, a traditional target for the treatment of mood disorders, modulates intracellular signalling pathways, such as the Extracellular signal-Regulated Kinases 1/2 (ERK1/2) pathway.  The present studies are the first to det. levels of phospho-ERK1/2 (pERK1/2) in brain using a quant. ELISA.  We examd. pERK1/2 levels in rat brain following administration of (+)8-OH-DPAT, buspirone as well as of the more selective, high-efficacy 5-HT1A agonists F 13640 and F 13714.  The i.p. injection of these compds. increased pERK1/2 in prefrontal cortex and hypothalamus, with a max. at 5-15 min and a significant effect lasting until 30-60 min post-injection.  However, these compds. reduced hippocampal pERK1/2 with a max. effect at 30 min, persisting until 60 min post-injection.  In hippocampus, F 13640, F 13714 and buspirone inhibited pERK1/2 in a dose-dependent manner as of 0.04, 0.04 and 2.5 mg/kg, resp.  Given these low doses, this response is likely related to activation of sensitive presynaptic 5-HT1A receptors in the raphe nucleus.  The 4- and 16-fold higher doses of these compds. were necessary to stimulate pERK1/2 in prefrontal cortex and hypothalamus, resp., via direct 5-HT1A receptor activation.  In contrast, (+)8-OH-DPAT was active at similar doses (0.63 mg/kg) in these different regions.  Pretreatment with the 5-HT1A antagonist, WAY 100635, completely blocked the effects of these compds., with the exception of buspirone-induced pERK1/2 increases in hypothalamus.  Thus, 5-HT1A agonist-induced changes in pERK1/2 in rat brain are time- and dose-dependent and region-specific.  Furthermore, F 13640, F 13714, buspirone, but not (+)8-OH-DPAT, exert their effects via preferential activation of presynaptic 5-HT1A receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcn5AM3go8i7Vg90H21EOLACvtfcHk0lhXE5VB4GJ17g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVGjtbY%253D&md5=cac9dfea001c6fbd4f7e0cb014d83fde</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2008.09.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2008.09.004%26sid%3Dliteratum%253Aachs%26aulast%3DBuritova%26aufirst%3DJ.%26aulast%3DBerrichon%26aufirst%3DG.%26aulast%3DCathala%26aufirst%3DC.%26aulast%3DColpaert%26aufirst%3DF.%26aulast%3DCussac%26aufirst%3DD.%26atitle%3DRegion-Specific%2520Changes%2520in%25205-HT1A%2520Agonist-Induced%2520Extracellular%2520Signal-Regulated%2520Kinases%25201%252F2%2520Phosphorylation%2520in%2520Rat%2520Brain%253A%2520A%2520Quantitative%2520ELISA%2520Study%26jtitle%3DNeuropharmacology%26date%3D2009%26volume%3D56%26spage%3D350%26epage%3D361%26doi%3D10.1016%2Fj.neuropharm.2008.09.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porsolt, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blavet, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jalfre, M.</span></span> <span> </span><span class="NLM_article-title">Behavioural Despair in Rats: A New Model Sensitive to Antidepressant Treatments</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1978</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">379</span>– <span class="NLM_lpage">391</span>, <span class="refDoi"> DOI: 10.1016/0014-2999(78)90118-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2F0014-2999%2878%2990118-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=204499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADyaE1cXhvVagsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=1978&pages=379-391&author=R.+D.+Porsoltauthor=G.+Antonauthor=N.+Blavetauthor=M.+Jalfre&title=Behavioural+Despair+in+Rats%3A+A+New+Model+Sensitive+to+Antidepressant+Treatments&doi=10.1016%2F0014-2999%2878%2990118-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Behavioral despair in rats:  a new model sensitive to antidepressant treatments</span></div><div class="casAuthors">Porsolt, Roger D.; Anton, Guy; Blavet, Nadine; Jalfre, Maurice</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1978</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">379-91</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    </div><div class="casAbstract">Rats when forced to swim in a cylinder from which they cannot escape will, after an initial period of vigorous activity, adopt a characteristic immobile posture which can be readily identified.  Immobility was decreased by various clin. effective antidepressant drugs at doses which otherwise decreased spontaneous motor activity in an open field.  Antidepressants could thus be distinguished from psychostimulants which decreased immobility at doses which increased general activity.  Anxiolytic compds. did not affect immobility, whereas major tranquilizers enhanced it.  Thus, immobility reflects a state of lowered mood in the rat which is selectively sensitive to antidepressant treatments.  Pos. findings with atypical antidepressant drugs such as iprindole and mianserin suggest that the method may be capable of discovering new antidepressants hitherto undetectable with classical pharmacol. tests.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0oUdFHAF1sLVg90H21EOLACvtfcHk0lhXE5VB4GJ17g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1cXhvVagsr0%253D&md5=293e1fe8766c76315e86bc375c810a58</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2878%2990118-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252878%252990118-8%26sid%3Dliteratum%253Aachs%26aulast%3DPorsolt%26aufirst%3DR.%2BD.%26aulast%3DAnton%26aufirst%3DG.%26aulast%3DBlavet%26aufirst%3DN.%26aulast%3DJalfre%26aufirst%3DM.%26atitle%3DBehavioural%2520Despair%2520in%2520Rats%253A%2520A%2520New%2520Model%2520Sensitive%2520to%2520Antidepressant%2520Treatments%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1978%26volume%3D47%26spage%3D379%26epage%3D391%26doi%3D10.1016%2F0014-2999%2878%2990118-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yankelevitch-Yahav, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huly, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doron, R.</span></span> <span> </span><span class="NLM_article-title">The Forced Swim Test as a Model of Depressive-like Behavior</span>. <i>J. Visualized Exp.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>, <span class="NLM_elocation-id">e52587</span> <span class="refDoi"> DOI: 10.3791/52587</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.3791%2F52587" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=R.+Yankelevitch-Yahavauthor=M.+Frankoauthor=A.+Hulyauthor=R.+Doron&title=The+Forced+Swim+Test+as+a+Model+of+Depressive-like+Behavior&doi=10.3791%2F52587"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.3791%2F52587&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3791%252F52587%26sid%3Dliteratum%253Aachs%26aulast%3DYankelevitch-Yahav%26aufirst%3DR.%26aulast%3DFranko%26aufirst%3DM.%26aulast%3DHuly%26aufirst%3DA.%26aulast%3DDoron%26aufirst%3DR.%26atitle%3DThe%2520Forced%2520Swim%2520Test%2520as%2520a%2520Model%2520of%2520Depressive-like%2520Behavior%26jtitle%3DJ.%2520Visualized%2520Exp.%26date%3D2015%26doi%3D10.3791%2F52587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Assié, M.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auclair, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carilla-Durand, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Depoortère, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koek, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleven, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colpaert, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman-Tancredi, A.</span></span> <span> </span><span class="NLM_article-title">F15599, a Highly Selective Post-Synaptic 5-HT(1A) Receptor Agonist: In-Vivo Profile in Behavioural Models of Antidepressant and Serotonergic Activity</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1285</span>– <span class="NLM_lpage">1298</span>, <span class="refDoi"> DOI: 10.1017/s1461145709991222</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1017%2Fs1461145709991222" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=20059805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1aktb3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=1285-1298&author=M.-B.+Assi%C3%A9author=L.+Bardinauthor=A.+L.+Auclairauthor=E.+Carilla-Durandauthor=R.+Depoort%C3%A8reauthor=W.+Koekauthor=M.+S.+Klevenauthor=F.+Colpaertauthor=B.+Vacherauthor=A.+Newman-Tancredi&title=F15599%2C+a+Highly+Selective+Post-Synaptic+5-HT%281A%29+Receptor+Agonist%3A+In-Vivo+Profile+in+Behavioural+Models+of+Antidepressant+and+Serotonergic+Activity&doi=10.1017%2Fs1461145709991222"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">F15599, a highly selective post-synaptic 5-HT1A receptor agonist: in-vivo profile in behavioural models of antidepressant and serotonergic activity</span></div><div class="casAuthors">Assie, Marie-Bernadette; Bardin, Laurent; Auclair, Agnes L.; Carilla-Durand, Elisabeth; Depoortere, Ronan; Koek, Wouter; Kleven, Mark S.; Colpaert, Francis; Vacher, Bernard; Newman-Tancredi, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1285-1298</span>CODEN:
                <span class="NLM_cas:coden">IJNUFB</span>;
        ISSN:<span class="NLM_cas:issn">1461-1457</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">F15599 is a novel agonist with high selectivity and efficacy at serotonin 5-HT1A receptors (5-HT1ARs).  In signal transduction, electrophysiol. and neurochem. tests, F15599 preferentially activates post-synaptic 5-HT1ARs in rat frontal cortex.  Such a profile may translate to an improved profile of therapeutic activity for mood disorders.  The in-vivo effects of F15599 were therefore compared with those of a related compd., F13714, in rat models of antidepressant activity and 5-HT1AR activation: forced swimming test (FST), conditioned stress-induced ultrasonic vocalization, 5-HT syndrome, plasma corticosterone and body temp.  Acute administration of F15599 or F13714 reduced immobility in the FST at low doses; these effects were long lasting and the effects of F15599 were maintained after repeated (5 d, p.o.) administration.  Both compds. decreased ultrasonic vocalization duration at low doses.  In contrast, higher doses of F15599 were required to induce lower lip retraction, elements of the 5-HT behavioral syndrome, hypothermia and to increase plasma corticosterone levels.  Notably, there was a greater sepn. of ED50 between FST and other effects for F15599 than for F13714.  Thus, the in-vivo potency of F15599 in models of antidepressant/anti-stress activity is similar to that of F13714, despite the fact that the latter has an in-vitro potency two orders of magnitude greater.  In contrast F15599 has a lower propensity than F13714 to induce other serotonergic signs.  The distinctive pharmacol. profile of F15599 suggests that preferential targeting of post-synaptic 5-HT1ARs constitutes a promising strategy for improved antidepressant therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo195YLEeqRsLVg90H21EOLACvtfcHk0ljopvd1zXmOlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1aktb3L&md5=a979820d0f8a211519ce86d4c56c8fd4</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1017%2Fs1461145709991222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252Fs1461145709991222%26sid%3Dliteratum%253Aachs%26aulast%3DAssi%25C3%25A9%26aufirst%3DM.-B.%26aulast%3DBardin%26aufirst%3DL.%26aulast%3DAuclair%26aufirst%3DA.%2BL.%26aulast%3DCarilla-Durand%26aufirst%3DE.%26aulast%3DDepoort%25C3%25A8re%26aufirst%3DR.%26aulast%3DKoek%26aufirst%3DW.%26aulast%3DKleven%26aufirst%3DM.%2BS.%26aulast%3DColpaert%26aufirst%3DF.%26aulast%3DVacher%26aufirst%3DB.%26aulast%3DNewman-Tancredi%26aufirst%3DA.%26atitle%3DF15599%252C%2520a%2520Highly%2520Selective%2520Post-Synaptic%25205-HT%25281A%2529%2520Receptor%2520Agonist%253A%2520In-Vivo%2520Profile%2520in%2520Behavioural%2520Models%2520of%2520Antidepressant%2520and%2520Serotonergic%2520Activity%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2010%26volume%3D13%26spage%3D1285%26epage%3D1298%26doi%3D10.1017%2Fs1461145709991222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kołaczkowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mierzejewski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bienkowski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wesołowska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman-Tancredi, A.</span></span> <span> </span><span class="NLM_article-title">Antipsychotic, Antidepressant, and Cognitive-Impairment Properties of Antipsychotics: Rat Profile and Implications for Behavioral and Psychological Symptoms of Dementia</span>. <i>N. Schmied. Arch. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>387</i></span>,  <span class="NLM_fpage">545</span>– <span class="NLM_lpage">557</span>, <span class="refDoi"> DOI: 10.1007/s00210-014-0966-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1007%2Fs00210-014-0966-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=2014&pages=545-557&author=M.+Ko%C5%82aczkowskiauthor=P.+Mierzejewskiauthor=P.+Bienkowskiauthor=A.+Weso%C5%82owskaauthor=A.+Newman-Tancredi&title=Antipsychotic%2C+Antidepressant%2C+and+Cognitive-Impairment+Properties+of+Antipsychotics%3A+Rat+Profile+and+Implications+for+Behavioral+and+Psychological+Symptoms+of+Dementia&doi=10.1007%2Fs00210-014-0966-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1007%2Fs00210-014-0966-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00210-014-0966-4%26sid%3Dliteratum%253Aachs%26aulast%3DKo%25C5%2582aczkowski%26aufirst%3DM.%26aulast%3DMierzejewski%26aufirst%3DP.%26aulast%3DBienkowski%26aufirst%3DP.%26aulast%3DWeso%25C5%2582owska%26aufirst%3DA.%26aulast%3DNewman-Tancredi%26aufirst%3DA.%26atitle%3DAntipsychotic%252C%2520Antidepressant%252C%2520and%2520Cognitive-Impairment%2520Properties%2520of%2520Antipsychotics%253A%2520Rat%2520Profile%2520and%2520Implications%2520for%2520Behavioral%2520and%2520Psychological%2520Symptoms%2520of%2520Dementia%26jtitle%3DN.%2520Schmied.%2520Arch.%2520Pharmacol.%26date%3D2014%26volume%3D387%26spage%3D545%26epage%3D557%26doi%3D10.1007%2Fs00210-014-0966-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.-J.</span></span> <span> </span><span class="NLM_article-title">Acute Administration of Ketamine in Rats Increases Hippocampal BDNF and MTOR Levels during Forced Swimming Test</span>. <i>Upsala J. Med. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.3109/03009734.2012.724118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.3109%2F03009734.2012.724118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=22970723" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2012&pages=3-8&author=C.+Yangauthor=Y.-M.+Huauthor=Z.-Q.+Zhouauthor=G.-F.+Zhangauthor=J.-J.+Yang&title=Acute+Administration+of+Ketamine+in+Rats+Increases+Hippocampal+BDNF+and+MTOR+Levels+during+Forced+Swimming+Test&doi=10.3109%2F03009734.2012.724118"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.3109%2F03009734.2012.724118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F03009734.2012.724118%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DY.-M.%26aulast%3DZhou%26aufirst%3DZ.-Q.%26aulast%3DZhang%26aufirst%3DG.-F.%26aulast%3DYang%26aufirst%3DJ.-J.%26atitle%3DAcute%2520Administration%2520of%2520Ketamine%2520in%2520Rats%2520Increases%2520Hippocampal%2520BDNF%2520and%2520MTOR%2520Levels%2520during%2520Forced%2520Swimming%2520Test%26jtitle%3DUpsala%2520J.%2520Med.%2520Sci.%26date%3D2012%26volume%3D118%26spage%3D3%26epage%3D8%26doi%3D10.3109%2F03009734.2012.724118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kołaczkowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bucki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawłowski, M.</span></span> <span> </span><span class="NLM_article-title">Ligand-Optimized Homology Models of D1 and D2 Dopamine Receptors: Application for Virtual Screening</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">638</span>– <span class="NLM_lpage">648</span>, <span class="refDoi"> DOI: 10.1021/ci300413h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci300413h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC3sXit1yhsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2013&pages=638-648&author=M.+Ko%C5%82aczkowskiauthor=A.+Buckiauthor=M.+Federauthor=M.+Paw%C5%82owski&title=Ligand-Optimized+Homology+Models+of+D1+and+D2+Dopamine+Receptors%3A+Application+for+Virtual+Screening&doi=10.1021%2Fci300413h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand-Optimized Homology Models of D1 and D2 Dopamine Receptors: Application for Virtual Screening</span></div><div class="casAuthors">Kolaczkowski, Marcin; Bucki, Adam; Feder, Marcin; Pawlowski, Maciej</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">638-648</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recent breakthroughs in crystallog. studies of G protein-coupled receptors (GPCRs), together with continuous progress in mol. modeling methods, have opened new perspectives for structure-based drug discovery.  A crucial enhancement in this area was development of induced fit docking procedures that allow optimization of binding pocket conformation guided by the features of its active ligands.  In the course of our research program aimed at discovery of novel antipsychotic agents, our attention focused on dopaminergic D2 and D1 receptors (D2R and D1R).  Thus, we decided to investigate whether the availability of a novel structure of the closely related D3 receptor and application of induced fit docking procedures for binding pocket refinement would permit the building of models of D2R and D1R that facilitate a successful virtual screening (VS).  Here, we provide an in-depth description of the modeling procedure and the discussion of the results of a VS benchmark we performed to compare efficiency of the ligand-optimized receptors in comparison with the regular homol. models.  We obsd. that application of the ligand-optimized models significantly improved the VS performance both in terms of BEDROC (0.325 vs 0.182 for D1R and 0.383 vs 0.301 for D2R) as well as EF1% (20 vs 11 for D1R and 18 vs 10 for D2R).  In contrast, no improvement was obsd. for the performance of a D2R model built on the D3R template, when compared with that derived from the structure of the previously published and more evolutionary distant β2 adrenergic receptor.  The comparison of results for receptors built according to various protocols and templates revealed that the most significant factor for the receptor performance was a proper selection of tool ligand used in induced fit docking procedure.  Taken together, our results suggest that the described homol. modeling procedure could be a viable tool for structure-based GPCR ligand design, even for the targets for which only a relatively distant structural template is available.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHGgw5lOnO9bVg90H21EOLACvtfcHk0ljopvd1zXmOlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXit1yhsb0%253D&md5=58f111e8132b7229898f1a44feb6199b</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1021%2Fci300413h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci300413h%26sid%3Dliteratum%253Aachs%26aulast%3DKo%25C5%2582aczkowski%26aufirst%3DM.%26aulast%3DBucki%26aufirst%3DA.%26aulast%3DFeder%26aufirst%3DM.%26aulast%3DPaw%25C5%2582owski%26aufirst%3DM.%26atitle%3DLigand-Optimized%2520Homology%2520Models%2520of%2520D1%2520and%2520D2%2520Dopamine%2520Receptors%253A%2520Application%2520for%2520Virtual%2520Screening%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2013%26volume%3D53%26spage%3D638%26epage%3D648%26doi%3D10.1021%2Fci300413h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wacker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vardy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melcher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H. E.</span></span> <span> </span><span class="NLM_article-title">Structural Basis for Molecular Recognition at Serotonin Receptors</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>340</i></span>,  <span class="NLM_fpage">610</span>– <span class="NLM_lpage">614</span>, <span class="refDoi"> DOI: 10.1126/science.1232807</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1126%2Fscience.1232807" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=23519210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmslWksbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=340&publication_year=2013&pages=610-614&author=C.+Wangauthor=Y.+Jiangauthor=J.+Maauthor=H.+Wuauthor=D.+Wackerauthor=V.+Katritchauthor=G.+W.+Hanauthor=W.+Liuauthor=X.-P.+Huangauthor=E.+Vardyauthor=J.+D.+McCorvyauthor=X.+Gaoauthor=X.+E.+Zhouauthor=K.+Melcherauthor=C.+Zhangauthor=F.+Baiauthor=H.+Yangauthor=L.+Yangauthor=H.+Jiangauthor=B.+L.+Rothauthor=V.+Cherezovauthor=R.+C.+Stevensauthor=H.+E.+Xu&title=Structural+Basis+for+Molecular+Recognition+at+Serotonin+Receptors&doi=10.1126%2Fscience.1232807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for Molecular Recognition at Serotonin Receptors</span></div><div class="casAuthors">Wang, Chong; Jiang, Yi; Ma, Jinming; Wu, Huixian; Wacker, Daniel; Katritch, Vsevolod; Han, Gye Won; Liu, Wei; Huang, Xi-Ping; Vardy, Eyal; McCorvy, John D.; Gao, Xiang; Zhou, X. Edward; Melcher, Karsten; Zhang, Chenghai; Bai, Fang; Yang, Huaiyu; Yang, Linlin; Jiang, Hualiang; Roth, Bryan L.; Cherezov, Vadim; Stevens, Raymond C.; Xu, H. Eric</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">340</span>
        (<span class="NLM_cas:issue">6132</span>),
    <span class="NLM_cas:pages">610-614</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Serotonin or 5-hydroxytryptamine (5-HT) regulates a wide spectrum of human physiol. through the 5-HT receptor family.  The authors report the crystal structures of the human 5-HT1B G protein-coupled receptor bound to the agonist antimigraine medications ergotamine and dihydroergotamine.  The structures reveal similar binding modes for these ligands, which occupy the orthosteric pocket and an extended binding pocket close to the extracellular loops.  The orthosteric pocket is formed by residues conserved in the 5-HT receptor family, clarifying the family-wide agonist activity of 5-HT.  Compared with the structure of the 5-HT2B receptor, the 5-HT1B receptor displays a 3 angstrom outward shift at the extracellular end of helix V, resulting in a more open extended pocket that explains subtype selectivity.  Together with docking and mutagenesis studies, these structures provide a comprehensive structural basis for understanding receptor-ligand interactions and designing subtype-selective serotonergic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLc0rOIqg_2bVg90H21EOLACvtfcHk0lj24hOr1KT-LA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmslWksbw%253D&md5=ce0773088a86f6a2c83b6cb77a63e708</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1126%2Fscience.1232807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1232807%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DC.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWacker%26aufirst%3DD.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DX.-P.%26aulast%3DVardy%26aufirst%3DE.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DX.%2BE.%26aulast%3DMelcher%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DBai%26aufirst%3DF.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DXu%26aufirst%3DH.%2BE.%26atitle%3DStructural%2520Basis%2520for%2520Molecular%2520Recognition%2520at%2520Serotonin%2520Receptors%26jtitle%3DScience%26date%3D2013%26volume%3D340%26spage%3D610%26epage%3D614%26doi%3D10.1126%2Fscience.1232807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kurowski, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bujnicki, J. M.</span></span> <span> </span><span class="NLM_article-title">GeneSilico Protein Structure Prediction Meta-Server</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">3305</span>– <span class="NLM_lpage">3307</span>, <span class="refDoi"> DOI: 10.1093/nar/gkg557</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1093%2Fnar%2Fgkg557" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2003&pages=3305-3307&author=M.+A.+Kurowskiauthor=J.+M.+Bujnicki&title=GeneSilico+Protein+Structure+Prediction+Meta-Server&doi=10.1093%2Fnar%2Fgkg557"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkg557&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkg557%26sid%3Dliteratum%253Aachs%26aulast%3DKurowski%26aufirst%3DM.%2BA.%26aulast%3DBujnicki%26aufirst%3DJ.%2BM.%26atitle%3DGeneSilico%2520Protein%2520Structure%2520Prediction%2520Meta-Server%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2003%26volume%3D31%26spage%3D3305%26epage%3D3307%26doi%3D10.1093%2Fnar%2Fgkg557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwede, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopp, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guex, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peitsch, M. C.</span></span> <span> </span><span class="NLM_article-title">SWISS-MODEL: An Automated Protein Homology-Modeling Server</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">3381</span>– <span class="NLM_lpage">3385</span>, <span class="refDoi"> DOI: 10.1093/nar/gkg520</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1093%2Fnar%2Fgkg520" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=12824332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BD3sXltVWjsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2003&pages=3381-3385&author=T.+Schwedeauthor=J.+Koppauthor=N.+Guexauthor=M.+C.+Peitsch&title=SWISS-MODEL%3A+An+Automated+Protein+Homology-Modeling+Server&doi=10.1093%2Fnar%2Fgkg520"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">SWISS-MODEL: an automated protein homology-modeling server</span></div><div class="casAuthors">Schwede, Torsten; Kopp, Juergen; Guex, Nicolas; Peitsch, Manuel C.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3381-3385</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">SWISS-MODEL is a server for automated comparative modeling of three-dimensional (3D) protein structures.  It pioneered the field of automated modeling starting in 1993 and is the most widely-used free web-based automated modeling facility today.  In 2002 the server computed 120 000 user requests for 3D protein models.  SWISS-MODEL provides several levels of user interaction through its World Wide Web interface: in the first approach mode' only an amino acid sequence of a protein is submitted to build a 3D model.  Template selection, alignment and model building are done completely automated by the server.  In the alignment mode', the modeling process is based on a user-defined target-template alignment.  Complex modeling tasks can be handled with the project mode' using DeepView (Swiss-PdbViewer), an integrated sequence-to-structure workbench.  All models are sent back via email with a detailed modeling report.  WhatCheck analyses and ANOLEA evaluations are provided optionally.  The reliability of SWISS-MODEL is continuously evaluated in the EVA-CM project.  The SWISS-MODEL server is under const. development to improve the successful implementation of expert knowledge into an easy-to-use server.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBh6H5AEIXubVg90H21EOLACvtfcHk0lj24hOr1KT-LA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXltVWjsLg%253D&md5=d49a9219efef81217013dc350e1a2fd5</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkg520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkg520%26sid%3Dliteratum%253Aachs%26aulast%3DSchwede%26aufirst%3DT.%26aulast%3DKopp%26aufirst%3DJ.%26aulast%3DGuex%26aufirst%3DN.%26aulast%3DPeitsch%26aufirst%3DM.%2BC.%26atitle%3DSWISS-MODEL%253A%2520An%2520Automated%2520Protein%2520Homology-Modeling%2520Server%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2003%26volume%3D31%26spage%3D3381%26epage%3D3385%26doi%3D10.1093%2Fnar%2Fgkg520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friesner, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farid, R.</span></span> <span> </span><span class="NLM_article-title">Novel Procedure for Modeling Ligand/Receptor Induced Fit Effects</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">534</span>– <span class="NLM_lpage">553</span>, <span class="refDoi"> DOI: 10.1021/jm050540c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050540c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlCgsr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=534-553&author=W.+Shermanauthor=T.+Dayauthor=M.+P.+Jacobsonauthor=R.+A.+Friesnerauthor=R.+Farid&title=Novel+Procedure+for+Modeling+Ligand%2FReceptor+Induced+Fit+Effects&doi=10.1021%2Fjm050540c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Procedure for Modeling Ligand/Receptor Induced Fit Effects</span></div><div class="casAuthors">Sherman, Woody; Day, Tyler; Jacobson, Matthew P.; Friesner, Richard A.; Farid, Ramy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">534-553</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We present a novel protein-ligand docking method that accurately accounts for both ligand and receptor flexibility by iteratively combining rigid receptor docking (Glide) with protein structure prediction (Prime) techniques.  While traditional rigid-receptor docking methods are useful when the receptor structure does not change substantially upon ligand binding, success is limited when the protein must be "induced" into the correct binding conformation for a given ligand.  We provide an in-depth description of our novel methodol. and present results for 21 pharmaceutically relevant examples.  Traditional rigid-receptor docking for these 21 cases yields an av. RMSD of 5.5 Å.  The av. ligand RMSD for docking to a flexible receptor for the 21 pairs is 1.4 Å; the RMSD is ≤1.8 Å for 18 of the cases.  For the three cases with RMSDs greater than 1.8 Å, the core of the ligand is properly docked and all key protein/ligand interactions are captured.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm3E6ctnPGSrVg90H21EOLACvtfcHk0lj24hOr1KT-LA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlCgsr7I&md5=388811ead5cee1fd460951263de486cb</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1021%2Fjm050540c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050540c%26sid%3Dliteratum%253Aachs%26aulast%3DSherman%26aufirst%3DW.%26aulast%3DDay%26aufirst%3DT.%26aulast%3DJacobson%26aufirst%3DM.%2BP.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26aulast%3DFarid%26aufirst%3DR.%26atitle%3DNovel%2520Procedure%2520for%2520Modeling%2520Ligand%252FReceptor%2520Induced%2520Fit%2520Effects%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D534%26epage%3D553%26doi%3D10.1021%2Fjm050540c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hidalgo, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raub, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borchardt, R. T.</span></span> <span> </span><span class="NLM_article-title">Characterization of the Human Colon Carcinoma Cell Line (Caco-2) as a Model System for Intestinal Epithelial Permeability</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">736</span>– <span class="NLM_lpage">749</span>, <span class="refDoi"> DOI: 10.1016/s0016-5085(89)80072-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2Fs0016-5085%2889%2980072-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=2914637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A280%3ADyaL1M7itFeqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1989&pages=736-749&author=I.+J.+Hidalgoauthor=T.+J.+Raubauthor=R.+T.+Borchardt&title=Characterization+of+the+Human+Colon+Carcinoma+Cell+Line+%28Caco-2%29+as+a+Model+System+for+Intestinal+Epithelial+Permeability&doi=10.1016%2Fs0016-5085%2889%2980072-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability</span></div><div class="casAuthors">Hidalgo I J; Raub T J; Borchardt R T</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">736-49</span>
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    </div><div class="casAbstract">Caco-2 cells develop morphologic characteristics of normal enterocytes when grown on plastic dishes or nitrocellulose filters.  The purpose of this study was to determine whether Caco-2 cells undergo similar differentiation when grown on Transwell polycarbonate membranes, and to study the suitability of Caco-2 monolayers as an intestinal epithelial transport model system.  Transepithelial electrical resistance values after confluence were 173.5 omega.cm2 and remained unchanged through day 17.  Permeabilities to the water-soluble fluid-phase markers that do not permeate the membrane, Lucifer yellow CH, [14C]inulin, [14C]polyethylene glycol, and [3H] dextran were less than 0.25% of the administered amount per hour after day 10.  Qualitative evaluation of uptake and permeability to horseradish peroxidase confirmed the similarity in uptake and barrier properties between this cell system and the small intestinal epithelial layer.  We conclude that Caco-2 cells grown on collagen-coated polycarbonate membranes should represent a valuable transport model system for the small intestinal epithelium.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSOn97989rzEIqdXsLcGTEUfW6udTcc2ea1CZXa8QS_SLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL1M7itFeqsg%253D%253D&md5=59ffccc1dd4dccb01400c05df95ac1ff</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1016%2Fs0016-5085%2889%2980072-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0016-5085%252889%252980072-1%26sid%3Dliteratum%253Aachs%26aulast%3DHidalgo%26aufirst%3DI.%2BJ.%26aulast%3DRaub%26aufirst%3DT.%2BJ.%26aulast%3DBorchardt%26aufirst%3DR.%2BT.%26atitle%3DCharacterization%2520of%2520the%2520Human%2520Colon%2520Carcinoma%2520Cell%2520Line%2520%2528Caco-2%2529%2520as%2520a%2520Model%2520System%2520for%2520Intestinal%2520Epithelial%2520Permeability%26jtitle%3DGastroenterology%26date%3D1989%26volume%3D96%26spage%3D736%26epage%3D749%26doi%3D10.1016%2Fs0016-5085%2889%2980072-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mathes, C.</span></span> <span> </span><span class="NLM_article-title">QPatch: The Past, Present and Future of Automated Patch Clamp</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">319</span>– <span class="NLM_lpage">327</span>, <span class="refDoi"> DOI: 10.1517/14728222.10.2.319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1517%2F14728222.10.2.319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=16548779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BD28XivVOmt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2006&pages=319-327&author=C.+Mathes&title=QPatch%3A+The+Past%2C+Present+and+Future+of+Automated+Patch+Clamp&doi=10.1517%2F14728222.10.2.319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">QPatch: the past, present and future of automated patch clamp</span></div><div class="casAuthors">Mathes, Chris</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">319-327</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  The QPatch 16 significantly increases throughput for gigaseal patch clamp expts., making direct measurements in ion channel drug discovery and safety testing feasible.  Released to the market in the Autumn of 2004 by Sophion Bioscience, the QPatch originated from work done at NeuroSearch (Denmark) in the early days of automated patch clamp.  Today, the QPatch provides many unique features.  For example, only the QPatch includes an automated cell prepn. station making several hours of unattended operation possible.  The 16-channel electrode array, called the QPlate, includes glass-coated microfluidic channels for less compd. absorption and, hence, more accurate IC50 values.  The microfluidic pathways also allow for very small amts. of compd. used for each expt. (∼ 5 μl per addn.).  Only the QPatch has four independent pipetting heads for more efficient liq. handling (esp. for ligand-gated ion channel expts.).  Patch clamp recordings with the QPatch match the high quality of conventional patch clamp and in some cases the results are even better.  For example, only the QPatch includes 100% series resistance compensation for the elimination of false positives due to voltage errors.  Finally, the modular QPatch 16 was designed with more channels in mind.  The upgrade pathway to 48-channels (the QPatch HT) will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqywPZMP8PNwrVg90H21EOLACvtfcHk0lgSzd2Z6vUH0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XivVOmt7k%253D&md5=7dcd02a69652955e261f6928fbb76b81</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1517%2F14728222.10.2.319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.10.2.319%26sid%3Dliteratum%253Aachs%26aulast%3DMathes%26aufirst%3DC.%26atitle%3DQPatch%253A%2520The%2520Past%252C%2520Present%2520and%2520Future%2520of%2520Automated%2520Patch%2520Clamp%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2006%26volume%3D10%26spage%3D319%26epage%3D327%26doi%3D10.1517%2F14728222.10.2.319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pauwels, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colpaert, F. C.</span></span> <span> </span><span class="NLM_article-title">Ca2+ Responses in Chinese Hamster Ovary-K1 Cells Demonstrate an Atypical Pattern of Ligand-Induced 5-HT1A Receptor Activation</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>307</i></span>,  <span class="NLM_fpage">608</span>– <span class="NLM_lpage">614</span>, <span class="refDoi"> DOI: 10.1124/jpet.103.055871</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1124%2Fjpet.103.055871" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=12970382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BD3sXos1SiurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=307&publication_year=2003&pages=608-614&author=P.+J.+Pauwelsauthor=F.+C.+Colpaert&title=Ca2%2B+Responses+in+Chinese+Hamster+Ovary-K1+Cells+Demonstrate+an+Atypical+Pattern+of+Ligand-Induced+5-HT1A+Receptor+Activation&doi=10.1124%2Fjpet.103.055871"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Ca2+ responses in Chinese hamster ovary-K1 cells demonstrate an atypical pattern of ligand-induced 5-HT1A receptor activation</span></div><div class="casAuthors">Pauwels, Petrus J.; Colpaert, Francis C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">307</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">608-614</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Little exptl. evidence has been reported for diverse signaling via 5-hydroxytryptamine (5-HT)1A receptors despite the fact that agonists seem to be more efficacious at dorsal raphe somatodendritic 5-HT1A autoreceptors than at postsynaptic 5-HT1A receptors.  The present study investigated Ca2+ responses in Chinese hamster ovary (CHO)-K1 cells expressing a human 5-HT1A receptor by 5-HT, prototypical 5-HT1A agonists, N-(3-chloro-4-fluorobenzoyl)-4-fluoro-4-[(5-methyl-6-; methylaminopyridin-2-yl)-methylaminomethyl]-piperidine (F 14679), and esp. N-(3-chloro-4-fluorobenzoyl)-4-fluoro-4-[(5-methylpyridin-2-yl)-; methylaminomethyl]piperidine (F 13640) as representative ligands of a new chem. class (methylamino-pyridine) that combines both high efficacy and selectivity for 5-HT1A receptors.  5-HT (pEC50 = 6.70) induced a pertussis toxin-sensitive, transient high-magnitude Ca2+ response.  High-magnitude Ca2+ responses (Emax, percentage vs. 5-HT) were also found with F 13640 (107), 5-carboxamidotryptamine (100), and F 14679 (87).  In contrast, the prototypical 5-HT1A receptor agonists buspirone, ipsapirone, and 8-hydroxy-2-(di-n-propylamino)tetralin, and also flesinoxan and eptapirone, were virtually inactive (≤5).  This atypical pattern of 5-HT1A receptor activation contrasts with the broad spectrum of the ligands' partial agonist properties as obsd. by measuring guanosine 5'-O -(3-[35 S]thio)triphosphate ([35S]GTPγS) binding responses with membranes of either CHO-K1 or C6-glial cells stably expressing a human 5-HT1A receptor.  Remarkably, differences between ligands that seem small in the [35S]GTPγS binding assay translate into huge differences in the magnitude of Ca2+ responses.  Therefore, some of these 5-HT1A ligands (i.e., F 13640) may in a selective way induce responses that may be not at all be achieved with other ligands (i.e., buspirone).  In conclusion, the pharmacol. of 5-HT1A receptor ligands seems to be codetd. by the effector pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHLWnIsyGNnLVg90H21EOLACvtfcHk0lgSzd2Z6vUH0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXos1SiurY%253D&md5=3d54df8c831b32c84acaca3c5d82c16a</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1124%2Fjpet.103.055871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.103.055871%26sid%3Dliteratum%253Aachs%26aulast%3DPauwels%26aufirst%3DP.%2BJ.%26aulast%3DColpaert%26aufirst%3DF.%2BC.%26atitle%3DCa2%252B%2520Responses%2520in%2520Chinese%2520Hamster%2520Ovary-K1%2520Cells%2520Demonstrate%2520an%2520Atypical%2520Pattern%2520of%2520Ligand-Induced%25205-HT1A%2520Receptor%2520Activation%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2003%26volume%3D307%26spage%3D608%26epage%3D614%26doi%3D10.1124%2Fjpet.103.055871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Detke, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rickels, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucki, I.</span></span> <span> </span><span class="NLM_article-title">Active Behaviors in the Rat Forced Swimming Test Differentially Produced by Serotonergic and Noradrenergic Antidepressants</span>. <i>Psychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">66</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1007/bf02245592</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1007%2Fbf02245592" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=8539342" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADyaK2MXos1WjsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=1995&pages=66-72&author=M.+J.+Detkeauthor=M.+Rickelsauthor=I.+Lucki&title=Active+Behaviors+in+the+Rat+Forced+Swimming+Test+Differentially+Produced+by+Serotonergic+and+Noradrenergic+Antidepressants&doi=10.1007%2Fbf02245592"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants</span></div><div class="casAuthors">Detke, Michael J.; Rickels, Michael; Lucki, Irwin</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Berlin)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">66-72</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">This study demonstrated that distinct patterns of active behaviors are produced by antidepressants that selectively inhibit norepinephrine (NE) or serotonin (5-HT) uptake in the rat forced swimming test (FST).  A behavior sampling technique was developed to score the active behaviors swimming, climbing and diving, as well as immobility.  The rat's behavior was recorded at the end of each 5-s period during the test session.  The sampling technique was both reliable, as demonstrated by test-retest reliability and inter-rater reliability, and valid, as shown by comparison to the timing of behavior durations.  Five different antidepressant drugs which block monoamine uptake and two 5-HT1A receptor agonists were shown to decreased immobility in the FST; however, they produced distinct patterns of active behaviors.  The selective NE uptake inhibitors desipramine and maprotiline selectively increased climbing, whereas the selective serotonin reuptake inhibitors (SSRIs) fluoxetine, sertraline and paroxetine selectively increased swimming.  The 5-HT1A receptor agonists 8-OH-DPAT and gepirone also selectively increased swimming.  These results show that: (1) SSRIs are not false negatives in the FST; (2) at least two behaviorally distinct processes occur in the FST; and (3) enhancement of NE neurotransmission may mediate climbing in the FST, whereas enhancement of 5-HT neurotransmission may mediate swimming.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQE5FGrHE00bVg90H21EOLACvtfcHk0ljlu8DNQKRcDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXos1WjsbY%253D&md5=1196566f76da5500d810f7806bb60cc2</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1007%2Fbf02245592&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fbf02245592%26sid%3Dliteratum%253Aachs%26aulast%3DDetke%26aufirst%3DM.%2BJ.%26aulast%3DRickels%26aufirst%3DM.%26aulast%3DLucki%26aufirst%3DI.%26atitle%3DActive%2520Behaviors%2520in%2520the%2520Rat%2520Forced%2520Swimming%2520Test%2520Differentially%2520Produced%2520by%2520Serotonergic%2520and%2520Noradrenergic%2520Antidepressants%26jtitle%3DPsychopharmacology%26date%3D1995%26volume%3D121%26spage%3D66%26epage%3D72%26doi%3D10.1007%2Fbf02245592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kleven, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assié, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koek, W.</span></span> <span> </span><span class="NLM_article-title">Pharmacological Characterization of in Vivo Properties of Putative Mixed 5-HT1A Agonist/5-HT(2A/2C) Antagonist Anxiolytics. II. Drug Discrimination and Behavioral Observation Studies in Rats</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>282</i></span>,  <span class="NLM_fpage">747</span>– <span class="NLM_lpage">759</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=9262338" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADyaK2sXltlSntLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=1997&pages=747-759&author=M.+S.+Klevenauthor=M.+B.+Assi%C3%A9author=W.+Koek&title=Pharmacological+Characterization+of+in+Vivo+Properties+of+Putative+Mixed+5-HT1A+Agonist%2F5-HT%282A%2F2C%29+Antagonist+Anxiolytics.+II.+Drug+Discrimination+and+Behavioral+Observation+Studies+in+Rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of in vivo properties of putative mixed 5-HT1A agonist/5-HT2A/2C antagonist anxiolytics. II. Drug discrimination and behavioral observation studies in rats</span></div><div class="casAuthors">Kleven, Mark S.; Assie, Marie-Bernadette; Koek, Wouter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">282</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">747-759</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">To characterize their in vivo 5-hydroxytryptamine (5-HT)2A antagonist properties, the ability of the putative mixed 5-HT1A agonists/5-HT2A/2C antagonists WY-50,324, FG5974, LEK-8804, and CGS 18102A to antagonize both head twitches and discriminative stimulus (DS) effects produced by (±)-2,5-dimethoxy-4-iodoamphetamine (DOI) in rats were compared with those of the 5-HT2 antagonists ketanserin and ritanserin, and the 5-HT1A agonists 8-OH-DPAT and buspirone.  All of these compds. produced dose-related decreases in DOI-induced head twitches; however pretreatment with the 5-HT1A antagonist WAY-100635 failed to alter the ability of ritanserin, ketanserin or CGS 18102A to attenuate DOI-induced head twitches.  In contrast, WAY-100635 completely blocked the effects of 8-OH-DPAT, buspirone and WY-50,324, and partially blocked the effects of LEK-8804, demonstrating that 5-HT1A agonist properties are involved in the effects of all of the mixed compds. except CGS 18102A.  In rats trained to discriminate DOI (0.63 mg/kg) from saline in a two-lever, FR10 drug discrimination paradigm, ketanserin, ritanserin and CGS 18102A blocked the DS effects of the training dose by more than 50%.  In contrast, WY-50,324, FG5974, LEK-8804, buspirone and 8-OH-DPAT, up to doses that completely suppressed responding, failed to produce more than a 33% blockade of the DS effects of DOI.  In vivo 5-HT1A agonist effects were demonstrated by the finding that relatively selective- and mixed-5-HT1A agonists produced one or more elements of the "serotonin syndrome," i.e., flatbody posture, forepaw treading, or lower-lip retraction, and produced high levels of drug-lever selection in rats trained to discriminate 8-OH-DPAT (0.16 mg/kg) from saline.  Because DOI-induced head twitches and DS effects are thought to be mediated by 5-HT2A receptors, the results demonstrate that the putative mixed compd., CGS 18102A has prominent 5-HT2A antagonist properties in vivo, whereas 5-HT2A antagonist effects of WY-50,324, FG5974 and LEK-8804 could not be clearly identified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiTw3FE5zW7bVg90H21EOLACvtfcHk0ljlu8DNQKRcDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXltlSntLk%253D&md5=786c71fe3e5f35399d4fb10341fe3b34</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKleven%26aufirst%3DM.%2BS.%26aulast%3DAssi%25C3%25A9%26aufirst%3DM.%2BB.%26aulast%3DKoek%26aufirst%3DW.%26atitle%3DPharmacological%2520Characterization%2520of%2520in%2520Vivo%2520Properties%2520of%2520Putative%2520Mixed%25205-HT1A%2520Agonist%252F5-HT%25282A%252F2C%2529%2520Antagonist%2520Anxiolytics.%2520II.%2520Drug%2520Discrimination%2520and%2520Behavioral%2520Observation%2520Studies%2520in%2520Rats%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1997%26volume%3D282%26spage%3D747%26epage%3D759" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span> </span><span class="NLM_article-title">Draft Guidance for Industry on Bioanalytical
Method Validation</span>. <a href="https://www.federalregister.gov/documents/2013/09/13/2013-22309/draft-guidance-for-industry-on-bioanalytical-method-validation-availability" class="extLink">https://www.federalregister.gov/documents/2013/09/13/2013-22309/draft-guidance-for-industry-on-bioanalytical-method-validation-availability</a> (accessed Mar 1, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Draft+Guidance+for+Industry+on+Bioanalytical%0AMethod+Validation.+https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2013%2F09%2F13%2F2013-22309%2Fdraft-guidance-for-industry-on-bioanalytical-method-validation-availability+%28accessed+Mar+1%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DDraft%2520Guidance%2520for%2520Industry%2520on%2520Bioanalytical%250AMethod%2520Validation%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 10 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Pasquale Linciano, Claudia Sorbi, Antonella Comitato, Anna Lesniak, Magdalena Bujalska-Zadrożny, Agata Pawłowska, Anna Bielenica, Jolanta Orzelska-Górka, Ewa Kędzierska, Grażyna Biała, Simone Ronsisvalle, Silvia Limoncella, Livio Casarini, Elena Cichero, Paola Fossa, Grzegorz Satała, Andrzej J. Bojarski, Livio Brasili, Rita Bardoni, <span class="NLM_string-name hlFld-ContribAuthor">Silvia Franchini</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of a Potent and Selective 5-HT1A Receptor Agonist with In Vitro and In Vivo Antinociceptive Activity. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Neuroscience</span><span> <strong>2020,</strong> <em>11 </em>
                                    (24)
                                     , 4111-4127. <a href="https://doi.org/10.1021/acschemneuro.0c00289" title="DOI URL">https://doi.org/10.1021/acschemneuro.0c00289</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschemneuro.0c00289&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschemneuro.0c00289%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Neuroscience%26atitle%3DIdentification%252Bof%252Ba%252BPotent%252Band%252BSelective%252B5-HT1A%252BReceptor%252BAgonist%252Bwith%252BIn%252BVitro%252Band%252BIn%252BVivo%252BAntinociceptive%252BActivity%26aulast%3DLinciano%26aufirst%3DPasquale%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D13052020%26date%3D11112020%26date%3D02122020%26volume%3D11%26issue%3D24%26spage%3D4111%26epage%3D4127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Joanna Sniecikowska, Monika Gluch-Lutwin, Adam Bucki, Anna Więckowska, Agata Siwek, Magdalena Jastrzebska-Wiesek, Anna Partyka, Daria Wilczyńska, Karolina Pytka, Gniewomir Latacz, Katarzyna Przejczowska-Pomierny, Elżbieta Wyska, Anna Wesołowska, Maciej Pawłowski, Adrian Newman-Tancredi, <span class="NLM_string-name hlFld-ContribAuthor">Marcin Kolaczkowski</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel pERK1/2- or β-Arrestin-Preferring 5-HT1A Receptor-Biased Agonists: Diversified Therapeutic-like versus Side Effect Profile. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (19)
                                     , 10946-10971. <a href="https://doi.org/10.1021/acs.jmedchem.0c00814" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00814</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00814&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00814%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNovel%252BpERK1%25252F2-%252Bor%252B%2525CE%2525B2-Arrestin-Preferring%252B5-HT1A%252BReceptor-Biased%252BAgonists%25253A%252BDiversified%252BTherapeutic-like%252Bversus%252BSide%252BEffect%252BProfile%26aulast%3DSniecikowska%26aufirst%3DJoanna%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D13052020%26date%3D23092020%26date%3D04092020%26volume%3D63%26issue%3D19%26spage%3D10946%26epage%3D10971" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Pravin Kumar, <span class="NLM_string-name hlFld-ContribAuthor">Manmohan Kapur</span>. </span><span class="cited-content_cbyCitation_article-title">Unusual Reactivity of 4-Vinyl Isoxazoles in the Copper-Mediated Synthesis of Pyridines, Employing DMSO as a One-Carbon Surrogate. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2020,</strong> <em>22 </em>
                                    (15)
                                     , 5855-5860. <a href="https://doi.org/10.1021/acs.orglett.0c01935" title="DOI URL">https://doi.org/10.1021/acs.orglett.0c01935</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.0c01935&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.0c01935%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DUnusual%252BReactivity%252Bof%252B4-Vinyl%252BIsoxazoles%252Bin%252Bthe%252BCopper-Mediated%252BSynthesis%252Bof%252BPyridines%25252C%252BEmploying%252BDMSO%252Bas%252Ba%252BOne-Carbon%252BSurrogate%26aulast%3DKumar%26aufirst%3DPravin%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D09062020%26date%3D09072020%26volume%3D22%26issue%3D15%26spage%3D5855%26epage%3D5860" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kinga  Sałaciak</span>, <span class="hlFld-ContribAuthor ">Karolina  Pytka</span>. </span><span class="cited-content_cbyCitation_article-title">Biased agonism in drug discovery: Is there a future for biased 5-HT1A receptor agonists in the treatment of neuropsychiatric diseases?. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology & Therapeutics</span><span> <strong>2021,</strong> <em>227 </em>, 107872. <a href="https://doi.org/10.1016/j.pharmthera.2021.107872" title="DOI URL">https://doi.org/10.1016/j.pharmthera.2021.107872</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pharmthera.2021.107872&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pharmthera.2021.107872%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520%2526%2520Therapeutics%26atitle%3DBiased%252Bagonism%252Bin%252Bdrug%252Bdiscovery%25253A%252BIs%252Bthere%252Ba%252Bfuture%252Bfor%252Bbiased%252B5-HT1A%252Breceptor%252Bagonists%252Bin%252Bthe%252Btreatment%252Bof%252Bneuropsychiatric%252Bdiseases%25253F%26aulast%3DSa%25C5%2582aciak%26aufirst%3DKinga%26date%3D2021%26volume%3D227%26spage%3D107872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mariusz  Papp</span>, <span class="hlFld-ContribAuthor ">Wiesław Jerzy  Cubala</span>, <span class="hlFld-ContribAuthor ">Lukasz  Swiecicki</span>, <span class="hlFld-ContribAuthor ">Adrian  Newman‐Tancredi</span>, <span class="hlFld-ContribAuthor ">Paul  Willner</span>. </span><span class="cited-content_cbyCitation_article-title">Perspectives for therapy of treatment‐resistant depression. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Pharmacology</span><span> <strong>2021,</strong> <em>190 </em><a href="https://doi.org/10.1111/bph.15596" title="DOI URL">https://doi.org/10.1111/bph.15596</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/bph.15596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fbph.15596%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Pharmacology%26atitle%3DPerspectives%252Bfor%252Btherapy%252Bof%252Btreatment%2525E2%252580%252590resistant%252Bdepression%26aulast%3DPapp%26aufirst%3DMariusz%26date%3D2021%26date%3D2021%26volume%3D190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adrian  Newman-Tancredi</span>, <span class="hlFld-ContribAuthor ">Ronan Y.  Depoortère</span>, <span class="hlFld-ContribAuthor ">Mark S.  Kleven</span>, <span class="hlFld-ContribAuthor ">Marcin  Kołaczkowski</span>, <span class="hlFld-ContribAuthor ">Luc  Zimmer</span>. </span><span class="cited-content_cbyCitation_article-title">Translating biased agonists from molecules to medications: Serotonin 5-HT1A receptor functional selectivity for CNS disorders. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology & Therapeutics</span><span> <strong>2021,</strong> <em>107 </em>, 107937. <a href="https://doi.org/10.1016/j.pharmthera.2021.107937" title="DOI URL">https://doi.org/10.1016/j.pharmthera.2021.107937</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pharmthera.2021.107937&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pharmthera.2021.107937%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520%2526%2520Therapeutics%26atitle%3DTranslating%252Bbiased%252Bagonists%252Bfrom%252Bmolecules%252Bto%252Bmedications%25253A%252BSerotonin%252B5-HT1A%252Breceptor%252Bfunctional%252Bselectivity%252Bfor%252BCNS%252Bdisorders%26aulast%3DNewman-Tancredi%26aufirst%3DAdrian%26date%3D2021%26volume%3D107%26spage%3D107937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mohamed Diwan M.  AbdulHameed</span>, <span class="hlFld-ContribAuthor ">Ruifeng  Liu</span>, <span class="hlFld-ContribAuthor ">Patric  Schyman</span>, <span class="hlFld-ContribAuthor ">Daniel  Sachs</span>, <span class="hlFld-ContribAuthor ">Zhen  Xu</span>, <span class="hlFld-ContribAuthor ">Valmik  Desai</span>, <span class="hlFld-ContribAuthor ">Anders  Wallqvist</span>. </span><span class="cited-content_cbyCitation_article-title">ToxProfiler: Toxicity-target profiler based on chemical similarity. </span><span class="cited-content_cbyCitation_journal-name">Computational Toxicology</span><span> <strong>2021,</strong> <em>18 </em>, 100162. <a href="https://doi.org/10.1016/j.comtox.2021.100162" title="DOI URL">https://doi.org/10.1016/j.comtox.2021.100162</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.comtox.2021.100162&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.comtox.2021.100162%26sid%3Dliteratum%253Aachs%26jtitle%3DComputational%2520Toxicology%26atitle%3DToxProfiler%25253A%252BToxicity-target%252Bprofiler%252Bbased%252Bon%252Bchemical%252Bsimilarity%26aulast%3DAbdulHameed%26aufirst%3DMohamed%2BDiwan%2BM.%26date%3D2021%26volume%3D18%26spage%3D100162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">D.  Wilczyńska</span>, <span class="hlFld-ContribAuthor ">M.  Jastrzębska-Więsek</span>, <span class="hlFld-ContribAuthor ">A.  Partyka</span>, <span class="hlFld-ContribAuthor ">A.  Wesołowska</span>, <span class="hlFld-ContribAuthor ">M.  Kołaczkowski</span>, <span class="hlFld-ContribAuthor ">J.  Śniecikowska</span>, <span class="hlFld-ContribAuthor ">A.  Newman-Tancredi</span>. </span><span class="cited-content_cbyCitation_article-title">P.640 Distinct involvement of intracellular signaling pathways in eliciting different behavioral effects by serotonin 1a receptor agonists. </span><span class="cited-content_cbyCitation_journal-name">European Neuropsychopharmacology</span><span> <strong>2020,</strong> <em>40 </em>, S361-S362. <a href="https://doi.org/10.1016/j.euroneuro.2020.09.468" title="DOI URL">https://doi.org/10.1016/j.euroneuro.2020.09.468</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.euroneuro.2020.09.468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.euroneuro.2020.09.468%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Neuropsychopharmacology%26atitle%3DP.640%252BDistinct%252Binvolvement%252Bof%252Bintracellular%252Bsignaling%252Bpathways%252Bin%252Beliciting%252Bdifferent%252Bbehavioral%252Beffects%252Bby%252Bserotonin%252B1a%252Breceptor%252Bagonists%26aulast%3DWilczy%25C5%2584ska%26aufirst%3DD.%26date%3D2020%26volume%3D40%26spage%3DS361%26epage%3DS362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joanna  Sniecikowska</span>, <span class="hlFld-ContribAuthor ">Adrian  Newman-Tancredi</span>, <span class="hlFld-ContribAuthor ">Marcin  Kolaczkowski</span>. </span><span class="cited-content_cbyCitation_article-title">From Receptor Selectivity to Functional Selectivity: The Rise of Biased Agonism in 5-HT1A Receptor Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">Current Topics in Medicinal Chemistry</span><span> <strong>2019,</strong> <em>19 </em>
                                    (26)
                                     , 2393-2420. <a href="https://doi.org/10.2174/1568026619666190911122040" title="DOI URL">https://doi.org/10.2174/1568026619666190911122040</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1568026619666190911122040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1568026619666190911122040%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Topics%2520in%2520Medicinal%2520Chemistry%26atitle%3DFrom%252BReceptor%252BSelectivity%252Bto%252BFunctional%252BSelectivity%25253A%252BThe%252BRise%252Bof%252BBiased%252BAgonism%252Bin%252B5-HT1A%252BReceptor%252BDrug%252BDiscovery%26aulast%3DSniecikowska%26aufirst%3DJoanna%26date%3D2019%26volume%3D19%26issue%3D26%26spage%3D2393%26epage%3D2420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ronan  Depoortère</span>, <span class="hlFld-ContribAuthor ">Mariusz  Papp</span>, <span class="hlFld-ContribAuthor ">Piotr  Gruca</span>, <span class="hlFld-ContribAuthor ">Magdalena  Lason-Tyburkiewicz</span>, <span class="hlFld-ContribAuthor ">Monika  Niemczyk</span>, <span class="hlFld-ContribAuthor ">Mark A  Varney</span>, <span class="hlFld-ContribAuthor ">Adrian  Newman-Tancredi</span>. </span><span class="cited-content_cbyCitation_article-title">Cortical 5-hydroxytryptamine 1A receptor biased agonist, NLX-101, displays rapid-acting antidepressant-like properties in the rat chronic mild stress model. </span><span class="cited-content_cbyCitation_journal-name">Journal of Psychopharmacology</span><span> <strong>2019,</strong> <em>33 </em>
                                    (11)
                                     , 1456-1466. <a href="https://doi.org/10.1177/0269881119860666" title="DOI URL">https://doi.org/10.1177/0269881119860666</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/0269881119860666&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F0269881119860666%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Psychopharmacology%26atitle%3DCortical%252B5-hydroxytryptamine%252B1A%252Breceptor%252Bbiased%252Bagonist%25252C%252BNLX-101%25252C%252Bdisplays%252Brapid-acting%252Bantidepressant-like%252Bproperties%252Bin%252Bthe%252Brat%252Bchronic%252Bmild%252Bstress%252Bmodel%26aulast%3DDepoort%25C3%25A8re%26aufirst%3DRonan%26date%3D2019%26date%3D2019%26volume%3D33%26issue%3D11%26spage%3D1456%26epage%3D1466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/medium/jm-2019-00062d_0020.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00062&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/medium/jm-2019-00062d_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Predicted binding mode of compound <b>1</b> in the site of the serotonin 5-HT<sub>1A</sub> receptor. Amino acid residues engaged in ligand binding (within 4 Å from the ligand atoms) are displayed as sticks, whereas crucial residues, for example, forming H-bonds (dotted yellow lines), π–π/CH−π stacking (dotted cyan lines), and cation−π interactions (dotted green line), are represented as thick sticks. ECL2 residues were hidden for clarity; ECL—extracellular loop. The homology model of the 5-HT<sub>1A</sub> receptor was prepared based on the crystal structure of the 5-HT<sub>1B</sub> receptor (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4IAR">4IAR</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00062&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/medium/jm-2019-00062d_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. General structure of the new series of selective 5-HT<sub>1A</sub> receptor agonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00062&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/medium/jm-2019-00062d_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Predicted binding mode of compound <b>1</b> (green) together with <b>16</b> (pink) and <b>17</b> (white) in the site of the serotonin 5-HT<sub>1A</sub> receptor. Amino acid residues engaged in ligand binding (within 4 Å from the ligand atoms) are displayed as sticks, whereas crucial residues, for example, forming H-bonds (dotted yellow lines), π–π/CH−π stacking (dotted cyan lines), and cation−π interactions (dotted green line), are represented as thick sticks. ECL2 residues were hidden for clarity; ECL—extracellular loop. The homology model of the 5-HT<sub>1A</sub> receptor prepared based on the crystal structure of the 5-HT<sub>1B</sub> receptor (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4IAR">4IAR</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00062&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/medium/jm-2019-00062d_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of 1-(1-Benzoyl-4-fluoropiperidin-4-yl)methanamine Derivatives<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00062&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Et<sub>3</sub>N, DCM, 0 °C then rt, 12 h, yield: 47–60%; (b) chloroacetonitrile, 30% NaOH, TBABr, DCM, rt, 3 h, yield: 80–87%; (c) HF/pyridine, DCM, −10 °C, 30 min then rt 24–36 h, yield: 54–68%; and (d) DABCO, NaCNBH<sub>3</sub>, FeSO<sub>4</sub> × 7H<sub>2</sub>O, molecular sieves, MeOH, rt, 36–72 h, yield: 23–66%.</p></p></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/medium/jm-2019-00062d_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Signaling pathways measured after activation of the 5-HT<sub>1A</sub> receptor; adapted from Chilmonczyk et al.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> and modified based on Rojas & Fiedler.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00062&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/medium/jm-2019-00062d_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A,B) Effect of compound <b>17</b> on phospho-ERK1/2 (pERK1/2) and total-ERK1/2 (tERK1/2) levels in rat PFC. (A) Time-course (5, 15, 30 and 60 min) of the effects induced by a single oral administration of compound <b>17</b> at a dose of 2.5 mg/kg or vehicle (water). (B) Dose response of the effects of compound <b>17</b> tested at 15 min after administration. All samples were tested in duplicate, in two separate experiments. For normalization purposes, the value of phospho-ERK1/2 was divided by a corresponding value of total-ERK1/2 for each sample, and then, the ratios were used for statistical analysis (time course: one-way ANOVA (<i>F</i>(4,30) = 10.87; <i>p</i> < 0.0001; dose response: one-way ANOVA (<i>F</i>(4,31) = 10.19; <i>p</i> < 0.0001) followed by Bonferroni’s post hoc test). For graphical presentations, data are expressed as the mean ± SEM (2 measures for each of 6–8 rats per group), the mean value of the vehicle-treated group was set at 100% (control value), and all data were expressed as a percentage relative to the control value. *<i>p</i> < 0.05, ****<i>p</i> < 0.0001 compared to vehicle group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00062&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/medium/jm-2019-00062d_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Serum and brain concentrations (mean ± SEM) of compound <b>17</b> following oral administration of a dose of 2.5 mg/kg to rats (<i>n</i> = 6–8 per time point).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00062&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/medium/jm-2019-00062d_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Dose dependence in compound <b>17</b> serum and brain concentrations 15 min after oral administration to rats (each bar represents mean of 6–8 concentrations ± SEM).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00062&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/medium/jm-2019-00062d_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Observed (symbols) and pharmacodynamic model-predicted (line) pERK/tERK ratio (normalized to the vehicle control) as a function of mean serum concentrations of compound <b>17</b>. ERK phosphorylation was measured 15 min following compound administration at four different oral doses (0.04, 0.16, 0.63, and 2.5 mg/kg) to rats (<i>n</i> = 6–8 per dose).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00062&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/medium/jm-2019-00062d_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Antidepressant-like activity of compound <b>17</b> in the FST in rats (15 min pretreatment time). Values represent the mean ± SEM of the immobility time during the 5 min test session compared to the vehicle group [one-way ANOVA (<i>F</i>(4,29) = 66.22; <i>p</i> < 0.0000001) followed by Bonferroni’s post hoc test] *<i>p</i> < 0.05, ****<i>p</i> < 0.00001, <i>n</i> = 6–8 per dose.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00062&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/medium/jm-2019-00062d_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0002.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Observed (symbols) and pharmacodynamic model-predicted (lines) immobility times (normalized to the vehicle control) as a function of mean serum concentrations of compound <b>17</b>. FST was performed 15 min following compound administration at four different oral doses (0.04, 0.16, 0.63, and 2.5 mg/kg) to rats (<i>n</i> = 6–8 per dose).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.9b00062/20190308/images/large/jm-2019-00062d_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00062&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i96">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41731" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41731" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 100 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Penn, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tracy, D. K.</span></span> <span> </span><span class="NLM_article-title">The drugs don’t work? antidepressants and the current and future pharmacological management of depression</span>. <i>Ther. Adv. Psychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">188</span>, <span class="refDoi"> DOI: 10.1177/2045125312445469</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1177%2F2045125312445469" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=23983973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A280%3ADC%252BC3sbjtVyhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=179-188&author=E.+Pennauthor=D.+K.+Tracy&title=The+drugs+don%E2%80%99t+work%3F+antidepressants+and+the+current+and+future+pharmacological+management+of+depression&doi=10.1177%2F2045125312445469"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The drugs don't work? antidepressants and the current and future pharmacological management of depression</span></div><div class="casAuthors">Penn Elizabeth; Tracy Derek K</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic advances in psychopharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">179-88</span>
        ISSN:<span class="NLM_cas:issn">2045-1253</span>.
    </div><div class="casAbstract">Depression is a potentially life-threatening disorder affecting millions of people across the globe.  It is a huge burden to both the individual and society, costing over £9 billion in 2000 alone: the World Health Organisation (WHO) cited it as the third leading cause of global disability in 2004 (first in the developed world), and project it will be the leading cause by 2030.  The serendipitous discovery of antidepressants has revolutionized both our understanding and management of depression: however, their efficacy in the treatment of depression has long been debated and recently been brought very much into the public limelight by a controversial publication by Kirsch, in which the role of placebo response in antidepressant efficacy trials is highlighted.  Whilst antidepressants offer benefits in both the short and long term, important problems persist such as intolerability, delayed therapeutic onset, limited efficacy in milder depression and the existence of treatment-resistant depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS4lvXZ8_ey5P6xYuD7tu2XfW6udTcc2eYCk0yfKg5OnLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sbjtVyhtg%253D%253D&md5=1528826a1609741dcda82afb14bcc619</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1177%2F2045125312445469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2045125312445469%26sid%3Dliteratum%253Aachs%26aulast%3DPenn%26aufirst%3DE.%26aulast%3DTracy%26aufirst%3DD.%2BK.%26atitle%3DThe%2520drugs%2520don%25E2%2580%2599t%2520work%253F%2520antidepressants%2520and%2520the%2520current%2520and%2520future%2520pharmacological%2520management%2520of%2520depression%26jtitle%3DTher.%2520Adv.%2520Psychopharmacol.%26date%3D2012%26volume%3D2%26spage%3D179%26epage%3D188%26doi%3D10.1177%2F2045125312445469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montgomery, S. A.</span></span> <span> </span><span class="NLM_article-title">Why Do We Need New and Better Antidepressants?</span>. <i>Int. Clin. Psychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">S1</span>– <span class="NLM_lpage">S10</span>, <span class="refDoi"> DOI: 10.1097/01.yic.0000199455.39552.1c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1097%2F01.yic.0000199455.39552.1c" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=16436933" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2006&pages=S1-S10&author=S.+A.+Montgomery&title=Why+Do+We+Need+New+and+Better+Antidepressants%3F&doi=10.1097%2F01.yic.0000199455.39552.1c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1097%2F01.yic.0000199455.39552.1c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.yic.0000199455.39552.1c%26sid%3Dliteratum%253Aachs%26aulast%3DMontgomery%26aufirst%3DS.%2BA.%26atitle%3DWhy%2520Do%2520We%2520Need%2520New%2520and%2520Better%2520Antidepressants%253F%26jtitle%3DInt.%2520Clin.%2520Psychopharmacol.%26date%3D2006%26volume%3D21%26spage%3DS1%26epage%3DS10%26doi%3D10.1097%2F01.yic.0000199455.39552.1c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baghai, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fountoulakis, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasper, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malt, U. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Versiani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Möller, H. J.</span></span> <span> </span><span class="NLM_article-title">General and Comparative Efficacy and Effectiveness of Antidepressants in the Acute Treatment of Depressive Disorders: A Report by the WPA Section of Pharmacopsychiatry</span>. <i>Eur. Arch. Psychiatry Clin. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>261</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">245</span>, <span class="refDoi"> DOI: 10.1007/s00406-011-0259-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1007%2Fs00406-011-0259-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=22033583" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A280%3ADC%252BC38%252Fmt1OrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=261&publication_year=2011&pages=207-245&author=T.+C.+Baghaiauthor=P.+Blierauthor=D.+S.+Baldwinauthor=M.+Bauerauthor=G.+M.+Goodwinauthor=K.+N.+Fountoulakisauthor=S.+Kasperauthor=B.+E.+Leonardauthor=U.+F.+Maltauthor=D.+Steinauthor=M.+Versianiauthor=H.+J.+M%C3%B6ller&title=General+and+Comparative+Efficacy+and+Effectiveness+of+Antidepressants+in+the+Acute+Treatment+of+Depressive+Disorders%3A+A+Report+by+the+WPA+Section+of+Pharmacopsychiatry&doi=10.1007%2Fs00406-011-0259-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry</span></div><div class="casAuthors">Baghai Thomas C; Blier Pierre; Baldwin David S; Bauer Michael; Goodwin Guy M; Fountoulakis Kostas N; Kasper Siegfried; Leonard Brian E; Malt Ulrik F; Stein Dan; Versiani Marcio; Moller Hans-Jurgen</div><div class="citationInfo"><span class="NLM_cas:title">European archives of psychiatry and clinical neuroscience</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">261 Suppl 3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">207-45</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Current gold standard approaches to the treatment of depression include pharmacotherapeutic and psychotherapeutic interventions with social support.  Due to current controversies concerning the efficacy of antidepressants in randomized controlled trials, the generalizability of study findings to wider clinical practice and the increasing importance of socioeconomic considerations, it seems timely to address the uncertainty of concerned patients and relatives, and their treating psychiatrists and general practitioners.  We therefore discuss both the efficacy and clinical effectiveness of antidepressants in the treatment of depressive disorders.  We explain and clarify useful measures for assessing clinically meaningful antidepressant treatment effects and the types of studies that are useful for addressing uncertainties.  This includes considerations of methodological issues in randomized controlled studies, meta-analyses, and effectiveness studies.  Furthermore, we summarize the differential efficacy and effectiveness of antidepressants with distinct pharmacodynamic properties, and differences between studies using antidepressants and/or psychotherapy.  We also address the differential effectiveness of antidepressant drugs with differing modes of action and in varying subtypes of depressive disorder.  After highlighting the clinical usefulness of treatment algorithms and the divergent biological, psychological, and clinical efforts to predict the effectiveness of antidepressant treatments, we conclude that the spectrum of different antidepressant treatments has broadened over the last few decades.  The efficacy and clinical effectiveness of antidepressants is statistically significant, clinically relevant, and proven repeatedly.  Further optimization of treatment can be helped by clearly structured treatment algorithms and the implementation of psychotherapeutic interventions.  Modern individualized antidepressant treatment is in most cases a well-tolerated and efficacious approach to minimize the negative impact of otherwise potentially devastating and life-threatening outcomes in depressive disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRvb7AacIlPvXT4ugvCDgnZfW6udTcc2eYCk0yfKg5OnLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38%252Fmt1OrsQ%253D%253D&md5=0a06880d02aae499c41c455d4d784100</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1007%2Fs00406-011-0259-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00406-011-0259-6%26sid%3Dliteratum%253Aachs%26aulast%3DBaghai%26aufirst%3DT.%2BC.%26aulast%3DBlier%26aufirst%3DP.%26aulast%3DBaldwin%26aufirst%3DD.%2BS.%26aulast%3DBauer%26aufirst%3DM.%26aulast%3DGoodwin%26aufirst%3DG.%2BM.%26aulast%3DFountoulakis%26aufirst%3DK.%2BN.%26aulast%3DKasper%26aufirst%3DS.%26aulast%3DLeonard%26aufirst%3DB.%2BE.%26aulast%3DMalt%26aufirst%3DU.%2BF.%26aulast%3DStein%26aufirst%3DD.%26aulast%3DVersiani%26aufirst%3DM.%26aulast%3DM%25C3%25B6ller%26aufirst%3DH.%2BJ.%26atitle%3DGeneral%2520and%2520Comparative%2520Efficacy%2520and%2520Effectiveness%2520of%2520Antidepressants%2520in%2520the%2520Acute%2520Treatment%2520of%2520Depressive%2520Disorders%253A%2520A%2520Report%2520by%2520the%2520WPA%2520Section%2520of%2520Pharmacopsychiatry%26jtitle%3DEur.%2520Arch.%2520Psychiatry%2520Clin.%2520Neurosci.%26date%3D2011%26volume%3D261%26spage%3D207%26epage%3D245%26doi%3D10.1007%2Fs00406-011-0259-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tylee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, P.</span></span> <span> </span><span class="NLM_article-title">Onset of Action of Antidepressants</span>. <i>BMJ</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>334</i></span>,  <span class="NLM_fpage">911</span>– <span class="NLM_lpage">912</span>, <span class="refDoi"> DOI: 10.1136/bmj.39197.619190.80</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1136%2Fbmj.39197.619190.80" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=334&publication_year=2007&pages=911-912&author=A.+Tyleeauthor=P.+Walters&title=Onset+of+Action+of+Antidepressants&doi=10.1136%2Fbmj.39197.619190.80"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1136%2Fbmj.39197.619190.80&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbmj.39197.619190.80%26sid%3Dliteratum%253Aachs%26aulast%3DTylee%26aufirst%3DA.%26aulast%3DWalters%26aufirst%3DP.%26atitle%3DOnset%2520of%2520Action%2520of%2520Antidepressants%26jtitle%3DBMJ%26date%3D2007%26volume%3D334%26spage%3D911%26epage%3D912%26doi%3D10.1136%2Fbmj.39197.619190.80" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Courtet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Castroman, J.</span></span> <span> </span><span class="NLM_article-title">Antidepressants and Suicide Risk in Depression</span>. <i>World Psychiatr.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">317</span>– <span class="NLM_lpage">318</span>, <span class="refDoi"> DOI: 10.1002/wps.20460</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1002%2Fwps.20460" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=28941085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A280%3ADC%252BC1M%252Fhs1ahsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=317-318&author=P.+Courtetauthor=J.+Lopez-Castroman&title=Antidepressants+and+Suicide+Risk+in+Depression&doi=10.1002%2Fwps.20460"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Antidepressants and suicide risk in depression</span></div><div class="casAuthors">Courtet Philppe; Courtet Philppe; Lopez-Castroman Jorge; Lopez-Castroman Jorge</div><div class="citationInfo"><span class="NLM_cas:title">World psychiatry : official journal of the World Psychiatric Association (WPA)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">317-318</span>
        ISSN:<span class="NLM_cas:issn">1723-8617</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTGBEosanZkZQ5nADWVYHg1fW6udTcc2eYhakn3PLZs-bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M%252Fhs1ahsQ%253D%253D&md5=4567eb186fcb2e633d52544afb91030d</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1002%2Fwps.20460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fwps.20460%26sid%3Dliteratum%253Aachs%26aulast%3DCourtet%26aufirst%3DP.%26aulast%3DLopez-Castroman%26aufirst%3DJ.%26atitle%3DAntidepressants%2520and%2520Suicide%2520Risk%2520in%2520Depression%26jtitle%3DWorld%2520Psychiatr.%26date%3D2017%26volume%3D16%26spage%3D317%26epage%3D318%26doi%3D10.1002%2Fwps.20460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lener, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadriu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarate, C. A.</span></span> <span> </span><span class="NLM_article-title">Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">381</span>– <span class="NLM_lpage">401</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0702-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1007%2Fs40265-017-0702-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=28194724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC2sXislOisbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=381-401&author=M.+S.+Lenerauthor=B.+Kadriuauthor=C.+A.+Zarate&title=Ketamine+and+Beyond%3A+Investigations+into+the+Potential+of+Glutamatergic+Agents+to+Treat+Depression&doi=10.1007%2Fs40265-017-0702-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression</span></div><div class="casAuthors">Lener, Marc S.; Kadriu, Bashkim; Zarate, Carlos A., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">381-401</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Clin. and preclin. studies suggest that dysfunction of the glutamatergic system is implicated in mood disorders such as major depressive disorder and bipolar depression.  In clin. studies of individuals with major depressive disorder and bipolar depression, rapid redns. in depressive symptoms have been obsd. in response to subanesthetic-dose ketamine, an agent whose mechanism of action involves the modulation of glutamatergic signaling.  The findings from these studies have prompted the repurposing and/or development of other glutamatergic modulators for antidepressant efficacy, both as monotherapy or as an adjunct to conventional monoaminergic antidepressants.  This review highlights the evidence supporting the antidepressant effects of subanesthetic-dose ketamine as well as other glutamatergic modulators, such as D-cycloserine, riluzole, CP-101,606, CERC-301 (previously known as MK-0657), basimglurant, JNJ-40411813, dextromethorphan, nitrous oxide, GLYX-13, and esketamine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKaE4wcW8Kd7Vg90H21EOLACvtfcHk0ljodFUOe5m88g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXislOisbs%253D&md5=dd210c1370996cf338574a71b5991c48</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0702-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0702-8%26sid%3Dliteratum%253Aachs%26aulast%3DLener%26aufirst%3DM.%2BS.%26aulast%3DKadriu%26aufirst%3DB.%26aulast%3DZarate%26aufirst%3DC.%2BA.%26atitle%3DKetamine%2520and%2520Beyond%253A%2520Investigations%2520into%2520the%2520Potential%2520of%2520Glutamatergic%2520Agents%2520to%2520Treat%2520Depression%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26spage%3D381%26epage%3D401%26doi%3D10.1007%2Fs40265-017-0702-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rakesh, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pae, C.-U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masand, P. S.</span></span> <span> </span><span class="NLM_article-title">Beyond Serotonin: Newer Antidepressants in the Future</span>. <i>Expert Rev. Neurother.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">777</span>– <span class="NLM_lpage">790</span>, <span class="refDoi"> DOI: 10.1080/14737175.2017.1341310</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1080%2F14737175.2017.1341310" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=28598698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVertLfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=777-790&author=G.+Rakeshauthor=C.-U.+Paeauthor=P.+S.+Masand&title=Beyond+Serotonin%3A+Newer+Antidepressants+in+the+Future&doi=10.1080%2F14737175.2017.1341310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Beyond serotonin: newer antidepressants in the future</span></div><div class="casAuthors">Rakesh, Gopalkumar; Pae, Chi-Un; Masand, Prakash S.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Neurotherapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">777-790</span>CODEN:
                <span class="NLM_cas:coden">ERNXAR</span>;
        ISSN:<span class="NLM_cas:issn">1473-7175</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">There are numerous antidepressants for the treatment of major depressive disorder (MDD) on the market.  However, inadequate treatment response, therapeutic lag between drug administration and the onset of clin. improvement, and safety/tolerability issues with the use of contemporary antidepressants have accelerated the search for newer antidepressants with novel mechanisms of action.  The authors review novel antidepressants with rapid efficacy for diverse MDD symptoms and have fewer adverse effects (AEs).  Mechanisms of action for novel therapeutic mols. are through glutamatergic, opiate, cholinergic receptors and neuroplasticity.  We enumerate results from human trials with novel agents in all phases, highlighting proximity to approval and therapeutic potential based on quality of evidence.  There is a huge unmet need to diversify conventional antidepressant targets.  Glutamatergic and opiate agents may be most promising among newer therapeutic agents.  It is also important to develop advanced but flexible synergistic treatment strategies with newer therapeutic agents that are usable in routine clin. practice.  This would include combining newer mols. with existing antidepressants and using mols. that target specific symptom dimensions of MDD.  These strategies would lead to a systematic approach to tackle treatment resistant depression (TRD) and treatment of residual symptoms in partially remitted MDD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6N2oSw1Gh8rVg90H21EOLACvtfcHk0ljodFUOe5m88g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVertLfF&md5=f732ffd43d8ac805eacac71fca678d9e</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1080%2F14737175.2017.1341310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14737175.2017.1341310%26sid%3Dliteratum%253Aachs%26aulast%3DRakesh%26aufirst%3DG.%26aulast%3DPae%26aufirst%3DC.-U.%26aulast%3DMasand%26aufirst%3DP.%2BS.%26atitle%3DBeyond%2520Serotonin%253A%2520Newer%2520Antidepressants%2520in%2520the%2520Future%26jtitle%3DExpert%2520Rev.%2520Neurother.%26date%3D2017%26volume%3D17%26spage%3D777%26epage%3D790%26doi%3D10.1080%2F14737175.2017.1341310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Serafini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howland, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rovedi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girardi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amore, M.</span></span> <span> </span><span class="NLM_article-title">The Role of Ketamine in Treatment-Resistant Depression: A Systematic Review</span>. <i>Curr. Neuropharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">444</span>– <span class="NLM_lpage">461</span>, <span class="refDoi"> DOI: 10.2174/1570159x12666140619204251</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.2174%2F1570159x12666140619204251" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=25426012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFakurfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=444-461&author=G.+Serafiniauthor=R.+Howlandauthor=F.+Rovediauthor=P.+Girardiauthor=M.+Amore&title=The+Role+of+Ketamine+in+Treatment-Resistant+Depression%3A+A+Systematic+Review&doi=10.2174%2F1570159x12666140619204251"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of Ketamine in Treatment-Resistant Depression: A Systematic Review</span></div><div class="casAuthors">Serafini, Gianluca; Howland, Robert H.; Rovedi, Fabiana; Girardi, Paolo; Amore, Mario</div><div class="citationInfo"><span class="NLM_cas:title">Current Neuropharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">444-461</span>CODEN:
                <span class="NLM_cas:coden">CNUEAN</span>;
        ISSN:<span class="NLM_cas:issn">1875-6190</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Background: At least 10-20% of the patients suffering from depression meet criteria for treatment-resistant depression (TRD).  In the last decades, an important role of glutamate in mood modulation has been hypothesized and ketamine, a non noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptors, has been demonstrated to be effective in both MDD and TRD.  However, concerns emerged about the optimal dosage, and frequency of administration of this treatment. ; Methods: aiming to systematically review the current literature focusing on the main pharmacol. properties and impact of ketamine in TRD, a detailed literature search in PubMed/Medline and ScienceDirect databases was conducted.  Twenty-four manuscripts including a total of 416 patients fulfilled inclusion criteria. ; Results: Most studies demonstrated that the NMDA antagonist ketamine has rapid antidepressant effects in TRD patients, confirming the active role of glutamate in the pathophysiol. of this complex condition.  Ketamine has been demonstrated to be rapidly effective and was assocd. with a significant clin. improvement in depressive symptoms within hours after administration.  Also, ketamine was also found to be effective in reducing suicidality in TRD samples. ; Limitations: The long-term efficacy of ketamine has not been investigated by most studies.  The psychotomimetic properties may complicate the application of this pharmacol. agent. ; Conclusions: Ketamine may be considered a valid and intriguing antidepressant option for the treatment of TRD.  Further studies are needed to evaluate its long-term antidepressant efficacy in patients with TRD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqypkbEXkKfV7Vg90H21EOLACvtfcHk0ljKkhgSb1lGtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFakurfI&md5=27d7a3cde89794743ffc6843539ca612</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.2174%2F1570159x12666140619204251&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1570159x12666140619204251%26sid%3Dliteratum%253Aachs%26aulast%3DSerafini%26aufirst%3DG.%26aulast%3DHowland%26aufirst%3DR.%26aulast%3DRovedi%26aufirst%3DF.%26aulast%3DGirardi%26aufirst%3DP.%26aulast%3DAmore%26aufirst%3DM.%26atitle%3DThe%2520Role%2520of%2520Ketamine%2520in%2520Treatment-Resistant%2520Depression%253A%2520A%2520Systematic%2520Review%26jtitle%3DCurr.%2520Neuropharmacol.%26date%3D2014%26volume%3D12%26spage%3D444%26epage%3D461%26doi%3D10.2174%2F1570159x12666140619204251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.-W.</span></span> <span> </span><span class="NLM_article-title">Focused Microwave Irradiation-Assisted Immunohistochemistry to Study Effects of Ketamine on Phospho-ERK Expression in the Mouse Brain</span>. <i>Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>1670</i></span>,  <span class="NLM_fpage">86</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1016/j.brainres.2017.05.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2Fj.brainres.2017.05.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=28501494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotFygu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1670&publication_year=2017&pages=86-95&author=A.+Fernandesauthor=Y.-W.+Li&title=Focused+Microwave+Irradiation-Assisted+Immunohistochemistry+to+Study+Effects+of+Ketamine+on+Phospho-ERK+Expression+in+the+Mouse+Brain&doi=10.1016%2Fj.brainres.2017.05.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Focused microwave irradiation-assisted immunohistochemistry to study effects of ketamine on phospho-ERK expression in the mouse brain</span></div><div class="casAuthors">Fernandes, Alda; Li, Yu-Wen</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">1670</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">86-95</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Ketamine produces rapid and long-lasting antidepressant effects in depressive patients.  Preclin. studies demonstrate that ketamine stimulates AMPA receptor transmission and activates BDNF/TrkB-Akt/ERK-mTOR signaling cascades, leading to a sustained increase in synaptic protein synthesis and strengthening of synaptic plasticity, a potential mechanism underlying the antidepressant effects.  The purpose of this study was to develop an immunohistochem. (IHC) assay to map the distribution of extracellular signal-regulated kinase (ERK) phosphorylation in the mouse brain in response to systemic ketamine treatment.  We established a focused microwave irradn.-assisted IHC assay to detect phosphorylated (phospho) proteins including phospho-ERK, phospho- cAMP-response- element-binding protein (CREB), phospho- glutamate receptor 1 (GluR1) and phospho- calcium/calmodulin-dependent protein kinase II (CaMKII) with greater sensitivity and reproducibility in comparison to conventional IHC methods.  A single dose of ketamine produced a robust, dose- and time-dependent increase in phospho-ERK immunoreactive (phospho-ERK-ir) neurons in the medial prefrontal cortex (mPFC) and the central nucleus of the amygdala.  Phospho-ERK-ir neurons in the mPFC were primarily located in the prelimbic and anterior cingulate subregions with the morphol. resembling pyramidal neurons.  An increase in phospho-ERK-ir was also obsd. in the brainstem dorsal raphe nucleus and locus coeruleus.  The NMDA GluN2B subtype receptor antagonist Ro 25-6981 increased phospho-ERK expression in the brain in a similar pattern as ketamine.  In summary, we have established a sensitive and reliable focused microwave irradn.-assisted IHC assay, and defined the activation pattern of ERK, in response to systemic ketamine and Ro 25-6981 treatment, in brain regions that are potentially responsible for mediating the antidepressant effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorq3Wzm3ayRrVg90H21EOLACvtfcHk0ljKkhgSb1lGtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotFygu7o%253D&md5=65a1b9ff548863472c95889f0efa1eaf</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.brainres.2017.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainres.2017.05.008%26sid%3Dliteratum%253Aachs%26aulast%3DFernandes%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DY.-W.%26atitle%3DFocused%2520Microwave%2520Irradiation-Assisted%2520Immunohistochemistry%2520to%2520Study%2520Effects%2520of%2520Ketamine%2520on%2520Phospho-ERK%2520Expression%2520in%2520the%2520Mouse%2520Brain%26jtitle%3DBrain%2520Res.%26date%3D2017%26volume%3D1670%26spage%3D86%26epage%3D95%26doi%3D10.1016%2Fj.brainres.2017.05.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lepack, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwyer, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duman, R. S.</span></span> <span> </span><span class="NLM_article-title">Fast-Acting Antidepressants Rapidly Stimulate ERK Signaling and BDNF Release in Primary Neuronal Cultures</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">242</span>– <span class="NLM_lpage">252</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2016.09.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2Fj.neuropharm.2016.09.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=27634096" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhslyjsb%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2016&pages=242-252&author=A.+E.+Lepackauthor=E.+Bangauthor=B.+Leeauthor=J.+M.+Dwyerauthor=R.+S.+Duman&title=Fast-Acting+Antidepressants+Rapidly+Stimulate+ERK+Signaling+and+BDNF+Release+in+Primary+Neuronal+Cultures&doi=10.1016%2Fj.neuropharm.2016.09.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Fast-acting antidepressants rapidly stimulate ERK signaling and BDNF release in primary neuronal cultures</span></div><div class="casAuthors">Lepack, Ashley E.; Bang, Eunyoung; Lee, Boyoung; Dwyer, Jason M.; Duman, Ronald S.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">242-252</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Recent preclin. and clin. studies demonstrate that three functionally different compds., the NMDA receptor channel blocker ketamine, mGlu2/3 receptor antagonist LY341495, and NMDA receptor glycine site agent GLYX-13 produce rapid and long lasting antidepressant effects.  Furthermore, these agents are reported to stimulate ERK and mTORC1 signaling in brain.  Here we used rat primary cortical culture neurons to further examine the cellular actions of these agents.  The results demonstrate that low concns. of all three compds. rapidly increase levels of the phosphorylated and activated forms of ERK and a downstream target of mTORC1, p70S6 kinase, in a concn. and time dependent manner.  In addn., each compd. rapidly increases BDNF release into the culture media.  Further studies demonstrate that induction of BDNF release, as well as stimulation of phospho-ERK is blocked by incubation with an AMPA receptor antagonist.  The requirement for AMPA receptor stimulation suggests that the effects of these rapid agents are activity dependent.  This possibility is supported by studies demonstrating that neuronal silencing, via incubation with the GABAA receptor agonist muscimol, completely blocks phospho-ERK and BDNF release by each agent.  Finally, incubation with each drug for 24 h increases the no. and length of neuronal branches.  Together, the results demonstrate that these three different rapid acting antidepressant agents increase ERK signaling and BDNF release in an activity dependent manner that leads to increased neuronal complexity.  Further studies will be required to det. the exact mechanisms underlying these effects in cultured neurons and in rodent models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7FoBc4FQVBLVg90H21EOLACvtfcHk0ljKkhgSb1lGtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhslyjsb%252FF&md5=ef46f641e3ea8359a523643064f05a2c</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2016.09.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2016.09.011%26sid%3Dliteratum%253Aachs%26aulast%3DLepack%26aufirst%3DA.%2BE.%26aulast%3DBang%26aufirst%3DE.%26aulast%3DLee%26aufirst%3DB.%26aulast%3DDwyer%26aufirst%3DJ.%2BM.%26aulast%3DDuman%26aufirst%3DR.%2BS.%26atitle%3DFast-Acting%2520Antidepressants%2520Rapidly%2520Stimulate%2520ERK%2520Signaling%2520and%2520BDNF%2520Release%2520in%2520Primary%2520Neuronal%2520Cultures%26jtitle%3DNeuropharmacology%26date%3D2016%26volume%3D111%26spage%3D242%26epage%3D252%26doi%3D10.1016%2Fj.neuropharm.2016.09.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Réus, G. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vieira, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abelaira, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michels, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomaz, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">dos Santos, M. A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlessi, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neotti, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matias, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luz, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dal-Pizzol, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quevedo, J.</span></span> <span> </span><span class="NLM_article-title">MAPK Signaling Correlates with the Antidepressant Effects of Ketamine</span>. <i>J. Psychiatr. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1016/j.jpsychires.2014.04.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2Fj.jpsychires.2014.04.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=24819632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A280%3ADC%252BC2cjhvFKruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2014&pages=15-21&author=G.+Z.+R%C3%A9usauthor=F.+G.+Vieiraauthor=H.+M.+Abelairaauthor=M.+Michelsauthor=D.+B.+Tomazauthor=M.+A.+B.+dos+Santosauthor=A.+S.+Carlessiauthor=M.+V.+Neottiauthor=B.+I.+Matiasauthor=J.+R.+Luzauthor=F.+Dal-Pizzolauthor=J.+Quevedo&title=MAPK+Signaling+Correlates+with+the+Antidepressant+Effects+of+Ketamine&doi=10.1016%2Fj.jpsychires.2014.04.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">MAPK signaling correlates with the antidepressant effects of ketamine</span></div><div class="casAuthors">Reus Gislaine Z; Vieira Flavio Geraldo; Abelaira Helena M; Tomaz Debora B; dos Santos Maria Augusta B; Carlessi Anelise S; Neotti Morgana V; Matias Beatriz I; Luz Jaine R; Michels Monique; Dal-Pizzol Felipe; Quevedo Joao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of psychiatric research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15-21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Studies have pointed to a relationship between MAPK kinase (MEK) signaling and the behavioral effects of antidepressant drugs.  So, in the present study we examined the behavioral and molecular effects of ketamine, an antagonist of the N-methyl-d-aspartate receptor (NMDA), which has been shown to have an antidepressant effect after the inhibition of MEK signaling in Wistar rats.  Our results showed that acute administration of the MEK inhibitor PD184161, produced depressive-like behavior and stopped antidepressant-like effects of ketamine in the forced swimming test.  The phosphorylation of extracellular signal-regulated kinase 1/2 (pERK 1/2) was decreased by PD184161 in the amygdala and nucleus accumbens, and the effects of ketamine on pERK 1/2 in the prefrontal cortex and hippocampus were inhibited by PD184161.  The ERK 2 levels were decreased by PD184161 in the nucleus accumbens; and the effects of ketamine were blocked in this brain area.  The p38 protein kinase (p38MAPK) and proBDNF were inhibited by PD184161, and the MEK inhibitor prevented the effects of ketamine in the nucleus accumbens.  In addition, ketamine increased pro-BDNF levels in the hippocampus.  In conclusion, our findings demonstrated that an acute blockade of MAPK signaling lead to depressive-like behavior and stopped the antidepressant response of ketamine, suggesting that the effects of ketamine could be mediated, at least in part, by the regulation of MAPK signaling in these specific brain areas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQx1WDbnTu0v-3MPKNEWB5RfW6udTcc2eaICix9wwaSN7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cjhvFKruw%253D%253D&md5=70c513c4c1b6d37e613f32cdf6a25633</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.jpsychires.2014.04.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpsychires.2014.04.010%26sid%3Dliteratum%253Aachs%26aulast%3DR%25C3%25A9us%26aufirst%3DG.%2BZ.%26aulast%3DVieira%26aufirst%3DF.%2BG.%26aulast%3DAbelaira%26aufirst%3DH.%2BM.%26aulast%3DMichels%26aufirst%3DM.%26aulast%3DTomaz%26aufirst%3DD.%2BB.%26aulast%3Ddos%2BSantos%26aufirst%3DM.%2BA.%2BB.%26aulast%3DCarlessi%26aufirst%3DA.%2BS.%26aulast%3DNeotti%26aufirst%3DM.%2BV.%26aulast%3DMatias%26aufirst%3DB.%2BI.%26aulast%3DLuz%26aufirst%3DJ.%2BR.%26aulast%3DDal-Pizzol%26aufirst%3DF.%26aulast%3DQuevedo%26aufirst%3DJ.%26atitle%3DMAPK%2520Signaling%2520Correlates%2520with%2520the%2520Antidepressant%2520Effects%2520of%2520Ketamine%26jtitle%3DJ.%2520Psychiatr.%2520Res.%26date%3D2014%26volume%3D55%26spage%3D15%26epage%3D21%26doi%3D10.1016%2Fj.jpsychires.2014.04.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pochwat, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rafało-Ulińska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misztak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szewczyk, B.</span></span> <span> </span><span class="NLM_article-title">Involvement of Extracellular Signal-Regulated Kinase (ERK) in the Short and Long-Lasting Antidepressant-like Activity of NMDA Receptor Antagonists (Zinc and Ro 25-6981) in the Forced Swim Test in Rats</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">333</span>– <span class="NLM_lpage">342</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2017.08.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2Fj.neuropharm.2017.08.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=28802646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlKmsLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2017&pages=333-342&author=B.+Pochwatauthor=A.+Rafa%C5%82o-Uli%C5%84skaauthor=H.+Dominauthor=P.+Misztakauthor=G.+Nowakauthor=B.+Szewczyk&title=Involvement+of+Extracellular+Signal-Regulated+Kinase+%28ERK%29+in+the+Short+and+Long-Lasting+Antidepressant-like+Activity+of+NMDA+Receptor+Antagonists+%28Zinc+and+Ro+25-6981%29+in+the+Forced+Swim+Test+in+Rats&doi=10.1016%2Fj.neuropharm.2017.08.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Involvement of extracellular signal-regulated kinase (ERK) in the short and long-lasting antidepressant-like activity of NMDA receptor antagonists (zinc and Ro 25-6981) in the forced swim test in rats</span></div><div class="casAuthors">Pochwat, Bartlomiej; Rafalo-Ulinska, Anna; Domin, Helena; Misztak, Paulina; Nowak, Gabriel; Szewczyk, Bernadeta</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">333-342</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Short and long acting NMDA receptor (NMDAR) antagonists exert their antidepressant-like effects by activating signaling pathways involved in the synthesis of synaptic proteins and formation of new synaptic connections in the prefrontal cortex (PFC) of rats.  The blockade of the ERK pathway abolishes ketamine and Ro 25-6981 antidepressant potency.  However, the role of ERK in the antidepressant-like activity of short acting NMDAR antagonists is still unclear.  More puzzling is the fact that the precise role of ERK in the short and long lasting effects of long-acting NMDAR antagonists is unknown.  In this study, we show that zinc, (Zn) a short-acting NMDAR antagonist evokes only transient ERK activation, which is obsd. 7 min after its administration in the PFC of rats.  In contrast to Zn, the long acting NMDAR antagonist Ro 25-6981 produces persistent ERK activation lasting up to 24 h.  Pretreatment with the MAPK/ERK inhibitor (U0126) totally abolished Zn and Ro 25-6981 antidepressant-like activities in the forced swim test in rats.  However, when U0126 is administered 15 min after Zn or Ro 25-6981 both compds. maintain their short-lasting antidepressant-like activity.  On the other hand, posttreatment with U0126 significantly attenuated the long lasting antidepressant-like activity of Ro 25-6981.  These results indicate that the activation of ERK is crucial for the short- and long lasting antidepressant-like activity obsd. in the FST in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNtx86wbhMyLVg90H21EOLACvtfcHk0liL-BmCa_4dnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlKmsLbM&md5=f20a82e808abcfcb84b9819b149ea540</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2017.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2017.08.006%26sid%3Dliteratum%253Aachs%26aulast%3DPochwat%26aufirst%3DB.%26aulast%3DRafa%25C5%2582o-Uli%25C5%2584ska%26aufirst%3DA.%26aulast%3DDomin%26aufirst%3DH.%26aulast%3DMisztak%26aufirst%3DP.%26aulast%3DNowak%26aufirst%3DG.%26aulast%3DSzewczyk%26aufirst%3DB.%26atitle%3DInvolvement%2520of%2520Extracellular%2520Signal-Regulated%2520Kinase%2520%2528ERK%2529%2520in%2520the%2520Short%2520and%2520Long-Lasting%2520Antidepressant-like%2520Activity%2520of%2520NMDA%2520Receptor%2520Antagonists%2520%2528Zinc%2520and%2520Ro%252025-6981%2529%2520in%2520the%2520Forced%2520Swim%2520Test%2520in%2520Rats%26jtitle%3DNeuropharmacology%26date%3D2017%26volume%3D125%26spage%3D333%26epage%3D342%26doi%3D10.1016%2Fj.neuropharm.2017.08.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niciu, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shovestul, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaso, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farmer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luckenbaugh, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brutsche, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarate, C. A.</span></span> <span> </span><span class="NLM_article-title">Features of Dissociation Differentially Predict Antidepressant Response to Ketamine in Treatment-Resistant Depression</span>. <i>J. Affective Disord.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>232</i></span>,  <span class="NLM_fpage">310</span>– <span class="NLM_lpage">315</span>, <span class="refDoi"> DOI: 10.1016/j.jad.2018.02.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2Fj.jad.2018.02.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=29501990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC1cXks1yltbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=232&publication_year=2018&pages=310-315&author=M.+J.+Niciuauthor=B.+J.+Shovestulauthor=B.+A.+Jasoauthor=C.+Farmerauthor=D.+A.+Luckenbaughauthor=N.+E.+Brutscheauthor=L.+T.+Parkauthor=E.+D.+Ballardauthor=C.+A.+Zarate&title=Features+of+Dissociation+Differentially+Predict+Antidepressant+Response+to+Ketamine+in+Treatment-Resistant+Depression&doi=10.1016%2Fj.jad.2018.02.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression</span></div><div class="casAuthors">Niciu, Mark J.; Shovestul, Bridget J.; Jaso, Brittany A.; Farmer, Cristan; Luckenbaugh, David A.; Brutsche, Nancy E.; Park, Lawrence T.; Ballard, Elizabeth D.; Zarate, Carlos A. Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Affective Disorders</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">232</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">310-315</span>CODEN:
                <span class="NLM_cas:coden">JADID7</span>;
        ISSN:<span class="NLM_cas:issn">0165-0327</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Ketamine induces rapid and robust antidepressant effects, and many patients also describe dissocn., which is assocd. with antidepressant response.  This follow-up study investigated whether antidepressant efficacy is uniquely related to dissociative symptom clusters.  Treatment-resistant patients with major depressive disorder (MDD) or bipolar disorder (BD) (n = 126) drawn from three studies received a single subanesthetic (0.5 mg/kg) ketamine infusion.  Dissociative effects were measured using the Clinician-Administered Dissociative States Scale (CADSS).  Antidepressant response was measured using the 17-item Hamilton Depression Rating Scale (HAM-D).  A confirmatory factor anal. established the validity of CADSS subscales (derealization, depersonalization, amnesia), and a general linear model with repeated measures was fitted to test whether subscale scores were assocd. with antidepressant response.  Factor validity was supported, with a root mean square error of approxn. of .06, a comparative fit index of .97, and a Tucker-Lewis index of .96.  Across all studies and timepoints, the depersonalization subscale was pos. related to HAM-D percent change.  A significant effect of derealization on HAM-D percent change was obsd. at one timepoint (Day 7) in one study.  The amnesia subscale was unrelated to HAM-D percent change.  Possible inadequate blinding; combined MDD/BD datasets might have underrepresented ketamine's antidepressant efficacy; the possibility of Type I errors in secondary analyses.  From a psychometric perspective, researchers may elect to administer only the CADSS depersonalization subscale, given that it was most closely related to antidepressant response.  From a neurobiol. perspective, mechanistic similarities may exist between ketamine-induced depersonalization and antidepressant response, although off-target effects cannot be excluded.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeGfMHJm_zZbVg90H21EOLACvtfcHk0liL-BmCa_4dnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXks1yltbY%253D&md5=1985c7fa8f1b975dd35624f35e8bcf60</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.jad.2018.02.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jad.2018.02.049%26sid%3Dliteratum%253Aachs%26aulast%3DNiciu%26aufirst%3DM.%2BJ.%26aulast%3DShovestul%26aufirst%3DB.%2BJ.%26aulast%3DJaso%26aufirst%3DB.%2BA.%26aulast%3DFarmer%26aufirst%3DC.%26aulast%3DLuckenbaugh%26aufirst%3DD.%2BA.%26aulast%3DBrutsche%26aufirst%3DN.%2BE.%26aulast%3DPark%26aufirst%3DL.%2BT.%26aulast%3DBallard%26aufirst%3DE.%2BD.%26aulast%3DZarate%26aufirst%3DC.%2BA.%26atitle%3DFeatures%2520of%2520Dissociation%2520Differentially%2520Predict%2520Antidepressant%2520Response%2520to%2520Ketamine%2520in%2520Treatment-Resistant%2520Depression%26jtitle%3DJ.%2520Affective%2520Disord.%26date%3D2018%26volume%3D232%26spage%3D310%26epage%3D315%26doi%3D10.1016%2Fj.jad.2018.02.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bartoli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clerici, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrà, G.</span></span> <span> </span><span class="NLM_article-title">Antidepressant Response and Dissociative Effects After Ketamine Treatment</span>. <i>J. Clin. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>78</i></span>, <span class="NLM_elocation-id">e1318</span> <span class="refDoi"> DOI: 10.4088/jcp.17lr11789</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.4088%2Fjcp.17lr11789" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=29345870" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2017&author=F.+Bartoliauthor=M.+Clericiauthor=G.+Carr%C3%A0&title=Antidepressant+Response+and+Dissociative+Effects+After+Ketamine+Treatment&doi=10.4088%2Fjcp.17lr11789"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.4088%2Fjcp.17lr11789&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4088%252Fjcp.17lr11789%26sid%3Dliteratum%253Aachs%26aulast%3DBartoli%26aufirst%3DF.%26aulast%3DClerici%26aufirst%3DM.%26aulast%3DCarr%25C3%25A0%26aufirst%3DG.%26atitle%3DAntidepressant%2520Response%2520and%2520Dissociative%2520Effects%2520After%2520Ketamine%2520Treatment%26jtitle%3DJ.%2520Clin.%2520Psychiatry%26date%3D2017%26volume%3D78%26doi%3D10.4088%2Fjcp.17lr11789" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeng, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, T.-C.</span></span> <span> </span><span class="NLM_article-title">Ketamine-Associated Ulcerative Cystitis</span>. <i>Tzu Chi Med. J.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">144</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.1016/s1016-3190(08)60026-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2Fs1016-3190%2808%2960026-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2008&pages=144-146&author=Y.-C.+Huangauthor=C.-M.+Jengauthor=T.-C.+Cheng&title=Ketamine-Associated+Ulcerative+Cystitis&doi=10.1016%2Fs1016-3190%2808%2960026-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fs1016-3190%2808%2960026-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs1016-3190%252808%252960026-9%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.-C.%26aulast%3DJeng%26aufirst%3DC.-M.%26aulast%3DCheng%26aufirst%3DT.-C.%26atitle%3DKetamine-Associated%2520Ulcerative%2520Cystitis%26jtitle%3DTzu%2520Chi%2520Med.%2520J.%26date%3D2008%26volume%3D20%26spage%3D144%26epage%3D146%26doi%3D10.1016%2Fs1016-3190%2808%2960026-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Riva-Posse, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiff, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Job, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galendez, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garlow, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saah, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunlop, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, W. M.</span></span> <span> </span><span class="NLM_article-title">Blood Pressure Safety of Subanesthetic Ketamine for Depression: A Report on 684 Infusions</span>. <i>J. Affective Disord.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>236</i></span>,  <span class="NLM_fpage">291</span>– <span class="NLM_lpage">297</span>, <span class="refDoi"> DOI: 10.1016/j.jad.2018.02.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2Fj.jad.2018.02.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=29525051" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC1cXks1yku7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=236&publication_year=2018&pages=291-297&author=P.+Riva-Posseauthor=C.+M.+Reiffauthor=J.+A.+Edwardsauthor=G.+P.+Jobauthor=G.+C.+Galendezauthor=S.+J.+Garlowauthor=T.+C.+Saahauthor=B.+W.+Dunlopauthor=W.+M.+McDonald&title=Blood+Pressure+Safety+of+Subanesthetic+Ketamine+for+Depression%3A+A+Report+on+684+Infusions&doi=10.1016%2Fj.jad.2018.02.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Blood pressure safety of subanesthetic ketamine for depression: A report on 684 infusions</span></div><div class="casAuthors">Riva-Posse, Patricio; Reiff, Collin R.; Edwards, Johnathan A.; Job, Gregory P.; Galendez, Gail C.; Garlow, Steven J.; Saah, Tammy C.; Dunlop, Boadie W.; McDonald, William M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Affective Disorders</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">236</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">291-297</span>CODEN:
                <span class="NLM_cas:coden">JADID7</span>;
        ISSN:<span class="NLM_cas:issn">0165-0327</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The dissociative anesthetic agent ketamine is increasingly being utilized to treat depression, despite not having FDA (Food and Drug Administration) approval for this indication.  There are many questions about the potential risks of this treatment and hence the proper setting and degree of monitoring required to ensure patient safety.  There is limited data about the cardiovascular safety of ketamine when administered at subanesthetic doses to treat depression.66 patients in the Department of Psychiatry at Emory University received a total of 684 ketamine infusions between 2014 and 2016.  Ketamine was dosed at 0.5 mg/kg body wt. and infused over 40 min.  Blood pressure was measured every 10 min during the infusions and every 15 min thereafter.Mean age of the patients was 56.7 years, 87.9% had unipolar depression and 36.1% had essential hypertension.  No infusions were discontinued due to instability of vital signs, adverse physiol. consequences or acute psychotomimetic effects.  The biggest increases in blood pressure were measured at 30 min (systolic 3.28 mmHg, diastolic 3.17 mmHg).  Hypertensive patients had higher blood pressure peaks during the infusions.  Blood pressures returned to baseline during post-infusion monitoring.  There was no development of tolerance to the blood pressure elevating effects of ketamine between the first and sixth infusions.  This is a single site, retrospective anal., of patients who were spontaneously seeking clin. care.  The blood pressure changes obsd. when ketamine is administered over 40 min at 0.5 mg/kg for the treatment of depression are small, well tolerated and clin. insignificant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo300Juo_t0ULVg90H21EOLACvtfcHk0li8VBuyMOQHbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXks1yku7g%253D&md5=12a334bd3433c8d4631267dbbaf253a0</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.jad.2018.02.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jad.2018.02.025%26sid%3Dliteratum%253Aachs%26aulast%3DRiva-Posse%26aufirst%3DP.%26aulast%3DReiff%26aufirst%3DC.%2BM.%26aulast%3DEdwards%26aufirst%3DJ.%2BA.%26aulast%3DJob%26aufirst%3DG.%2BP.%26aulast%3DGalendez%26aufirst%3DG.%2BC.%26aulast%3DGarlow%26aufirst%3DS.%2BJ.%26aulast%3DSaah%26aufirst%3DT.%2BC.%26aulast%3DDunlop%26aufirst%3DB.%2BW.%26aulast%3DMcDonald%26aufirst%3DW.%2BM.%26atitle%3DBlood%2520Pressure%2520Safety%2520of%2520Subanesthetic%2520Ketamine%2520for%2520Depression%253A%2520A%2520Report%2520on%2520684%2520Infusions%26jtitle%3DJ.%2520Affective%2520Disord.%26date%3D2018%26volume%3D236%26spage%3D291%26epage%3D297%26doi%3D10.1016%2Fj.jad.2018.02.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mason, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cottrell, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corrigan, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillatt, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchelmore, A. E.</span></span> <span> </span><span class="NLM_article-title">Ketamine-Associated Lower Urinary Tract Destruction: A New Radiological Challenge</span>. <i>Clin. Radiol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">795</span>– <span class="NLM_lpage">800</span>, <span class="refDoi"> DOI: 10.1016/j.crad.2010.05.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2Fj.crad.2010.05.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=20797465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A280%3ADC%252BC3cjpt12muw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2010&pages=795-800&author=K.+Masonauthor=A.+M.+Cottrellauthor=A.+G.+Corriganauthor=D.+A.+Gillattauthor=A.+E.+Mitchelmore&title=Ketamine-Associated+Lower+Urinary+Tract+Destruction%3A+A+New+Radiological+Challenge&doi=10.1016%2Fj.crad.2010.05.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Ketamine-associated lower urinary tract destruction: a new radiological challenge</span></div><div class="casAuthors">Mason K; Cottrell A M; Corrigan A G; Gillatt D A; Mitchelmore A E</div><div class="citationInfo"><span class="NLM_cas:title">Clinical radiology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">795-800</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">AIM:  Ketamine is a short-acting dissociative anaesthetic whose hallucinogenic side effects have led to an increase in its illicit use amongst club and party goers.  There is a general misconception amongst users that it is a safe drug with few long term side effects, however ketamine abuse is associated with severe urinary tract dysfunction.  Presenting symptoms include urinary frequency, nocturia, dysuria, haematuria and incontinence.  MATERIALS AND METHODS:  We describe the radiological findings found in a series of 23 patients, all with a history of ketamine abuse, who presented with severe lower urinary tract symptoms (LUTS).  Imaging techniques used included ultrasonography (US), intravenous urography (IVU), and computed tomography (CT).  These examinations were reviewed to identify common imaging findings.  All patients with positive imaging findings had also undergone cystoscopy and bladder wall biopsies, which confirmed the diagnosis.  The patients in this series have consented to the use of their data in the ongoing research into ketamine-induced bladder pathology.  RESULTS:  Ultrasound demonstrated small bladder volume and wall thickening.  CT revealed marked, generalized bladder wall thickening, mucosal enhancement, and perivesical inflammation.  Ureteric wall thickening and enhancement were also observed.  In advanced cases ureteric narrowing and strictures were identified using both CT and IVU.  Correlation of clinical history, radiological and pathological findings was performed to confirm the diagnosis.  CONCLUSION:  This case series illustrates the harmful effects of ketamine on the urinary tract and the associated radiological findings.  Delayed diagnosis can result in irreversible renal tract damage requiring surgical intervention.  It is important that radiologists are aware of this emerging clinical entity as early diagnosis and treatment are essential for successful management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRdwVg4GK2qdtbHMBt0mMIXfW6udTcc2eb4yZckBVcDprntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjpt12muw%253D%253D&md5=9d4b6f425edc86d9202212f8edd2cd75</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.crad.2010.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.crad.2010.05.003%26sid%3Dliteratum%253Aachs%26aulast%3DMason%26aufirst%3DK.%26aulast%3DCottrell%26aufirst%3DA.%2BM.%26aulast%3DCorrigan%26aufirst%3DA.%2BG.%26aulast%3DGillatt%26aufirst%3DD.%2BA.%26aulast%3DMitchelmore%26aufirst%3DA.%2BE.%26atitle%3DKetamine-Associated%2520Lower%2520Urinary%2520Tract%2520Destruction%253A%2520A%2520New%2520Radiological%2520Challenge%26jtitle%3DClin.%2520Radiol.%26date%3D2010%26volume%3D65%26spage%3D795%26epage%3D800%26doi%3D10.1016%2Fj.crad.2010.05.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gigliucci, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Dowd, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibney, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harkin, A.</span></span> <span> </span><span class="NLM_article-title">Ketamine Elicits Sustained Antidepressant-like Activity via a Serotonin-Dependent Mechanism</span>. <i>Psychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>228</i></span>,  <span class="NLM_fpage">157</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1007/s00213-013-3024-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1007%2Fs00213-013-3024-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=23455595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtlykuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=2013&pages=157-166&author=V.+Gigliucciauthor=G.+O%E2%80%99Dowdauthor=S.+Caseyauthor=D.+Eganauthor=S.+Gibneyauthor=A.+Harkin&title=Ketamine+Elicits+Sustained+Antidepressant-like+Activity+via+a+Serotonin-Dependent+Mechanism&doi=10.1007%2Fs00213-013-3024-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Ketamine elicits sustained antidepressant-like activity via a serotonin-dependent mechanism</span></div><div class="casAuthors">Gigliucci, Valentina; O'Dowd, Grainne; Casey, Sheena; Egan, Danielle; Gibney, Sinead; Harkin, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Heidelberg, Germany)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">228</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">157-166</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Rationale: Behavioral antidepressant-like effects of ketamine have been reported in the forced swimming test (FST).  The mechanisms mediating such effects are unknown.  Objectives: As serotonin (5-HT) is an important transmitter mediating antidepressant responsiveness in the FST, the influence of 5-HT depletion on the antidepressant-like effect of ketamine was assessed.  Methods: The effect of ketamine (25 mg/kg, i.p., 1 or 24 h prior to test) was assessed in the FST in naive rats or animals subjected to 5-HT depletion, repeated stress or following a combination of 5-HT depletion and stress.  Endogenous 5-HT was depleted using the tryptophan hydroxylase inhibitor para-chlorophenylalanine (3 × 150 mg/kg, i.p.).  Stress was induced by phys. restraint (2 h/day for 10 days).  Results: In naive rats, ketamine administered 24 or 1 h prior to test produced a characteristic antidepressant-like redn. in immobility time in the FST.  Depletion of 5-HT blocked this redn. in immobility when ketamine was administered 24 h prior FST, indicative of 5-HT dependency.  The increase in immobility provoked by repeated restraint stress (2 h/day for 10 days) was blocked by ketamine when administered 24 h prior to FST, but this effect dissipated when animals were subjected to 5-HT depletion.  Conclusions: These observations are consistent with a role for 5-HT in mediating sustained antidepressant activity of ketamine in the FST.  Mol. and cellular changes induced by ketamine may produce a rapid adaptation of 5-HT transmission which underlies the antidepressant response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxzV815691OLVg90H21EOLACvtfcHk0lggNNPZi02M5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtlykuro%253D&md5=017d811af5d2f0ac5733d32acd4e7e8c</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1007%2Fs00213-013-3024-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-013-3024-x%26sid%3Dliteratum%253Aachs%26aulast%3DGigliucci%26aufirst%3DV.%26aulast%3DO%25E2%2580%2599Dowd%26aufirst%3DG.%26aulast%3DCasey%26aufirst%3DS.%26aulast%3DEgan%26aufirst%3DD.%26aulast%3DGibney%26aufirst%3DS.%26aulast%3DHarkin%26aufirst%3DA.%26atitle%3DKetamine%2520Elicits%2520Sustained%2520Antidepressant-like%2520Activity%2520via%2520a%2520Serotonin-Dependent%2520Mechanism%26jtitle%3DPsychopharmacology%26date%3D2013%26volume%3D228%26spage%3D157%26epage%3D166%26doi%3D10.1007%2Fs00213-013-3024-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fukumoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iijima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funakoshi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaki, S.</span></span> <span> </span><span class="NLM_article-title">Role of 5-HT1A Receptor Stimulation in the Medial Prefrontal Cortex in the Sustained Antidepressant Effects of Ketamine</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">371</span>– <span class="NLM_lpage">381</span>, <span class="refDoi"> DOI: 10.1093/ijnp/pyx116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1093%2Fijnp%2Fpyx116" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2017&pages=371-381&author=K.+Fukumotoauthor=M.+Iijimaauthor=T.+Funakoshiauthor=S.+Chaki&title=Role+of+5-HT1A+Receptor+Stimulation+in+the+Medial+Prefrontal+Cortex+in+the+Sustained+Antidepressant+Effects+of+Ketamine&doi=10.1093%2Fijnp%2Fpyx116"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1093%2Fijnp%2Fpyx116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fijnp%252Fpyx116%26sid%3Dliteratum%253Aachs%26aulast%3DFukumoto%26aufirst%3DK.%26aulast%3DIijima%26aufirst%3DM.%26aulast%3DFunakoshi%26aufirst%3DT.%26aulast%3DChaki%26aufirst%3DS.%26atitle%3DRole%2520of%25205-HT1A%2520Receptor%2520Stimulation%2520in%2520the%2520Medial%2520Prefrontal%2520Cortex%2520in%2520the%2520Sustained%2520Antidepressant%2520Effects%2520of%2520Ketamine%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2017%26volume%3D21%26spage%3D371%26epage%3D381%26doi%3D10.1093%2Fijnp%2Fpyx116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fukumoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iijima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaki, S.</span></span> <span> </span><span class="NLM_article-title">Serotonin-1A Receptor Stimulation Mediates Effects of a Metabotropic Glutamate 2/3 Receptor Antagonist, 2S-2-Amino-2-(1S,2S-2-Carboxycycloprop-1-Yl)-3-(Xanth-9-Yl)Propanoic Acid (LY341495), and an N-Methyl-D-Aspartate Receptor Antagonist, Ketamine, in the Novelty-Suppressed Feeding Test</span>. <i>Psychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>231</i></span>,  <span class="NLM_fpage">2291</span>– <span class="NLM_lpage">2298</span>, <span class="refDoi"> DOI: 10.1007/s00213-013-3378-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1007%2Fs00213-013-3378-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=24402133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC2cXksFOnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=231&publication_year=2014&pages=2291-2298&author=K.+Fukumotoauthor=M.+Iijimaauthor=S.+Chaki&title=Serotonin-1A+Receptor+Stimulation+Mediates+Effects+of+a+Metabotropic+Glutamate+2%2F3+Receptor+Antagonist%2C+2S-2-Amino-2-%281S%2C2S-2-Carboxycycloprop-1-Yl%29-3-%28Xanth-9-Yl%29Propanoic+Acid+%28LY341495%29%2C+and+an+N-Methyl-D-Aspartate+Receptor+Antagonist%2C+Ketamine%2C+in+the+Novelty-Suppressed+Feeding+Test&doi=10.1007%2Fs00213-013-3378-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Serotonin-1A receptor stimulation mediates effects of a metabotropic glutamate 2/3 receptor antagonist, 2S-2-amino-2-(1S,2S-2-carboxycycloprop-1-yl)-3-(xanth-9-yl)propanoic acid (LY341495), and an N-methyl-D-aspartate receptor antagonist, ketamine, in the novelty-suppressed feeding test</span></div><div class="casAuthors">Fukumoto, Kenichi; Iijima, Michihiko; Chaki, Shigeyuki</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Heidelberg, Germany)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">231</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2291-2298</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Rationale: α-Amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor stimulation has been proposed to be a common neural mechanism of metabotropic glutamate 2/3 (mGlu2/3) receptor antagonists and an N-methyl-D-aspartate receptor antagonist, ketamine, exerting antidepressant effects in animal models.  AMPA receptor stimulation has also been shown to mediate an increase in the extracellular level of serotonin (5-HT) in the medial prefrontal cortex by an mGlu2/3 receptor antagonist in rats.  However, involvement of the serotonergic system in the actions of mGlu2/3 receptor antagonists and ketamine is not well understood.  Objectives: We investigated involvement of the serotonergic system in the effects of an mGlu2/3 receptor antagonist, 2S-2-amino-2-(1S,2S-2-carboxycycloprop-1-yl)-3-(xanth-9-yl)propanoic acid (LY341495), and ketamine in a novelty-suppressed feeding (NSF) test in mice.  Results: The i.p. administration of LY341495 or ketamine at 30 min prior to the test significantly shortened latency to feed, which was attenuated by an AMPA receptor antagonist, 2,3-dioxo-6-nitro-1,2,3,4-tetrahydr-obenzo[f]quinoxaline-7-sulfonamide (NBQX).  The effects of LY341495 and ketamine were no longer obsd. in mice pretreated with a tryptophan hydroxylase inhibitor, para-chlorophenylalanine (PCPA).  Moreover, the effects of LY341495 and ketamine were blocked by a 5-HT1A receptor antagonist, N-{2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl}-N-(2-pyridynyl) cyclohexane-carboxamide (WAY100635), but not by a 5-HT2A/2C receptor antagonist, ritanserin.  Likewise, an AMPA receptor potentiator, 2,3-dihydro-1,4-benzodioxin-7-yl-(1-piperidyl)methanone (CX546), shortened latency to feed in the NSF test, which was prevented by depletion of 5-HT and blockade of 5-HT1A receptor.  Conclusions: These results suggest that AMPA receptor-dependent 5-HT release and subsequent 5-HT1A receptor stimulation may be involved in the actions of an mGlu2/3 receptor antagonist and ketamine in the NSF test.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXxOAK0MC9U7Vg90H21EOLACvtfcHk0lggNNPZi02M5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXksFOnsA%253D%253D&md5=0b6fbc2993f11b4863f4451d00786297</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1007%2Fs00213-013-3378-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-013-3378-0%26sid%3Dliteratum%253Aachs%26aulast%3DFukumoto%26aufirst%3DK.%26aulast%3DIijima%26aufirst%3DM.%26aulast%3DChaki%26aufirst%3DS.%26atitle%3DSerotonin-1A%2520Receptor%2520Stimulation%2520Mediates%2520Effects%2520of%2520a%2520Metabotropic%2520Glutamate%25202%252F3%2520Receptor%2520Antagonist%252C%25202S-2-Amino-2-%25281S%252C2S-2-Carboxycycloprop-1-Yl%2529-3-%2528Xanth-9-Yl%2529Propanoic%2520Acid%2520%2528LY341495%2529%252C%2520and%2520an%2520N-Methyl-D-Aspartate%2520Receptor%2520Antagonist%252C%2520Ketamine%252C%2520in%2520the%2520Novelty-Suppressed%2520Feeding%2520Test%26jtitle%3DPsychopharmacology%26date%3D2014%26volume%3D231%26spage%3D2291%26epage%3D2298%26doi%3D10.1007%2Fs00213-013-3378-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Albert, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vahid-Ansari, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luckhart, C.</span></span> <span> </span><span class="NLM_article-title">Serotonin-Prefrontal Cortical Circuitry in Anxiety and Depression Phenotypes: Pivotal Role of Pre- and Post-Synaptic 5-HT1A Receptor Expression</span>. <i>Front. Behav. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">199</span>, <span class="refDoi"> DOI: 10.3389/fnbeh.2014.00199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.3389%2Ffnbeh.2014.00199" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=24936175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A280%3ADC%252BC2cflvF2ktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=199&author=P.+R.+Albertauthor=F.+Vahid-Ansariauthor=C.+Luckhart&title=Serotonin-Prefrontal+Cortical+Circuitry+in+Anxiety+and+Depression+Phenotypes%3A+Pivotal+Role+of+Pre-+and+Post-Synaptic+5-HT1A+Receptor+Expression&doi=10.3389%2Ffnbeh.2014.00199"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Serotonin-prefrontal cortical circuitry in anxiety and depression phenotypes: pivotal role of pre- and post-synaptic 5-HT1A receptor expression</span></div><div class="casAuthors">Albert Paul R; Vahid-Ansari Faranak; Luckhart Christine</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in behavioral neuroscience</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">199</span>
        ISSN:<span class="NLM_cas:issn">1662-5153</span>.
    </div><div class="casAbstract">Decreased serotonergic activity has been implicated in anxiety and major depression, and antidepressants directly or indirectly increase the long-term activity of the serotonin system.  A key component of serotonin circuitry is the 5-HT1A autoreceptor, which functions as the major somatodendritic autoreceptor to negatively regulate the "gain" of the serotonin system.  In addition, 5-HT1A heteroreceptors are abundantly expressed post-synaptically in the prefrontal cortex (PFC), amygdala, and hippocampus to mediate serotonin actions on fear, anxiety, stress, and cognition.  Importantly, in the PFC 5-HT1A heteroreceptors are expressed on at least two antagonist neuronal populations: excitatory pyramidal neurons and inhibitory interneurons.  Rodent models implicate the 5-HT1A receptor in anxiety- and depression-like phenotypes with distinct roles for pre- and post-synaptic 5-HT1A receptors.  In this review, we present a model of serotonin-PFC circuitry that integrates evidence from mouse genetic models of anxiety and depression involving knockout, suppression, over-expression, or mutation of genes of the serotonin system including 5-HT1A receptors.  The model postulates that behavioral phenotype shifts as serotonin activity increases from none (depressed/aggressive not anxious) to low (anxious/depressed) to high (anxious, not depressed).  We identify a set of conserved transcription factors including Deaf1, Freud-1/CC2D1A, Freud-2/CC2D1B and glucocorticoid receptors that may confer deleterious regional changes in 5-HT1A receptors in depression, and how future treatments could target these mechanisms.  Further studies to specifically test the roles and regulation of pyramidal vs. interneuronal populations of 5-HT receptors are needed better understand the role of serotonin in anxiety and depression and to devise more effective targeted therapeutic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTQeWflPetSDSjiVMCqkKxVfW6udTcc2eaQHuedUgSzKbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cflvF2ktg%253D%253D&md5=8594327308f364e47912b31720c3be41</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.3389%2Ffnbeh.2014.00199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnbeh.2014.00199%26sid%3Dliteratum%253Aachs%26aulast%3DAlbert%26aufirst%3DP.%2BR.%26aulast%3DVahid-Ansari%26aufirst%3DF.%26aulast%3DLuckhart%26aufirst%3DC.%26atitle%3DSerotonin-Prefrontal%2520Cortical%2520Circuitry%2520in%2520Anxiety%2520and%2520Depression%2520Phenotypes%253A%2520Pivotal%2520Role%2520of%2520Pre-%2520and%2520Post-Synaptic%25205-HT1A%2520Receptor%2520Expression%26jtitle%3DFront.%2520Behav.%2520Neurosci.%26date%3D2014%26volume%3D8%26spage%3D199%26doi%3D10.3389%2Ffnbeh.2014.00199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kimbrell, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ketter, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Little, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benson, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willis, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herscovitch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Post, R. M.</span></span> <span> </span><span class="NLM_article-title">Regional Cerebral Glucose Utilization in Patients with a Range of Severities of Unipolar Depression</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">237</span>– <span class="NLM_lpage">252</span>, <span class="refDoi"> DOI: 10.1016/s0006-3223(01)01216-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2Fs0006-3223%2801%2901216-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=11839367" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BD38Xht1ajsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2002&pages=237-252&author=T.+A.+Kimbrellauthor=T.+A.+Ketterauthor=M.+S.+Georgeauthor=J.+T.+Littleauthor=B.+E.+Bensonauthor=M.+W.+Willisauthor=P.+Herscovitchauthor=R.+M.+Post&title=Regional+Cerebral+Glucose+Utilization+in+Patients+with+a+Range+of+Severities+of+Unipolar+Depression&doi=10.1016%2Fs0006-3223%2801%2901216-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Regional cerebral glucose utilization in patients with a range of severities of unipolar depression</span></div><div class="casAuthors">Kimbrell, Tim A.; Ketter, Terence A.; George, Mark S.; Little, John T.; Benson, Brenda E.; Willis, Mark W.; Herscovitch, Peter; Post, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">237-252</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">Patients with unipolar depression are most often reported to have decreased regional cerebral glucose metab. (rCMRglu) in dorsal prefrontal and anterior cingulate cortices compared with healthy control subjects, often correlating inversely with severity of depression.  We measured rCMRglu with fluorine-18 deoxyglucose positron emission tomog. (PET) in 38 medication-free patients with unipolar depression and 37 healthy control subjects performing an auditory continuous performance task to further investigate potential prefrontal and anterior paralimbic rCMRglu abnormalities in patients attending to this task.  Compared with control subjects, the subgroup of patients with Hamilton depression scores of 22 or greater demonstrated decreased abs. rCMRglu in right prefrontal cortex and paralimbic/amygdala regions as well as bilaterally in the insula and temporoparietal cortex (right > left); they also exhibited increased normalized metabolic activity bilaterally in the cerebellum, lingula/cuneus, and brain stem.  Severity of depression neg. correlated with abs. rCMRglu in almost the entire extent of the right cingulate cortex as well as bilaterally in prefrontal cortex, insula, basal ganglia, and temporoparietal cortex (right > left).  Conclusions: Areas of frontal, cingulate, insula, and temporal cortex appear hypometabolic in assocn. with different components of the severity and course of illness in treatment-resistant unipolar depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIEel89Cl1bLVg90H21EOLACvtfcHk0ljCfHJ6sfsNBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xht1ajsbg%253D&md5=d24e8724bf7ddce23ed525323690745f</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fs0006-3223%2801%2901216-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0006-3223%252801%252901216-1%26sid%3Dliteratum%253Aachs%26aulast%3DKimbrell%26aufirst%3DT.%2BA.%26aulast%3DKetter%26aufirst%3DT.%2BA.%26aulast%3DGeorge%26aufirst%3DM.%2BS.%26aulast%3DLittle%26aufirst%3DJ.%2BT.%26aulast%3DBenson%26aufirst%3DB.%2BE.%26aulast%3DWillis%26aufirst%3DM.%2BW.%26aulast%3DHerscovitch%26aufirst%3DP.%26aulast%3DPost%26aufirst%3DR.%2BM.%26atitle%3DRegional%2520Cerebral%2520Glucose%2520Utilization%2520in%2520Patients%2520with%2520a%2520Range%2520of%2520Severities%2520of%2520Unipolar%2520Depression%26jtitle%3DBiol.%2520Psychiatry%26date%3D2002%26volume%3D51%26spage%3D237%26epage%3D252%26doi%3D10.1016%2Fs0006-3223%2801%2901216-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cervo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samanin, R.</span></span> <span> </span><span class="NLM_article-title">Potential antidepressant properties of 8-hydroxy-2-(di-n-propylamino) tetralin, a selective serotonin1A receptor agonist</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">223</span>– <span class="NLM_lpage">229</span>, <span class="refDoi"> DOI: 10.1016/0014-2999(87)90523-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2F0014-2999%2887%2990523-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=2963752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADyaL1cXkvFamtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=1987&pages=223-229&author=L.+Cervoauthor=R.+Samanin&title=Potential+antidepressant+properties+of+8-hydroxy-2-%28di-n-propylamino%29+tetralin%2C+a+selective+serotonin1A+receptor+agonist&doi=10.1016%2F0014-2999%2887%2990523-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Potential antidepressant properties of 8-hydroxy-2-(di-n-propylamino)tetralin, a selective serotonin1A receptor agonist</span></div><div class="casAuthors">Cervo, L.; Samanin, R.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">223-9</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    </div><div class="casAbstract">The title compd., 8-OH-DPAT, a selective serotonin S1A receptor agonist, was studied for its anti-immobility activity in the forced-swimming test after different schedules of treatment.  Single doses of 0.250 and 0.500 mg 8-OH-DPAT/kg s.c., reduced the immobility time of rats with no effect on open-field activity.  Similar results were obtained with a 3-injection course of 8-OH-DPAT in 24 h (0.125-0.500 mg/kg, s.c.) or with a once daily injection of 0.250 mg/kg, s.c., for 7 or 21 days.  Methiothepin (0.2 mg/kg, s.c.) and l-propranolol (20 mg/kg, s.c.) antagonized the anti-immobility effect of 3 injections of 0.25 mg 8-OH-DPAT/kg, s.c., but 2 mg metergoline/kg, i.p., had no such effect.  The effect of 8-OH-DPAT was also antagonized both by 0.5 mg haloperidol/kg, i.p., and 100 mg sulpiride/kg, i.p., and in animals given an intracerebroventricular injection of 150 μg 5,7-dihydroxytryptamine to deplete brain serotonin levels.  Apparently, 8-OH-DPAT, by acting on serotonin neurons in the brain, produces disinhibitory effects in a rat model predictive of antidepressant activity.  Serotonin S1A agonists such as 8-OH-DPAT may constitute a novel class of fast acting antidepressant drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjYXTcCqxgs7Vg90H21EOLACvtfcHk0ljCfHJ6sfsNBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXkvFamtA%253D%253D&md5=5fb67229822b635b0eee1bc20f0f3452</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2887%2990523-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252887%252990523-1%26sid%3Dliteratum%253Aachs%26aulast%3DCervo%26aufirst%3DL.%26aulast%3DSamanin%26aufirst%3DR.%26atitle%3DPotential%2520antidepressant%2520properties%2520of%25208-hydroxy-2-%2528di-n-propylamino%2529%2520tetralin%252C%2520a%2520selective%2520serotonin1A%2520receptor%2520agonist%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1987%26volume%3D144%26spage%3D223%26epage%3D229%26doi%3D10.1016%2F0014-2999%2887%2990523-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luscombe, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchins, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gosden, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heal, D. J.</span></span> <span> </span><span class="NLM_article-title">Mediation of the Antidepressant-like Effect of 8-OH-DPAT in Mice by Postsynaptic 5-HT1A Receptors</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">669</span>– <span class="NLM_lpage">677</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.1993.tb12859.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1111%2Fj.1476-5381.1993.tb12859.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=8467355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADyaK3sXit1GnurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=1993&pages=669-677&author=G.+P.+Luscombeauthor=K.+F.+Martinauthor=L.+J.+Hutchinsauthor=J.+Gosdenauthor=D.+J.+Heal&title=Mediation+of+the+Antidepressant-like+Effect+of+8-OH-DPAT+in+Mice+by+Postsynaptic+5-HT1A+Receptors&doi=10.1111%2Fj.1476-5381.1993.tb12859.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Mediation of the antidepressant-like effect of 8-OH-DPAT in mice by postsynaptic 5-HT1A receptors</span></div><div class="casAuthors">Luscombe, Graham P.; Martin, Keith F.; Hutchins, Lisa J.; Gosden, Jane; Heal, David J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">669-77</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    </div><div class="casAbstract">The 5-HT1A agonist 8-hydroxy-2-(dipropylamino)tetralin (8-OH-DPAT) was evaluated in a mouse model used for the detection of potential antidepressants by the Porsolt test.  The effects of various receptor antagonists, lesions of brain monoaminergic neurons, and chronic drug treatments on 8-OH-DPAT-induced responses were detd.  8-OH-DPAT (0.3-10.0 mg/kg s.c.) dose-dependently increased the mobility of mice in the Porsolt test.  Other selective 5-HT1A receptor ligands (0.3-30 mg/kg s.c.) either mimicked the 8-OH-DPAT responses (ipsapirone at 10 and 30 mg/kg s.c.) or were inactive (buspirone and gepirone).  These compds. (≤100 mg/kg orally) inhibited the responses to 8-OH-DPAT (3 mg/kg s.c.) when given concurrently.  The putative 5-HT1A antagonists spiroxatrine (1-30 mg/kg), (±)-pindolol (30 mg/kg), and methiothepin (3-10 mg/kg), given orally each attenuated the 8-OH-DPAT (3 mg/kg s.c.)-induced increases in mobility.  The dopaminergic D1 receptor antagonist SCH-23390 (3-10 mg/kg orally) weakly reversed the 8-OH-DPAT responses.  Antagonists at the 5-HT1C/5-HT2 receptors (ketanserin 0.1-3.0 mg/kg), 5-HT3 receptors (ondansetron 0.03-10 mg/kg), α1-adrenoceptors (prazosin 1-3 mg/kg), α2-adrenoceptors (idazoxan 3-30 mg/kg), β1-adrenoceptors (metoprolol 1-30 mg/kg), β2-adrenoceptors (ICI-118,551 1-30 mg/kg), dopaminergic D2 receptors (sulpiride 10-300 mg/kg), and opiate receptors (naloxone 3-100 mg/kg) given orally had no effect on the 8-OH-DPAT responses.  Selective destruction of 5-HT neurons with 5,7-dihydroxytryptamine or inhibition of 5-HT synthesis with p-chlorophenylalanine did not change the 8-OH-DPAT responses in the Porsolt test.  The responses were also unaltered by pretreatment with the noradrenergic neurotoxin DSP-4.  Administration of 8-OH-DPAT (3 mg/kg s.c.) twice-daily for 10 days attenuated hypothermia, but not the increased mobility induced by 8-OH-DPAT at 93 mg/kg s.c.).  Repeated administration of amitriptyline (3-30 mg/kg), desipramine (3-30 mg/kg), or dothiepin (10-100 mg/kg) also attenuated the former, but not the latter, response.  Thus, 8-OH-DPAT has an antidepressant-like effect mediated by postsynaptic 5-HT1A receptors in the Porsolt test.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyNIFX2lf4ZLVg90H21EOLACvtfcHk0ljCfHJ6sfsNBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXit1GnurY%253D&md5=a11231401cc5ef3e2e44c29aa4bbe919</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.1993.tb12859.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.1993.tb12859.x%26sid%3Dliteratum%253Aachs%26aulast%3DLuscombe%26aufirst%3DG.%2BP.%26aulast%3DMartin%26aufirst%3DK.%2BF.%26aulast%3DHutchins%26aufirst%3DL.%2BJ.%26aulast%3DGosden%26aufirst%3DJ.%26aulast%3DHeal%26aufirst%3DD.%2BJ.%26atitle%3DMediation%2520of%2520the%2520Antidepressant-like%2520Effect%2520of%25208-OH-DPAT%2520in%2520Mice%2520by%2520Postsynaptic%25205-HT1A%2520Receptors%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1993%26volume%3D108%26spage%3D669%26epage%3D677%26doi%3D10.1111%2Fj.1476-5381.1993.tb12859.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miyata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamei, J.</span></span> <span> </span><span class="NLM_article-title">Diabetes Attenuates the Antidepressant-like Effect Mediated by the Activation of 5-HT1A Receptor in the Mouse Tail Suspension Test</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">461</span>– <span class="NLM_lpage">469</span>, <span class="refDoi"> DOI: 10.1038/sj.npp.1300354</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1038%2Fsj.npp.1300354" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2003&pages=461-469&author=S.+Miyataauthor=S.+Hiranoauthor=J.+Kamei&title=Diabetes+Attenuates+the+Antidepressant-like+Effect+Mediated+by+the+Activation+of+5-HT1A+Receptor+in+the+Mouse+Tail+Suspension+Test&doi=10.1038%2Fsj.npp.1300354"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fsj.npp.1300354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.npp.1300354%26sid%3Dliteratum%253Aachs%26aulast%3DMiyata%26aufirst%3DS.%26aulast%3DHirano%26aufirst%3DS.%26aulast%3DKamei%26aufirst%3DJ.%26atitle%3DDiabetes%2520Attenuates%2520the%2520Antidepressant-like%2520Effect%2520Mediated%2520by%2520the%2520Activation%2520of%25205-HT1A%2520Receptor%2520in%2520the%2520Mouse%2520Tail%2520Suspension%2520Test%26jtitle%3DNeuropsychopharmacology%26date%3D2003%26volume%3D29%26spage%3D461%26epage%3D469%26doi%3D10.1038%2Fsj.npp.1300354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prinsze, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, G.</span></span> <span> </span><span class="NLM_article-title">Flesinoxan in the Treatment of Major Depressive Disorder: A Fixed Dose, Placebo-Controlled Trial</span>. <i>Eur. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">S4</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.1016/0924-977x(96)83084-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2F0924-977x%2896%2983084-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1996&pages=S4-73&author=C.+Prinszeauthor=G.+Stevens&title=Flesinoxan+in+the+Treatment+of+Major+Depressive+Disorder%3A+A+Fixed+Dose%2C+Placebo-Controlled+Trial&doi=10.1016%2F0924-977x%2896%2983084-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2F0924-977x%2896%2983084-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0924-977x%252896%252983084-7%26sid%3Dliteratum%253Aachs%26aulast%3DPrinsze%26aufirst%3DC.%26aulast%3DStevens%26aufirst%3DG.%26atitle%3DFlesinoxan%2520in%2520the%2520Treatment%2520of%2520Major%2520Depressive%2520Disorder%253A%2520A%2520Fixed%2520Dose%252C%2520Placebo-Controlled%2520Trial%26jtitle%3DEur.%2520Neuropsychopharmacol.%26date%3D1996%26volume%3D6%26spage%3DS4%26epage%3D73%26doi%3D10.1016%2F0924-977x%2896%2983084-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Newman-Tancredi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martel, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assié, M.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buritova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauressergues, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heusler, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruins Slot, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colpaert, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cussac, D.</span></span> <span> </span><span class="NLM_article-title">Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1Areceptor agonist</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>156</i></span>,  <span class="NLM_fpage">338</span>– <span class="NLM_lpage">353</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2008.00001.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1111%2Fj.1476-5381.2008.00001.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=19154445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1Wlsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2009&pages=338-353&author=A.+Newman-Tancrediauthor=J.-C.+Martelauthor=M.-B.+Assi%C3%A9author=J.+Buritovaauthor=E.+Lauresserguesauthor=C.+Cosiauthor=P.+Heuslerauthor=L.+Bruins+Slotauthor=F.+Colpaertauthor=B.+Vacherauthor=D.+Cussac&title=Signal+transduction+and+functional+selectivity+of+F15599%2C+a+preferential+post-synaptic+5-HT1Areceptor+agonist&doi=10.1111%2Fj.1476-5381.2008.00001.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonist</span></div><div class="casAuthors">Newman-Tancredi, A.; Martel, J.-C.; Assie, M.-B.; Buritova, J.; Lauressergues, E.; Cosi, C.; Heusler, P.; Slot, L. Bruins; Colpaert, F. C.; Vacher, B.; Cussac, D.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">338-353</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Activation of post-synaptic 5-HT1A receptors may provide enhanced therapy against depression.  We describe the signal transduction profile of F15599, a novel 5-HT1A receptor agonist.  F15599 was compared with a chem. congener, F13714, and with (+)8-OH-DPAT in models of signal transduction in vitro and ex vivo.  F15599 was highly selective for 5-HT1A receptors in binding expts. and in [35S]-GTPγS autoradiog. of rat brain, where F15599 increased labeling in regions expressing 5-HT1A receptors.  In cell lines expressing h5-HT1A receptors, F15599 more potently stimulated extracellular signal-regulated kinase (ERK1/2) phosphorylation, compared with G-protein activation, internalization of h5-HT1A receptors or inhibition of cAMP accumulation.  F13714, (+)8-OH-DPAT and 5-HT displayed a different rank order of potency for these responses.  F15599 stimulated [35S]-GTPγS binding more potently in frontal cortex than raphe.  F15599, unlike 5-HT, more potently and efficaciously stimulated Gαi than Gαo activation.  In rat prefrontal cortex (a region expressing post-synaptic 5-HT1A receptors), F15599 potently activated ERK1/2 phosphorylation and strongly induced c-fos mRNA expression.  In contrast, in raphe regions (expressing pre-synaptic 5-HT1A receptors) F15599 only weakly or did not induce c-fos mRNA expression.  Finally, despite its more modest affinity in vitro, F15599 bound to 5-HT1A receptors in vivo almost as potently as F13714.  F15599 showed a distinctive activation profiles for 5-HT1A receptor-mediated signaling pathways, unlike those of ref. agonists and consistent with functional selectivity at 5-HT1A receptors.  In rat, F15599 potently activated signaling in prefrontal cortex, a feature likely to underlie its beneficial effects in models of depression and cognition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrB5iCRk8KT7LVg90H21EOLACvtfcHk0ljUaR2GcEsLyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1Wlsrw%253D&md5=59559010ca0e8c57848a1a433fe15f59</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2008.00001.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2008.00001.x%26sid%3Dliteratum%253Aachs%26aulast%3DNewman-Tancredi%26aufirst%3DA.%26aulast%3DMartel%26aufirst%3DJ.-C.%26aulast%3DAssi%25C3%25A9%26aufirst%3DM.-B.%26aulast%3DBuritova%26aufirst%3DJ.%26aulast%3DLauressergues%26aufirst%3DE.%26aulast%3DCosi%26aufirst%3DC.%26aulast%3DHeusler%26aufirst%3DP.%26aulast%3DBruins%2BSlot%26aufirst%3DL.%26aulast%3DColpaert%26aufirst%3DF.%26aulast%3DVacher%26aufirst%3DB.%26aulast%3DCussac%26aufirst%3DD.%26atitle%3DSignal%2520transduction%2520and%2520functional%2520selectivity%2520of%2520F15599%252C%2520a%2520preferential%2520post-synaptic%25205-HT1Areceptor%2520agonist%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2009%26volume%3D156%26spage%3D338%26epage%3D353%26doi%3D10.1111%2Fj.1476-5381.2008.00001.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maurel, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Autin, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman-Tancredi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colpaert, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacher, B.</span></span> <span> </span><span class="NLM_article-title">High-Efficacy 5-HT1AAgonists for Antidepressant Treatment: A Renewed Opportunity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">5024</span>– <span class="NLM_lpage">5033</span>, <span class="refDoi"> DOI: 10.1021/jm070714l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070714l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=5024-5033&author=J.+L.+Maurelauthor=J.-M.+Autinauthor=P.+Funesauthor=A.+Newman-Tancrediauthor=F.+Colpaertauthor=B.+Vacher&title=High-Efficacy+5-HT1AAgonists+for+Antidepressant+Treatment%3A+A+Renewed+Opportunity&doi=10.1021%2Fjm070714l"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm070714l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070714l%26sid%3Dliteratum%253Aachs%26aulast%3DMaurel%26aufirst%3DJ.%2BL.%26aulast%3DAutin%26aufirst%3DJ.-M.%26aulast%3DFunes%26aufirst%3DP.%26aulast%3DNewman-Tancredi%26aufirst%3DA.%26aulast%3DColpaert%26aufirst%3DF.%26aulast%3DVacher%26aufirst%3DB.%26atitle%3DHigh-Efficacy%25205-HT1AAgonists%2520for%2520Antidepressant%2520Treatment%253A%2520A%2520Renewed%2520Opportunity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D5024%26epage%3D5033%26doi%3D10.1021%2Fjm070714l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Becker, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolbos, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costes, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redouté, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman-Tancredi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmer, L.</span></span> <span> </span><span class="NLM_article-title">Selective Serotonin 5-HT1A Receptor Biased Agonists Elicitdistinct Brain Activation Patterns: A PharmacoMRI Study</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">26633</span>, <span class="refDoi"> DOI: 10.1038/srep26633</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1038%2Fsrep26633" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=27211078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC28XosVSlsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=26633&author=G.+Beckerauthor=R.+Bolbosauthor=N.+Costesauthor=J.+Redout%C3%A9author=A.+Newman-Tancrediauthor=L.+Zimmer&title=Selective+Serotonin+5-HT1A+Receptor+Biased+Agonists+Elicitdistinct+Brain+Activation+Patterns%3A+A+PharmacoMRI+Study&doi=10.1038%2Fsrep26633"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Selective serotonin 5-HT1A receptor biased agonists elicit distinct brain activation patterns: a pharmacoMRI study</span></div><div class="casAuthors">Becker, G.; Bolbos, R.; Costes, N.; Redoute, J.; Newman-Tancredi, A.; Zimmer, L.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">26633</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Serotonin 1A (5-HT1A) receptors are involved in several physiol. and pathol. processes and constitute therefore an important therapeutic target.  The recent pharmacol. concept of biased agonism asserts that highly selective agonists can preferentially direct receptor signaling to specific intracellular responses, opening the possibility of drugs targeting a receptor subtype in specific brain regions.  The present study brings addnl. support to this concept thanks to functional magnetic resonance imaging (7 T-fMRI) in anesthetized rats.  Three 5-HT1A receptor agonists (8-OH-DPAT, F13714 and F15599) and one 5-HT1A receptor antagonist (MPPF) were compared in terms of influence on the brain blood oxygen level-dependent (BOLD) signal.  Our study revealed for the first time contrasting BOLD signal patterns of biased agonists in comparison to a classical agonist and a silent antagonist.  By providing functional information on the influence of pharmacol. activation of 5-HT1A receptors in specific brain regions, this neuroimaging approach, translatable to the clinic, promises to be useful in exploring the new concept of biased agonism in neuropsychopharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptDDMqKoAGBbVg90H21EOLACvtfcHk0liGLe9tv2cBFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosVSlsrY%253D&md5=c054e4c2e584080164f76f64a9675c81</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fsrep26633&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep26633%26sid%3Dliteratum%253Aachs%26aulast%3DBecker%26aufirst%3DG.%26aulast%3DBolbos%26aufirst%3DR.%26aulast%3DCostes%26aufirst%3DN.%26aulast%3DRedout%25C3%25A9%26aufirst%3DJ.%26aulast%3DNewman-Tancredi%26aufirst%3DA.%26aulast%3DZimmer%26aufirst%3DL.%26atitle%3DSelective%2520Serotonin%25205-HT1A%2520Receptor%2520Biased%2520Agonists%2520Elicitdistinct%2520Brain%2520Activation%2520Patterns%253A%2520A%2520PharmacoMRI%2520Study%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D26633%26doi%3D10.1038%2Fsrep26633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lladó-Pelfort, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assié, M.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman-Tancredi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artigas, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celada, P.</span></span> <span> </span><span class="NLM_article-title">Preferential in vivo action of F15599, a novel 5-HT1A receptor agonist, at postsynaptic 5-HT1A receptors</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>160</i></span>,  <span class="NLM_fpage">1929</span>– <span class="NLM_lpage">1940</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2010.00738.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1111%2Fj.1476-5381.2010.00738.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=20649591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1KjurzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2010&pages=1929-1940&author=L.+Llad%C3%B3-Pelfortauthor=M.-B.+Assi%C3%A9author=A.+Newman-Tancrediauthor=F.+Artigasauthor=P.+Celada&title=Preferential+in+vivo+action+of+F15599%2C+a+novel+5-HT1A+receptor+agonist%2C+at+postsynaptic+5-HT1A+receptors&doi=10.1111%2Fj.1476-5381.2010.00738.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Preferential in vivo action of F15599, a novel 5-HT1A receptor agonist, at postsynaptic 5-HT1A receptors</span></div><div class="casAuthors">Llado-Pelfort, L.; Assie, M.-B.; Newman-Tancredi, A.; Artigas, F.; Celada, P.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1929-1940</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">F15599, a novel 5-hydroxytryptamine (5-HT)1A receptor agonist with 1000-fold selectivity for 5-HT compared with other monoamine receptors, shows antidepressant and procognitive activity at very low doses in animal models.  We examd. the in vivo activity of F15599 at somatodendritic autoreceptors and postsynaptic 5-HT1A heteroreceptors.  In vivo single unit and local field potential recordings and microdialysis in the rat.  F15599 increased the discharge rate of pyramidal neurons in medial prefrontal cortex (mPFC) from 0.2 μg·kg-1 i.v and reduced that of dorsal raphe 5-hydroxytryptaminergic neurons at doses >10-fold higher (minimal ED 8.2 μg·kg-1 i.v.).  Both effects were reversed by the 5-HT1A antagonist (±)WAY100635.  F15599 did not alter low frequency oscillations (∼1 Hz) in mPFC.  In microdialysis studies, F15599 increased dopamine output in mPFC (an effect dependent on the activation of postsynaptic 5-HT1A receptors) with an ED50 of 30 μg·kg-1 i.p., whereas it reduced hippocampal 5-HT release (an effect dependent exclusively on 5-HT1A autoreceptor activation) with an ED50 of 240 μg·kg-1 i.p.  Likewise, application of F15599 by reverse dialysis in mPFC increased dopamine output in a concn.-dependent manner.  All neurochem. responses to F15599 were prevented by administration of (±)WAY100635.  These results indicate that systemic administration of F15599 preferentially activates postsynaptic 5-HT1A receptors in PFC rather than somatodendritic 5-HT1A autoreceptors.  This regional selectivity distinguishes F15599 from previously developed 5-HT1A receptor agonists, which preferentially activate somatodendritic 5-HT1A autoreceptors, suggesting that F15599 may be particularly useful in the treatment of depression and of cognitive deficits in schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5_O5rsSUv3LVg90H21EOLACvtfcHk0liGLe9tv2cBFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1KjurzF&md5=062adb7f40fdbd9ae10fdd6900713e97</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2010.00738.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2010.00738.x%26sid%3Dliteratum%253Aachs%26aulast%3DLlad%25C3%25B3-Pelfort%26aufirst%3DL.%26aulast%3DAssi%25C3%25A9%26aufirst%3DM.-B.%26aulast%3DNewman-Tancredi%26aufirst%3DA.%26aulast%3DArtigas%26aufirst%3DF.%26aulast%3DCelada%26aufirst%3DP.%26atitle%3DPreferential%2520in%2520vivo%2520action%2520of%2520F15599%252C%2520a%2520novel%25205-HT1A%2520receptor%2520agonist%252C%2520at%2520postsynaptic%25205-HT1A%2520receptors%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D160%26spage%3D1929%26epage%3D1940%26doi%3D10.1111%2Fj.1476-5381.2010.00738.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Assié, M.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auclair, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carilla-Durand, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Depoortère, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koek, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleven, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colpaert, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman-Tancredi, A.</span></span> <span> </span><span class="NLM_article-title">F15599, a highly selective post-synaptic 5-HT1A receptor agonist: in-vivo profile in behavioural models of antidepressant and serotonergic activity</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1285</span>– <span class="NLM_lpage">1298</span>, <span class="refDoi"> DOI: 10.1017/s1461145709991222</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1017%2Fs1461145709991222" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=20059805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1aktb3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=1285-1298&author=M.-B.+Assi%C3%A9author=L.+Bardinauthor=A.+L.+Auclairauthor=E.+Carilla-Durandauthor=R.+Depoort%C3%A8reauthor=W.+Koekauthor=M.+S.+Klevenauthor=F.+Colpaertauthor=B.+Vacherauthor=A.+Newman-Tancredi&title=F15599%2C+a+highly+selective+post-synaptic+5-HT1A+receptor+agonist%3A+in-vivo+profile+in+behavioural+models+of+antidepressant+and+serotonergic+activity&doi=10.1017%2Fs1461145709991222"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">F15599, a highly selective post-synaptic 5-HT1A receptor agonist: in-vivo profile in behavioural models of antidepressant and serotonergic activity</span></div><div class="casAuthors">Assie, Marie-Bernadette; Bardin, Laurent; Auclair, Agnes L.; Carilla-Durand, Elisabeth; Depoortere, Ronan; Koek, Wouter; Kleven, Mark S.; Colpaert, Francis; Vacher, Bernard; Newman-Tancredi, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1285-1298</span>CODEN:
                <span class="NLM_cas:coden">IJNUFB</span>;
        ISSN:<span class="NLM_cas:issn">1461-1457</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">F15599 is a novel agonist with high selectivity and efficacy at serotonin 5-HT1A receptors (5-HT1ARs).  In signal transduction, electrophysiol. and neurochem. tests, F15599 preferentially activates post-synaptic 5-HT1ARs in rat frontal cortex.  Such a profile may translate to an improved profile of therapeutic activity for mood disorders.  The in-vivo effects of F15599 were therefore compared with those of a related compd., F13714, in rat models of antidepressant activity and 5-HT1AR activation: forced swimming test (FST), conditioned stress-induced ultrasonic vocalization, 5-HT syndrome, plasma corticosterone and body temp.  Acute administration of F15599 or F13714 reduced immobility in the FST at low doses; these effects were long lasting and the effects of F15599 were maintained after repeated (5 d, p.o.) administration.  Both compds. decreased ultrasonic vocalization duration at low doses.  In contrast, higher doses of F15599 were required to induce lower lip retraction, elements of the 5-HT behavioral syndrome, hypothermia and to increase plasma corticosterone levels.  Notably, there was a greater sepn. of ED50 between FST and other effects for F15599 than for F13714.  Thus, the in-vivo potency of F15599 in models of antidepressant/anti-stress activity is similar to that of F13714, despite the fact that the latter has an in-vitro potency two orders of magnitude greater.  In contrast F15599 has a lower propensity than F13714 to induce other serotonergic signs.  The distinctive pharmacol. profile of F15599 suggests that preferential targeting of post-synaptic 5-HT1ARs constitutes a promising strategy for improved antidepressant therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo195YLEeqRsLVg90H21EOLACvtfcHk0liGLe9tv2cBFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1aktb3L&md5=a979820d0f8a211519ce86d4c56c8fd4</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1017%2Fs1461145709991222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252Fs1461145709991222%26sid%3Dliteratum%253Aachs%26aulast%3DAssi%25C3%25A9%26aufirst%3DM.-B.%26aulast%3DBardin%26aufirst%3DL.%26aulast%3DAuclair%26aufirst%3DA.%2BL.%26aulast%3DCarilla-Durand%26aufirst%3DE.%26aulast%3DDepoort%25C3%25A8re%26aufirst%3DR.%26aulast%3DKoek%26aufirst%3DW.%26aulast%3DKleven%26aufirst%3DM.%2BS.%26aulast%3DColpaert%26aufirst%3DF.%26aulast%3DVacher%26aufirst%3DB.%26aulast%3DNewman-Tancredi%26aufirst%3DA.%26atitle%3DF15599%252C%2520a%2520highly%2520selective%2520post-synaptic%25205-HT1A%2520receptor%2520agonist%253A%2520in-vivo%2520profile%2520in%2520behavioural%2520models%2520of%2520antidepressant%2520and%2520serotonergic%2520activity%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2010%26volume%3D13%26spage%3D1285%26epage%3D1298%26doi%3D10.1017%2Fs1461145709991222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jastrzębska-Więsek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Partyka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rychtyk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Śniecikowska, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kołaczkowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wesołowska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varney, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman-Tancredi, A.</span></span> <span> </span><span class="NLM_article-title">Activity of Serotonin 5-HT1AReceptor Biased Agonists in Rat: Anxiolytic and Antidepressant-like Properties</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1040</span>– <span class="NLM_lpage">1050</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.7b00443</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.7b00443" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=1040-1050&author=M.+Jastrz%C4%99bska-Wi%C4%99sekauthor=A.+Partykaauthor=J.+Rychtykauthor=J.+%C5%9Aniecikowskaauthor=M.+Ko%C5%82aczkowskiauthor=A.+Weso%C5%82owskaauthor=M.+A.+Varneyauthor=A.+Newman-Tancredi&title=Activity+of+Serotonin+5-HT1AReceptor+Biased+Agonists+in+Rat%3A+Anxiolytic+and+Antidepressant-like+Properties&doi=10.1021%2Facschemneuro.7b00443"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.7b00443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.7b00443%26sid%3Dliteratum%253Aachs%26aulast%3DJastrz%25C4%2599bska-Wi%25C4%2599sek%26aufirst%3DM.%26aulast%3DPartyka%26aufirst%3DA.%26aulast%3DRychtyk%26aufirst%3DJ.%26aulast%3D%25C5%259Aniecikowska%26aufirst%3DJ.%26aulast%3DKo%25C5%2582aczkowski%26aufirst%3DM.%26aulast%3DWeso%25C5%2582owska%26aufirst%3DA.%26aulast%3DVarney%26aufirst%3DM.%2BA.%26aulast%3DNewman-Tancredi%26aufirst%3DA.%26atitle%3DActivity%2520of%2520Serotonin%25205-HT1AReceptor%2520Biased%2520Agonists%2520in%2520Rat%253A%2520Anxiolytic%2520and%2520Antidepressant-like%2520Properties%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2017%26volume%3D9%26spage%3D1040%26epage%3D1050%26doi%3D10.1021%2Facschemneuro.7b00443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
Goethem, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman-Tancredi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varney, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prickaerts, J.</span></span> <span> </span><span class="NLM_article-title">Divergent effects of the ‘biased’ 5-HT1Areceptor agonists F15599 and F13714 in a novel object pattern separation task</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">2532</span>– <span class="NLM_lpage">2543</span>, <span class="refDoi"> DOI: 10.1111/bph.13071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1111%2Fbph.13071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=25572672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVent77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2015&pages=2532-2543&author=N.+P.+van%0AGoethemauthor=R.+Schreiberauthor=A.+Newman-Tancrediauthor=M.+Varneyauthor=J.+Prickaerts&title=Divergent+effects+of+the+%E2%80%98biased%E2%80%99+5-HT1Areceptor+agonists+F15599+and+F13714+in+a+novel+object+pattern+separation+task&doi=10.1111%2Fbph.13071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Divergent effects of the 'biased' 5-HT1A receptor agonists F15599 and F13714 in a novel object pattern separation task</span></div><div class="casAuthors">van Goethem, N. P.; Schreiber, R.; Newman-Tancredi, A.; Varney, M.; Prickaerts, J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2532-2543</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : Pattern sepn., i.e., the formation of distinct representations from similar inputs, is an important hippocampal process implicated in cognitive domains like episodic memory.  A deficit in pattern sepn. could lead to memory impairments in several psychiatric and neurol. disorders.  Hence, mechanisms by which pattern sepn. can be increased are of potential therapeutic interest.  Exptl. approach : 5-HT1A receptors are involved in spatial memory.  Herein we tested the 'biased' 5-HT1A receptor agonists F15599, which preferentially activates post-synaptic heteroreceptors, and F13714, which preferentially activates raphe-located autoreceptors, in rats in a novel spatial task assessing pattern sepn., the object pattern sepn. (OPS) task.  Key Results : The acetylcholinesterase inhibitor donepezil, which served as a pos. control, significantly improved spatial pattern sepn. at a dose of 1 mg·kg-1, p.o.  F15599 increased pattern sepn. at 0.04 mg·kg-1, i.p., while F13714 decreased pattern sepn. at 0.0025 mg·kg-1, i.p.  The selective 5-HT1A receptor antagonist WAY-100635 (0.63 mg·kg-1, s.c.) counteracted the effects of both agonists.  These data suggest that acute preferential activation of post-synaptic 5-HT1A heteroreceptors improves spatial pattern sepn., whereas acute preferential activation of raphe-located 5-HT1A autoreceptors impairs performance.  Conclusions and Implications : We successfully established and validated a novel, simple and robust OPS task and obsd. a diverging profile of response with 'biased' 5-HT1A receptor agonists based on their targeting of receptors in distinct brain regions.  Our data suggest that the post-synaptic 5-HT1A receptor consists of a potential novel mol. target to improve pattern sepn. performance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYOfTXnh6VkrVg90H21EOLACvtfcHk0ljf2-vFxXIuWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVent77M&md5=e9434ddb0cae42d46626cd05e73ef1e1</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1111%2Fbph.13071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.13071%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BGoethem%26aufirst%3DN.%2BP.%26aulast%3DSchreiber%26aufirst%3DR.%26aulast%3DNewman-Tancredi%26aufirst%3DA.%26aulast%3DVarney%26aufirst%3DM.%26aulast%3DPrickaerts%26aufirst%3DJ.%26atitle%3DDivergent%2520effects%2520of%2520the%2520%25E2%2580%2598biased%25E2%2580%2599%25205-HT1Areceptor%2520agonists%2520F15599%2520and%2520F13714%2520in%2520a%2520novel%2520object%2520pattern%2520separation%2520task%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D172%26spage%3D2532%26epage%3D2543%26doi%3D10.1111%2Fbph.13071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Newman-Tancredi, A.</span></span> <span> </span><span class="NLM_article-title">Biased Agonism at Serotonin 5HT1A Receptors: Preferential Postsynaptic Activity for Improved Therapy of CNS Disorders</span>. <i>Neuropsychiatry</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">149</span>, <span class="refDoi"> DOI: 10.2217/npy.11.12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.2217%2Fnpy.11.12" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2011&pages=149&author=A.+Newman-Tancredi&title=Biased+Agonism+at+Serotonin+5HT1A+Receptors%3A+Preferential+Postsynaptic+Activity+for+Improved+Therapy+of+CNS+Disorders&doi=10.2217%2Fnpy.11.12"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.2217%2Fnpy.11.12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fnpy.11.12%26sid%3Dliteratum%253Aachs%26aulast%3DNewman-Tancredi%26aufirst%3DA.%26atitle%3DBiased%2520Agonism%2520at%2520Serotonin%25205HT1A%2520Receptors%253A%2520Preferential%2520Postsynaptic%2520Activity%2520for%2520Improved%2520Therapy%2520of%2520CNS%2520Disorders%26jtitle%3DNeuropsychiatry%26date%3D2011%26volume%3D1%26spage%3D149%26doi%3D10.2217%2Fnpy.11.12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Depoortère, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auclair, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colpaert, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman-Tancredi, A.</span></span> <span> </span><span class="NLM_article-title">F15599, a Preferential Post-Synaptic 5-HT1A Receptor Agonist: Activity in Models of Cognition in Comparison with Reference 5-HT1A Receptor Agonists</span>. <i>Eur. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">641</span>– <span class="NLM_lpage">654</span>, <span class="refDoi"> DOI: 10.1016/j.euroneuro.2010.04.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2Fj.euroneuro.2010.04.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=20488670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC3cXps1ehurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=641-654&author=R.+Depoort%C3%A8reauthor=A.+L.+Auclairauthor=L.+Bardinauthor=F.+C.+Colpaertauthor=B.+Vacherauthor=A.+Newman-Tancredi&title=F15599%2C+a+Preferential+Post-Synaptic+5-HT1A+Receptor+Agonist%3A+Activity+in+Models+of+Cognition+in+Comparison+with+Reference+5-HT1A+Receptor+Agonists&doi=10.1016%2Fj.euroneuro.2010.04.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">F15599, a preferential post-synaptic 5-HT1A receptor agonist: Activity in models of cognition in comparison with reference 5-HT1A receptor agonists</span></div><div class="casAuthors">Depoortere, Ronan; Auclair, Agnes L.; Bardin, Laurent; Colpaert, Francis C.; Vacher, Bernard; Newman-Tancredi, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">European Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">641-654</span>CODEN:
                <span class="NLM_cas:coden">EURNE8</span>;
        ISSN:<span class="NLM_cas:issn">0924-977X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We assessed the activity of F15599, a selective and high efficacy 5-HT1A agonist that preferentially activates post- vs. pre-synaptic receptors, in rat cognition/memory models.  F15599 (0.16 mg/kg i.p.) partially alleviated detrimental effects of phencyclidine on working and ref. memory deficit in a hole-board model.  It also attenuated phencyclidine-induced deficit of cognitive flexibility in a reversal learning task, without effects of its own.  F13714 (0.04 mg/kg) a chem. congener of F15599, and 8-OH-DPAT (0.01 or 0.16), were inactive against these phencyclidine-induced deficits, and/or even worsened basal performances.  F15599 (0.04-2.5) was less disruptive than F13714 (0.005-0.16) or 8-OH-DPAT (0.01-0.63), on basal performance in models of attention (5-choice serial reaction time task) and working memory (delayed non-matching to position).  Finally, unlike either comparator, F15599 reduced PPI with modest potency and only partially.  To conclude, F15599, in models of memory/cognition, has a more favorable profile than F13714 and 8-OH-DPAT.  This suggests that preferential activation of post-synaptic 5-HT1A receptors could prove useful in pathologies characterized by cognitive/memory deficiencies, such as schizophrenia and depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3znexqVaNSbVg90H21EOLACvtfcHk0ljf2-vFxXIuWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXps1ehurk%253D&md5=f1598c2e68a80c345f34f0be89707c1d</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.euroneuro.2010.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.euroneuro.2010.04.005%26sid%3Dliteratum%253Aachs%26aulast%3DDepoort%25C3%25A8re%26aufirst%3DR.%26aulast%3DAuclair%26aufirst%3DA.%2BL.%26aulast%3DBardin%26aufirst%3DL.%26aulast%3DColpaert%26aufirst%3DF.%2BC.%26aulast%3DVacher%26aufirst%3DB.%26aulast%3DNewman-Tancredi%26aufirst%3DA.%26atitle%3DF15599%252C%2520a%2520Preferential%2520Post-Synaptic%25205-HT1A%2520Receptor%2520Agonist%253A%2520Activity%2520in%2520Models%2520of%2520Cognition%2520in%2520Comparison%2520with%2520Reference%25205-HT1A%2520Receptor%2520Agonists%26jtitle%3DEur.%2520Neuropsychopharmacol.%26date%3D2010%26volume%3D20%26spage%3D641%26epage%3D654%26doi%3D10.1016%2Fj.euroneuro.2010.04.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mawatari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawasaki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onoe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman-Tancredi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onoe, H.</span></span> <span> </span><span class="NLM_article-title">Marmoset Serotonin 5-HT1A Receptor Mapping with a Biased Agonist PET Probe 18F-F13714: Comparison with an Antagonist Tracer 18F-MPPF in Awake and Anesthetized States</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">pyw079</span>, <span class="refDoi"> DOI: 10.1093/ijnp/pyw079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1093%2Fijnp%2Fpyw079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=27608810" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2016&pages=pyw079&author=C.+Yokoyamaauthor=A.+Mawatariauthor=A.+Kawasakiauthor=C.+Takedaauthor=K.+Onoeauthor=H.+Doiauthor=A.+Newman-Tancrediauthor=L.+Zimmerauthor=H.+Onoe&title=Marmoset+Serotonin+5-HT1A+Receptor+Mapping+with+a+Biased+Agonist+PET+Probe+18F-F13714%3A+Comparison+with+an+Antagonist+Tracer+18F-MPPF+in+Awake+and+Anesthetized+States&doi=10.1093%2Fijnp%2Fpyw079"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1093%2Fijnp%2Fpyw079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fijnp%252Fpyw079%26sid%3Dliteratum%253Aachs%26aulast%3DYokoyama%26aufirst%3DC.%26aulast%3DMawatari%26aufirst%3DA.%26aulast%3DKawasaki%26aufirst%3DA.%26aulast%3DTakeda%26aufirst%3DC.%26aulast%3DOnoe%26aufirst%3DK.%26aulast%3DDoi%26aufirst%3DH.%26aulast%3DNewman-Tancredi%26aufirst%3DA.%26aulast%3DZimmer%26aufirst%3DL.%26aulast%3DOnoe%26aufirst%3DH.%26atitle%3DMarmoset%2520Serotonin%25205-HT1A%2520Receptor%2520Mapping%2520with%2520a%2520Biased%2520Agonist%2520PET%2520Probe%252018F-F13714%253A%2520Comparison%2520with%2520an%2520Antagonist%2520Tracer%252018F-MPPF%2520in%2520Awake%2520and%2520Anesthetized%2520States%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2016%26volume%3D19%26spage%3Dpyw079%26doi%3D10.1093%2Fijnp%2Fpyw079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Boer, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman-Tancredi, A.</span></span> <span> </span><span class="NLM_article-title">Anti-aggressive effects of the selective high-efficacy ‘biased’ 5-HT1A receptor agonists F15599 and F13714 in male WTG rats</span>. <i>Psychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>233</i></span>,  <span class="NLM_fpage">937</span>– <span class="NLM_lpage">947</span>, <span class="refDoi"> DOI: 10.1007/s00213-015-4173-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1007%2Fs00213-015-4173-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=26694810" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=233&publication_year=2015&pages=937-947&author=S.+F.+de%0ABoerauthor=A.+Newman-Tancredi&title=Anti-aggressive+effects+of+the+selective+high-efficacy+%E2%80%98biased%E2%80%99+5-HT1A+receptor+agonists+F15599+and+F13714+in+male+WTG+rats&doi=10.1007%2Fs00213-015-4173-x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1007%2Fs00213-015-4173-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-015-4173-x%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BBoer%26aufirst%3DS.%2BF.%26aulast%3DNewman-Tancredi%26aufirst%3DA.%26atitle%3DAnti-aggressive%2520effects%2520of%2520the%2520selective%2520high-efficacy%2520%25E2%2580%2598biased%25E2%2580%2599%25205-HT1A%2520receptor%2520agonists%2520F15599%2520and%2520F13714%2520in%2520male%2520WTG%2520rats%26jtitle%3DPsychopharmacology%26date%3D2015%26volume%3D233%26spage%3D937%26epage%3D947%26doi%3D10.1007%2Fs00213-015-4173-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bucki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcinkowska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Śniecikowska, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Więckowski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawłowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Głuch-Lutwin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gryboś, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siwek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pytka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jastrzębska-Więsek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Partyka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wesołowska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mierzejewski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kołaczkowski, M.</span></span> <span> </span><span class="NLM_article-title">Novel 3-(1,2,3,6-Tetrahydropyridin-4-Yl)-1H-Indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7483</span>– <span class="NLM_lpage">7501</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00839</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00839" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1KrtbbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7483-7501&author=A.+Buckiauthor=M.+Marcinkowskaauthor=J.+%C5%9Aniecikowskaauthor=K.+Wi%C4%99ckowskiauthor=M.+Paw%C5%82owskiauthor=M.+G%C5%82uch-Lutwinauthor=A.+Grybo%C5%9Bauthor=A.+Siwekauthor=K.+Pytkaauthor=M.+Jastrz%C4%99bska-Wi%C4%99sekauthor=A.+Partykaauthor=A.+Weso%C5%82owskaauthor=P.+Mierzejewskiauthor=M.+Ko%C5%82aczkowski&title=Novel+3-%281%2C2%2C3%2C6-Tetrahydropyridin-4-Yl%29-1H-Indole-Based+Multifunctional+Ligands+with+Antipsychotic-Like%2C+Mood-Modulating%2C+and+Procognitive+Activity&doi=10.1021%2Facs.jmedchem.7b00839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity</span></div><div class="casAuthors">Bucki, Adam; Marcinkowska, Monika; Sniecikowska, Joanna; Wieckowski, Krzysztof; Pawlowski, Maciej; Gluch-Lutwin, Monika; Grybos, Anna; Siwek, Agata; Pytka, Karolina; Jastrzebska-Wiesek, Magdalena; Partyka, Anna; Wesolowska, Anna; Mierzejewski, Pawel; Kolaczkowski, Marcin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7483-7501</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The most troublesome aspects of behavioral and psychol. symptoms of dementia (BPSD) are nowadays addressed by antidepressant, anxiolytic, and antipsychotic drugs, often administered off-label.  Considering their modest effectiveness in dementia patients, the increased risk of adverse events and cognitive decline, there is an unmet need for well-tolerated and effective therapy of BPSD.  We designed and synthesized multifunctional ligands characterized in vitro as high-affinity partial agonists of D2R, antagonists of 5-HT6R, and blockers of SERT.  Moreover, the mols. activated 5-HT1AR and blocked 5-HT7R while having no relevant affinity for off-target M1R and hERG channel.  Compd. I, (N-{2-[4-(5-chloro-1H-indol-3-yl)-1,2,3,6-tetrahydropyridin-1-yl]ethyl}-3-methylbenzene-1-sulfonamide), exhibited a broad antipsychotic-, antidepressant-, and anxiolytic-like activity, not eliciting motor impairments in mice.  Most importantly, I showed memory-enhancing properties and it ameliorated memory deficits induced by scopolamine.  The mol. outperformed most important comparators in selected tests, indicating its potential in the treatment of both cognitive and noncognitive (behavioral and psychol.) symptoms of dementia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_i47_Akgt17Vg90H21EOLACvtfcHk0lgtAstEa8aTkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1KrtbbF&md5=9bb21d4918f0c0575aeef817b89b9b19</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00839%26sid%3Dliteratum%253Aachs%26aulast%3DBucki%26aufirst%3DA.%26aulast%3DMarcinkowska%26aufirst%3DM.%26aulast%3D%25C5%259Aniecikowska%26aufirst%3DJ.%26aulast%3DWi%25C4%2599ckowski%26aufirst%3DK.%26aulast%3DPaw%25C5%2582owski%26aufirst%3DM.%26aulast%3DG%25C5%2582uch-Lutwin%26aufirst%3DM.%26aulast%3DGrybo%25C5%259B%26aufirst%3DA.%26aulast%3DSiwek%26aufirst%3DA.%26aulast%3DPytka%26aufirst%3DK.%26aulast%3DJastrz%25C4%2599bska-Wi%25C4%2599sek%26aufirst%3DM.%26aulast%3DPartyka%26aufirst%3DA.%26aulast%3DWeso%25C5%2582owska%26aufirst%3DA.%26aulast%3DMierzejewski%26aufirst%3DP.%26aulast%3DKo%25C5%2582aczkowski%26aufirst%3DM.%26atitle%3DNovel%25203-%25281%252C2%252C3%252C6-Tetrahydropyridin-4-Yl%2529-1H-Indole-Based%2520Multifunctional%2520Ligands%2520with%2520Antipsychotic-Like%252C%2520Mood-Modulating%252C%2520and%2520Procognitive%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D7483%26epage%3D7501%26doi%3D10.1021%2Facs.jmedchem.7b00839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nygaard, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frimurer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holst, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenkilde, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, T. W.</span></span> <span> </span><span class="NLM_article-title">Ligand Binding and Micro-Switches in 7TM Receptor Structures</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">249</span>– <span class="NLM_lpage">259</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2009.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2Fj.tips.2009.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=19375807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltlKktr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=249-259&author=R.+Nygaardauthor=T.+M.+Frimurerauthor=B.+Holstauthor=M.+M.+Rosenkildeauthor=T.+W.+Schwartz&title=Ligand+Binding+and+Micro-Switches+in+7TM+Receptor+Structures&doi=10.1016%2Fj.tips.2009.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand binding and micro-switches in 7TM receptor structures</span></div><div class="casAuthors">Nygaard, Rie; Frimurer, Thomas M.; Holst, Birgitte; Rosenkilde, Mette M.; Schwartz, Thue W.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">249-259</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The past couple of years have seen several novel X-ray structures of 7 transmembrane (7TM) receptors in complex with antagonists and even with a peptide fragment of a G protein.  These structures demonstrate that the main ligand-binding pocket in 7TM receptors is like a funnel with a partial 'lid' in which extracellular loop 2b, in particular, functions as a gating element.  Small-mol. antagonists and inverse agonists bind in very different modes: some very deeply and others more superficially, even reaching out above the transmembrane region.  Several highly conserved residues seem to function as micro-switches of which ArgIII:26 (Arg3.50) in its active conformation interacts directly with the G protein.  These micro-switches together with a hydrogen-bond network between conserved polar residues and structural water mols. are proposed to constitute an extended allosteric interface between the domains (i.e. esp. TM-VI), which performs the large, global toggle switch movements connecting ligand binding with intracellular signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0A3KKnq_9dLVg90H21EOLACvtfcHk0lgtAstEa8aTkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltlKktr8%253D&md5=d0384d34d39e08f9b82e6752c358a6cb</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2009.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2009.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DNygaard%26aufirst%3DR.%26aulast%3DFrimurer%26aufirst%3DT.%2BM.%26aulast%3DHolst%26aufirst%3DB.%26aulast%3DRosenkilde%26aufirst%3DM.%2BM.%26aulast%3DSchwartz%26aufirst%3DT.%2BW.%26atitle%3DLigand%2520Binding%2520and%2520Micro-Switches%2520in%25207TM%2520Receptor%2520Structures%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2009%26volume%3D30%26spage%3D249%26epage%3D259%26doi%3D10.1016%2Fj.tips.2009.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vacher, B.</span>; <span class="NLM_string-name">Maurel, J. L.</span>; <span class="NLM_string-name">Brunel, S.</span></span> <span> </span><span class="NLM_article-title">Method for Preparing (3-Chloro-4-Fluorophenyl)-(4-Fluoro-4-{[(5methyl-Pyrimidin-2-Ylmethyl)-Amino]-Methyl}-Piperidin-1-Yl)-Methanone and Novel Intermediate Pyrimidine Derivatives</span>. WO <span class="NLM_patent">039499 A1</span>, Sept 22, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=B.+Vacher&author=J.+L.+Maurel&author=S.+Brunel&title=Method+for+Preparing+%283-Chloro-4-Fluorophenyl%29-%284-Fluoro-4-%7B%5B%285methyl-Pyrimidin-2-Ylmethyl%29-Amino%5D-Methyl%7D-Piperidin-1-Yl%29-Methanone+and+Novel+Intermediate+Pyrimidine+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DVacher%26aufirst%3DB.%26atitle%3DMethod%2520for%2520Preparing%2520%25283-Chloro-4-Fluorophenyl%2529-%25284-Fluoro-4-%257B%255B%25285methyl-Pyrimidin-2-Ylmethyl%2529-Amino%255D-Methyl%257D-Piperidin-1-Yl%2529-Methanone%2520and%2520Novel%2520Intermediate%2520Pyrimidine%2520Derivatives%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maurel, J. L.</span>; <span class="NLM_string-name">Bonnaud, B.</span>; <span class="NLM_string-name">Ribet, J.-P.</span>; <span class="NLM_string-name">Vacher, B.</span></span> <span> </span><span class="NLM_article-title">Synthesis Method and Intermediates of Pyridin-2-Yl-Methylamine</span>. WO <span class="NLM_patent">064585 A1</span>, Feb 11, <span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=J.+L.+Maurel&author=B.+Bonnaud&author=J.-P.+Ribet&author=B.+Vacher&title=Synthesis+Method+and+Intermediates+of+Pyridin-2-Yl-Methylamine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMaurel%26aufirst%3DJ.%2BL.%26atitle%3DSynthesis%2520Method%2520and%2520Intermediates%2520of%2520Pyridin-2-Yl-Methylamine%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jończyk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedoryński, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mąkosza, M.</span></span> <span> </span><span class="NLM_article-title">Reactions of Organic Anions. XLIII. Catalytic Method for Synthesis of Glycidic Nitriles in Aqueous Medium</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1972</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">2395</span>– <span class="NLM_lpage">2396</span>, <span class="refDoi"> DOI: 10.1016/s0040-4039(01)85312-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2Fs0040-4039%2801%2985312-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1972&pages=2395-2396&author=A.+Jo%C5%84czykauthor=M.+Fedory%C5%84skiauthor=M.+M%C4%85kosza&title=Reactions+of+Organic+Anions.+XLIII.+Catalytic+Method+for+Synthesis+of+Glycidic+Nitriles+in+Aqueous+Medium&doi=10.1016%2Fs0040-4039%2801%2985312-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fs0040-4039%2801%2985312-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0040-4039%252801%252985312-0%26sid%3Dliteratum%253Aachs%26aulast%3DJo%25C5%2584czyk%26aufirst%3DA.%26aulast%3DFedory%25C5%2584ski%26aufirst%3DM.%26aulast%3DM%25C4%2585kosza%26aufirst%3DM.%26atitle%3DReactions%2520of%2520Organic%2520Anions.%2520XLIII.%2520Catalytic%2520Method%2520for%2520Synthesis%2520of%2520Glycidic%2520Nitriles%2520in%2520Aqueous%2520Medium%26jtitle%3DTetrahedron%2520Lett.%26date%3D1972%26volume%3D13%26spage%3D2395%26epage%3D2396%26doi%3D10.1016%2Fs0040-4039%2801%2985312-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vacher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnaud, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jubault, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koek, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assié, M.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleven, M.</span></span> <span> </span><span class="NLM_article-title">Novel Derivatives of 2-Pyridinemethylamine as Selective, Potent, and Orally Active Agonists at 5-HT1AReceptors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">1648</span>– <span class="NLM_lpage">1660</span>, <span class="refDoi"> DOI: 10.1021/jm9806906</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9806906" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=1648-1660&author=B.+Vacherauthor=B.+Bonnaudauthor=P.+Funesauthor=N.+Jubaultauthor=W.+Koekauthor=M.-B.+Assi%C3%A9author=C.+Cosiauthor=M.+Kleven&title=Novel+Derivatives+of+2-Pyridinemethylamine+as+Selective%2C+Potent%2C+and+Orally+Active+Agonists+at+5-HT1AReceptors&doi=10.1021%2Fjm9806906"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm9806906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9806906%26sid%3Dliteratum%253Aachs%26aulast%3DVacher%26aufirst%3DB.%26aulast%3DBonnaud%26aufirst%3DB.%26aulast%3DFunes%26aufirst%3DP.%26aulast%3DJubault%26aufirst%3DN.%26aulast%3DKoek%26aufirst%3DW.%26aulast%3DAssi%25C3%25A9%26aufirst%3DM.-B.%26aulast%3DCosi%26aufirst%3DC.%26aulast%3DKleven%26aufirst%3DM.%26atitle%3DNovel%2520Derivatives%2520of%25202-Pyridinemethylamine%2520as%2520Selective%252C%2520Potent%252C%2520and%2520Orally%2520Active%2520Agonists%2520at%25205-HT1AReceptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D1648%26epage%3D1660%26doi%3D10.1021%2Fjm9806906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suga, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamatani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlosser, M.</span></span> <span> </span><span class="NLM_article-title">Regioselective Formation of Fluorohydrins and Their Stereoselective Conversion to Fluoroolefins</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">4247</span>– <span class="NLM_lpage">4254</span>, <span class="refDoi"> DOI: 10.1016/s0040-4020(01)86761-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2Fs0040-4020%2801%2986761-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADyaK3MXmtFCqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=1990&pages=4247-4254&author=H.+Sugaauthor=T.+Hamataniauthor=M.+Schlosser&title=Regioselective+Formation+of+Fluorohydrins+and+Their+Stereoselective+Conversion+to+Fluoroolefins&doi=10.1016%2Fs0040-4020%2801%2986761-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Regioselective formation of fluorohydrins and their stereoselective conversion to fluoroolefins</span></div><div class="casAuthors">Suga, Hiroaki; Hamatani, Takeshi; Schlosser, Manfred</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4247-54</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    </div><div class="casAbstract">When treated with KOCMe3 in THF, fluorohydrin p-tosylates afford fluoro olefins, e.g., Z- or E-Me(CH2)4CF:CH(CH2)4Me, in high yields.  Fluorohydrins are readily and stereoselectively accessible by antiperiplanar addn. of HF to oxiranes.  Terminal epoxides give preferentially 2-fluoro-1-alkanols with HF-pyridine mixt. in PhMe, while mainly 1-fluoro-2-alkanols result from reaction with Huenig's hydrofluoride (i.e., the adduct of HF and (Me2CH)2NEt.  With 2-hydroxymethyl-substituted oxiranes, 3-fluoro-1,2-alkanediols are obtained predominantly if not exclusively.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0t0to3qWYaLVg90H21EOLACvtfcHk0lhJsIz0UpOeMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXmtFCqsQ%253D%253D&md5=63e5111920196b068df6dd832e9460f6</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fs0040-4020%2801%2986761-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0040-4020%252801%252986761-2%26sid%3Dliteratum%253Aachs%26aulast%3DSuga%26aufirst%3DH.%26aulast%3DHamatani%26aufirst%3DT.%26aulast%3DSchlosser%26aufirst%3DM.%26atitle%3DRegioselective%2520Formation%2520of%2520Fluorohydrins%2520and%2520Their%2520Stereoselective%2520Conversion%2520to%2520Fluoroolefins%26jtitle%3DTetrahedron%26date%3D1990%26volume%3D46%26spage%3D4247%26epage%3D4254%26doi%3D10.1016%2Fs0040-4020%2801%2986761-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipinski, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominy, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feeney, P. J.</span></span> <span> </span><span class="NLM_article-title">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3-25. 1</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1016/s0169-409x(00)00129-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2Fs0169-409x%2800%2900129-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=11259830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitVOhs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2001&pages=3-26&author=C.+A.+Lipinskiauthor=F.+Lombardoauthor=B.+W.+Dominyauthor=P.+J.+Feeney&title=Experimental+and+computational+approaches+to+estimate+solubility+and+permeability+in+drug+discovery+and+development+settings+1PII+of+original+article%3A+S0169-409X%2896%2900423-1.+The+article+was+originally+published+in+Advanced+Drug+Delivery+Reviews+23+%281997%29+3-25.+1&doi=10.1016%2Fs0169-409x%2800%2900129-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span></div><div class="casAuthors">Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">3-26</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">A review with 50 refs.  Exptl. and computational approaches to est. soly. and permeability in discovery and development settings are described.  In the discovery setting 'the rule of 5' predicts that poor absorption or permeation is more likely when there are more than 5 H-bond donors, 10 H-bond acceptors, the mol. wt. (MWT) is greater than 500 and the calcd. Log P (CLogP) is greater than 5 (or MlogP >4.15).  Computational methodol. for the rule-based Moriguchi Log P (MLogP) calcn. is described.  Turbidimetric soly. measurement is described and applied to known drugs.  High throughput screening (HTS) leads tend to have higher MWT and Log P and lower turbidimetric soly. than leads in the pre-HTS era.  In the development setting, soly. calcns. focus on exact value prediction and are difficult because of polymorphism.  Recent work on linear free energy relationships and Log P approaches are critically reviewed.  Useful predictions are possible in closely related analog series when coupled with exptl. thermodn. soly. measurements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYDqa02g16urVg90H21EOLACvtfcHk0lhJsIz0UpOeMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitVOhs7o%253D&md5=c60bb89da68f051c0ee7ac4c0468a0e4</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fs0169-409x%2800%2900129-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0169-409x%252800%252900129-0%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DDominy%26aufirst%3DB.%2BW.%26aulast%3DFeeney%26aufirst%3DP.%2BJ.%26atitle%3DExperimental%2520and%2520computational%2520approaches%2520to%2520estimate%2520solubility%2520and%2520permeability%2520in%2520drug%2520discovery%2520and%2520development%2520settings%25201PII%2520of%2520original%2520article%253A%2520S0169-409X%252896%252900423-1.%2520The%2520article%2520was%2520originally%2520published%2520in%2520Advanced%2520Drug%2520Delivery%2520Reviews%252023%2520%25281997%2529%25203-25.%25201%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2001%26volume%3D46%26spage%3D3%26epage%3D26%26doi%3D10.1016%2Fs0169-409x%2800%2900129-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wager, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhoest, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villalobos, A.</span></span> <span> </span><span class="NLM_article-title">Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike Properties</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">435</span>– <span class="NLM_lpage">449</span>, <span class="refDoi"> DOI: 10.1021/cn100008c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn100008c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvVejtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=435-449&author=T.+T.+Wagerauthor=X.+Houauthor=P.+R.+Verhoestauthor=A.+Villalobos&title=Moving+beyond+Rules%3A+The+Development+of+a+Central+Nervous+System+Multiparameter+Optimization+%28CNS+MPO%29+Approach+To+Enable+Alignment+of+Druglike+Properties&doi=10.1021%2Fcn100008c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike Properties</span></div><div class="casAuthors">Wager, Travis T.; Hou, Xinjun; Verhoest, Patrick R.; Villalobos, Anabella</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">435-449</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The interplay among commonly used physicochem. properties in drug design was examd. and utilized to create a prospective design tool focused on the alignment of key druglike attributes.  Using a set of six physicochem. parameters ((a) lipophilicity, calcd. partition coeff. (ClogP); (b) calcd. distribution coeff. at pH = 7.4 (ClogD); (c) mol. wt. (MW); (d) topol. polar surface area (TPSA); (e) no. of hydrogen bond donors (HBD); (f) most basic center (pKa)), a druglikeness central nervous system multiparameter optimization (CNS MPO) algorithm was built and applied to a set of marketed CNS drugs (N = 119) and Pfizer CNS candidates (N = 108), as well as to a large diversity set of Pfizer proprietary compds. (N = 11 303).  The novel CNS MPO algorithm showed that 74% of marketed CNS drugs displayed a high CNS MPO score (MPO desirability score ≥ 4, using a scale of 0-6), in comparison to 60% of the Pfizer CNS candidates.  This anal. suggests that this algorithm could potentially be used to identify compds. with a higher probability of successfully testing hypotheses in the clinic.  In addn., a relationship between an increasing CNS MPO score and alignment of key in vitro attributes of drug discovery (favorable permeability, P-glycoprotein (P-gp) efflux, metabolic stability, and safety) was seen in the marketed CNS drug set, the Pfizer candidate set, and the Pfizer proprietary diversity set.  The CNS MPO scoring function offers advantages over hard cutoffs or utilization of single parameters to optimize structure-activity relationships (SAR) by expanding medicinal chem. design space through a holistic assessment approach.  Based on six physicochem. properties commonly used by medicinal chemists, the CNS MPO function may be used prospectively at the design stage to accelerate the identification of compds. with increased probability of success.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB3Mvkgm_X5bVg90H21EOLACvtfcHk0lix50lky6ixkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvVejtr8%253D&md5=e94998f65a420be6ee4dec4a987cb983</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fcn100008c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn100008c%26sid%3Dliteratum%253Aachs%26aulast%3DWager%26aufirst%3DT.%2BT.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DVerhoest%26aufirst%3DP.%2BR.%26aulast%3DVillalobos%26aufirst%3DA.%26atitle%3DMoving%2520beyond%2520Rules%253A%2520The%2520Development%2520of%2520a%2520Central%2520Nervous%2520System%2520Multiparameter%2520Optimization%2520%2528CNS%2520MPO%2529%2520Approach%2520To%2520Enable%2520Alignment%2520of%2520Druglike%2520Properties%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2010%26volume%3D1%26spage%3D435%26epage%3D449%26doi%3D10.1021%2Fcn100008c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waring, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrowsmith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandrell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pairaudeau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennie, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickett, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, A.</span></span> <span> </span><span class="NLM_article-title">An Analysis of the Attrition of Drug Candidates from Four Major Pharmaceutical Companies</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">475</span>– <span class="NLM_lpage">486</span>, <span class="refDoi"> DOI: 10.1038/nrd4609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1038%2Fnrd4609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=26091267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=475-486&author=M.+J.+Waringauthor=J.+Arrowsmithauthor=A.+R.+Leachauthor=P.+D.+Leesonauthor=S.+Mandrellauthor=R.+M.+Owenauthor=G.+Pairaudeauauthor=W.+D.+Pennieauthor=S.+D.+Pickettauthor=J.+Wangauthor=O.+Wallaceauthor=A.+Weir&title=An+Analysis+of+the+Attrition+of+Drug+Candidates+from+Four+Major+Pharmaceutical+Companies&doi=10.1038%2Fnrd4609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">An analysis of the attrition of drug candidates from four major pharmaceutical companies</span></div><div class="casAuthors">Waring, Michael J.; Arrowsmith, John; Leach, Andrew R.; Leeson, Paul D.; Mandrell, Sam; Owen, Robert M.; Pairaudeau, Garry; Pennie, William D.; Pickett, Stephen D.; Wang, Jibo; Wallace, Owen; Weir, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">475-486</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The pharmaceutical industry remains under huge pressure to address the high attrition rates in drug development.  Attempts to reduce the no. of efficacy- and safety-related failures by analyzing possible links to the physicochem. properties of small-mol. drug candidates have been inconclusive because of the limited size of data sets from individual companies.  Here, we describe the compilation and anal. of combined data on the attrition of drug candidates from AstraZeneca, Eli Lilly and Company, GlaxoSmithKline and Pfizer.  The anal. reaffirms that control of physicochem. properties during compd. optimization is beneficial in identifying compds. of candidate drug quality and indicates for the first time a link between the physicochem. properties of compds. and clin. failure due to safety issues.  The results also suggest that further control of physicochem. properties is unlikely to have a significant effect on attrition rates and that addnl. work is required to address safety-related failures.  Further cross-company collaborations will be crucial to future progress in this area.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsLfBWrLC3ZLVg90H21EOLACvtfcHk0lix50lky6ixkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7jM&md5=1fdc374d32816b1e91438152299dd1b1</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1038%2Fnrd4609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4609%26sid%3Dliteratum%253Aachs%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DArrowsmith%26aufirst%3DJ.%26aulast%3DLeach%26aufirst%3DA.%2BR.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DMandrell%26aufirst%3DS.%26aulast%3DOwen%26aufirst%3DR.%2BM.%26aulast%3DPairaudeau%26aufirst%3DG.%26aulast%3DPennie%26aufirst%3DW.%2BD.%26aulast%3DPickett%26aufirst%3DS.%2BD.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWallace%26aufirst%3DO.%26aulast%3DWeir%26aufirst%3DA.%26atitle%3DAn%2520Analysis%2520of%2520the%2520Attrition%2520of%2520Drug%2520Candidates%2520from%2520Four%2520Major%2520Pharmaceutical%2520Companies%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D475%26epage%3D486%26doi%3D10.1038%2Fnrd4609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wager, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandrasekaran, R. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troutman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhoest, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villalobos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, Y.</span></span> <span> </span><span class="NLM_article-title">Defining Desirable Central Nervous System Drug Space through the Alignment of Molecular Properties, in Vitro ADME, and Safety Attributes</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">420</span>– <span class="NLM_lpage">434</span>, <span class="refDoi"> DOI: 10.1021/cn100007x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn100007x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvVaqtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=420-434&author=T.+T.+Wagerauthor=R.+Y.+Chandrasekaranauthor=X.+Houauthor=M.+D.+Troutmanauthor=P.+R.+Verhoestauthor=A.+Villalobosauthor=Y.+Will&title=Defining+Desirable+Central+Nervous+System+Drug+Space+through+the+Alignment+of+Molecular+Properties%2C+in+Vitro+ADME%2C+and+Safety+Attributes&doi=10.1021%2Fcn100007x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Defining Desirable Central Nervous System Drug Space through the Alignment of Molecular Properties, in Vitro ADME, and Safety Attributes</span></div><div class="casAuthors">Wager, Travis T.; Chandrasekaran, Ramalakshmi Y.; Hou, Xinjun; Troutman, Matthew D.; Verhoest, Patrick R.; Villalobos, Anabella; Will, Yvonne</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">420-434</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">As part of our effort to increase survival of drug candidates and to move our medicinal chem. design to higher probability space for success in the Neuroscience therapeutic area, we embarked on a detailed study of the property space for a collection of central nervous system (CNS) mols.  We carried out a thorough anal. of properties for 119 marketed CNS drugs and a set of 108 Pfizer CNS candidates.  In particular, we focused on understanding the relationships between physicochem. properties, in vitro ADME (absorption, distribution, metab., and elimination) attributes, primary pharmacol. binding efficiencies, and in vitro safety data for these two sets of compds.  This scholarship provides guidance for the design of CNS mols. in a property space with increased probability of success and may lead to the identification of druglike candidates with favorable safety profiles that can successfully test hypotheses in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvEMBo2f34BrVg90H21EOLACvtfcHk0li4agMu4m0uag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvVaqtbk%253D&md5=85716be86290fd85e93c6b8d5621683c</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fcn100007x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn100007x%26sid%3Dliteratum%253Aachs%26aulast%3DWager%26aufirst%3DT.%2BT.%26aulast%3DChandrasekaran%26aufirst%3DR.%2BY.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DTroutman%26aufirst%3DM.%2BD.%26aulast%3DVerhoest%26aufirst%3DP.%2BR.%26aulast%3DVillalobos%26aufirst%3DA.%26aulast%3DWill%26aufirst%3DY.%26atitle%3DDefining%2520Desirable%2520Central%2520Nervous%2520System%2520Drug%2520Space%2520through%2520the%2520Alignment%2520of%2520Molecular%2520Properties%252C%2520in%2520Vitro%2520ADME%252C%2520and%2520Safety%2520Attributes%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2010%26volume%3D1%26spage%3D420%26epage%3D434%26doi%3D10.1021%2Fcn100007x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tarcsay, Á.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyíri, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keserű, G. M.</span></span> <span> </span><span class="NLM_article-title">Impact of Lipophilic Efficiency on Compound Quality</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1252</span>– <span class="NLM_lpage">1260</span>, <span class="refDoi"> DOI: 10.1021/jm201388p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201388p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC38XktVKjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1252-1260&author=%C3%81.+Tarcsayauthor=K.+Ny%C3%ADriauthor=G.+M.+Keser%C5%B1&title=Impact+of+Lipophilic+Efficiency+on+Compound+Quality&doi=10.1021%2Fjm201388p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of Lipophilic Efficiency on Compound Quality</span></div><div class="casAuthors">Tarcsay, Akos; Nyiri, Kinga; Keseru, Gyorgy M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1252-1260</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Lipophilic efficiency indexes such as LLE and LELP were suggested to support balanced optimization of potency and ADMET profile.  Here we investigated the performance of LLE and LELP on multiple data sets representing different stages of drug discovery including fragment and HTS hits and leads, development candidates, phase II compds., and launched drugs.  Analyzing their impact on ADME and safety properties and binding thermodn., we found that both LLE and LELP help identifying better quality compds.  LLE is sensible for the development stages but does not prefer fragment-type hits, while LELP has an advantage for this class of compds. and discriminates preferred starting points effectively.  Both LLE and LELP have significant impact on ADME and safety profiles; however, LELP outperforms LLE in risk assessment at least on the present data set.  On the basis of the results reported here, monitoring lipophilic efficiency metrics could contribute significantly to compd. quality and might improve the output of medicinal chem. programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxB8xs6-5DL7Vg90H21EOLACvtfcHk0li4agMu4m0uag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktVKjsQ%253D%253D&md5=2536abef781f52806013016971c78bcb</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjm201388p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201388p%26sid%3Dliteratum%253Aachs%26aulast%3DTarcsay%26aufirst%3D%25C3%2581.%26aulast%3DNy%25C3%25ADri%26aufirst%3DK.%26aulast%3DKeser%25C5%25B1%26aufirst%3DG.%2BM.%26atitle%3DImpact%2520of%2520Lipophilic%2520Efficiency%2520on%2520Compound%2520Quality%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1252%26epage%3D1260%26doi%3D10.1021%2Fjm201388p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dahlin, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissink, J. W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strasser, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgins, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, M. A.</span></span> <span> </span><span class="NLM_article-title">PAINS in the Assay: Chemical Mechanisms of Assay Interference and Promiscuous Enzymatic Inhibition Observed during a Sulfhydryl-Scavenging HTS</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">2091</span>– <span class="NLM_lpage">2113</span>, <span class="refDoi"> DOI: 10.1021/jm5019093</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5019093" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVeisbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2091-2113&author=J.+L.+Dahlinauthor=J.+W.+M.+Nissinkauthor=J.+M.+Strasserauthor=S.+Francisauthor=L.+Higginsauthor=H.+Zhouauthor=Z.+Zhangauthor=M.+A.+Walters&title=PAINS+in+the+Assay%3A+Chemical+Mechanisms+of+Assay+Interference+and+Promiscuous+Enzymatic+Inhibition+Observed+during+a+Sulfhydryl-Scavenging+HTS&doi=10.1021%2Fjm5019093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">PAINS in the Assay: Chemical Mechanisms of Assay Interference and Promiscuous Enzymatic Inhibition Observed during a Sulfhydryl-Scavenging HTS</span></div><div class="casAuthors">Dahlin, Jayme L.; Nissink, J. Willem M.; Strasser, Jessica M.; Francis, Subhashree; Higgins, LeeAnn; Zhou, Hui; Zhang, Zhiguo; Walters, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2091-2113</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Significant resources in early drug discovery are spent unknowingly pursuing artifacts and promiscuous bioactive compds., while understanding the chem. basis for these adverse behaviors often goes unexplored in pursuit of lead compds.  Nearly all the hits from our recent sulfhydryl-scavenging high-throughput screen (HTS) targeting the histone acetyltransferase Rtt109 were such compds.  Herein, we characterize the chem. basis for assay interference and promiscuous enzymic inhibition for several prominent chemotypes identified by this HTS, including some pan-assay interference compds. (PAINS).  Protein mass spectrometry and ALARM NMR confirmed these compds. react covalently with cysteines on multiple proteins.  Unfortunately, compds. contg. these chemotypes have been published as screening actives in reputable journals and even touted as chem. probes or preclin. candidates.  Our detailed characterization and identification of such thiol-reactive chemotypes should accelerate triage of nuisance compds., guide screening library design, and prevent follow-up on undesirable chem. matter.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4XTJapoezkrVg90H21EOLACvtfcHk0li4agMu4m0uag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVeisbY%253D&md5=3f77702544cea2ec4c8184b60dd38b8a</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fjm5019093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5019093%26sid%3Dliteratum%253Aachs%26aulast%3DDahlin%26aufirst%3DJ.%2BL.%26aulast%3DNissink%26aufirst%3DJ.%2BW.%2BM.%26aulast%3DStrasser%26aufirst%3DJ.%2BM.%26aulast%3DFrancis%26aufirst%3DS.%26aulast%3DHiggins%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DWalters%26aufirst%3DM.%2BA.%26atitle%3DPAINS%2520in%2520the%2520Assay%253A%2520Chemical%2520Mechanisms%2520of%2520Assay%2520Interference%2520and%2520Promiscuous%2520Enzymatic%2520Inhibition%2520Observed%2520during%2520a%2520Sulfhydryl-Scavenging%2520HTS%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D2091%26epage%3D2113%26doi%3D10.1021%2Fjm5019093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pouliot, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeanmart, S.</span></span> <span> </span><span class="NLM_article-title">Pan Assay Interference Compounds (PAINS) and Other Promiscuous Compounds in Antifungal Research</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">497</span>– <span class="NLM_lpage">503</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00361</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00361" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=497-503&author=M.+Pouliotauthor=S.+Jeanmart&title=Pan+Assay+Interference+Compounds+%28PAINS%29+and+Other+Promiscuous+Compounds+in+Antifungal+Research&doi=10.1021%2Facs.jmedchem.5b00361"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00361%26sid%3Dliteratum%253Aachs%26aulast%3DPouliot%26aufirst%3DM.%26aulast%3DJeanmart%26aufirst%3DS.%26atitle%3DPan%2520Assay%2520Interference%2520Compounds%2520%2528PAINS%2529%2520and%2520Other%2520Promiscuous%2520Compounds%2520in%2520Antifungal%2520Research%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D59%26spage%3D497%26epage%3D503%26doi%3D10.1021%2Facs.jmedchem.5b00361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brenk, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schipani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krasowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frearson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyatt, P. G.</span></span> <span> </span><span class="NLM_article-title">Lessons Learnt from Assembling Screening Libraries for Drug Discovery for Neglected Diseases</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">435</span>– <span class="NLM_lpage">444</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200700139</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1002%2Fcmdc.200700139" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=18064617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlt1Krtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=435-444&author=R.+Brenkauthor=A.+Schipaniauthor=D.+Jamesauthor=A.+Krasowskiauthor=I.+H.+Gilbertauthor=J.+Frearsonauthor=P.+G.+Wyatt&title=Lessons+Learnt+from+Assembling+Screening+Libraries+for+Drug+Discovery+for+Neglected+Diseases&doi=10.1002%2Fcmdc.200700139"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Lessons learned from assembling screening libraries for drug discovery for neglected diseases</span></div><div class="casAuthors">Brenk, Ruth; Schipani, Alessandro; James, Daniel; Krasowski, Agata; Gilbert, Ian Hugh; Frearson, Julie; Wyatt, Paul Graham</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">435-444</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">To enable the establishment of a drug discovery operation for neglected diseases, out of 2.3 million com. available compds. 222 552 compds. were selected for an in silico library, 57 438 for a diverse general screening library, and 1 697 compds. for a focused kinase set.  Compiling these libraries required a robust strategy for compd. selection.  Rules for unwanted groups were defined and selection criteria to enrich for lead-like compds. which facilitate straightforward structure-activity relationship exploration were established.  Further, a literature and patent review was undertaken to ext. key recognition elements of kinase inhibitors ("core fragments") to assemble a focused library for hit discovery for kinases.  Computational and exptl. characterization of the general screening library revealed that the selected compds. (1) span a broad range of lead-like space, (2) show a high degree of structural integrity and purity, and (3) demonstrate appropriate soly. for the purposes of biochem. screening.  The implications of this study for compd. selection, esp. in an academic environment with limited resources, are considered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy_Ybsdg8QS7Vg90H21EOLACvtfcHk0lhsbyRuvnb1Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlt1Krtb4%253D&md5=b804d0ac8766e954391798e24aa7fbff</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200700139&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200700139%26sid%3Dliteratum%253Aachs%26aulast%3DBrenk%26aufirst%3DR.%26aulast%3DSchipani%26aufirst%3DA.%26aulast%3DJames%26aufirst%3DD.%26aulast%3DKrasowski%26aufirst%3DA.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26aulast%3DFrearson%26aufirst%3DJ.%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26atitle%3DLessons%2520Learnt%2520from%2520Assembling%2520Screening%2520Libraries%2520for%2520Drug%2520Discovery%2520for%2520Neglected%2520Diseases%26jtitle%3DChemMedChem%26date%3D2008%26volume%3D3%26spage%3D435%26epage%3D444%26doi%3D10.1002%2Fcmdc.200700139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michielin, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoete, V.</span></span> <span> </span><span class="NLM_article-title">SwissADME: A Free Web Tool to Evaluate Pharmacokinetics, Drug-Likeness and Medicinal Chemistry Friendliness of Small Molecules</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">42717</span>, <span class="refDoi"> DOI: 10.1038/srep42717</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1038%2Fsrep42717" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=28256516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A280%3ADC%252BC1czisFSrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=42717&author=A.+Dainaauthor=O.+Michielinauthor=V.+Zoete&title=SwissADME%3A+A+Free+Web+Tool+to+Evaluate+Pharmacokinetics%2C+Drug-Likeness+and+Medicinal+Chemistry+Friendliness+of+Small+Molecules&doi=10.1038%2Fsrep42717"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules</span></div><div class="casAuthors">Daina Antoine; Michielin Olivier; Zoete Vincent; Michielin Olivier; Michielin Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">42717</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">To be effective as a drug, a potent molecule must reach its target in the body in sufficient concentration, and stay there in a bioactive form long enough for the expected biologic events to occur.  Drug development involves assessment of absorption, distribution, metabolism and excretion (ADME) increasingly earlier in the discovery process, at a stage when considered compounds are numerous but access to the physical samples is limited.  In that context, computer models constitute valid alternatives to experiments.  Here, we present the new SwissADME web tool that gives free access to a pool of fast yet robust predictive models for physicochemical properties, pharmacokinetics, drug-likeness and medicinal chemistry friendliness, among which in-house proficient methods such as the BOILED-Egg, iLOGP and Bioavailability Radar.  Easy efficient input and interpretation are ensured thanks to a user-friendly interface through the login-free website http://www.swissadme.ch.  Specialists, but also nonexpert in cheminformatics or computational chemistry can predict rapidly key parameters for a collection of molecules to support their drug discovery endeavours.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRl_Uk5dOMKs6qcneEtCi92fW6udTcc2eZnjxv4aTxWb7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czisFSrtg%253D%253D&md5=9715b8cb8a34b17c4c73ff69a5a8cc50</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1038%2Fsrep42717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep42717%26sid%3Dliteratum%253Aachs%26aulast%3DDaina%26aufirst%3DA.%26aulast%3DMichielin%26aufirst%3DO.%26aulast%3DZoete%26aufirst%3DV.%26atitle%3DSwissADME%253A%2520A%2520Free%2520Web%2520Tool%2520to%2520Evaluate%2520Pharmacokinetics%252C%2520Drug-Likeness%2520and%2520Medicinal%2520Chemistry%2520Friendliness%2520of%2520Small%2520Molecules%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D42717%26doi%3D10.1038%2Fsrep42717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bowes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarolimek, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldron, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitebread, S.</span></span> <span> </span><span class="NLM_article-title">Reducing Safety-Related Drug Attrition: The Use of in Vitro Pharmacological Profiling</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">909</span>– <span class="NLM_lpage">922</span>, <span class="refDoi"> DOI: 10.1038/nrd3845</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1038%2Fnrd3845" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=23197038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslCnur%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=909-922&author=J.+Bowesauthor=A.+J.+Brownauthor=J.+Hamonauthor=W.+Jarolimekauthor=A.+Sridharauthor=G.+Waldronauthor=S.+Whitebread&title=Reducing+Safety-Related+Drug+Attrition%3A+The+Use+of+in+Vitro+Pharmacological+Profiling&doi=10.1038%2Fnrd3845"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Reducing safety-related drug attrition: the use of in vitro pharmacological profiling</span></div><div class="casAuthors">Bowes, Joanne; Brown, Andrew J.; Hamon, Jacques; Jarolimek, Wolfgang; Sridhar, Arun; Waldron, Gareth; Whitebread, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">909-922</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In vitro pharmacol. profiling is increasingly being used earlier in the drug discovery process to identify undesirable off-target activity profiles that could hinder or halt the development of candidate drugs or even lead to market withdrawal if discovered after a drug is approved.  Here, for the first time, the rationale, strategies and methodologies for in vitro pharmacol. profiling at four major pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Novartis and Pfizer) are presented and illustrated with examples of their impact on the drug discovery process.  We hope that this will enable other companies and academic institutions to benefit from this knowledge and consider joining us in our collaborative knowledge sharing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomVp3wnTONWrVg90H21EOLACvtfcHk0lhsbyRuvnb1Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslCnur%252FJ&md5=7559001563ef3febd610535b8f096a45</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1038%2Fnrd3845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3845%26sid%3Dliteratum%253Aachs%26aulast%3DBowes%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DA.%2BJ.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DJarolimek%26aufirst%3DW.%26aulast%3DSridhar%26aufirst%3DA.%26aulast%3DWaldron%26aufirst%3DG.%26aulast%3DWhitebread%26aufirst%3DS.%26atitle%3DReducing%2520Safety-Related%2520Drug%2520Attrition%253A%2520The%2520Use%2520of%2520in%2520Vitro%2520Pharmacological%2520Profiling%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D909%26epage%3D922%26doi%3D10.1038%2Fnrd3845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gintant, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sager, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stockbridge, N.</span></span> <span> </span><span class="NLM_article-title">Evolution of Strategies to Improve Preclinical Cardiac Safety Testing</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">457</span>– <span class="NLM_lpage">471</span>, <span class="refDoi"> DOI: 10.1038/nrd.2015.34</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1038%2Fnrd.2015.34" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=26893184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC28XivVCju7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=457-471&author=G.+Gintantauthor=P.+T.+Sagerauthor=N.+Stockbridge&title=Evolution+of+Strategies+to+Improve+Preclinical+Cardiac+Safety+Testing&doi=10.1038%2Fnrd.2015.34"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Evolution of strategies to improve preclinical cardiac safety testing</span></div><div class="casAuthors">Gintant, Gary; Sager, Philip T.; Stockbridge, Norman</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">457-471</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The early and efficient assessment of cardiac safety liabilities is essential to confidently advance novel drug candidates.  This article discusses evolving mechanistically based preclin. strategies for detecting drug-induced electrophysiol. and structural cardiotoxicity using in vitro human ion channel assays, human-based in silico reconstructions and human stem cell-derived cardiomyocytes.  These strategies represent a paradigm shift from current approaches, which rely on simplistic in vitro assays that measure blockade of the Kv11.1 current (also known as the hERG current or IKr) and on the use of non-human cells or tissues.  These new strategies have the potential to improve sensitivity and specificity in the early detection of genuine cardiotoxicity risks, thereby reducing the likelihood of mistakenly discarding viable drug candidates and speeding the progression of worthy drugs into clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-kYgmcNzy-bVg90H21EOLACvtfcHk0lhtzCvdZ_T00w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XivVCju7s%253D&md5=0a6fa907a6d85fa0a3b42188a22165b9</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2015.34&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2015.34%26sid%3Dliteratum%253Aachs%26aulast%3DGintant%26aufirst%3DG.%26aulast%3DSager%26aufirst%3DP.%2BT.%26aulast%3DStockbridge%26aufirst%3DN.%26atitle%3DEvolution%2520of%2520Strategies%2520to%2520Improve%2520Preclinical%2520Cardiac%2520Safety%2520Testing%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2016%26volume%3D15%26spage%3D457%26epage%3D471%26doi%3D10.1038%2Fnrd.2015.34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span>; <span class="NLM_string-name">Kerns, E.
H.</span></span> <i>Drug-like Properties: Concepts, Structure Design and Methods: From ADME to Toxicity Optimization</i>; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">Burlington, MA</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=L.+Di&author=E.%0AH.+Kerns&title=Drug-like+Properties%3A+Concepts%2C+Structure+Design+and+Methods%3A+From+ADME+to+Toxicity+Optimization"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26btitle%3DDrug-like%2520Properties%253A%2520Concepts%252C%2520Structure%2520Design%2520and%2520Methods%253A%2520From%2520ADME%2520to%2520Toxicity%2520Optimization%26pub%3DAcademic%2520Press%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wood, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldron, G. J.</span></span> <span> </span><span class="NLM_article-title">Patch Clamping by Numbers</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">434</span>– <span class="NLM_lpage">441</span>, <span class="refDoi"> DOI: 10.1016/s1359-6446(04)03064-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2Fs1359-6446%2804%2903064-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=15109948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjtl2ls7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=434-441&author=C.+Woodauthor=C.+Williamsauthor=G.+J.+Waldron&title=Patch+Clamping+by+Numbers&doi=10.1016%2Fs1359-6446%2804%2903064-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Patch clamping by numbers</span></div><div class="casAuthors">Wood, Claire; Williams, Christine; Waldron, Gareth J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">434-441</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Many ion channels are recognized as amenable targets for a range of disease states and conditions.  However, the process of discovering drugs is highly influenced by the chem. doability, the biol. confidence in rationale of the approach and the 'screen-ability'.  To date, the absence of informative high throughput technologies for ion channel screening has resulted in ion channels remaining a largely unexplored class of drug targets.  This, however, is about to change - a large increase in the no. of data points per day should be achieved by the introduction of automated-high throughput' patch clamp machines.  New automated technologies are set to open up the field of screening compds. for functional effects on ion channels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofJg6-kJcJj7Vg90H21EOLACvtfcHk0lhtzCvdZ_T00w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjtl2ls7c%253D&md5=65614d9614c4faa86bbd8356731731d3</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fs1359-6446%2804%2903064-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs1359-6446%252804%252903064-8%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DC.%26aulast%3DWilliams%26aufirst%3DC.%26aulast%3DWaldron%26aufirst%3DG.%2BJ.%26atitle%3DPatch%2520Clamping%2520by%2520Numbers%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26spage%3D434%26epage%3D441%26doi%3D10.1016%2Fs1359-6446%2804%2903064-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span> </span><span class="NLM_article-title">Research, C. for D. E. and. About the Center
for Drug Evaluation
and Research—The Biopharmaceutics Classification System (BCS)
Guidance</span>. <a href="https://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm128219.htm" class="extLink">https://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm128219.htm</a> (accessed Feb 14, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Research%2C+C.+for+D.+E.+and.+About+the+Center%0Afor+Drug+Evaluation%0Aand+Research%E2%80%94The+Biopharmaceutics+Classification+System+%28BCS%29%0AGuidance.+https%3A%2F%2Fwww.fda.gov%2Faboutfda%2Fcentersoffices%2Fofficeofmedicalproductsandtobacco%2Fcder%2Fucm128219.htm+%28accessed+Feb+14%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DResearch%252C%2520C.%2520for%2520D.%2520E.%2520and.%2520About%2520the%2520Center%250Afor%2520Drug%2520Evaluation%250Aand%2520Research%25E2%2580%2594The%2520Biopharmaceutics%2520Classification%2520System%2520%2528BCS%2529%250AGuidance%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uzawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yawata, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uezono, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narita, M.</span></span> <span> </span><span class="NLM_article-title">Characterization of Methadone as a β-Arrestin-Biased μ-Opioid Receptor Agonist</span>. <i>Mol. Pain</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.1177/1744806916654146</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1177%2F1744806916654146" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVGmsLrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=1-9&author=S.+Doiauthor=T.+Moriauthor=N.+Uzawaauthor=T.+Arimaauthor=T.+Takahashiauthor=M.+Uchidaauthor=A.+Yawataauthor=M.+Naritaauthor=Y.+Uezonoauthor=T.+Suzukiauthor=M.+Narita&title=Characterization+of+Methadone+as+a+%CE%B2-Arrestin-Biased+%CE%BC-Opioid+Receptor+Agonist&doi=10.1177%2F1744806916654146"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of methadone as a β-arrestin-biased μ-opioid receptor agonist</span></div><div class="casAuthors">Doi, Seira; Mori, Tomohisa; Uzawa, Naoki; Arima, Takamichi; Takahashi, Tomoyuki; Uchida, Masashi; Yawata, Ayaka; Narita, Michiko; Uezono, Yasuhito; Suzuki, Tsutomu; Narita, Minoru</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pain</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-9</span>CODEN:
                <span class="NLM_cas:coden">MPOAC5</span>;
        ISSN:<span class="NLM_cas:issn">1744-8069</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Background: Methadone is a unique μ-opioid receptor agonist.  Although several researchers have insisted that the pharmacol. effects of methadone are mediated through the blockade of NMDA receptor, the underlying mechanism by which methadone exerts its distinct pharmacol. effects compared to those of other μ-opioid receptor agonists is still controversial.  In the present study, we further investigated the pharmacol. profile of methadone compared to those of fentanyl and morphine as measured mainly by the discriminative stimulus effect and in vitro assays for NMDA receptor binding, μ-opioid receptor-internalization, and μ-opioid receptor-mediated β-arrestin recruitment.  Results: We found that fentanyl substituted for the discriminative stimulus effects of methadone, whereas a relatively high dose of morphine was required to substitute for the discriminative stimulus effects of methadone in rats.  Under these conditions, the non-competitive NMDA receptor antagonist MK-801 did not substitute for the discriminative stimulus effects of methadone.  In assocn. with its discriminative stimulus effect, methadone failed to displace the receptor binding of MK801 using mouse brain membrane.  Methadone and fentanyl, but not morphine, induced potent μ-opioid receptor internalization accompanied by the strong recruitment of β-arrestin-2 in μ-opioid receptor-overexpressing cells.  Conclusions: These results suggest that methadone may, at least partly, produce its pharmacol. effect as a β-arrestin-biased μ-opioid receptor agonist, similar to fentanyl, and NMDA receptor blockade is not the main contributor to the pharmacol. profile of methadone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXYiSGUxy4PrVg90H21EOLACvtfcHk0liyykWOpmVDpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVGmsLrJ&md5=3a990184826094cd4e6366389975f36c</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1177%2F1744806916654146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1744806916654146%26sid%3Dliteratum%253Aachs%26aulast%3DDoi%26aufirst%3DS.%26aulast%3DMori%26aufirst%3DT.%26aulast%3DUzawa%26aufirst%3DN.%26aulast%3DArima%26aufirst%3DT.%26aulast%3DTakahashi%26aufirst%3DT.%26aulast%3DUchida%26aufirst%3DM.%26aulast%3DYawata%26aufirst%3DA.%26aulast%3DNarita%26aufirst%3DM.%26aulast%3DUezono%26aufirst%3DY.%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DNarita%26aufirst%3DM.%26atitle%3DCharacterization%2520of%2520Methadone%2520as%2520a%2520%25CE%25B2-Arrestin-Biased%2520%25CE%25BC-Opioid%2520Receptor%2520Agonist%26jtitle%3DMol.%2520Pain%26date%3D2016%26volume%3D12%26spage%3D1%26epage%3D9%26doi%3D10.1177%2F1744806916654146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxter, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liston, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silber, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacIntyre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rance, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wastall, P.</span></span> <span> </span><span class="NLM_article-title">The Prediction of Human Pharmacokinetic Parameters from Preclinical and in Vitro Metabolism Data</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">46</span>– <span class="NLM_lpage">58</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=9336307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADyaK2sXmslCltr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=1997&pages=46-58&author=R.+S.+Obachauthor=J.+G.+Baxterauthor=T.+E.+Listonauthor=B.+M.+Silberauthor=B.+C.+Jonesauthor=F.+MacIntyreauthor=D.+J.+Ranceauthor=P.+Wastall&title=The+Prediction+of+Human+Pharmacokinetic+Parameters+from+Preclinical+and+in+Vitro+Metabolism+Data"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data</span></div><div class="casAuthors">Obach, R. Scott; Baxter, James G.; Liston, Theodore E.; Silber, B. Michael; Jones, Barry C.; Macintyre, Flona; Rance, David J.; Wastall, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">46-58</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">A review with 35 refs.  We describe a comprehensive retrospective anal. in which the abilities of several methods by which human pharmacokinetic parameters are predicted from preclin. pharmacokinetic data and/or in vitro metab. data were assessed.  The prediction methods examd. included both methods from the scientific literature as well as some described in this report for the first time.  Four methods were examd. for their ability to predict human vol. of distribution.  Three were highly predictive, yielding, on av., predictions that were within 60% to 90% of actual values.  Twelve methods were assessed for their utility in predicting clearance.  The most successful allometric scaling method yielded clearance predictions that were, on av., within 80% of actual values.  The best methods in which in vitro metab. data from human liver microsomes were scaled to in vivo clearance values yielded predicted clearance values that were, on av., within 70% to 80% of actual values.  Human t1/2 was predicted by combining predictions of human vol. of distribution and clearance.  The best t1/2 prediction methods successfully assigned compds. to appropriate dosing regimen categories (e.g., once daily, twice daily and so forth) 70% to 80% of the time.  In addn., correlations between human t1/2 and t1/2 values from preclin. species were also generally successful (72-87%) when used to predict human dosing regimens.  In summary, this retrospective anal. has identified several approaches by which human pharmacokinetic data can be predicted from preclin. data.  Such approaches should find utility in the drug discovery and development processes in the identification and selection of compds. that will possess appropriate pharmacokinetic characteristics in humans for progression to clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppAngniZ4izLVg90H21EOLACvtfcHk0liyykWOpmVDpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmslCltr0%253D&md5=68d1910d925e26ec4a8ef23043ffb1ed</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DBaxter%26aufirst%3DJ.%2BG.%26aulast%3DListon%26aufirst%3DT.%2BE.%26aulast%3DSilber%26aufirst%3DB.%2BM.%26aulast%3DJones%26aufirst%3DB.%2BC.%26aulast%3DMacIntyre%26aufirst%3DF.%26aulast%3DRance%26aufirst%3DD.%2BJ.%26aulast%3DWastall%26aufirst%3DP.%26atitle%3DThe%2520Prediction%2520of%2520Human%2520Pharmacokinetic%2520Parameters%2520from%2520Preclinical%2520and%2520in%2520Vitro%2520Metabolism%2520Data%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1997%26volume%3D283%26spage%3D46%26epage%3D58" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. A.</span></span> <span> </span><span class="NLM_article-title">Development and Validation of a 96-Well Equilibrium Dialysis Apparatus for Measuring Plasma Protein Binding</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">967</span>– <span class="NLM_lpage">974</span>, <span class="refDoi"> DOI: 10.1002/jps.10332</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1002%2Fjps.10332" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=12712416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjs1ehsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2003&pages=967-974&author=M.+J.+Bankerauthor=T.+H.+Clarkauthor=J.+A.+Williams&title=Development+and+Validation+of+a+96-Well+Equilibrium+Dialysis+Apparatus+for+Measuring+Plasma+Protein+Binding&doi=10.1002%2Fjps.10332"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding</span></div><div class="casAuthors">Banker, Michael J.; Clark, Tracey H.; Williams, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">967-974</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A 96-well equil. dialysis block was designed and constructed that is compatible with most std. 96-well format lab. supplies and instruments.  The unique design of the dialysis app. allows one to dispense and aspirate from either or both the sample and dialyzate sides from the top of the app., which is not possible with systems currently on the market.  This feature permits the investigator to analyze a large no. of samples, time points, or replicates in the same expt.  The novel alignment of the dialysis membrane vertically in the well maximizes the surface-to-vol. ratio, eliminates problems assocd. with trapped air pockets, and allows one to add or remove samples independently or all at once.  Furthermore, the design of the app. allows both the sample and dialyzate sides of the dialysis well to be accessible by robotic systems, so assays can be readily automated.  Teflon construction is used to minimize nonspecific binding of test samples to the app.  The device is reusable, easily assembled, and can be shaken in controlled temp. environments to decrease the time required to reach equil. as well as facilitate dissoln. of test compds.  Plasma protein binding values obtained for 10 diverse compds. using std. dialysis equipment and the 96-well dialysis block validates this method.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp9qyX_9tHHrVg90H21EOLACvtfcHk0liyykWOpmVDpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjs1ehsrs%253D&md5=0948f0a11373c57be06be9e0d604ad40</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1002%2Fjps.10332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.10332%26sid%3Dliteratum%253Aachs%26aulast%3DBanker%26aufirst%3DM.%2BJ.%26aulast%3DClark%26aufirst%3DT.%2BH.%26aulast%3DWilliams%26aufirst%3DJ.%2BA.%26atitle%3DDevelopment%2520and%2520Validation%2520of%2520a%252096-Well%2520Equilibrium%2520Dialysis%2520Apparatus%2520for%2520Measuring%2520Plasma%2520Protein%2520Binding%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2003%26volume%3D92%26spage%3D967%26epage%3D974%26doi%3D10.1002%2Fjps.10332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Polli, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wring, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphreys, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, L. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serabjit-Singh, C. S.</span></span> <span> </span><span class="NLM_article-title">Rational use of in vitro P-glycoprotein assays in drug discovery</span>. <i>J Pharmacol Exp Ther</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>299</i></span>,  <span class="NLM_fpage">620</span>– <span class="NLM_lpage">628</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=11602674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnvV2qt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=299&publication_year=2001&pages=620-628&author=J.+W.+Polliauthor=S.+A.+Wringauthor=J.+E.+Humphreysauthor=L.+Huangauthor=J.+B.+Morganauthor=L.+O.+Websterauthor=C.+S.+Serabjit-Singh&title=Rational+use+of+in+vitro+P-glycoprotein+assays+in+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Rational use of in vitro P-glycoprotein assays in drug discovery</span></div><div class="casAuthors">Polli, Joseph W.; Wring, Stephen A.; Humphreys, Joan E.; Huang, Liyue; Morgan, Jonathon B.; Webster, Lindsey O.; Serabjit-Singh, Cosette S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">299</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">620-628</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">P-glycoprotein (Pgp) affects the absorption, distribution, and clearance of a variety of compds.  Thus, identification of compds. that are Pgp substrates can aid drug candidate selection and optimization.  Our goal was to evaluate three assays used to det. whether compds. are Pgp substrates.  Sixty-six compds. were tested in monolayer efflux, ATPase, and calcein-AM assays.  Assay results yielded two categories of compds.  Category I (n = 35) exhibited concordance across the assays.  Category II (n = 31) revealed differences among the assays that related to the apparent permeability (Papp) of the compds.  Within category II, two groups were discerned based on the absence (group IIA, n = 10, nontransported substrates) or presence (group IIB, n = 21, transported substrates) of monolayer efflux.  Detection of efflux (group IIB) was assocd. with compds. having low/moderate Papp values (mean = 16.6 nm/s), whereas inability to detect efflux (group IIA) was assocd. with compds. having high Papp values (mean = 535 nm/s).  The calcein-AM and ATPase assays revealed Pgp interactions for highly permeable group IIA compds. but were less responsive than monolayer efflux for low/moderate Papp compds. of group IIB.  All assays detected substrates across a broad range of Papp, but the efflux assay was more prone to fail at high Papp, whereas the calcein-AM and ATPase assays were more prone to fail at low Papp.  When Papp is low, efflux is a greater factor in the disposition of Pgp substrates.  The efflux assay is more reliable at low/moderate Papp and is the method of choice for evaluating drug candidates despite low throughput and reliance on liq. chromatog. with tandem mass spectrometry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEXGQjVBl5H7Vg90H21EOLACvtfcHk0lipMm6EvX5F5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnvV2qt78%253D&md5=77bd80ec2000fa4806bee5614c31279d</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPolli%26aufirst%3DJ.%2BW.%26aulast%3DWring%26aufirst%3DS.%2BA.%26aulast%3DHumphreys%26aufirst%3DJ.%2BE.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DMorgan%26aufirst%3DJ.%2BB.%26aulast%3DWebster%26aufirst%3DL.%2BO.%26aulast%3DSerabjit-Singh%26aufirst%3DC.%2BS.%26atitle%3DRational%2520use%2520of%2520in%2520vitro%2520P-glycoprotein%2520assays%2520in%2520drug%2520discovery%26jtitle%3DJ%2520Pharmacol%2520Exp%2520Ther%26date%3D2001%26volume%3D299%26spage%3D620%26epage%3D628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stresser, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erve, J. C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dandeneau, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crespi, C. L.</span></span> <span> </span><span class="NLM_article-title">Substrate-Dependent Modulation of CYP3A4 Catalytic Activity: Analysis of 27 Test Compounds with Four Fluorometric Substrates</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1440</span>– <span class="NLM_lpage">1448</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=11095581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BD3cXos1Srsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2000&pages=1440-1448&author=D.+M.+Stresserauthor=A.+P.+Blanchardauthor=S.+D.+Turnerauthor=J.+C.+L.+Erveauthor=A.+A.+Dandeneauauthor=V.+P.+Millerauthor=C.+L.+Crespi&title=Substrate-Dependent+Modulation+of+CYP3A4+Catalytic+Activity%3A+Analysis+of+27+Test+Compounds+with+Four+Fluorometric+Substrates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates</span></div><div class="casAuthors">Stresser, David M.; Blanchard, Andrew P.; Turner, Stephanie D.; Erve, John C. L.; Dandeneau, Andre A.; Miller, Vaughn P.; Crespi, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1440-1448</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Inhibition of cytochrome P 450 catalytic activity is a principal mechanism for pharmacokinetic drug-drug interactions.  Rapid, in vitro testing for cytochrome P 450 inhibition potential is part of the current paradigm for identifying drug candidates likely to give such interactions.  We have explored the extent that qual. and quant. inhibition parameters are dependent on the cytochrome P 450 (CYP) 3A4 probe substrate.  Inhibition potential (e.g., IC50 values from 8-point inhibition curves) or activation potential for most compds. varied dramatically depending on the fluorometric probe substrates for CYP3A4 [benzyloxyresorufin (BzRes), 7-benzyloxy-4-trifluoromethylcoumarin (BFC), 7-benzyloxyquinoline (BQ), and dibenzylfluorescein (DBF)].  For 21 compds. that were primarily inhibitors, the range of IC50 values for the four substrates varied from 2.1- to 195-fold with an av. of 29-fold.  While the rank order of sensitivity among the fluorometric substrates varied among the individual inhibitors, on av., BFC dealkylation was the most sensitive to inhibition, while BQ dealkylation was least sensitive.  Partial inhibition was obsd. with BzRes and BQ but not for BFC and DBF.  BzRes was more prone to activation, whereas dramatic changes in IC50 values were obsd. when the BQ concn. was below the S50.  Three different correlation analyses indicated that IC50 values with BFC, BQ, and DBF correlated well with each other, whereas the response with BzRes correlated more weakly with the other substrates.  One of these correlation analyses was extended to the percent inhibition of 10 μM inhibitor with the std. CYP3A4 probe substrates testosterone, midazolam, and nifedipine.  In this anal. the responses with BQ, BFC and DBF correlated well with testosterone and midazolam but more poorly with nifedipine.  In the aggregate, BFC and DBF appear more suitable as an initial screen for CYP3A4 inhibition.  However, the substrate-dependent effects reported here and by others indicate that all CYP3A4 inhibition data should be interpreted with caution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiXpN24u_VFbVg90H21EOLACvtfcHk0lipMm6EvX5F5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXos1Srsrk%253D&md5=f33b6a772bb3329ce72849ece9efb61d</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStresser%26aufirst%3DD.%2BM.%26aulast%3DBlanchard%26aufirst%3DA.%2BP.%26aulast%3DTurner%26aufirst%3DS.%2BD.%26aulast%3DErve%26aufirst%3DJ.%2BC.%2BL.%26aulast%3DDandeneau%26aufirst%3DA.%2BA.%26aulast%3DMiller%26aufirst%3DV.%2BP.%26aulast%3DCrespi%26aufirst%3DC.%2BL.%26atitle%3DSubstrate-Dependent%2520Modulation%2520of%2520CYP3A4%2520Catalytic%2520Activity%253A%2520Analysis%2520of%252027%2520Test%2520Compounds%2520with%2520Four%2520Fluorometric%2520Substrates%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2000%26volume%3D28%26spage%3D1440%26epage%3D1448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ono, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hotta, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satoh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsutsui, M.</span></span> <span> </span><span class="NLM_article-title">Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation ofin vitrometabolism using cDNA-expressed human P450s and human liver microsomes</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">681</span>– <span class="NLM_lpage">693</span>, <span class="refDoi"> DOI: 10.3109/00498259609046742</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.3109%2F00498259609046742" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=8819299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADyaK28Xkt1Cks7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1996&pages=681-693&author=S.+Onoauthor=T.+Hatanakaauthor=H.+Hottaauthor=T.+Satohauthor=F.+J.+Gonzalezauthor=M.+Tsutsui&title=Specificity+of+substrate+and+inhibitor+probes+for+cytochrome+P450s%3A+evaluation+ofin+vitrometabolism+using+cDNA-expressed+human+P450s+and+human+liver+microsomes&doi=10.3109%2F00498259609046742"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes</span></div><div class="casAuthors">Ono, S.; Hatanaka, T.; Hotta, H.; Satoh, T.; Gonzalez, F. J.; Tsutsui, M.</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">681-693</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis</span>)
        </div><div class="casAbstract">We evaluated the specificity of 15 substrates and 14 inhibitors of the cytochrome P450s using nine human P 450 isoforms expressed in HepG2 cells using a recombinant vaccinia virus and also in human liver microsomes.  Coumarin, 7-ethoxyresorufin, 7-benzyloxyresorufin, tolbutamide, aniline and diazepam were isoform-selective substrates towards CYP2A6, the CYP1A subfamily, CYP2B6, the CYP2C subfamily, CYP2E1 and the CYP3A subfamily, resp.  However, a selective substrate for CYP2D6 was not found among the chems. tested.  SKF-525A inhibited > 40% of the metabolic activity of all substrates tested, and the inhibitory effects differed among P 450 isoforms.  Sulfaphenazole, 7,8-benzoflavone, quinidine and troleandomycin were selective inhibitors of the CYP2C subfamily (except CYP2C19), the CYP1A subfamily, CYP2D6 and the CYP3A subfamily, resp.  Methoxsalen (CYP2A6 inhibitor) inhibited the metabolic activity of CYP1A2 as well as that of CYP2A6.  Diethyldithiocarbamate (CYP2E1 inhibitor) inhibited the metabolic activities of CYP2A6 and CYP2C19 in addn. to that of CYP2E1.  Our results indicated that substrates and inhibitors reported as P 450 selective probes are not necessarily specific for individual human P 450 isoforms.  These results may provide useful information regarding human P 450 substrates and inhibitors in vitro using human liver microsomal samples.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS0KhjocrvGLVg90H21EOLACvtfcHk0lipMm6EvX5F5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xkt1Cks7w%253D&md5=b2a750427667920a3605930dcd021304</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.3109%2F00498259609046742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F00498259609046742%26sid%3Dliteratum%253Aachs%26aulast%3DOno%26aufirst%3DS.%26aulast%3DHatanaka%26aufirst%3DT.%26aulast%3DHotta%26aufirst%3DH.%26aulast%3DSatoh%26aufirst%3DT.%26aulast%3DGonzalez%26aufirst%3DF.%2BJ.%26aulast%3DTsutsui%26aufirst%3DM.%26atitle%3DSpecificity%2520of%2520substrate%2520and%2520inhibitor%2520probes%2520for%2520cytochrome%2520P450s%253A%2520evaluation%2520ofin%2520vitrometabolism%2520using%2520cDNA-expressed%2520human%2520P450s%2520and%2520human%2520liver%2520microsomes%26jtitle%3DXenobiotica%26date%3D1996%26volume%3D26%26spage%3D681%26epage%3D693%26doi%3D10.3109%2F00498259609046742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
Wijngaarden, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tulp, M. T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soudijn, W.</span></span> <span> </span><span class="NLM_article-title">The Concept of Selectivity in 5-HT Receptor Research</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>188</i></span>,  <span class="NLM_fpage">301</span>– <span class="NLM_lpage">312</span>, <span class="refDoi"> DOI: 10.1016/0922-4106(90)90190-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2F0922-4106%2890%2990190-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=2164935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADyaK3cXkvFWnurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=188&publication_year=1990&pages=301-312&author=I.+Van%0AWijngaardenauthor=M.+T.+M.+Tulpauthor=W.+Soudijn&title=The+Concept+of+Selectivity+in+5-HT+Receptor+Research&doi=10.1016%2F0922-4106%2890%2990190-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">The concept of selectivity in 5-HT receptor research</span></div><div class="casAuthors">Van Wijngaarden, I.; Tulp, M. Th. M.; Soudijn, W.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology, Molecular Pharmacology Section</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">188</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">301-12</span>CODEN:
                <span class="NLM_cas:coden">EJPPET</span>;
        ISSN:<span class="NLM_cas:issn">0922-4106</span>.
    </div><div class="casAbstract">A review, with 47 refs., of the serotonin receptor subtype affinity of putative selective ligands from the affinity profiles of 22 ref. compds. for 6 5-HT receptor subtypes and 18 other neurotransmitter receptors.  It is evident that the majority of reputed selective compds. are not selective (ratio ≥100) at all potent and selective ligands are only available for 5-HT1A and 5-HT3 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPzQA5cXCtCLVg90H21EOLACvtfcHk0lhr8dTfPzVosg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXkvFWnurw%253D&md5=82109dee9eb325561c57464332a66b52</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2F0922-4106%2890%2990190-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0922-4106%252890%252990190-9%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BWijngaarden%26aufirst%3DI.%26aulast%3DTulp%26aufirst%3DM.%2BT.%2BM.%26aulast%3DSoudijn%26aufirst%3DW.%26atitle%3DThe%2520Concept%2520of%2520Selectivity%2520in%25205-HT%2520Receptor%2520Research%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1990%26volume%3D188%26spage%3D301%26epage%3D312%26doi%3D10.1016%2F0922-4106%2890%2990190-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fattaccini, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adrien, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallissot, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gozlan, H.</span></span> <span> </span><span class="NLM_article-title">Alterations of central serotonin and dopamine turnover in rats treated with ipsapirone and other 5-hydroxytryptamine1A agonists with potential anxiolytic properties</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>246</i></span>,  <span class="NLM_fpage">745</span>– <span class="NLM_lpage">752</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=2457083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADyaL1cXls1ehurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=246&publication_year=1988&pages=745-752&author=M.+Hamonauthor=C.+M.+Fattacciniauthor=J.+Adrienauthor=M.+C.+Gallissotauthor=P.+Martinauthor=H.+Gozlan&title=Alterations+of+central+serotonin+and+dopamine+turnover+in+rats+treated+with+ipsapirone+and+other+5-hydroxytryptamine1A+agonists+with+potential+anxiolytic+properties"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Alterations of central serotonin and dopamine turnover in rats treated with ipsapirone and other 5-hydroxytryptamine1A agonists with potential anxiolytic properties</span></div><div class="casAuthors">Hamon, M.; Fattaccini, C. M.; Adrien, J.; Gallissot, M. C.; Martin, P.; Gozlan, H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">246</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">745-52</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">Measurements of tissue levels of monoamines and their metabolites, and of the rates of 5-hydroxytryptophan and dihydroxyphenylalanine accumulation after blockade of arom. amino acid decarboxylase by benserazid indicated that ipsapirone (1-10 mg/kg, i.p.) decreased 5-HT turnover and accelerated dopamine (DA) turnover in various rat brain regions.  The decreased 5-HT turnover probably resulted from the stimulation of 5-HT1A autoreceptors within the anterior raphe nuclei as in vitro tests [[3H]-8-hydroxy-2-[di-n-propylamino]tetralin (8-OH-DPAT)] binding and adenylate cyclase assays) demonstrated that ipsapirone was a 5-HT1A agonist almost as potent as 8-OH-DPAT, and the same decrease in 5-hydroxytryptophan accumulation could be induced by the i.p. (5 mg/kg) or intraraphe (1 μg) injection of ipsapirone.  Ipsapirone-induced acceleration of DA turnover persisted after the selective degeneration of serotoninergic neurons by intraraphe 5,7-dihydroxytryptamine infusion, and could be reproduced by i.p. administration of other 5-HT1A agonists like buspirone and gepirone, but not 8-OH-DPAT.  Apparently, the ipsapirone-induced acceleration of DA turnover did not result from the stimulation of 5-HT1A (auto)receptors, but involved addnl. target(s) of the drug.  The possible participation of dopaminergic systems in the anxiolytic properties of ipsapirone should deserve further investigations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruw0Ksnve-4LVg90H21EOLACvtfcHk0lhr8dTfPzVosg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXls1ehurs%253D&md5=51e2b340e916af876b7bca4e1c39675a</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHamon%26aufirst%3DM.%26aulast%3DFattaccini%26aufirst%3DC.%2BM.%26aulast%3DAdrien%26aufirst%3DJ.%26aulast%3DGallissot%26aufirst%3DM.%2BC.%26aulast%3DMartin%26aufirst%3DP.%26aulast%3DGozlan%26aufirst%3DH.%26atitle%3DAlterations%2520of%2520central%2520serotonin%2520and%2520dopamine%2520turnover%2520in%2520rats%2520treated%2520with%2520ipsapirone%2520and%2520other%25205-hydroxytryptamine1A%2520agonists%2520with%2520potential%2520anxiolytic%2520properties%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1988%26volume%3D246%26spage%3D745%26epage%3D752" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foreman, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuller, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leander, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benvenga, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calligaro, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanson, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucot, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaugh, M. E.</span></span> <span> </span><span class="NLM_article-title">Preclinical Studies on LY228729: A Potent and Selective Serotonin1A Agonist</span>. <i>J Pharmacol Exp Ther</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>267</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">71</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=8229788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADyaK2cXksFOhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=1993&pages=58-71&author=M.+M.+Foremanauthor=R.+W.+Fullerauthor=J.+D.+Leanderauthor=M.+J.+Benvengaauthor=D.+T.+Wongauthor=D.+L.+Nelsonauthor=D.+O.+Calligaroauthor=S.+P.+Swansonauthor=J.+B.+Lucotauthor=M.+E.+Flaugh&title=Preclinical+Studies+on+LY228729%3A+A+Potent+and+Selective+Serotonin1A+Agonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical studies on LY228729: A potent and selective serotonin1A agonist</span></div><div class="casAuthors">Foreman, Mark M.; Fuller, Ray W.; Leander, J. David; Benvenga, Mark J.; Wong, David T.; Nelson, David L.; Calligaro, David O.; Swanson, Steven P.; Lucot, James B.; Flaugh, Michael E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">267</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-71</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">LY228729 is a conformationally restricted tryptamine deriv. with a carboxamide serving as a protophilic group to mimic the hydroxyl in serotonin (5-HT).  LY228729 has high affinity for the 5-HT1A receptor, weak affinity for the 5-HT1D receptor and no significant affinity for other monoaminergic receptors studied.  LY228729 was less effective than 5-carboxamidotrytamine in suppressing K+-evoked release of 3H-5-HT from parietal-occipital cortical slices from guinea pigs, which is in agreement with its weak 5-HT1D receptor affinity.  LY228729 reduced hypothalamic 5-hydroxyindole-3-acetic acid levels and increased serum corticosterone levels in rats.  LY228729n reduced hypothalamic 5-hydroxytryptophan accumulation after decarboxylase inhibition.  LY228729 increased flat posture and lower lip retraction scores in rats at doses between 0.1 and 1 mg/kg s.c. (p.o. doses were 10 times higher) and these effects were blocked by (±) pindolol.  LY228729 induced a hypothermic response in rats, which was blocked by (±) pindolol.  These in vivo responses are characteristics of compds. with 5-HT1A agonist activity.  In the preclin. efficacy models, LY228729 suppressed motion sickness responses in cats; decreased ejaculatory latency and the increased copulatory efficiency and rate in rats and increased punished responding at lower doses than it lowered unpunished responding in rats.  Collectively, these results indicate that LY228729 is potent 5-HT1A agonist with bioavailability properties sufficient for clin. evaluation and with efficacy in preclin. models of anxiety, sexual disorders and motion sickness.  Since the 5-HT1A agonists that have been studied previously have antidepressant activity, this indication will also be evaluated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjdhGlugXjrrVg90H21EOLACvtfcHk0lhr8dTfPzVosg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXksFOhsQ%253D%253D&md5=a517f2ba1734a1f77260304bdecd1a61</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DForeman%26aufirst%3DM.%2BM.%26aulast%3DFuller%26aufirst%3DR.%2BW.%26aulast%3DLeander%26aufirst%3DJ.%2BD.%26aulast%3DBenvenga%26aufirst%3DM.%2BJ.%26aulast%3DWong%26aufirst%3DD.%2BT.%26aulast%3DNelson%26aufirst%3DD.%2BL.%26aulast%3DCalligaro%26aufirst%3DD.%2BO.%26aulast%3DSwanson%26aufirst%3DS.%2BP.%26aulast%3DLucot%26aufirst%3DJ.%2BB.%26aulast%3DFlaugh%26aufirst%3DM.%2BE.%26atitle%3DPreclinical%2520Studies%2520on%2520LY228729%253A%2520A%2520Potent%2520and%2520Selective%2520Serotonin1A%2520Agonist%26jtitle%3DJ%2520Pharmacol%2520Exp%2520Ther%26date%3D1993%26volume%3D267%26spage%3D58%26epage%3D71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chilmonczyk, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bojarski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilc, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sylte, I.</span></span> <span> </span><span class="NLM_article-title">Functional Selectivity and Antidepressant Activity of Serotonin 1A Receptor Ligands</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">18474</span>– <span class="NLM_lpage">18506</span>, <span class="refDoi"> DOI: 10.3390/ijms160818474</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.3390%2Fijms160818474" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=26262615" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC28XivVahsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=18474-18506&author=Z.+Chilmonczykauthor=A.+Bojarskiauthor=A.+Pilcauthor=I.+Sylte&title=Functional+Selectivity+and+Antidepressant+Activity+of+Serotonin+1A+Receptor+Ligands&doi=10.3390%2Fijms160818474"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Functional selectivity and antidepressant activity of serotonin 1A receptor ligands</span></div><div class="casAuthors">Chilmonczyk, Zdzislaw; Bojarski, Andrzej Jacek; Pilc, Andrzej; Sylte, Ingebrigt</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">18474-18506</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Serotonin (5-HT) is a monoamine neurotransmitter that plays an important role in physiol. functions.  5-HT has been implicated in sleep, feeding, sexual behavior, temp. regulation, pain, and cognition as well as in pathol. states including disorders connected to mood, anxiety, psychosis and pain.  5-HT1A receptors has for a long time been considered as an interesting target for the action of antidepressant drugs.  It was postulated that postsynaptic 5-HT1A agonists could form a new class of antidepressant drugs, and mixed 5-HT1A receptor ligands/serotonin transporter (SERT) inhibitors seem to possess an interesting pharmacol. profile.  It should, however, be noted that 5-HT1A receptors can activate several different biochem. pathways and signal through both G protein-dependent and G protein-independent pathways.  The variables that affect the multiplicity of 5-HT1A receptor signaling pathways would thus result from the summation of effects specific to the host cell milieu.  Moreover, receptor trafficking appears different at pre- and postsynaptic sites.  It should also be noted that the 5-HT1A receptor cooperates with other signal transduction systems (like the 5-HT1B or 5-HT2A/2B/2C receptors, the GABAergic and the glutaminergic systems), which also contribute to its antidepressant and/or anxiolytic activity.  Thus identifying brain specific mol. targets for 5-HT1A receptor ligands may result in a better targeting, raising a hope for more effective medicines for various pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR_H0f5Gc5qbVg90H21EOLACvtfcHk0lhr8dTfPzVosg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XivVahsro%253D&md5=4b1bfdaadbb20b31d99622b61a49df2d</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.3390%2Fijms160818474&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms160818474%26sid%3Dliteratum%253Aachs%26aulast%3DChilmonczyk%26aufirst%3DZ.%26aulast%3DBojarski%26aufirst%3DA.%26aulast%3DPilc%26aufirst%3DA.%26aulast%3DSylte%26aufirst%3DI.%26atitle%3DFunctional%2520Selectivity%2520and%2520Antidepressant%2520Activity%2520of%2520Serotonin%25201A%2520Receptor%2520Ligands%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2015%26volume%3D16%26spage%3D18474%26epage%3D18506%26doi%3D10.3390%2Fijms160818474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rojas, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiedler, J. L.</span></span> <span> </span><span class="NLM_article-title">What Do We Really Know About 5-HT1A Receptor Signaling in Neuronal Cells?</span>. <i>Front. Cell. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">272</span>, <span class="refDoi"> DOI: 10.3389/fncel.2016.00272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.3389%2Ffncel.2016.00272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=27932955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtV2itrvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=272&author=P.+S.+Rojasauthor=J.+L.+Fiedler&title=What+Do+We+Really+Know+About+5-HT1A+Receptor+Signaling+in+Neuronal+Cells%3F&doi=10.3389%2Ffncel.2016.00272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">What do we really know about 5-HT1A receptor signaling in neuronal cells?</span></div><div class="casAuthors">Rojas, Paulina S.; Fiedler, Jenny L.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Cellular Neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">272/1-272/8</span>CODEN:
                <span class="NLM_cas:coden">FCNRAH</span>;
        ISSN:<span class="NLM_cas:issn">1662-5102</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Serotonin (5-HT) is a neurotransmitter that plays an important role in neuronal plasticity.  Variations in the levels of 5-HT at the synaptic cleft, expression or dysfunction of 5-HT receptors may alter brain development and predispose to various mental diseases.  Here, we review the transduction pathways described in various cell types transfected with recombinant 5-HT1A receptor (5-HT1AR), specially contrasting with those findings obtained in neuronal cells.  The 5-HT1AR is detected in early stages of neural development and is located in the soma, dendrites and spines of hippocampal neurons.  The 5-HT1AR differs from other 5-HT receptors because it is coupled to different pathways, depending on the targeted cell.  The signaling pathway assocd. with this receptor is detd. by Gα isoforms and some cascades involve βγ signaling.  The activity of 5-HT1AR usually promotes a redn. in neuronal excitability and firing, provokes a variation in cAMP and Ca2+, levels which may be linked to specific types of behavior and cognition.  Furthermore, evidence indicates that 5-HT1AR induces neuritogesis and synapse formation, probably by modulation of the neuronal cytoskeleton through MAPK and phosphoinositide-3-kinase (PI3K)-Akt signaling pathways.  Advances in understanding the actions of 5-HT1AR and its assocn. with different signaling pathways in the central nervous system will reveal their pivotal role in health and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaMzoxXqS0FLVg90H21EOLACvtfcHk0ljWrk6yWyRl0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtV2itrvO&md5=02d5a8bcf058014fb893fe5c84594759</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.3389%2Ffncel.2016.00272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffncel.2016.00272%26sid%3Dliteratum%253Aachs%26aulast%3DRojas%26aufirst%3DP.%2BS.%26aulast%3DFiedler%26aufirst%3DJ.%2BL.%26atitle%3DWhat%2520Do%2520We%2520Really%2520Know%2520About%25205-HT1A%2520Receptor%2520Signaling%2520in%2520Neuronal%2520Cells%253F%26jtitle%3DFront.%2520Cell.%2520Neurosci.%26date%3D2016%26volume%3D10%26spage%3D272%26doi%3D10.3389%2Ffncel.2016.00272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stroth, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svenningsson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacivita, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leopoldo, M.</span></span> <span> </span><span class="NLM_article-title">Arylpiperazine Agonists of the Serotonin 5-HT1A Receptor Preferentially Activate CAMP Signaling versus Recruitment of β-Arrestin-2</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">4824</span>– <span class="NLM_lpage">4830</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.05.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2Fj.bmc.2015.05.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=26081758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsFaqsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=4824-4830&author=N.+Strothauthor=M.+Nisoauthor=N.+A.+Colabufoauthor=R.+Perroneauthor=P.+Svenningssonauthor=E.+Lacivitaauthor=M.+Leopoldo&title=Arylpiperazine+Agonists+of+the+Serotonin+5-HT1A+Receptor+Preferentially+Activate+CAMP+Signaling+versus+Recruitment+of+%CE%B2-Arrestin-2&doi=10.1016%2Fj.bmc.2015.05.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Arylpiperazine agonists of the serotonin 5-HT1A receptor preferentially activate cAMP signaling versus recruitment of β-arrestin-2</span></div><div class="casAuthors">Stroth, Nikolas; Niso, Mauro; Colabufo, Nicola A.; Perrone, Roberto; Svenningsson, Per; Lacivita, Enza; Leopoldo, Marcello</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4824-4830</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">G protein-coupled receptors (GPCRs) mediate biol. signal transduction through complex mol. pathways.  Therapeutic effects of GPCR-directed drugs are typically accompanied by unwanted side effects, owing in part to the parallel engagement of multiple signaling mechanisms.  The discovery of drugs that are 'functionally selective' towards therapeutic effects, based on their selective control of cellular responses through a given GPCR, is thus a major goal in pharmacol. today.  In the present study, we show that several arylpiperazine ligands of the serotonin 5-HT1A receptor (5-HT1AR) preferentially activate 3',5'-cyclic adenosine monophosphate (cAMP) signaling vs. β-arrestin-2 recruitment.  The pharmacol. of these compds. is thus qual. different from the endogenous agonist serotonin, indicating functional selectivity of 5-HT1AR-mediated response pathways.  Preliminary evidence suggests that phosphorylation of extracellular signal-regulated kinases 1/2 (ERK1/2) downstream of 5-HT1AR is a substrate of functionally selective signaling by partial agonists.  We propose that the compds. described in the present study are useful starting points for the development of signaling pathway-selective drugs targeting 5-HT1AR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPeYBWeUhs9LVg90H21EOLACvtfcHk0lgPR5r5_dwMag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsFaqsLg%253D&md5=58d15ba400884622e76923e88bbe6194</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.05.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.05.042%26sid%3Dliteratum%253Aachs%26aulast%3DStroth%26aufirst%3DN.%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DPerrone%26aufirst%3DR.%26aulast%3DSvenningsson%26aufirst%3DP.%26aulast%3DLacivita%26aufirst%3DE.%26aulast%3DLeopoldo%26aufirst%3DM.%26atitle%3DArylpiperazine%2520Agonists%2520of%2520the%2520Serotonin%25205-HT1A%2520Receptor%2520Preferentially%2520Activate%2520CAMP%2520Signaling%2520versus%2520Recruitment%2520of%2520%25CE%25B2-Arrestin-2%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D4824%26epage%3D4830%26doi%3D10.1016%2Fj.bmc.2015.05.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brust, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roman, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, V. J.</span></span> <span> </span><span class="NLM_article-title">Bias Analyses of Preclinical and Clinical D2 Dopamine Ligands: Studies with Immediate and Complex Signaling Pathways</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">480</span>– <span class="NLM_lpage">493</span>, <span class="refDoi"> DOI: 10.1124/jpet.114.220293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1124%2Fjpet.114.220293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=25539635" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2014&pages=480-493&author=T.+F.+Brustauthor=M.+P.+Hayesauthor=D.+L.+Romanauthor=K.+D.+Burrisauthor=V.+J.+Watts&title=Bias+Analyses+of+Preclinical+and+Clinical+D2+Dopamine+Ligands%3A+Studies+with+Immediate+and+Complex+Signaling+Pathways&doi=10.1124%2Fjpet.114.220293"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.220293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.220293%26sid%3Dliteratum%253Aachs%26aulast%3DBrust%26aufirst%3DT.%2BF.%26aulast%3DHayes%26aufirst%3DM.%2BP.%26aulast%3DRoman%26aufirst%3DD.%2BL.%26aulast%3DBurris%26aufirst%3DK.%2BD.%26aulast%3DWatts%26aufirst%3DV.%2BJ.%26atitle%3DBias%2520Analyses%2520of%2520Preclinical%2520and%2520Clinical%2520D2%2520Dopamine%2520Ligands%253A%2520Studies%2520with%2520Immediate%2520and%2520Complex%2520Signaling%2520Pathways%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D352%26spage%3D480%26epage%3D493%26doi%3D10.1124%2Fjpet.114.220293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figueroa, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehlert, F. J.</span></span> <span> </span><span class="NLM_article-title">Estimation of Agonist Activity at G Protein-Coupled Receptors: Analysis of M2 Muscarinic Receptor Signaling through Gi/o,Gs, and G15</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>321</i></span>,  <span class="NLM_fpage">1193</span>– <span class="NLM_lpage">1207</span>, <span class="refDoi"> DOI: 10.1124/jpet.107.120857</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1124%2Fjpet.107.120857" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=17392404" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmsFeqsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=321&publication_year=2007&pages=1193-1207&author=M.+T.+Griffinauthor=K.+W.+Figueroaauthor=S.+Lillerauthor=F.+J.+Ehlert&title=Estimation+of+Agonist+Activity+at+G+Protein-Coupled+Receptors%3A+Analysis+of+M2+Muscarinic+Receptor+Signaling+through+Gi%2Fo%2CGs%2C+and+G15&doi=10.1124%2Fjpet.107.120857"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Estimation of agonist activity at G protein-coupled receptors: analysis of M2 muscarinic receptor signaling through Gi/o, Gs, and G15</span></div><div class="casAuthors">Griffin, Michael T.; Figueroa, Katherine W.; Liller, Sarah; Ehlert, Frederick J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">321</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1193-1207</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">We developed novel methods for analyzing the concn.-response curve of an agonist to est. the product of obsd. affinity and intrinsic efficacy, expressed relative to that of a std. agonist.  This parameter, termed intrinsic relative activity (RAi), is most applicable for the anal. of responses at G protein-coupled receptors.  RAi is equiv. to the potency ratios that agonists would exhibit in a hypothetical, highly sensitive assay in which all agonists behave as full agonists, even those with little intrinsic efficacy.  We investigated muscarinic responses at the M2 receptor, including stimulation of phosphoinositide hydrolysis through Gα15 in HEK 293T cells, inhibition of cAMP accumulation through Gi in Chinese hamster ovary (CHO) cells, and stimulation of cAMP accumulation through Gs in CHO cells treated with pertussis toxin.  The RAi values of carbachol, oxotremorine-M, and the enantiomers of aceclidine were approx. the same in the three assay systems.  In contrast, the activity of 4-[[N-[3-chlorophenyl]carbamoy]oxy-2-butynyl]trimethylammonium chloride (McN-A-343) was ∼10-fold greater at M2 receptors coupled to Gα15 in HEK 293T cells compared with M2 receptors coupled to Gi in the same cells or in CHO cells.  Our results show that the RAi est. is a useful measure for quantifying agonist activity across different assay systems and for detecting agonist directed signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPP24F4WMXY7Vg90H21EOLACvtfcHk0lgPR5r5_dwMag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmsFeqsLc%253D&md5=f6b6a16a899f634d3be42c6ada98e002</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1124%2Fjpet.107.120857&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.107.120857%26sid%3Dliteratum%253Aachs%26aulast%3DGriffin%26aufirst%3DM.%2BT.%26aulast%3DFigueroa%26aufirst%3DK.%2BW.%26aulast%3DLiller%26aufirst%3DS.%26aulast%3DEhlert%26aufirst%3DF.%2BJ.%26atitle%3DEstimation%2520of%2520Agonist%2520Activity%2520at%2520G%2520Protein-Coupled%2520Receptors%253A%2520Analysis%2520of%2520M2%2520Muscarinic%2520Receptor%2520Signaling%2520through%2520Gi%252Fo%252CGs%252C%2520and%2520G15%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D321%26spage%3D1193%26epage%3D1207%26doi%3D10.1124%2Fjpet.107.120857" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ehlert, F. J.</span></span> <span> </span><span class="NLM_article-title">On the Analysis of Ligand-Directed Signaling at G Protein-Coupled Receptors</span>. <i>Naunyn-Schmiedeberg’s Arch. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">549</span>– <span class="NLM_lpage">577</span>, <span class="refDoi"> DOI: 10.1007/s00210-008-0260-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1007%2Fs00210-008-0260-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=18253722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsVSqtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2008&pages=549-577&author=F.+J.+Ehlert&title=On+the+Analysis+of+Ligand-Directed+Signaling+at+G+Protein-Coupled+Receptors&doi=10.1007%2Fs00210-008-0260-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">On the analysis of ligand-directed signaling at G protein-coupled receptors</span></div><div class="casAuthors">Ehlert, Frederick J.</div><div class="citationInfo"><span class="NLM_cas:title">Naunyn-Schmiedeberg's Archives of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">4-6</span>),
    <span class="NLM_cas:pages">549-577</span>CODEN:
                <span class="NLM_cas:coden">NSAPCC</span>;
        ISSN:<span class="NLM_cas:issn">0028-1298</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  The phenomenon of "ligand-directed signaling" is often considered to be inconsistent with the traditional receptor theory.  In this review, I show how the mathematics of the receptor theory can be used to measure the obsd. affinity and relative efficacy of protean ligands at G protein-coupled receptors.  The basis of this anal. rests on the assumption that the fraction of agonist bound in the form of the active receptor-G protein-guanine nucleotide complex is the biochem. equiv. of the pharmacol. stimulus.  Consequently, this stimulus function is analogous to the current response of a ligand-gated ion channel.  Because guanosine triphosphate (GTP) greatly inhibits the formation of the active quaternary complex, even the most efficacious agonists probably only elicit partial receptor activation, and it seems likely that the ceiling of 100% receptor activation is not reached in the intact cell with high intracellular concns. of GTP.  Under these conditions, the max. of the stimulus function is proportional to the ratio of microscopic affinity consts. of the agonist for ground and active states.  Ligand-directed signaling depends on the existence of different active states of the receptor with different selectivities for different G proteins or other effectors.  This phenomenon can be characterized using classic pharmacol. methods.  Although not widely appreciated, it is possible to est. the product of obsd. affinity and intrinsic efficacy expressed relative to that of another agonist (intrinsic relative activity) through the anal. of the concn.-response curves.  No other information is required.  This approach should be useful in quantifying agonist activity and in converting the two disparate parameters of potency and maximal response into a single parameter dependent only on the agonist-receptor-effector complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjPkYAlcl8-LVg90H21EOLACvtfcHk0lgPR5r5_dwMag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsVSqtr4%253D&md5=31aceaf811a5473e4899088f3f2e177e</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1007%2Fs00210-008-0260-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00210-008-0260-4%26sid%3Dliteratum%253Aachs%26aulast%3DEhlert%26aufirst%3DF.%2BJ.%26atitle%3DOn%2520the%2520Analysis%2520of%2520Ligand-Directed%2520Signaling%2520at%2520G%2520Protein-Coupled%2520Receptors%26jtitle%3DNaunyn-Schmiedeberg%25E2%2580%2599s%2520Arch.%2520Pharmacol.%26date%3D2008%26volume%3D377%26spage%3D549%26epage%3D577%26doi%3D10.1007%2Fs00210-008-0260-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rajagopal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rominger, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gowen-MacDonald, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeWire, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Violin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span> <span> </span><span class="NLM_article-title">Quantifying Ligand Bias at Seven-Transmembrane Receptors</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">367</span>– <span class="NLM_lpage">377</span>, <span class="refDoi"> DOI: 10.1124/mol.111.072801</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1124%2Fmol.111.072801" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=21610196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1ektb7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2011&pages=367-377&author=S.+Rajagopalauthor=S.+Ahnauthor=D.+H.+Romingerauthor=W.+Gowen-MacDonaldauthor=C.+M.+Lamauthor=S.+M.+DeWireauthor=J.+D.+Violinauthor=R.+J.+Lefkowitz&title=Quantifying+Ligand+Bias+at+Seven-Transmembrane+Receptors&doi=10.1124%2Fmol.111.072801"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Quantifying ligand bias at seven-transmembrane receptors</span></div><div class="casAuthors">Rajagopal, Sudarshan; Ahn, Seungkirl; Rominger, David H.; Gowen-MacDonald, William; Lam, Christopher M.; DeWire, Scott M.; Violin, Jonathan D.; Lefkowitz, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">367-377</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Seven transmembrane receptors (7TMRs), commonly referred to as G protein-coupled receptors, form a large part of the "druggable" genome.  7TMRs can signal through parallel pathways simultaneously, such as through heterotrimeric G proteins from different families, or, as more recently appreciated, through the multifunctional adapters, β-arrestins.  Biased agonists, which signal with different efficacies to a receptor's multiple downstream pathways, are useful tools for deconvoluting this signaling complexity.  These compds. may also be of therapeutic use because they have distinct functional and therapeutic profiles from "balanced agonists.".  Although some methods have been proposed to identify biased ligands, no comparison of these methods applied to the same set of data has been performed.  Therefore, at this time, there are no generally accepted methods to quantify the relative bias of different ligands, making studies of biased signaling difficult.  Here, we use complementary computational approaches for the quantification of ligand bias and demonstrate their application to two well known drug targets, the β2 adrenergic and angiotensin II type 1A receptors.  The strategy outlined here allows a quantification of ligand bias and the identification of weakly biased compds.  This general method should aid in deciphering complex signaling pathways and may be useful for the development of novel biased therapeutic ligands as drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwS1RZ3pzY3LVg90H21EOLACvtfcHk0liHu8eJQaARPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1ektb7J&md5=3af41d68a6e41d477610338f8e7041f0</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1124%2Fmol.111.072801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.111.072801%26sid%3Dliteratum%253Aachs%26aulast%3DRajagopal%26aufirst%3DS.%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DRominger%26aufirst%3DD.%2BH.%26aulast%3DGowen-MacDonald%26aufirst%3DW.%26aulast%3DLam%26aufirst%3DC.%2BM.%26aulast%3DDeWire%26aufirst%3DS.%2BM.%26aulast%3DViolin%26aufirst%3DJ.%2BD.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26atitle%3DQuantifying%2520Ligand%2520Bias%2520at%2520Seven-Transmembrane%2520Receptors%26jtitle%3DMol.%2520Pharmacol.%26date%3D2011%26volume%3D80%26spage%3D367%26epage%3D377%26doi%3D10.1124%2Fmol.111.072801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fumagalli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molteni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calabrese, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frasca, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Racagni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riva, M. A.</span></span> <span> </span><span class="NLM_article-title">Chronic Fluoxetine Administration Inhibits Extracellular Signal-Regulated Kinase 1/2 Phosphorylation in Rat Brain</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">1551</span>– <span class="NLM_lpage">1560</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.2005.03149.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1111%2Fj.1471-4159.2005.03149.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=15935071" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsFemsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2005&pages=1551-1560&author=F.+Fumagalliauthor=R.+Molteniauthor=F.+Calabreseauthor=A.+Frascaauthor=G.+Racagniauthor=M.+A.+Riva&title=Chronic+Fluoxetine+Administration+Inhibits+Extracellular+Signal-Regulated+Kinase+1%2F2+Phosphorylation+in+Rat+Brain&doi=10.1111%2Fj.1471-4159.2005.03149.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic fluoxetine administration inhibits extracellular signal-regulated kinase 1/2 phosphorylation in rat brain</span></div><div class="casAuthors">Fumagalli, F.; Molteni, R.; Calabrese, F.; Frasca, A.; Racagni, G.; Riva, M. A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1551-1560</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Accumulating evidence indicates that antidepressants alter intracellular signaling mechanisms resulting in long-term synaptic alterations which probably account for the delay in clin. action of these drugs.  Therefore, we investigated the effects of chronic fluoxetine administration on extracellular signal-regulated kinase (ERK) 1 and 2, a group of MAPKs that mediate signal transduction from the cell surface downstream to the nucleus.  Our data demonstrate that 3-wk fluoxetine treatment resulted in long-lasting redn. of phospho-ERK 1 and 2.  Such an effect depends on the length of the treatment given that no changes were obsd. after a single drug injection or after 2 wk of treatment and it is region specific, being obsd. in hippocampus and frontal cortex but not in striatum.  Finally, phospho-ERK 1 and 2 were differently modulated within nucleus and cytosol in hippocampus but similarly reduced in the same compartments of the frontal cortex, highlighting the specific subcellular compartmentalization of fluoxetine.  Conversely, imipramine did not reduce the hippocampal phosphorylation of both ERK subtypes whereas it selectively increased ERK 1 phosphorylation in the cytosolic compartment of frontal cortex suggesting a drug-specific effect on this intracellular target.  These results point to modulation of phosphorylation, rather than altered expression, as the main target in the action of fluoxetine on this pathway.  The redn. of ERK 1/2 function herein reported may be assocd. with the therapeutic effects of fluoxetine in the treatment of depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrf4MNOmugmqbVg90H21EOLACvtfcHk0liHu8eJQaARPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsFemsLo%253D&md5=bb08fe951895b30d79ee7f7e2e684f06</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2005.03149.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2005.03149.x%26sid%3Dliteratum%253Aachs%26aulast%3DFumagalli%26aufirst%3DF.%26aulast%3DMolteni%26aufirst%3DR.%26aulast%3DCalabrese%26aufirst%3DF.%26aulast%3DFrasca%26aufirst%3DA.%26aulast%3DRacagni%26aufirst%3DG.%26aulast%3DRiva%26aufirst%3DM.%2BA.%26atitle%3DChronic%2520Fluoxetine%2520Administration%2520Inhibits%2520Extracellular%2520Signal-Regulated%2520Kinase%25201%252F2%2520Phosphorylation%2520in%2520Rat%2520Brain%26jtitle%3DJ.%2520Neurochem.%26date%3D2005%26volume%3D93%26spage%3D1551%26epage%3D1560%26doi%3D10.1111%2Fj.1471-4159.2005.03149.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dwivedi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span> <span> </span><span class="NLM_article-title">Altered ERK1/2 Signaling in the Brain of Learned Helpless Rats: Relevance in Vulnerability to Developing Stress-Induced Depression</span>. <i>Neural Plast.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2016</i></span>,  <span class="NLM_fpage">7383724</span>, <span class="refDoi"> DOI: 10.1155/2016/7383724</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1155%2F2016%2F7383724" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=26839717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A280%3ADC%252BC28nnt1Ojuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2016&publication_year=2016&pages=7383724&author=Y.+Dwivediauthor=H.+Zhang&title=Altered+ERK1%2F2+Signaling+in+the+Brain+of+Learned+Helpless+Rats%3A+Relevance+in+Vulnerability+to+Developing+Stress-Induced+Depression&doi=10.1155%2F2016%2F7383724"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Altered ERK1/2 Signaling in the Brain of Learned Helpless Rats: Relevance in Vulnerability to Developing Stress-Induced Depression</span></div><div class="casAuthors">Dwivedi Yogesh; Zhang Hui</div><div class="citationInfo"><span class="NLM_cas:title">Neural plasticity</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">2016</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">7383724</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Extracellular signal-regulated kinase 1/2- (ERK1/2-) mediated cellular signaling plays a major role in synaptic and structural plasticity.  Although ERK1/2 signaling has been shown to be involved in stress and depression, whether vulnerability to develop depression is associated with abnormalities in ERK1/2 signaling is not clearly known.  The present study examined ERK1/2 signaling in frontal cortex and hippocampus of rats that showed vulnerability (learned helplessness, (LH)) or resiliency (non-learned helplessness, (non-LH)) to developing stress-induced depression.  In frontal cortex and hippocampus of LH rats, we found that mRNA and protein expressions of ERK1 and ERK2 were significantly reduced, which was associated with their reduced activation and phosphorylation in cytosolic and nuclear fractions, where ERK1 and ERK2 target their substrates.  In addition, ERK1/2-mediated catalytic activities and phosphorylation of downstream substrates RSK1 (cytosolic and nuclear) and MSK1 (nuclear) were also lower in the frontal cortex and hippocampus of LH rats without any change in their mRNA or protein expression.  None of these changes were evident in non-LH rats.  Our study indicates that ERK1/2 signaling is differentially regulated in LH and non-LH rats and suggests that abnormalities in ERK1/2 signaling may be crucial in the vulnerability to developing depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSR7Tw4Ij203Vw2ofyr07jXfW6udTcc2eZyWTla0F7nT7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28nnt1Ojuw%253D%253D&md5=00fff19b4b0173b360f36f272ec0ff60</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1155%2F2016%2F7383724&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2016%252F7383724%26sid%3Dliteratum%253Aachs%26aulast%3DDwivedi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%26atitle%3DAltered%2520ERK1%252F2%2520Signaling%2520in%2520the%2520Brain%2520of%2520Learned%2520Helpless%2520Rats%253A%2520Relevance%2520in%2520Vulnerability%2520to%2520Developing%2520Stress-Induced%2520Depression%26jtitle%3DNeural%2520Plast.%26date%3D2016%26volume%3D2016%26spage%3D7383724%26doi%3D10.1155%2F2016%2F7383724" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dwivedi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizavi, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conley, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamminga, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, G. N.</span></span> <span> </span><span class="NLM_article-title">Reduced Activation and Expression of ERK1/2 MAP Kinase in the Post-Mortem Brain of Depressed Suicide Subjects</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">916</span>– <span class="NLM_lpage">928</span>, <span class="refDoi"> DOI: 10.1046/j.1471-4159.2001.00300.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1046%2Fj.1471-4159.2001.00300.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=11331420" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjs1Wltr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2001&pages=916-928&author=Y.+Dwivediauthor=H.+S.+Rizaviauthor=R.+C.+Robertsauthor=R.+C.+Conleyauthor=C.+A.+Tammingaauthor=G.+N.+Pandey&title=Reduced+Activation+and+Expression+of+ERK1%2F2+MAP+Kinase+in+the+Post-Mortem+Brain+of+Depressed+Suicide+Subjects&doi=10.1046%2Fj.1471-4159.2001.00300.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Reduced activation and expression of ERK1/2 MAP kinase in the post-mortem brain of depressed suicide subjects</span></div><div class="casAuthors">Dwivedi, Y.; Rizavi, H. S.; Roberts, R. C.; Conley, R. C.; Tamminga, C. A.; Pandey, G. N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">916-928</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">The extracellular regulated kinases (ERK) 1 and ERK2 are members of mitogen-activated protein (MAP) kinase family that play an important role in transducing extracellular signals to the nucleus and have been implicated in a broad spectrum of biol. responses.  To test the hypothesis that MAP kinases may be involved in depression, the authors examd. the activation of p44/42 MAP kinase and expression of ERK1 and ERK2 in the post-mortem brain tissue obtained from non-psychiatric control subjects and age- and the post-mortem interval-matched depressed suicide subjects.  The authors obsd. that p44/42 MAP kinase activity was significantly decreased in the prefrontal cortical areas (Brodmann's areas 8, 9 and 10) and the hippocampus of depressed suicide subjects without any change in the cerebellum.  This decrease was assocd. with a decrease in mRNA and protein levels of ERK1 and ERK2.  In addn., the expression of MAP kinase phosphatase (MKP)2, a "dual function" ERK1/2 phosphatase, was increased in the prefrontal cortex and hippocampus.  These studies suggest that p44/42 MAP kinases are less activated in the post-mortem brain of depressed suicide subjects and this may be because of reduced expression of ERK1/2 and increased expression of MKP2.  Given the role of MAP kinases in various physiol. functions and gene expression, alterations in p44/42 MAP kinase activation and expression of ERK1/2 may contribute significantly to the pathophysiol. of depressive disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1ZfmbOoP1j7Vg90H21EOLACvtfcHk0li26CCx1mn7xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjs1Wltr8%253D&md5=4d335c04bce5834af1ab4457bb7123c7</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1046%2Fj.1471-4159.2001.00300.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1471-4159.2001.00300.x%26sid%3Dliteratum%253Aachs%26aulast%3DDwivedi%26aufirst%3DY.%26aulast%3DRizavi%26aufirst%3DH.%2BS.%26aulast%3DRoberts%26aufirst%3DR.%2BC.%26aulast%3DConley%26aufirst%3DR.%2BC.%26aulast%3DTamminga%26aufirst%3DC.%2BA.%26aulast%3DPandey%26aufirst%3DG.%2BN.%26atitle%3DReduced%2520Activation%2520and%2520Expression%2520of%2520ERK1%252F2%2520MAP%2520Kinase%2520in%2520the%2520Post-Mortem%2520Brain%2520of%2520Depressed%2520Suicide%2520Subjects%26jtitle%3DJ.%2520Neurochem.%26date%3D2001%26volume%3D77%26spage%3D916%26epage%3D928%26doi%3D10.1046%2Fj.1471-4159.2001.00300.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dwivedi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizavi, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conley, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, G. N.</span></span> <span> </span><span class="NLM_article-title">Aberrant Extracellular Signal-Regulated Kinase (ERK)1/2 Signalling in Suicide Brain: Role of ERK Kinase 1 (MEK1)</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1337</span>– <span class="NLM_lpage">1354</span>, <span class="refDoi"> DOI: 10.1017/s1461145709990575</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1017%2Fs1461145709990575" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=19835659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1ylsbvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2009&pages=1337-1354&author=Y.+Dwivediauthor=H.+S.+Rizaviauthor=H.+Zhangauthor=R.+C.+Robertsauthor=R.+R.+Conleyauthor=G.+N.+Pandey&title=Aberrant+Extracellular+Signal-Regulated+Kinase+%28ERK%291%2F2+Signalling+in+Suicide+Brain%3A+Role+of+ERK+Kinase+1+%28MEK1%29&doi=10.1017%2Fs1461145709990575"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Aberrant extracellular signal-regulated kinase (ERK)1/2 signalling in suicide brain: role of ERK kinase 1 (MEK1)</span></div><div class="casAuthors">Dwivedi, Yogesh; Rizavi, Hooriyah S.; Zhang, Hui; Roberts, Rosalinda C.; Conley, Robert R.; Pandey, Ghanshyam N.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1337-1354</span>CODEN:
                <span class="NLM_cas:coden">IJNUFB</span>;
        ISSN:<span class="NLM_cas:issn">1461-1457</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">Extracellular signal-regulated kinase (ERK)1/2 signaling plays a crit. role in synaptic and structural plasticity.  Recent preclin. and human brain studies suggest that depression and suicidal behavior are assocd. with aberrant ERK1/2 signaling.  MEK, is a dual-specificity kinase, which is the immediate upstream regulator of ERK1/2.  Two isoforms of MEK (MEK1 and MEK2) exist.  By phosphorylating at Ser and Thr residues, MEK activates ERK1/2, which then phosphorylates cytoplasmic and nuclear substrates.  On the other hand, MEK itself is regulated through phosphorylation by upstream Raf kinases.  Recently, we demonstrated that activation of ERK1/2 and B-Raf was attenuated in the brains of suicide subjects.  To further investigate the regulation of ERK1/2 signaling, we examd. the expression and activation of MEKs, the interaction of MEK with ERKs, MEK-mediated activation of ERK1/2, and ERK1/2-mediated activation of nuclear substrate Elk-1 in the prefrontal cortex and hippocampus of suicide subjects.  In addn., to investigate whether MEK is regulated by B-Raf, we examd. the B-Raf and MEK interaction.  No significant changes were obsd. in expression levels of MEK1 or MEK2; however, the catalytic activity of only MEK1 (not MEK2) was decreased in both the prefrontal cortex and hippocampus of suicide subjects.  The interaction of MEK1 with ERK1 and ERK2 was increased along with decreased phosphorylation and catalytic activity of ERK1/2.  In addn., we found decreased phosphorylation of MEK1 and less interaction of B-Raf with MEK1.  Our results demonstrate abnormalities in MEK1 at multiple levels and suggest that these abnormalities in MEK1 are crucial for aberrant ERK1/2 signaling in suicide brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoM4VBpYyoElLVg90H21EOLACvtfcHk0li26CCx1mn7xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1ylsbvP&md5=006f481c41f554dce39d16fd54380277</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1017%2Fs1461145709990575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252Fs1461145709990575%26sid%3Dliteratum%253Aachs%26aulast%3DDwivedi%26aufirst%3DY.%26aulast%3DRizavi%26aufirst%3DH.%2BS.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DR.%2BC.%26aulast%3DConley%26aufirst%3DR.%2BR.%26aulast%3DPandey%26aufirst%3DG.%2BN.%26atitle%3DAberrant%2520Extracellular%2520Signal-Regulated%2520Kinase%2520%2528ERK%25291%252F2%2520Signalling%2520in%2520Suicide%2520Brain%253A%2520Role%2520of%2520ERK%2520Kinase%25201%2520%2528MEK1%2529%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2009%26volume%3D12%26spage%3D1337%26epage%3D1354%26doi%3D10.1017%2Fs1461145709990575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">First, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil-Ad, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarasenko, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novak, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weizman, A.</span></span> <span> </span><span class="NLM_article-title">The Effects of Fluoxetine Treatment in a Chronic Mild Stress Rat Model on Depression-Related Behavior, Brain Neurotrophins and ERK Expression</span>. <i>J. Mol. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">246</span>, <span class="refDoi"> DOI: 10.1007/s12031-011-9515-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1007%2Fs12031-011-9515-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=21479508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1ajtr7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2011&pages=246&author=M.+Firstauthor=I.+Gil-Adauthor=M.+Talerauthor=I.+Tarasenkoauthor=N.+Novakauthor=A.+Weizman&title=The+Effects+of+Fluoxetine+Treatment+in+a+Chronic+Mild+Stress+Rat+Model+on+Depression-Related+Behavior%2C+Brain+Neurotrophins+and+ERK+Expression&doi=10.1007%2Fs12031-011-9515-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">The Effects of Fluoxetine Treatment in a Chronic Mild Stress Rat Model on Depression-Related Behavior, Brain Neurotrophins and ERK Expression</span></div><div class="casAuthors">First, Maya; Gil-Ad, Irit; Taler, Michal; Tarasenko, Igor; Novak, Nurit; Weizman, Abraham</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Neuroscience</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">246-255</span>CODEN:
                <span class="NLM_cas:coden">JMNEES</span>;
        ISSN:<span class="NLM_cas:issn">0895-8696</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">Depression is assocd. with hippocampus (HC) vol. loss.  Chronic mild stress (CMS) in rats is a model of depression.  Antidepressants attenuate HC vol. loss and reverse the depression-like symptoms of stressed animals.  We evaluated the effect of CMS and the selective serotonin reuptake inhibitor, fluoxetine (FLX) treatment on behavioral and cognitive parameters in rats, and on HC and frontal cortex (FC) neurotrophic factors levels.  Male rats were exposed sequentially, over a period of 5 wk, to a variety of mild stressors.  FLX (5 mg/kg/day i.p.) was administered to the stressed group and controls (unstressed).  After 5 wk of CMS, animals were tested using the Morris Water Maze (MWM).  In the MWM, we obsd. that FLX had a transitory effect on unstressed rats.  CMS reduced insulin-like growth factor-1 receptor (IGF-1R) levels in the HC whereas after FLX treatment these levels reverted to normal range.  CMS rats revealed a significant decrease in extracellular signal-regulated kinase (ERK) phosphorylation in both HC and FC regions, while FLX normalized these levels.  This study suggests that IGF-1R and ERK may have a role in mediating the neural stress response and the mode of action of FLX.  This role seems to be independent of the BDNF alterations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwzM2KCuHqXbVg90H21EOLACvtfcHk0li26CCx1mn7xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1ajtr7F&md5=fa6c71ef07dbc197c8b81a8f57be7433</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1007%2Fs12031-011-9515-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12031-011-9515-5%26sid%3Dliteratum%253Aachs%26aulast%3DFirst%26aufirst%3DM.%26aulast%3DGil-Ad%26aufirst%3DI.%26aulast%3DTaler%26aufirst%3DM.%26aulast%3DTarasenko%26aufirst%3DI.%26aulast%3DNovak%26aufirst%3DN.%26aulast%3DWeizman%26aufirst%3DA.%26atitle%3DThe%2520Effects%2520of%2520Fluoxetine%2520Treatment%2520in%2520a%2520Chronic%2520Mild%2520Stress%2520Rat%2520Model%2520on%2520Depression-Related%2520Behavior%252C%2520Brain%2520Neurotrophins%2520and%2520ERK%2520Expression%26jtitle%3DJ.%2520Mol.%2520Neurosci.%26date%3D2011%26volume%3D45%26spage%3D246%26doi%3D10.1007%2Fs12031-011-9515-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.-G.</span></span> <span> </span><span class="NLM_article-title">Antidepressant Effects of a Plant-Derived Flavonoid Baicalein Involving Extracellular Signal-Regulated Kinases Cascade</span>. <i>Biol. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">253</span>– <span class="NLM_lpage">259</span>, <span class="refDoi"> DOI: 10.1248/bpb.34.253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1248%2Fbpb.34.253" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=21415537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC38XovFartg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2011&pages=253-259&author=Z.+Xiongauthor=B.+Jiangauthor=P.-F.+Wuauthor=J.+Tianauthor=L.-L.+Shiauthor=J.+Guauthor=Z.-L.+Huauthor=H.+Fuauthor=F.+Wangauthor=J.-G.+Chen&title=Antidepressant+Effects+of+a+Plant-Derived+Flavonoid+Baicalein+Involving+Extracellular+Signal-Regulated+Kinases+Cascade&doi=10.1248%2Fbpb.34.253"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Antidepressant effects of a plant-derived flavonoid baicalein involving extracellular signal-regulated kinases cascade</span></div><div class="casAuthors">Xiong, Zhe; Jiang, Bo; Wu, Peng-Fei; Tian, Jia; Shi, Liang-Liang; Gu, Jun; Hu, Zhuang-Li; Fu, Hui; Wang, Fang; Chen, Jian-Guo</div><div class="citationInfo"><span class="NLM_cas:title">Biological & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">253-259</span>CODEN:
                <span class="NLM_cas:coden">BPBLEO</span>;
        ISSN:<span class="NLM_cas:issn">0918-6158</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">Depression and related mood disorders are among the world's greatest public health problems.  Previous studies have demonstrated that baicalein (Bai), one plant-derived active flavonoid, exhibits neuroprotection against ischemic brain injury and stimulates the levels of phosphorylation of extracellular signal-regulated kinase (pERK) and brain-derived neurotrophic factor (BDNF) expression in vivo.  In this study, the antidepressant-like effects of baicalein was investigated using acute and chronic animal models of depression.  The results showed that acute application of Bai at doses of 1, 2 and 4 mg/kg by i.p. injection (i.p.) significantly reduced the immobility time in the forced swimming test (FST) and tail suspending test (TST) of mice.  In addn., the chronic application of Bai by i.p. for 21 d also reduced the immobility time and improved locomotor activity in chronic unpredictable mild stress (CMS) model rats.  Furthermore, it was shown that Bai reversed the redn. of extracellular ERKs phosphorylation and the level of BDNF expression in the hippocampus of CMS model rats.  These results suggest that Bai produce an antidepressant-like effect and this effect is at least partly mediated by hippocampal ERK-mediated neurotrophic action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEc-MeaJSj3bVg90H21EOLACvtfcHk0ljyQgZcXhoYrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovFartg%253D%253D&md5=a582aa1ead3345c64c13a2e77dbed5ac</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1248%2Fbpb.34.253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fbpb.34.253%26sid%3Dliteratum%253Aachs%26aulast%3DXiong%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DP.-F.%26aulast%3DTian%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DL.-L.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DZ.-L.%26aulast%3DFu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DJ.-G.%26atitle%3DAntidepressant%2520Effects%2520of%2520a%2520Plant-Derived%2520Flavonoid%2520Baicalein%2520Involving%2520Extracellular%2520Signal-Regulated%2520Kinases%2520Cascade%26jtitle%3DBiol.%2520Pharm.%2520Bull.%26date%3D2011%26volume%3D34%26spage%3D253%26epage%3D259%26doi%3D10.1248%2Fbpb.34.253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span> <span> </span><span class="NLM_article-title">The Depressive-like Behaviors Are Correlated with Decreased Phosphorylation of Mitogen-Activated Protein Kinases in Rat Brain Following Chronic Forced Swim Stress</span>. <i>Behav. Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>175</i></span>,  <span class="NLM_fpage">233</span>– <span class="NLM_lpage">240</span>, <span class="refDoi"> DOI: 10.1016/j.bbr.2006.08.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2Fj.bbr.2006.08.035" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2006&pages=233-240&author=X.+Qiauthor=W.+Linauthor=J.+Liauthor=Y.+Panauthor=W.+Wang&title=The+Depressive-like+Behaviors+Are+Correlated+with+Decreased+Phosphorylation+of+Mitogen-Activated+Protein+Kinases+in+Rat+Brain+Following+Chronic+Forced+Swim+Stress&doi=10.1016%2Fj.bbr.2006.08.035"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.bbr.2006.08.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbr.2006.08.035%26sid%3Dliteratum%253Aachs%26aulast%3DQi%26aufirst%3DX.%26aulast%3DLin%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DW.%26atitle%3DThe%2520Depressive-like%2520Behaviors%2520Are%2520Correlated%2520with%2520Decreased%2520Phosphorylation%2520of%2520Mitogen-Activated%2520Protein%2520Kinases%2520in%2520Rat%2520Brain%2520Following%2520Chronic%2520Forced%2520Swim%2520Stress%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2006%26volume%3D175%26spage%3D233%26epage%3D240%26doi%3D10.1016%2Fj.bbr.2006.08.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, M.</span></span> <span> </span><span class="NLM_article-title">Fluoxetine Increases the Activity of the ERK-CREB Signal System and Alleviates the Depressive-like Behavior in Rats Exposed to Chronic Forced Swim Stress</span>. <i>Neurobiol. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">278</span>– <span class="NLM_lpage">285</span>, <span class="refDoi"> DOI: 10.1016/j.nbd.2008.05.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2Fj.nbd.2008.05.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=18586506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslOht78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2008&pages=278-285&author=X.+Qiauthor=W.+Linauthor=J.+Liauthor=H.+Liauthor=W.+Wangauthor=D.+Wangauthor=M.+Sun&title=Fluoxetine+Increases+the+Activity+of+the+ERK-CREB+Signal+System+and+Alleviates+the+Depressive-like+Behavior+in+Rats+Exposed+to+Chronic+Forced+Swim+Stress&doi=10.1016%2Fj.nbd.2008.05.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Fluoxetine increases the activity of the ERK-CREB signal system and alleviates the depressive-like behavior in rats exposed to chronic forced swim stress</span></div><div class="casAuthors">Qi, Xiaoli; Lin, Wenjuan; Li, Junfa; Li, Huanhuan; Wang, Weiwen; Wang, Donglin; Sun, Meng</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Disease</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">278-285</span>CODEN:
                <span class="NLM_cas:coden">NUDIEM</span>;
        ISSN:<span class="NLM_cas:issn">0969-9961</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Our previous research indicates that the extracellular signal-regulated kinase (ERK)-cAMP-responsive-element-binding protein (CREB) signal system may be involved in the mol. mechanism of depression.  The present study further investigated the effect of antidepressant fluoxetine on the ERK-CREB signal system and the depressive-like behaviors in rats.  Fluoxetine was administrated to either naive rats or stressed rats for 21 days.  The results showed that chronic forced swim stress induced depressive-like behaviors and decreased the levels of P-ERK2, P-CREB, ERK1/2 and CREB in hippocampus and prefrontal cortex.  Fluoxetine alleviated the depressive-like behaviors and reversed the disruptions of the P-ERK2 and P-CREB in stressed rats.  Fluoxetine also exerted mood-elevating effect and increased the levels of the P-ERK2 and P-CREB in naive rats.  These results suggest that the ERK-CREB signal system may be the targets of the antidepressant action of fluoxetine and participate in the neuronal mechanism of depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcX6qEug-NwbVg90H21EOLACvtfcHk0ljyQgZcXhoYrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslOht78%253D&md5=1345027e44afcb8dd7ae24f81d9b38bc</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.nbd.2008.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nbd.2008.05.003%26sid%3Dliteratum%253Aachs%26aulast%3DQi%26aufirst%3DX.%26aulast%3DLin%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DSun%26aufirst%3DM.%26atitle%3DFluoxetine%2520Increases%2520the%2520Activity%2520of%2520the%2520ERK-CREB%2520Signal%2520System%2520and%2520Alleviates%2520the%2520Depressive-like%2520Behavior%2520in%2520Rats%2520Exposed%2520to%2520Chronic%2520Forced%2520Swim%2520Stress%26jtitle%3DNeurobiol.%2520Dis.%26date%3D2008%26volume%3D31%26spage%3D278%26epage%3D285%26doi%3D10.1016%2Fj.nbd.2008.05.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moyano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Río, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frechilla, D.</span></span> <span> </span><span class="NLM_article-title">Role of Hippocampal CaMKII in Serotonin 5-HT(1A) Receptor-Mediated Learning Deficit in Rats</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">2216</span>– <span class="NLM_lpage">2224</span>, <span class="refDoi"> DOI: 10.1038/sj.npp.1300504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1038%2Fsj.npp.1300504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=15199370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVSmsrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2004&pages=2216-2224&author=S.+Moyanoauthor=J.+D.+R%C3%ADoauthor=D.+Frechilla&title=Role+of+Hippocampal+CaMKII+in+Serotonin+5-HT%281A%29+Receptor-Mediated+Learning+Deficit+in+Rats&doi=10.1038%2Fsj.npp.1300504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Role of hippocampal CaMKII in serotonin 5-HT1A receptor-mediated learning deficit in rats</span></div><div class="casAuthors">Moyano, Sonia; Del Rio, Joaquin; Frechilla, Diana</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2216-2224</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The serotonin 5-HT1A receptor agonist, 8-OH-DPAT (8-hydroxy-2-di-n-propylamino-tetralin), impairs retention performance in a passive avoidance learning task in rats.  In the hippocampus of rats trained on this procedure and killed 1 h after the acquisition trial, an increase in the membrane levels of both Ca2+/calmodulin-dependent protein kinase II (CaMKII) and phosphorylated CaMKII, as well as in total and Ca2+-independent enzyme activity in tissue lysates was found.  These effects were learning-specific as no changes in CaMKII levels or activity were found in rats receiving a footshock identical to the trained rats.  The effect of training on CaMKII was prevented by a low 8-OH-DPAT dose.  The 5-HT1A agonist also reduced protein kinase A (PKA) activity and increased the membrane levels of phosphatase 1 (PP1) and PP1 enzyme activity in the hippocampus.  All of the changes induced by 8-OH-DPAT were reversed by the selective 5-HT1A antagonist WAY-100635, indicating receptor-specific effects.  The authors suggest that 5-HT1A receptor-mediated disruption of retention performance is a consequence of the reduced PKA activity and the ensuing enhancement in PP1 activity, possibly through decreased phosphorylation/activation of endogenous PP1 inhibitors, that cause a reduced activity of phosphorylated CaMKII, a key enzyme in early stages of memory formation.  This study provides an in vivo mol. basis for the cognitive deficits induced by stimulation of hippocampal 5-HT1A receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolIn_ZpIZT_rVg90H21EOLACvtfcHk0ljyQgZcXhoYrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVSmsrbJ&md5=ac56509753dcb3f9afe5efe8687f7408</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1038%2Fsj.npp.1300504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.npp.1300504%26sid%3Dliteratum%253Aachs%26aulast%3DMoyano%26aufirst%3DS.%26aulast%3DR%25C3%25ADo%26aufirst%3DJ.%2BD.%26aulast%3DFrechilla%26aufirst%3DD.%26atitle%3DRole%2520of%2520Hippocampal%2520CaMKII%2520in%2520Serotonin%25205-HT%25281A%2529%2520Receptor-Mediated%2520Learning%2520Deficit%2520in%2520Rats%26jtitle%3DNeuropsychopharmacology%26date%3D2004%26volume%3D29%26spage%3D2216%26epage%3D2224%26doi%3D10.1038%2Fsj.npp.1300504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buritova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berrichon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cathala, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colpaert, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cussac, D.</span></span> <span> </span><span class="NLM_article-title">Region-Specific Changes in 5-HT1A Agonist-Induced Extracellular Signal-Regulated Kinases 1/2 Phosphorylation in Rat Brain: A Quantitative ELISA Study</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">350</span>– <span class="NLM_lpage">361</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2008.09.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2Fj.neuropharm.2008.09.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=18809418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVGjtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2009&pages=350-361&author=J.+Buritovaauthor=G.+Berrichonauthor=C.+Cathalaauthor=F.+Colpaertauthor=D.+Cussac&title=Region-Specific+Changes+in+5-HT1A+Agonist-Induced+Extracellular+Signal-Regulated+Kinases+1%2F2+Phosphorylation+in+Rat+Brain%3A+A+Quantitative+ELISA+Study&doi=10.1016%2Fj.neuropharm.2008.09.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Region-specific changes in 5-HT1A agonist-induced Extracellular signal-Regulated Kinases 1/2 phosphorylation in rat brain: A quantitative ELISA study</span></div><div class="casAuthors">Buritova, Jaroslava; Berrichon, Geraldine; Cathala, Claudie; Colpaert, Francis; Cussac, Didier</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">350-361</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Brain serotonin 5-HT1A receptor, a traditional target for the treatment of mood disorders, modulates intracellular signalling pathways, such as the Extracellular signal-Regulated Kinases 1/2 (ERK1/2) pathway.  The present studies are the first to det. levels of phospho-ERK1/2 (pERK1/2) in brain using a quant. ELISA.  We examd. pERK1/2 levels in rat brain following administration of (+)8-OH-DPAT, buspirone as well as of the more selective, high-efficacy 5-HT1A agonists F 13640 and F 13714.  The i.p. injection of these compds. increased pERK1/2 in prefrontal cortex and hypothalamus, with a max. at 5-15 min and a significant effect lasting until 30-60 min post-injection.  However, these compds. reduced hippocampal pERK1/2 with a max. effect at 30 min, persisting until 60 min post-injection.  In hippocampus, F 13640, F 13714 and buspirone inhibited pERK1/2 in a dose-dependent manner as of 0.04, 0.04 and 2.5 mg/kg, resp.  Given these low doses, this response is likely related to activation of sensitive presynaptic 5-HT1A receptors in the raphe nucleus.  The 4- and 16-fold higher doses of these compds. were necessary to stimulate pERK1/2 in prefrontal cortex and hypothalamus, resp., via direct 5-HT1A receptor activation.  In contrast, (+)8-OH-DPAT was active at similar doses (0.63 mg/kg) in these different regions.  Pretreatment with the 5-HT1A antagonist, WAY 100635, completely blocked the effects of these compds., with the exception of buspirone-induced pERK1/2 increases in hypothalamus.  Thus, 5-HT1A agonist-induced changes in pERK1/2 in rat brain are time- and dose-dependent and region-specific.  Furthermore, F 13640, F 13714, buspirone, but not (+)8-OH-DPAT, exert their effects via preferential activation of presynaptic 5-HT1A receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcn5AM3go8i7Vg90H21EOLACvtfcHk0lg8pm400vxjUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVGjtbY%253D&md5=cac9dfea001c6fbd4f7e0cb014d83fde</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2008.09.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2008.09.004%26sid%3Dliteratum%253Aachs%26aulast%3DBuritova%26aufirst%3DJ.%26aulast%3DBerrichon%26aufirst%3DG.%26aulast%3DCathala%26aufirst%3DC.%26aulast%3DColpaert%26aufirst%3DF.%26aulast%3DCussac%26aufirst%3DD.%26atitle%3DRegion-Specific%2520Changes%2520in%25205-HT1A%2520Agonist-Induced%2520Extracellular%2520Signal-Regulated%2520Kinases%25201%252F2%2520Phosphorylation%2520in%2520Rat%2520Brain%253A%2520A%2520Quantitative%2520ELISA%2520Study%26jtitle%3DNeuropharmacology%26date%3D2009%26volume%3D56%26spage%3D350%26epage%3D361%26doi%3D10.1016%2Fj.neuropharm.2008.09.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porsolt, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blavet, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jalfre, M.</span></span> <span> </span><span class="NLM_article-title">Behavioural Despair in Rats: A New Model Sensitive to Antidepressant Treatments</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1978</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">379</span>– <span class="NLM_lpage">391</span>, <span class="refDoi"> DOI: 10.1016/0014-2999(78)90118-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2F0014-2999%2878%2990118-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=204499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADyaE1cXhvVagsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=1978&pages=379-391&author=R.+D.+Porsoltauthor=G.+Antonauthor=N.+Blavetauthor=M.+Jalfre&title=Behavioural+Despair+in+Rats%3A+A+New+Model+Sensitive+to+Antidepressant+Treatments&doi=10.1016%2F0014-2999%2878%2990118-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Behavioral despair in rats:  a new model sensitive to antidepressant treatments</span></div><div class="casAuthors">Porsolt, Roger D.; Anton, Guy; Blavet, Nadine; Jalfre, Maurice</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1978</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">379-91</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    </div><div class="casAbstract">Rats when forced to swim in a cylinder from which they cannot escape will, after an initial period of vigorous activity, adopt a characteristic immobile posture which can be readily identified.  Immobility was decreased by various clin. effective antidepressant drugs at doses which otherwise decreased spontaneous motor activity in an open field.  Antidepressants could thus be distinguished from psychostimulants which decreased immobility at doses which increased general activity.  Anxiolytic compds. did not affect immobility, whereas major tranquilizers enhanced it.  Thus, immobility reflects a state of lowered mood in the rat which is selectively sensitive to antidepressant treatments.  Pos. findings with atypical antidepressant drugs such as iprindole and mianserin suggest that the method may be capable of discovering new antidepressants hitherto undetectable with classical pharmacol. tests.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0oUdFHAF1sLVg90H21EOLACvtfcHk0lg8pm400vxjUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1cXhvVagsr0%253D&md5=293e1fe8766c76315e86bc375c810a58</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2878%2990118-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252878%252990118-8%26sid%3Dliteratum%253Aachs%26aulast%3DPorsolt%26aufirst%3DR.%2BD.%26aulast%3DAnton%26aufirst%3DG.%26aulast%3DBlavet%26aufirst%3DN.%26aulast%3DJalfre%26aufirst%3DM.%26atitle%3DBehavioural%2520Despair%2520in%2520Rats%253A%2520A%2520New%2520Model%2520Sensitive%2520to%2520Antidepressant%2520Treatments%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1978%26volume%3D47%26spage%3D379%26epage%3D391%26doi%3D10.1016%2F0014-2999%2878%2990118-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yankelevitch-Yahav, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huly, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doron, R.</span></span> <span> </span><span class="NLM_article-title">The Forced Swim Test as a Model of Depressive-like Behavior</span>. <i>J. Visualized Exp.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>, <span class="NLM_elocation-id">e52587</span> <span class="refDoi"> DOI: 10.3791/52587</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.3791%2F52587" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=R.+Yankelevitch-Yahavauthor=M.+Frankoauthor=A.+Hulyauthor=R.+Doron&title=The+Forced+Swim+Test+as+a+Model+of+Depressive-like+Behavior&doi=10.3791%2F52587"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.3791%2F52587&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3791%252F52587%26sid%3Dliteratum%253Aachs%26aulast%3DYankelevitch-Yahav%26aufirst%3DR.%26aulast%3DFranko%26aufirst%3DM.%26aulast%3DHuly%26aufirst%3DA.%26aulast%3DDoron%26aufirst%3DR.%26atitle%3DThe%2520Forced%2520Swim%2520Test%2520as%2520a%2520Model%2520of%2520Depressive-like%2520Behavior%26jtitle%3DJ.%2520Visualized%2520Exp.%26date%3D2015%26doi%3D10.3791%2F52587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Assié, M.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auclair, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carilla-Durand, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Depoortère, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koek, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleven, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colpaert, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman-Tancredi, A.</span></span> <span> </span><span class="NLM_article-title">F15599, a Highly Selective Post-Synaptic 5-HT(1A) Receptor Agonist: In-Vivo Profile in Behavioural Models of Antidepressant and Serotonergic Activity</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1285</span>– <span class="NLM_lpage">1298</span>, <span class="refDoi"> DOI: 10.1017/s1461145709991222</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1017%2Fs1461145709991222" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=20059805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1aktb3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=1285-1298&author=M.-B.+Assi%C3%A9author=L.+Bardinauthor=A.+L.+Auclairauthor=E.+Carilla-Durandauthor=R.+Depoort%C3%A8reauthor=W.+Koekauthor=M.+S.+Klevenauthor=F.+Colpaertauthor=B.+Vacherauthor=A.+Newman-Tancredi&title=F15599%2C+a+Highly+Selective+Post-Synaptic+5-HT%281A%29+Receptor+Agonist%3A+In-Vivo+Profile+in+Behavioural+Models+of+Antidepressant+and+Serotonergic+Activity&doi=10.1017%2Fs1461145709991222"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">F15599, a highly selective post-synaptic 5-HT1A receptor agonist: in-vivo profile in behavioural models of antidepressant and serotonergic activity</span></div><div class="casAuthors">Assie, Marie-Bernadette; Bardin, Laurent; Auclair, Agnes L.; Carilla-Durand, Elisabeth; Depoortere, Ronan; Koek, Wouter; Kleven, Mark S.; Colpaert, Francis; Vacher, Bernard; Newman-Tancredi, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1285-1298</span>CODEN:
                <span class="NLM_cas:coden">IJNUFB</span>;
        ISSN:<span class="NLM_cas:issn">1461-1457</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">F15599 is a novel agonist with high selectivity and efficacy at serotonin 5-HT1A receptors (5-HT1ARs).  In signal transduction, electrophysiol. and neurochem. tests, F15599 preferentially activates post-synaptic 5-HT1ARs in rat frontal cortex.  Such a profile may translate to an improved profile of therapeutic activity for mood disorders.  The in-vivo effects of F15599 were therefore compared with those of a related compd., F13714, in rat models of antidepressant activity and 5-HT1AR activation: forced swimming test (FST), conditioned stress-induced ultrasonic vocalization, 5-HT syndrome, plasma corticosterone and body temp.  Acute administration of F15599 or F13714 reduced immobility in the FST at low doses; these effects were long lasting and the effects of F15599 were maintained after repeated (5 d, p.o.) administration.  Both compds. decreased ultrasonic vocalization duration at low doses.  In contrast, higher doses of F15599 were required to induce lower lip retraction, elements of the 5-HT behavioral syndrome, hypothermia and to increase plasma corticosterone levels.  Notably, there was a greater sepn. of ED50 between FST and other effects for F15599 than for F13714.  Thus, the in-vivo potency of F15599 in models of antidepressant/anti-stress activity is similar to that of F13714, despite the fact that the latter has an in-vitro potency two orders of magnitude greater.  In contrast F15599 has a lower propensity than F13714 to induce other serotonergic signs.  The distinctive pharmacol. profile of F15599 suggests that preferential targeting of post-synaptic 5-HT1ARs constitutes a promising strategy for improved antidepressant therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo195YLEeqRsLVg90H21EOLACvtfcHk0lg8pm400vxjUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1aktb3L&md5=a979820d0f8a211519ce86d4c56c8fd4</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1017%2Fs1461145709991222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252Fs1461145709991222%26sid%3Dliteratum%253Aachs%26aulast%3DAssi%25C3%25A9%26aufirst%3DM.-B.%26aulast%3DBardin%26aufirst%3DL.%26aulast%3DAuclair%26aufirst%3DA.%2BL.%26aulast%3DCarilla-Durand%26aufirst%3DE.%26aulast%3DDepoort%25C3%25A8re%26aufirst%3DR.%26aulast%3DKoek%26aufirst%3DW.%26aulast%3DKleven%26aufirst%3DM.%2BS.%26aulast%3DColpaert%26aufirst%3DF.%26aulast%3DVacher%26aufirst%3DB.%26aulast%3DNewman-Tancredi%26aufirst%3DA.%26atitle%3DF15599%252C%2520a%2520Highly%2520Selective%2520Post-Synaptic%25205-HT%25281A%2529%2520Receptor%2520Agonist%253A%2520In-Vivo%2520Profile%2520in%2520Behavioural%2520Models%2520of%2520Antidepressant%2520and%2520Serotonergic%2520Activity%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2010%26volume%3D13%26spage%3D1285%26epage%3D1298%26doi%3D10.1017%2Fs1461145709991222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kołaczkowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mierzejewski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bienkowski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wesołowska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman-Tancredi, A.</span></span> <span> </span><span class="NLM_article-title">Antipsychotic, Antidepressant, and Cognitive-Impairment Properties of Antipsychotics: Rat Profile and Implications for Behavioral and Psychological Symptoms of Dementia</span>. <i>N. Schmied. Arch. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>387</i></span>,  <span class="NLM_fpage">545</span>– <span class="NLM_lpage">557</span>, <span class="refDoi"> DOI: 10.1007/s00210-014-0966-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1007%2Fs00210-014-0966-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=2014&pages=545-557&author=M.+Ko%C5%82aczkowskiauthor=P.+Mierzejewskiauthor=P.+Bienkowskiauthor=A.+Weso%C5%82owskaauthor=A.+Newman-Tancredi&title=Antipsychotic%2C+Antidepressant%2C+and+Cognitive-Impairment+Properties+of+Antipsychotics%3A+Rat+Profile+and+Implications+for+Behavioral+and+Psychological+Symptoms+of+Dementia&doi=10.1007%2Fs00210-014-0966-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1007%2Fs00210-014-0966-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00210-014-0966-4%26sid%3Dliteratum%253Aachs%26aulast%3DKo%25C5%2582aczkowski%26aufirst%3DM.%26aulast%3DMierzejewski%26aufirst%3DP.%26aulast%3DBienkowski%26aufirst%3DP.%26aulast%3DWeso%25C5%2582owska%26aufirst%3DA.%26aulast%3DNewman-Tancredi%26aufirst%3DA.%26atitle%3DAntipsychotic%252C%2520Antidepressant%252C%2520and%2520Cognitive-Impairment%2520Properties%2520of%2520Antipsychotics%253A%2520Rat%2520Profile%2520and%2520Implications%2520for%2520Behavioral%2520and%2520Psychological%2520Symptoms%2520of%2520Dementia%26jtitle%3DN.%2520Schmied.%2520Arch.%2520Pharmacol.%26date%3D2014%26volume%3D387%26spage%3D545%26epage%3D557%26doi%3D10.1007%2Fs00210-014-0966-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.-J.</span></span> <span> </span><span class="NLM_article-title">Acute Administration of Ketamine in Rats Increases Hippocampal BDNF and MTOR Levels during Forced Swimming Test</span>. <i>Upsala J. Med. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.3109/03009734.2012.724118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.3109%2F03009734.2012.724118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=22970723" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2012&pages=3-8&author=C.+Yangauthor=Y.-M.+Huauthor=Z.-Q.+Zhouauthor=G.-F.+Zhangauthor=J.-J.+Yang&title=Acute+Administration+of+Ketamine+in+Rats+Increases+Hippocampal+BDNF+and+MTOR+Levels+during+Forced+Swimming+Test&doi=10.3109%2F03009734.2012.724118"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.3109%2F03009734.2012.724118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F03009734.2012.724118%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DY.-M.%26aulast%3DZhou%26aufirst%3DZ.-Q.%26aulast%3DZhang%26aufirst%3DG.-F.%26aulast%3DYang%26aufirst%3DJ.-J.%26atitle%3DAcute%2520Administration%2520of%2520Ketamine%2520in%2520Rats%2520Increases%2520Hippocampal%2520BDNF%2520and%2520MTOR%2520Levels%2520during%2520Forced%2520Swimming%2520Test%26jtitle%3DUpsala%2520J.%2520Med.%2520Sci.%26date%3D2012%26volume%3D118%26spage%3D3%26epage%3D8%26doi%3D10.3109%2F03009734.2012.724118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kołaczkowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bucki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawłowski, M.</span></span> <span> </span><span class="NLM_article-title">Ligand-Optimized Homology Models of D1 and D2 Dopamine Receptors: Application for Virtual Screening</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">638</span>– <span class="NLM_lpage">648</span>, <span class="refDoi"> DOI: 10.1021/ci300413h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci300413h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC3sXit1yhsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2013&pages=638-648&author=M.+Ko%C5%82aczkowskiauthor=A.+Buckiauthor=M.+Federauthor=M.+Paw%C5%82owski&title=Ligand-Optimized+Homology+Models+of+D1+and+D2+Dopamine+Receptors%3A+Application+for+Virtual+Screening&doi=10.1021%2Fci300413h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand-Optimized Homology Models of D1 and D2 Dopamine Receptors: Application for Virtual Screening</span></div><div class="casAuthors">Kolaczkowski, Marcin; Bucki, Adam; Feder, Marcin; Pawlowski, Maciej</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">638-648</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recent breakthroughs in crystallog. studies of G protein-coupled receptors (GPCRs), together with continuous progress in mol. modeling methods, have opened new perspectives for structure-based drug discovery.  A crucial enhancement in this area was development of induced fit docking procedures that allow optimization of binding pocket conformation guided by the features of its active ligands.  In the course of our research program aimed at discovery of novel antipsychotic agents, our attention focused on dopaminergic D2 and D1 receptors (D2R and D1R).  Thus, we decided to investigate whether the availability of a novel structure of the closely related D3 receptor and application of induced fit docking procedures for binding pocket refinement would permit the building of models of D2R and D1R that facilitate a successful virtual screening (VS).  Here, we provide an in-depth description of the modeling procedure and the discussion of the results of a VS benchmark we performed to compare efficiency of the ligand-optimized receptors in comparison with the regular homol. models.  We obsd. that application of the ligand-optimized models significantly improved the VS performance both in terms of BEDROC (0.325 vs 0.182 for D1R and 0.383 vs 0.301 for D2R) as well as EF1% (20 vs 11 for D1R and 18 vs 10 for D2R).  In contrast, no improvement was obsd. for the performance of a D2R model built on the D3R template, when compared with that derived from the structure of the previously published and more evolutionary distant β2 adrenergic receptor.  The comparison of results for receptors built according to various protocols and templates revealed that the most significant factor for the receptor performance was a proper selection of tool ligand used in induced fit docking procedure.  Taken together, our results suggest that the described homol. modeling procedure could be a viable tool for structure-based GPCR ligand design, even for the targets for which only a relatively distant structural template is available.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHGgw5lOnO9bVg90H21EOLACvtfcHk0ljiMNyG2-wq8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXit1yhsb0%253D&md5=58f111e8132b7229898f1a44feb6199b</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1021%2Fci300413h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci300413h%26sid%3Dliteratum%253Aachs%26aulast%3DKo%25C5%2582aczkowski%26aufirst%3DM.%26aulast%3DBucki%26aufirst%3DA.%26aulast%3DFeder%26aufirst%3DM.%26aulast%3DPaw%25C5%2582owski%26aufirst%3DM.%26atitle%3DLigand-Optimized%2520Homology%2520Models%2520of%2520D1%2520and%2520D2%2520Dopamine%2520Receptors%253A%2520Application%2520for%2520Virtual%2520Screening%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2013%26volume%3D53%26spage%3D638%26epage%3D648%26doi%3D10.1021%2Fci300413h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wacker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vardy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melcher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H. E.</span></span> <span> </span><span class="NLM_article-title">Structural Basis for Molecular Recognition at Serotonin Receptors</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>340</i></span>,  <span class="NLM_fpage">610</span>– <span class="NLM_lpage">614</span>, <span class="refDoi"> DOI: 10.1126/science.1232807</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1126%2Fscience.1232807" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=23519210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmslWksbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=340&publication_year=2013&pages=610-614&author=C.+Wangauthor=Y.+Jiangauthor=J.+Maauthor=H.+Wuauthor=D.+Wackerauthor=V.+Katritchauthor=G.+W.+Hanauthor=W.+Liuauthor=X.-P.+Huangauthor=E.+Vardyauthor=J.+D.+McCorvyauthor=X.+Gaoauthor=X.+E.+Zhouauthor=K.+Melcherauthor=C.+Zhangauthor=F.+Baiauthor=H.+Yangauthor=L.+Yangauthor=H.+Jiangauthor=B.+L.+Rothauthor=V.+Cherezovauthor=R.+C.+Stevensauthor=H.+E.+Xu&title=Structural+Basis+for+Molecular+Recognition+at+Serotonin+Receptors&doi=10.1126%2Fscience.1232807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for Molecular Recognition at Serotonin Receptors</span></div><div class="casAuthors">Wang, Chong; Jiang, Yi; Ma, Jinming; Wu, Huixian; Wacker, Daniel; Katritch, Vsevolod; Han, Gye Won; Liu, Wei; Huang, Xi-Ping; Vardy, Eyal; McCorvy, John D.; Gao, Xiang; Zhou, X. Edward; Melcher, Karsten; Zhang, Chenghai; Bai, Fang; Yang, Huaiyu; Yang, Linlin; Jiang, Hualiang; Roth, Bryan L.; Cherezov, Vadim; Stevens, Raymond C.; Xu, H. Eric</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">340</span>
        (<span class="NLM_cas:issue">6132</span>),
    <span class="NLM_cas:pages">610-614</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Serotonin or 5-hydroxytryptamine (5-HT) regulates a wide spectrum of human physiol. through the 5-HT receptor family.  The authors report the crystal structures of the human 5-HT1B G protein-coupled receptor bound to the agonist antimigraine medications ergotamine and dihydroergotamine.  The structures reveal similar binding modes for these ligands, which occupy the orthosteric pocket and an extended binding pocket close to the extracellular loops.  The orthosteric pocket is formed by residues conserved in the 5-HT receptor family, clarifying the family-wide agonist activity of 5-HT.  Compared with the structure of the 5-HT2B receptor, the 5-HT1B receptor displays a 3 angstrom outward shift at the extracellular end of helix V, resulting in a more open extended pocket that explains subtype selectivity.  Together with docking and mutagenesis studies, these structures provide a comprehensive structural basis for understanding receptor-ligand interactions and designing subtype-selective serotonergic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLc0rOIqg_2bVg90H21EOLACvtfcHk0ljiMNyG2-wq8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmslWksbw%253D&md5=ce0773088a86f6a2c83b6cb77a63e708</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1126%2Fscience.1232807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1232807%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DC.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWacker%26aufirst%3DD.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DX.-P.%26aulast%3DVardy%26aufirst%3DE.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DX.%2BE.%26aulast%3DMelcher%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DBai%26aufirst%3DF.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DXu%26aufirst%3DH.%2BE.%26atitle%3DStructural%2520Basis%2520for%2520Molecular%2520Recognition%2520at%2520Serotonin%2520Receptors%26jtitle%3DScience%26date%3D2013%26volume%3D340%26spage%3D610%26epage%3D614%26doi%3D10.1126%2Fscience.1232807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kurowski, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bujnicki, J. M.</span></span> <span> </span><span class="NLM_article-title">GeneSilico Protein Structure Prediction Meta-Server</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">3305</span>– <span class="NLM_lpage">3307</span>, <span class="refDoi"> DOI: 10.1093/nar/gkg557</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1093%2Fnar%2Fgkg557" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2003&pages=3305-3307&author=M.+A.+Kurowskiauthor=J.+M.+Bujnicki&title=GeneSilico+Protein+Structure+Prediction+Meta-Server&doi=10.1093%2Fnar%2Fgkg557"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkg557&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkg557%26sid%3Dliteratum%253Aachs%26aulast%3DKurowski%26aufirst%3DM.%2BA.%26aulast%3DBujnicki%26aufirst%3DJ.%2BM.%26atitle%3DGeneSilico%2520Protein%2520Structure%2520Prediction%2520Meta-Server%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2003%26volume%3D31%26spage%3D3305%26epage%3D3307%26doi%3D10.1093%2Fnar%2Fgkg557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwede, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopp, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guex, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peitsch, M. C.</span></span> <span> </span><span class="NLM_article-title">SWISS-MODEL: An Automated Protein Homology-Modeling Server</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">3381</span>– <span class="NLM_lpage">3385</span>, <span class="refDoi"> DOI: 10.1093/nar/gkg520</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1093%2Fnar%2Fgkg520" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=12824332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BD3sXltVWjsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2003&pages=3381-3385&author=T.+Schwedeauthor=J.+Koppauthor=N.+Guexauthor=M.+C.+Peitsch&title=SWISS-MODEL%3A+An+Automated+Protein+Homology-Modeling+Server&doi=10.1093%2Fnar%2Fgkg520"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">SWISS-MODEL: an automated protein homology-modeling server</span></div><div class="casAuthors">Schwede, Torsten; Kopp, Juergen; Guex, Nicolas; Peitsch, Manuel C.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3381-3385</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">SWISS-MODEL is a server for automated comparative modeling of three-dimensional (3D) protein structures.  It pioneered the field of automated modeling starting in 1993 and is the most widely-used free web-based automated modeling facility today.  In 2002 the server computed 120 000 user requests for 3D protein models.  SWISS-MODEL provides several levels of user interaction through its World Wide Web interface: in the first approach mode' only an amino acid sequence of a protein is submitted to build a 3D model.  Template selection, alignment and model building are done completely automated by the server.  In the alignment mode', the modeling process is based on a user-defined target-template alignment.  Complex modeling tasks can be handled with the project mode' using DeepView (Swiss-PdbViewer), an integrated sequence-to-structure workbench.  All models are sent back via email with a detailed modeling report.  WhatCheck analyses and ANOLEA evaluations are provided optionally.  The reliability of SWISS-MODEL is continuously evaluated in the EVA-CM project.  The SWISS-MODEL server is under const. development to improve the successful implementation of expert knowledge into an easy-to-use server.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBh6H5AEIXubVg90H21EOLACvtfcHk0lgvOD9o3sE9sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXltVWjsLg%253D&md5=d49a9219efef81217013dc350e1a2fd5</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkg520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkg520%26sid%3Dliteratum%253Aachs%26aulast%3DSchwede%26aufirst%3DT.%26aulast%3DKopp%26aufirst%3DJ.%26aulast%3DGuex%26aufirst%3DN.%26aulast%3DPeitsch%26aufirst%3DM.%2BC.%26atitle%3DSWISS-MODEL%253A%2520An%2520Automated%2520Protein%2520Homology-Modeling%2520Server%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2003%26volume%3D31%26spage%3D3381%26epage%3D3385%26doi%3D10.1093%2Fnar%2Fgkg520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friesner, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farid, R.</span></span> <span> </span><span class="NLM_article-title">Novel Procedure for Modeling Ligand/Receptor Induced Fit Effects</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">534</span>– <span class="NLM_lpage">553</span>, <span class="refDoi"> DOI: 10.1021/jm050540c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050540c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlCgsr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=534-553&author=W.+Shermanauthor=T.+Dayauthor=M.+P.+Jacobsonauthor=R.+A.+Friesnerauthor=R.+Farid&title=Novel+Procedure+for+Modeling+Ligand%2FReceptor+Induced+Fit+Effects&doi=10.1021%2Fjm050540c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Procedure for Modeling Ligand/Receptor Induced Fit Effects</span></div><div class="casAuthors">Sherman, Woody; Day, Tyler; Jacobson, Matthew P.; Friesner, Richard A.; Farid, Ramy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">534-553</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We present a novel protein-ligand docking method that accurately accounts for both ligand and receptor flexibility by iteratively combining rigid receptor docking (Glide) with protein structure prediction (Prime) techniques.  While traditional rigid-receptor docking methods are useful when the receptor structure does not change substantially upon ligand binding, success is limited when the protein must be "induced" into the correct binding conformation for a given ligand.  We provide an in-depth description of our novel methodol. and present results for 21 pharmaceutically relevant examples.  Traditional rigid-receptor docking for these 21 cases yields an av. RMSD of 5.5 Å.  The av. ligand RMSD for docking to a flexible receptor for the 21 pairs is 1.4 Å; the RMSD is ≤1.8 Å for 18 of the cases.  For the three cases with RMSDs greater than 1.8 Å, the core of the ligand is properly docked and all key protein/ligand interactions are captured.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm3E6ctnPGSrVg90H21EOLACvtfcHk0lgvOD9o3sE9sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlCgsr7I&md5=388811ead5cee1fd460951263de486cb</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1021%2Fjm050540c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050540c%26sid%3Dliteratum%253Aachs%26aulast%3DSherman%26aufirst%3DW.%26aulast%3DDay%26aufirst%3DT.%26aulast%3DJacobson%26aufirst%3DM.%2BP.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26aulast%3DFarid%26aufirst%3DR.%26atitle%3DNovel%2520Procedure%2520for%2520Modeling%2520Ligand%252FReceptor%2520Induced%2520Fit%2520Effects%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D534%26epage%3D553%26doi%3D10.1021%2Fjm050540c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hidalgo, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raub, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borchardt, R. T.</span></span> <span> </span><span class="NLM_article-title">Characterization of the Human Colon Carcinoma Cell Line (Caco-2) as a Model System for Intestinal Epithelial Permeability</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">736</span>– <span class="NLM_lpage">749</span>, <span class="refDoi"> DOI: 10.1016/s0016-5085(89)80072-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1016%2Fs0016-5085%2889%2980072-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=2914637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A280%3ADyaL1M7itFeqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1989&pages=736-749&author=I.+J.+Hidalgoauthor=T.+J.+Raubauthor=R.+T.+Borchardt&title=Characterization+of+the+Human+Colon+Carcinoma+Cell+Line+%28Caco-2%29+as+a+Model+System+for+Intestinal+Epithelial+Permeability&doi=10.1016%2Fs0016-5085%2889%2980072-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability</span></div><div class="casAuthors">Hidalgo I J; Raub T J; Borchardt R T</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">736-49</span>
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    </div><div class="casAbstract">Caco-2 cells develop morphologic characteristics of normal enterocytes when grown on plastic dishes or nitrocellulose filters.  The purpose of this study was to determine whether Caco-2 cells undergo similar differentiation when grown on Transwell polycarbonate membranes, and to study the suitability of Caco-2 monolayers as an intestinal epithelial transport model system.  Transepithelial electrical resistance values after confluence were 173.5 omega.cm2 and remained unchanged through day 17.  Permeabilities to the water-soluble fluid-phase markers that do not permeate the membrane, Lucifer yellow CH, [14C]inulin, [14C]polyethylene glycol, and [3H] dextran were less than 0.25% of the administered amount per hour after day 10.  Qualitative evaluation of uptake and permeability to horseradish peroxidase confirmed the similarity in uptake and barrier properties between this cell system and the small intestinal epithelial layer.  We conclude that Caco-2 cells grown on collagen-coated polycarbonate membranes should represent a valuable transport model system for the small intestinal epithelium.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSOn97989rzEIqdXsLcGTEUfW6udTcc2ebTUUAAmXhAULntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL1M7itFeqsg%253D%253D&md5=59ffccc1dd4dccb01400c05df95ac1ff</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1016%2Fs0016-5085%2889%2980072-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0016-5085%252889%252980072-1%26sid%3Dliteratum%253Aachs%26aulast%3DHidalgo%26aufirst%3DI.%2BJ.%26aulast%3DRaub%26aufirst%3DT.%2BJ.%26aulast%3DBorchardt%26aufirst%3DR.%2BT.%26atitle%3DCharacterization%2520of%2520the%2520Human%2520Colon%2520Carcinoma%2520Cell%2520Line%2520%2528Caco-2%2529%2520as%2520a%2520Model%2520System%2520for%2520Intestinal%2520Epithelial%2520Permeability%26jtitle%3DGastroenterology%26date%3D1989%26volume%3D96%26spage%3D736%26epage%3D749%26doi%3D10.1016%2Fs0016-5085%2889%2980072-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mathes, C.</span></span> <span> </span><span class="NLM_article-title">QPatch: The Past, Present and Future of Automated Patch Clamp</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">319</span>– <span class="NLM_lpage">327</span>, <span class="refDoi"> DOI: 10.1517/14728222.10.2.319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1517%2F14728222.10.2.319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=16548779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BD28XivVOmt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2006&pages=319-327&author=C.+Mathes&title=QPatch%3A+The+Past%2C+Present+and+Future+of+Automated+Patch+Clamp&doi=10.1517%2F14728222.10.2.319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">QPatch: the past, present and future of automated patch clamp</span></div><div class="casAuthors">Mathes, Chris</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">319-327</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  The QPatch 16 significantly increases throughput for gigaseal patch clamp expts., making direct measurements in ion channel drug discovery and safety testing feasible.  Released to the market in the Autumn of 2004 by Sophion Bioscience, the QPatch originated from work done at NeuroSearch (Denmark) in the early days of automated patch clamp.  Today, the QPatch provides many unique features.  For example, only the QPatch includes an automated cell prepn. station making several hours of unattended operation possible.  The 16-channel electrode array, called the QPlate, includes glass-coated microfluidic channels for less compd. absorption and, hence, more accurate IC50 values.  The microfluidic pathways also allow for very small amts. of compd. used for each expt. (∼ 5 μl per addn.).  Only the QPatch has four independent pipetting heads for more efficient liq. handling (esp. for ligand-gated ion channel expts.).  Patch clamp recordings with the QPatch match the high quality of conventional patch clamp and in some cases the results are even better.  For example, only the QPatch includes 100% series resistance compensation for the elimination of false positives due to voltage errors.  Finally, the modular QPatch 16 was designed with more channels in mind.  The upgrade pathway to 48-channels (the QPatch HT) will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqywPZMP8PNwrVg90H21EOLACvtfcHk0lhy9zUQfT1OWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XivVOmt7k%253D&md5=7dcd02a69652955e261f6928fbb76b81</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1517%2F14728222.10.2.319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.10.2.319%26sid%3Dliteratum%253Aachs%26aulast%3DMathes%26aufirst%3DC.%26atitle%3DQPatch%253A%2520The%2520Past%252C%2520Present%2520and%2520Future%2520of%2520Automated%2520Patch%2520Clamp%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2006%26volume%3D10%26spage%3D319%26epage%3D327%26doi%3D10.1517%2F14728222.10.2.319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pauwels, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colpaert, F. C.</span></span> <span> </span><span class="NLM_article-title">Ca2+ Responses in Chinese Hamster Ovary-K1 Cells Demonstrate an Atypical Pattern of Ligand-Induced 5-HT1A Receptor Activation</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>307</i></span>,  <span class="NLM_fpage">608</span>– <span class="NLM_lpage">614</span>, <span class="refDoi"> DOI: 10.1124/jpet.103.055871</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1124%2Fjpet.103.055871" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=12970382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADC%252BD3sXos1SiurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=307&publication_year=2003&pages=608-614&author=P.+J.+Pauwelsauthor=F.+C.+Colpaert&title=Ca2%2B+Responses+in+Chinese+Hamster+Ovary-K1+Cells+Demonstrate+an+Atypical+Pattern+of+Ligand-Induced+5-HT1A+Receptor+Activation&doi=10.1124%2Fjpet.103.055871"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Ca2+ responses in Chinese hamster ovary-K1 cells demonstrate an atypical pattern of ligand-induced 5-HT1A receptor activation</span></div><div class="casAuthors">Pauwels, Petrus J.; Colpaert, Francis C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">307</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">608-614</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Little exptl. evidence has been reported for diverse signaling via 5-hydroxytryptamine (5-HT)1A receptors despite the fact that agonists seem to be more efficacious at dorsal raphe somatodendritic 5-HT1A autoreceptors than at postsynaptic 5-HT1A receptors.  The present study investigated Ca2+ responses in Chinese hamster ovary (CHO)-K1 cells expressing a human 5-HT1A receptor by 5-HT, prototypical 5-HT1A agonists, N-(3-chloro-4-fluorobenzoyl)-4-fluoro-4-[(5-methyl-6-; methylaminopyridin-2-yl)-methylaminomethyl]-piperidine (F 14679), and esp. N-(3-chloro-4-fluorobenzoyl)-4-fluoro-4-[(5-methylpyridin-2-yl)-; methylaminomethyl]piperidine (F 13640) as representative ligands of a new chem. class (methylamino-pyridine) that combines both high efficacy and selectivity for 5-HT1A receptors.  5-HT (pEC50 = 6.70) induced a pertussis toxin-sensitive, transient high-magnitude Ca2+ response.  High-magnitude Ca2+ responses (Emax, percentage vs. 5-HT) were also found with F 13640 (107), 5-carboxamidotryptamine (100), and F 14679 (87).  In contrast, the prototypical 5-HT1A receptor agonists buspirone, ipsapirone, and 8-hydroxy-2-(di-n-propylamino)tetralin, and also flesinoxan and eptapirone, were virtually inactive (≤5).  This atypical pattern of 5-HT1A receptor activation contrasts with the broad spectrum of the ligands' partial agonist properties as obsd. by measuring guanosine 5'-O -(3-[35 S]thio)triphosphate ([35S]GTPγS) binding responses with membranes of either CHO-K1 or C6-glial cells stably expressing a human 5-HT1A receptor.  Remarkably, differences between ligands that seem small in the [35S]GTPγS binding assay translate into huge differences in the magnitude of Ca2+ responses.  Therefore, some of these 5-HT1A ligands (i.e., F 13640) may in a selective way induce responses that may be not at all be achieved with other ligands (i.e., buspirone).  In conclusion, the pharmacol. of 5-HT1A receptor ligands seems to be codetd. by the effector pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHLWnIsyGNnLVg90H21EOLACvtfcHk0lhy9zUQfT1OWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXos1SiurY%253D&md5=3d54df8c831b32c84acaca3c5d82c16a</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1124%2Fjpet.103.055871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.103.055871%26sid%3Dliteratum%253Aachs%26aulast%3DPauwels%26aufirst%3DP.%2BJ.%26aulast%3DColpaert%26aufirst%3DF.%2BC.%26atitle%3DCa2%252B%2520Responses%2520in%2520Chinese%2520Hamster%2520Ovary-K1%2520Cells%2520Demonstrate%2520an%2520Atypical%2520Pattern%2520of%2520Ligand-Induced%25205-HT1A%2520Receptor%2520Activation%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2003%26volume%3D307%26spage%3D608%26epage%3D614%26doi%3D10.1124%2Fjpet.103.055871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Detke, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rickels, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucki, I.</span></span> <span> </span><span class="NLM_article-title">Active Behaviors in the Rat Forced Swimming Test Differentially Produced by Serotonergic and Noradrenergic Antidepressants</span>. <i>Psychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">66</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1007/bf02245592</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=10.1007%2Fbf02245592" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=8539342" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADyaK2MXos1WjsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=1995&pages=66-72&author=M.+J.+Detkeauthor=M.+Rickelsauthor=I.+Lucki&title=Active+Behaviors+in+the+Rat+Forced+Swimming+Test+Differentially+Produced+by+Serotonergic+and+Noradrenergic+Antidepressants&doi=10.1007%2Fbf02245592"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants</span></div><div class="casAuthors">Detke, Michael J.; Rickels, Michael; Lucki, Irwin</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Berlin)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">66-72</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">This study demonstrated that distinct patterns of active behaviors are produced by antidepressants that selectively inhibit norepinephrine (NE) or serotonin (5-HT) uptake in the rat forced swimming test (FST).  A behavior sampling technique was developed to score the active behaviors swimming, climbing and diving, as well as immobility.  The rat's behavior was recorded at the end of each 5-s period during the test session.  The sampling technique was both reliable, as demonstrated by test-retest reliability and inter-rater reliability, and valid, as shown by comparison to the timing of behavior durations.  Five different antidepressant drugs which block monoamine uptake and two 5-HT1A receptor agonists were shown to decreased immobility in the FST; however, they produced distinct patterns of active behaviors.  The selective NE uptake inhibitors desipramine and maprotiline selectively increased climbing, whereas the selective serotonin reuptake inhibitors (SSRIs) fluoxetine, sertraline and paroxetine selectively increased swimming.  The 5-HT1A receptor agonists 8-OH-DPAT and gepirone also selectively increased swimming.  These results show that: (1) SSRIs are not false negatives in the FST; (2) at least two behaviorally distinct processes occur in the FST; and (3) enhancement of NE neurotransmission may mediate climbing in the FST, whereas enhancement of 5-HT neurotransmission may mediate swimming.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQE5FGrHE00bVg90H21EOLACvtfcHk0lhy9zUQfT1OWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXos1WjsbY%253D&md5=1196566f76da5500d810f7806bb60cc2</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1007%2Fbf02245592&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fbf02245592%26sid%3Dliteratum%253Aachs%26aulast%3DDetke%26aufirst%3DM.%2BJ.%26aulast%3DRickels%26aufirst%3DM.%26aulast%3DLucki%26aufirst%3DI.%26atitle%3DActive%2520Behaviors%2520in%2520the%2520Rat%2520Forced%2520Swimming%2520Test%2520Differentially%2520Produced%2520by%2520Serotonergic%2520and%2520Noradrenergic%2520Antidepressants%26jtitle%3DPsychopharmacology%26date%3D1995%26volume%3D121%26spage%3D66%26epage%3D72%26doi%3D10.1007%2Fbf02245592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kleven, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assié, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koek, W.</span></span> <span> </span><span class="NLM_article-title">Pharmacological Characterization of in Vivo Properties of Putative Mixed 5-HT1A Agonist/5-HT(2A/2C) Antagonist Anxiolytics. II. Drug Discrimination and Behavioral Observation Studies in Rats</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>282</i></span>,  <span class="NLM_fpage">747</span>– <span class="NLM_lpage">759</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=9262338" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;key=1%3ACAS%3A528%3ADyaK2sXltlSntLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=1997&pages=747-759&author=M.+S.+Klevenauthor=M.+B.+Assi%C3%A9author=W.+Koek&title=Pharmacological+Characterization+of+in+Vivo+Properties+of+Putative+Mixed+5-HT1A+Agonist%2F5-HT%282A%2F2C%29+Antagonist+Anxiolytics.+II.+Drug+Discrimination+and+Behavioral+Observation+Studies+in+Rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of in vivo properties of putative mixed 5-HT1A agonist/5-HT2A/2C antagonist anxiolytics. II. Drug discrimination and behavioral observation studies in rats</span></div><div class="casAuthors">Kleven, Mark S.; Assie, Marie-Bernadette; Koek, Wouter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">282</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">747-759</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">To characterize their in vivo 5-hydroxytryptamine (5-HT)2A antagonist properties, the ability of the putative mixed 5-HT1A agonists/5-HT2A/2C antagonists WY-50,324, FG5974, LEK-8804, and CGS 18102A to antagonize both head twitches and discriminative stimulus (DS) effects produced by (±)-2,5-dimethoxy-4-iodoamphetamine (DOI) in rats were compared with those of the 5-HT2 antagonists ketanserin and ritanserin, and the 5-HT1A agonists 8-OH-DPAT and buspirone.  All of these compds. produced dose-related decreases in DOI-induced head twitches; however pretreatment with the 5-HT1A antagonist WAY-100635 failed to alter the ability of ritanserin, ketanserin or CGS 18102A to attenuate DOI-induced head twitches.  In contrast, WAY-100635 completely blocked the effects of 8-OH-DPAT, buspirone and WY-50,324, and partially blocked the effects of LEK-8804, demonstrating that 5-HT1A agonist properties are involved in the effects of all of the mixed compds. except CGS 18102A.  In rats trained to discriminate DOI (0.63 mg/kg) from saline in a two-lever, FR10 drug discrimination paradigm, ketanserin, ritanserin and CGS 18102A blocked the DS effects of the training dose by more than 50%.  In contrast, WY-50,324, FG5974, LEK-8804, buspirone and 8-OH-DPAT, up to doses that completely suppressed responding, failed to produce more than a 33% blockade of the DS effects of DOI.  In vivo 5-HT1A agonist effects were demonstrated by the finding that relatively selective- and mixed-5-HT1A agonists produced one or more elements of the "serotonin syndrome," i.e., flatbody posture, forepaw treading, or lower-lip retraction, and produced high levels of drug-lever selection in rats trained to discriminate 8-OH-DPAT (0.16 mg/kg) from saline.  Because DOI-induced head twitches and DS effects are thought to be mediated by 5-HT2A receptors, the results demonstrate that the putative mixed compd., CGS 18102A has prominent 5-HT2A antagonist properties in vivo, whereas 5-HT2A antagonist effects of WY-50,324, FG5974 and LEK-8804 could not be clearly identified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiTw3FE5zW7bVg90H21EOLACvtfcHk0lj67DMVTfEhkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXltlSntLk%253D&md5=786c71fe3e5f35399d4fb10341fe3b34</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKleven%26aufirst%3DM.%2BS.%26aulast%3DAssi%25C3%25A9%26aufirst%3DM.%2BB.%26aulast%3DKoek%26aufirst%3DW.%26atitle%3DPharmacological%2520Characterization%2520of%2520in%2520Vivo%2520Properties%2520of%2520Putative%2520Mixed%25205-HT1A%2520Agonist%252F5-HT%25282A%252F2C%2529%2520Antagonist%2520Anxiolytics.%2520II.%2520Drug%2520Discrimination%2520and%2520Behavioral%2520Observation%2520Studies%2520in%2520Rats%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1997%26volume%3D282%26spage%3D747%26epage%3D759" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span> </span><span class="NLM_article-title">Draft Guidance for Industry on Bioanalytical
Method Validation</span>. <a href="https://www.federalregister.gov/documents/2013/09/13/2013-22309/draft-guidance-for-industry-on-bioanalytical-method-validation-availability" class="extLink">https://www.federalregister.gov/documents/2013/09/13/2013-22309/draft-guidance-for-industry-on-bioanalytical-method-validation-availability</a> (accessed Mar 1, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Draft+Guidance+for+Industry+on+Bioanalytical%0AMethod+Validation.+https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2013%2F09%2F13%2F2013-22309%2Fdraft-guidance-for-industry-on-bioanalytical-method-validation-availability+%28accessed+Mar+1%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DDraft%2520Guidance%2520for%2520Industry%2520on%2520Bioanalytical%250AMethod%2520Validation%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4IAR" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4IAR','PDB','4IAR'); return false;">PDB: 4IAR</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i92"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00062">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_80235"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.9b00062">10.1021/acs.jmedchem.9b00062</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Tables of functional activity data with SEM values, radioligand binding assay results and methodology for 5-HT<sub>2A</sub>, M<sub>1</sub>, and H<sub>1</sub> receptors, dose-response curves for functional activity, and detailed data of the effects of compound <b>17</b> in the FST test (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00062/suppl_file/jm9b00062_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00062/suppl_file/jm9b00062_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00062/suppl_file/jm9b00062_si_001.pdf">jm9b00062_si_001.pdf (532.15 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00062/suppl_file/jm9b00062_si_002.csv">jm9b00062_si_002.csv (2.7 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b00062&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-5%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b00062%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b00062" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67998d21b8983d2a","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
